WO2015154630A1 - Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors - Google Patents

Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors Download PDF

Info

Publication number
WO2015154630A1
WO2015154630A1 PCT/CN2015/075363 CN2015075363W WO2015154630A1 WO 2015154630 A1 WO2015154630 A1 WO 2015154630A1 CN 2015075363 W CN2015075363 W CN 2015075363W WO 2015154630 A1 WO2015154630 A1 WO 2015154630A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
benzo
imidazo
pyrazole
carboxamide
Prior art date
Application number
PCT/CN2015/075363
Other languages
French (fr)
Chinese (zh)
Inventor
丁照中
陈曙辉
李刚
王才林
张志博
Original Assignee
南京明德新药研发股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410144173.0A external-priority patent/CN104974161B/en
Priority to JP2017504223A priority Critical patent/JP6359175B2/en
Priority to ES15777444T priority patent/ES2754590T3/en
Priority to PL15777444T priority patent/PL3130592T3/en
Priority to EP15777444.9A priority patent/EP3130592B1/en
Priority to MX2016013265A priority patent/MX368496B/en
Priority to BR112016023397-2A priority patent/BR112016023397B1/en
Priority to AU2015245786A priority patent/AU2015245786B2/en
Priority to CN201580017657.1A priority patent/CN106459057B/en
Priority to RU2016144202A priority patent/RU2672722C2/en
Priority to KR1020167031520A priority patent/KR101921486B1/en
Priority to DK15777444T priority patent/DK3130592T3/en
Priority to US15/302,588 priority patent/US9856262B2/en
Priority to CA2944801A priority patent/CA2944801C/en
Priority to SG11201608438YA priority patent/SG11201608438YA/en
Priority to NZ725165A priority patent/NZ725165A/en
Application filed by 南京明德新药研发股份有限公司 filed Critical 南京明德新药研发股份有限公司
Publication of WO2015154630A1 publication Critical patent/WO2015154630A1/en
Priority to IL248258A priority patent/IL248258B/en
Priority to ZA2016/07736A priority patent/ZA201607736B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to a series of analogs of 4H-pyrazolo[1,5-alpha]benzimidazole compounds as PARP inhibitors. Specifically, the present invention relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.
  • PARP is a family of enzymes that catalyze the addition of ADP-ribose residues to various target proteins. Up to now, up to 18 subtypes have been identified and characterized. Despite the large number of enzymes in this family, PARP-1 is responsible for more than 90% of ADP-ribosylation in cells.
  • PARP-1 has been associated with DNA repair and maintenance of genomic functions. After DNA damage, PARP-1 is transiently activated by binding to DNA breaks. After the structure changes, it begins to use NAD+ synthetic poly(ADP) ribose as a signal for other repair enzymes (such as DNA ligase III, DNA polymerase ⁇ ).
  • the process of binding and activation of PARP-1 (called base excision repair) facilitates the amplification of the repair process with the goal of single-stranded DNA breaks (SSB).
  • SSB is usually initiated by oxidative damage caused by the metabolic processes of the cell itself, as well as by exogenous chemotherapeutic agents and radiation.
  • BRCA1 and BRCA2 play important roles in homologous recombination (HR). DNA breaks generated during DNA replication can only be repaired by HR.
  • HR homologous recombination
  • BRCA1/2 has long been characterized as a tumor suppressor gene, which plays an indispensable role in the repair of DNA double-strand breaks. Mutation vectors for BRCA1/2 in ovarian and prostate cancers are also at high risk. Therefore, PARP-1 inhibitors can also be used as an independent therapy for tumor types that are already deficient in certain types of DNA repair mechanisms.
  • PARP-1 inhibition has been a drug target that has been actively explored, with treatments surrounding stroke, myocardial ischemia, inflammation, and diabetes (Pharmacol. Rev. 2002, 54, 375.).
  • R 1-3 , R d1 , R d2 are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 or a C 1-10 alkyl group optionally substituted by R 01 Or a heteroalkyl group, a C 3-10 cycloalkyl or heterocycloalkyl group, a C 1-10 alkyl or heteroalkyl group substituted by a C 3-10 cycloalkyl or heterocycloalkyl;
  • R 01 is selected from the group consisting of F, Cl, Br, I, CN, OH, SH, NH 2 , R 02 ;
  • R 02 is selected from C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1 -10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 cycloalkoxy, C 3-10 cycloalkyl acyl, C 3-10 cycloalkoxycarbonyl, C 3-10 cycloalkylsulfonyl, C 3-10 cycloalkylsulfinyl;
  • R d3 - d7 are each independently selected from H, R 03 ;
  • R 03 is selected from C 1-10 alkyl, C 1-10 alkyl acyl, C 1-10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 a cycloalkyl group, a C 3-10 cycloalkyl acyl group, a C 3-10 cycloalkoxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
  • R 02 and R 03 are optionally substituted by R 001 ;
  • R 001 is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH 3 ) 2 , NH(CH 3 ), NH 2 , trifluoromethyl, aminomethyl, hydroxymethyl, methyl, methoxy Base, formyl group, methoxycarbonyl group, methylsulfonyl group, methylsulfinyl group;
  • R 01 , R 001 , heteroatoms or heteroatoms is independently selected from 0, 1, 2 or 3.
  • the D is selected from the group consisting of -NH-, -N(CH 3 )-, -C(F) 2 -, -C(H)(F)-, -C(H)(OH) -.
  • the R 1-3 are independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-6 alkyl, C 1-6 alkoxy Base, benzyloxy, -CH 2 N(R 21 )(R 22 ), among them,
  • L can also be a single bond that only serves as a connection
  • T 21-22 are independently selected from C(R t ), N;
  • X is selected from (CH2) n optionally substituted by R 01 , and n is selected from 0, 1, 2 or 3, preferably 0, 1, or 2;
  • Y is selected from (CH2) m optionally substituted by R 01 , and m is selected from 0, 1, 2 or 3, preferably 1, 2, or 3;
  • R 21-23 , R d3 - d7 are each independently selected from H, R 03 ;
  • R 24-27 , R d1 , R d2 , R t are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 or C 1- optionally substituted by R 01 a 10 alkyl or heteroalkyl group, a C 3-10 cycloalkyl or heterocycloalkyl group, a C 1-10 alkyl or heteroalkyl group substituted by a C 3-10 cycloalkyl or heterocycloalkyl;
  • R 01 is selected from the group consisting of F, Cl, Br, I, CN, OH, SH, NH 2 , R 02 ;
  • R 02 is selected from C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1 -10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 cycloalkoxy, C 3-10 cycloalkyl acyl, C 3-10 cycloalkoxycarbonyl, C 3-10 cycloalkylsulfonyl, C 3-10 cycloalkylsulfinyl;
  • R d3 - d7 are each independently selected from H, R 03 ;
  • R 03 is selected from C 1-10 alkyl, C 1-10 alkyl acyl, C 1-10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 a cycloalkyl group, a C 3-10 cycloalkyl acyl group, a C 3-10 cycloalkoxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
  • R 02 and R 03 are optionally substituted by R 001 ;
  • R 001 is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH 3 ) 2 , NH(CH 3 ), NH 2 , trifluoromethyl, aminomethyl, hydroxymethyl, methyl, methoxy Base, formyl group, methoxycarbonyl group, methylsulfonyl group, methylsulfinyl group;
  • R 01 , R 001 , heteroatoms or heteroatoms is independently selected from 0, 1, 2 or 3.
  • the R 1 and R 3 are each independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-3 alkyl, C 1-3 alkane.
  • Oxyl, benzyloxy or R 101 is selected from H, methyl, ethyl, n-propyl or isopropyl.
  • the R 1 is selected from the group consisting of H, methyl, methoxy, benzyloxy,
  • R 3 is selected from the group consisting of H, F, Cl, Br, CN, methyl.
  • the R 2 is selected from -CH 2 N(R 201 )(R 202 ), and R 201 and R 202 are each independently selected from H, C 1-3 alkyl, C 1-3 alkane. a acyl group, a C 3-6 cycloalkyl acyl group or a C 3-6 cycloalkyl group;
  • the R 201 and R 202 are each independently selected from H or a cyclopropionyl group.
  • the R 2 is selected from
  • the R 2 is selected from R 203 , R 204 , R 217 , R 218 are each independently selected from H, optionally substituted C 1-3 alkyl, cyclopropyl or cyclopropyl methylene, and the substituent is selected from the group consisting of F, Cl, Br. , I, CN, OH, NH 2 , methyl or methoxy, the number of substituents is 0, 1, 2 or 3.
  • the R 203 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, -CH 2 C(CH 3 )(CH 3 )(OH), cyclopropylmethylene.
  • the R 204 is selected from the group consisting of methyl, ethyl, n-propyl, and isopropyl.
  • the R 217-219 are each independently selected from the group consisting of an ethyl group and a methyl group.
  • the R 2 is selected from
  • the R 2 is selected from R 205 and R 206 are each independently selected from H, optionally substituted C 1-3 alkyl, cyclopropyl or cyclopropyl methylene, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl or methoxy, the number of substituents is 0, 1, 2 or 3.
  • the R 205 and R 206 are each independently preferably H, methyl, ethyl, n-propyl or isopropyl, and R 206 may also preferably be F, Cl, Br, I, CN, OH. , NH 2 .
  • the R 2 is selected from
  • the R 2 is selected from
  • the R 2 is selected from R 207 is selected from H, optionally substituted C 1-3 alkyl, cyclopropyl, cyclopropylmethylene, cyclobutyl, cyclobutyl methylene, oxetanyl or oxetane a methylidene group, the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, trifluoromethyl, methoxy, methylsulfonyl, and the number of substituents is 0, 1, 2 Or 3.
  • the R 2 is selected from
  • the R 2 is selected from or R 208 is selected from H, optionally substituted C 1-4 alkyl, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, trifluoromethyl, methoxy, A Sulfonyl, the number of substituents is 0, 1, 2 or 3.
  • the R 208 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethylene, cyclobutyl.
  • the R 2 is selected from
  • the R 2 is selected from R 210 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , N,N-di(C 1-3 alkyl)amino, C 1-3 alkylamino.
  • the R 210 is selected from the group consisting of dimethylamino, methylamino, H, F, Cl, Br, I, CN, OH, NH 2 .
  • the R 2 is selected from
  • R 211-214 is selected from H or C 1-4 alkoxycarbonyl, C 1-4 alkyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkylmethylene or 5 optionally substituted by R 215 a -6 member unsaturated heterocyclic hydrocarbon group, R 211-213 is also selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 ,
  • the cycloalkyl or unsaturated heterocyclic hydrocarbon group contains 0, 1 or 2 O, S or NR 216 ,
  • R 216 is selected from C 1-4 alkyl optionally substituted by H, R 215 ,
  • R 215 is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, ethyl, methoxy, ethoxy, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl , ethoxycarbonyl, dimethylamino, diethylamino, dimethylaminocarbonyl, diethylaminocarbonyl, oxo, the number of R 215 is 1, 1, 2 or 3,
  • R 212 and R 213 together form a linkage -CH 2 -, -CH 2 CH 2 - or -CH 2 CH 2 CH 2 -;
  • R 211 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , methyl, ethyl, hydroxymethyl, methoxycarbonyl,
  • R 212 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , methyl,
  • R 213 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 ,
  • the R 2 is selected from
  • the R 2 is selected from T 22 is selected from N or C (R 224 ); R 220-224 are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-3 alkylamino C 1-3 alkyl,
  • the C 1-3 alkylamino C 1-3 alkyl group is selected from the group consisting of methylaminomethylene.
  • the R 2 is selected from
  • the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of
  • C 1-10 is selected from C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 ;
  • C 3-10 is selected from C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 .
  • C 1-10 alkyl or heteroalkyl, C 3-10 cyclo or heterocycloalkyl, C 1-10 alkyl or heteroalkyl substituted by C 3-10 cycloalkyl or heterocycloalkyl includes, but is not limited to:
  • pharmaceutically acceptable as used herein is intended to mean that those compounds, materials, compositions and/or dosage forms are within the scope of sound medical judgment and are suitable for use in contact with human and animal tissues. Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to a salt of a compound of the invention prepared from a compound having a particular substituent found in the present invention and a relatively non-toxic acid or base.
  • a base addition salt can be obtained by contacting a neutral amount of such a compound with a sufficient amount of a base in a neat solution or a suitable inert solvent.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts.
  • an acid addition salt can be obtained by contacting a neutral form of such a compound with a sufficient amount of an acid in a neat solution or a suitable inert solvent.
  • pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogencarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and an organic acid salt, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and me
  • the salt is contacted with a base or acid in a conventional manner, and the parent compound is separated, thereby regenerating the neutral form of the compound.
  • the parent form of the compound differs from the form of its various salts by certain physical properties, such as differences in solubility in polar solvents.
  • a "pharmaceutically acceptable salt” is a derivative of a compound of the invention wherein the parent compound is modified by salt formation with an acid or with a base.
  • pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic salts of acid groups such as carboxylic acids, and the like.
  • Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound, for example salts formed from non-toxic inorganic or organic acids.
  • non-toxic salts include, but are not limited to, those derived from inorganic acids and organic acids selected from the group consisting of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, Benzenesulfonic acid, benzoic acid, hydrogencarbonate, carbonic acid, citric acid, edetic acid, ethane disulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid, Hydrobromic acid, hydrochloric acid, hydroiodide, hydroxyl, hydroxynaphthalene, isethionethane, lactic acid, lactose, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, nitric acid, oxalic acid, Pamoic acid, pantothenic acid, phenylacetic acid, phen
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing an acid group or a base by conventional chemical methods.
  • such salts are prepared by reacting these compounds in water or an organic solvent or a mixture of the two via a free acid or base form with a stoichiometric amount of a suitable base or acid.
  • a nonaqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile is preferred.
  • the compounds provided herein also exist in the form of prodrugs.
  • Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the invention.
  • prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an in vivo setting.
  • Certain compounds of the invention may exist in unsolvated or solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are included within the scope of the invention. Certain compounds of the invention may exist in polycrystalline or amorphous form.
  • Certain compounds of the invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the invention.
  • the compounds of the invention may exist in specific geometric or stereoisomeric forms.
  • the present invention contemplates all such compounds, including the cis and trans isomers, the (-)- and (+)-p-enantiomers, the (R)- and (S)-enantiomers, and the diastereomeric a conformation, a (D)-isomer, a (L)-isomer, and a racemic mixture thereof, and other mixtures, such as enantiomerically or diastereomeric enriched mixtures, all of which belong to It is within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in the substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the invention.
  • optically active (R)- and (S)-isomers as well as the D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary. Wherein the resulting mixture of diastereomers is separated and the auxiliary group cleaved to provide the pure desired enantiomer.
  • a salt of a diastereomer is formed with a suitable optically active acid or base, followed by stepping as is known in the art.
  • the diastereomeric resolution is carried out by crystallization or chromatography, and then the pure enantiomer is recovered.
  • the separation of enantiomers and diastereomers is generally accomplished by the use of chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (eg, formation of an amino group from an amine). Formate).
  • the compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound.
  • radiolabeled compounds can be used, such as tritium (3 H), iodine -125 (125 I) or C-14 (14 C). Alterations of all isotopic compositions of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
  • pharmaceutically acceptable carrier refers to any formulation or carrier medium that is capable of delivering an effective amount of an active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects to the host or patient, including water, oil, Vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, tackifiers, transdermal enhancers and the like. Their formulations are well known to those skilled in the cosmetic or topical pharmaceutical arts. For additional information on vectors, reference is made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are hereby incorporated by reference.
  • excipient generally refers to the carrier, diluent and/or vehicle required to formulate an effective pharmaceutical composition.
  • an "effective amount” or “therapeutically effective amount” with respect to a pharmaceutical or pharmacologically active agent refers to a sufficient amount of a drug or agent that is non-toxic but that achieves the desired effect.
  • an "effective amount” of an active substance in a composition refers to the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount will vary from person to person, depending on the age and general condition of the recipient, and also on the particular active substance, and a suitable effective amount in a case can be determined by one skilled in the art based on routine experimentation.
  • active ingredient refers to a chemical entity that is effective in treating a target disorder, disease or condition.
  • substituted means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, including variants of heavy hydrogen and hydrogen, as long as the valence of the particular atom is normal and the substituted compound is stable.
  • it means that two hydrogen atoms are substituted.
  • Ketone substitution does not occur on the aryl group.
  • optionally substituted means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemically achievable.
  • any variable eg, R
  • its definition in each case is independent.
  • the group may optionally be substituted with at most two R, and each case has an independent option.
  • combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
  • substituents When a bond of a substituent can be cross-linked to two atoms on a ring, the substituent can be bonded to any atom on the ring.
  • substituents do not indicate which atom is attached to a compound included in the chemical structural formula including but not specifically mentioned, such a substituent may be bonded through any atomic phase thereof. Combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
  • alkyl and heteroalkyl radicals (including what are commonly referred to as alkylene, alkenyl, heteroalkyl, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl and heterocycloalkenyl)
  • R', R", R"', R"" and R""' are each independently preferably hydrogen, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted aryl group (for example, an aryl group substituted by 1 to 3 halogens), a substituted or unsubstituted alkyl group, an alkoxy group, or a thioalkyl group oxygen a group or an aralkyl group.
  • each R group is independently selected, as when more than one R', R", R"' Each of these groups, R"" and R""' groups.
  • R' and R" When R' and R" are attached to the same nitrogen atom, they can form a 5-, 6- or 7-member with the nitrogen atom. ring.
  • -NR'R is intended to include, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is intended to include carbon.
  • a group bonded to a non-hydrogen group such as a haloalkyl group (e.g., -CF 3 , -CH 2 CF 3 ) and an acyl group (e.g., -C(O)CH 3 , -C(O)CF 3 ,- C(O)CH 2 OCH 3 , etc.).
  • a non-hydrogen group such as a haloalkyl group (e.g., -CF 3 , -CH 2 CF 3 ) and an acyl group (e.g., -C(O)CH 3 , -C(O)CF 3 ,- C(O)CH 2 OCH 3 , etc.).
  • Two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a substituent of the formula -TC(O)-(CRR')qU-, wherein T and U are independently selected From -NR-, -O-, CRR'- or a single bond, q is an integer from 0 to 3.
  • two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a substituent of the formula -A(CH2)r B-, wherein A and B are independently selected From -CRR'-, -O-, -NR-, -S-, -S(O)-, S(O) 2 -, -S(O) 2 NR'- or a single bond, r is 1 to 4 The integer.
  • a single bond on the new ring thus formed can be replaced with a double bond.
  • two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a substituent of the formula -A(CH2)r B-, wherein s and d are each independently An integer selected from 0 to 3, X is -O-, -NR', -S-, -S(O)-, -S(O) 2 - or -S(O) 2 NR'-.
  • the substituents R, R', R" and R"' are each independently preferably selected from hydrogen and substituted or unsubstituted (C 1 -C 6 )alkyl.
  • hydrocarbyl or its subordinate concept (such as alkyl, alkenyl, alkynyl, phenyl, etc.) by itself or as part of another substituent means straight-chain, branched or cyclic
  • the hydrocarbon radical or a combination thereof may be fully saturated, unitary or polyunsaturated, may be monosubstituted, disubstituted or polysubstituted, and may include divalent or polyvalent radicals having a specified number of carbon atoms (eg, C1 ) -C 10 represents 1 to 10 carbons).
  • Hydrocarbyl includes, but is not limited to, aliphatic hydrocarbyl groups including chain and cyclic, including but not limited to alkyl, alkenyl, alkynyl groups including, but not limited to, 6-12 members.
  • An aromatic hydrocarbon group such as benzene, naphthalene or the like.
  • alkyl refers to a straight or branched chain of atoms or a combination thereof, which may be fully saturated, unitary or polyunsaturated, and may include divalent and multivalent radicals.
  • saturated hydrocarbon radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, isobutyl, cyclohexyl, (cyclohexyl).
  • a homolog or isomer of a methyl group, a cyclopropylmethyl group, and an atomic group such as n-pentyl, n-hexyl, n-heptyl, n-octyl.
  • the unsaturated alkyl group has one or more double or triple bonds, and examples thereof include, but are not limited to, a vinyl group, a 2-propenyl group, a butenyl group, a crotyl group, a 2-isopentenyl group, and a 2-(butadienyl group). ), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and Structure.
  • heterohydrocarbyl or its subordinate concept (such as heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, etc.), by itself or in combination with another term, means a stable straight chain, branched chain. Or a cyclic hydrocarbon radical or a combination thereof having a number of carbon atoms and at least one heteroatom.
  • heteroalkyl by itself or in conjunction with another term refers to a stable straight chain, branched hydrocarbon radical or combination thereof, having a number of carbon atoms and at least one heteroatom.
  • the heteroatoms are selected from the group consisting of B, O, N, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatoms are optionally quaternized.
  • the heteroatoms B, O, N and S may be located at any internal position of the heterohydrocarbyl group (except where the hydrocarbyl group is attached to the rest of the molecule).
  • Up to two heteroatoms may be consecutive, for example, -CH 2 -NH-OCH 3.
  • alkoxy alkylamino and “alkylthio” (or thioalkoxy) are customary expressions and refer to those alkane which are attached to the remainder of the molecule through an oxygen atom, an amino group or a sulfur atom, respectively.
  • Base group alkoxy
  • cycloalkyl Unless otherwise specified, the terms “cycloalkyl”, “heterocycloalkyl”, “cyclohetero” or subordinates thereof (such as aryl, heteroaryl, aryl, cycloalkyl, heterocycloalkyl, ring) Alkyl, cycloalkenyl, heterocycloalkenyl, cycloalkenyl, cycloalkynyl, heterocycloalkynyl, cycloalkynyl, and the like, by themselves or in combination with other terms, respectively denote a cyclized “hydrocarbyl group", Heterohydrocarbyl” or “hydrocarbyl”.
  • a hetero atom may occupy a position at which the hetero ring is attached to the rest of the molecule.
  • cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocyclic groups include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl and 2-piperazinyl.
  • halo or halogen
  • haloalkyl is intended to include both monohaloalkyl and polyhaloalkyl.
  • halo(C 1 -C 4 )alkyl is intended to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. Wait.
  • aryl denotes a polyunsaturated, aromatic hydrocarbon substituent which may be monosubstituted, disubstituted or polysubstituted, which may be monocyclic or polycyclic (preferably 1 to 3 rings), They are fused together or covalently linked.
  • heteroaryl refers to an aryl (or ring) containing one to four heteroatoms. In an illustrative example, the heteroatoms are selected from the group consisting of B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
  • Non-limiting examples of aryl or heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyridyl Azyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxan Azyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thiophene , 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, indolyl, 2-benzimidazolyl, 5-indenyl
  • aryl groups when used in conjunction with other terms (eg, aryloxy, arylthio, aralkyl), include aryl and heteroaryl rings as defined above.
  • aralkyl is intended to include those radicals to which an aryl group is attached to an alkyl group (eg, benzyl, phenethyl, pyridylmethyl) And the like, including those in which a carbon atom such as a methylene group has been replaced by, for example, an oxygen atom, such as a phenoxymethyl group, a 2-pyridyloxymethyl 3-(1-naphthyloxy)propyl group or the like.
  • Ring means a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
  • the so-called ring includes a fused ring.
  • the number of atoms on the ring is usually defined as the number of elements of the ring.
  • “5 to 7-membered ring” means 5 to 7 atoms arranged in a circle. Unless otherwise specified, the ring optionally contains from 1 to 3 heteroatoms.
  • 5- to 7-membered ring includes, for example, phenylpyridine and piperidinyl; on the other hand, the term “5- to 7-membered heterocycloalkyl ring” includes pyridyl and piperidinyl, but does not include phenyl.
  • ring also includes ring systems containing at least one ring, each of which "ring” independently conforms to the above definition.
  • heteroatom as used herein includes atoms other than carbon (C) and hydrogen (H), including, for example, oxygen (O), nitrogen (N), sulfur (S), silicon (Si), germanium (Ge), aluminum ( Al) and boron (B) and the like.
  • leaving group refers to a functional group or atom which may be substituted by another functional group or atom by a substitution reaction (for example, an affinity substitution reaction).
  • substituent groups include triflate; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonic acid Esters and the like; acyloxy groups such as acetoxy, trifluoroacetoxy and the like.
  • protecting group includes, but is not limited to, "amino protecting group", “hydroxy protecting group” or “thiol protecting group”.
  • amino protecting group refers to a protecting group suitable for preventing side reactions at the amino nitrogen position.
  • Representative amino protecting groups include, but are not limited to, formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, e.g., tert-butoxycarbonyl (Boc) Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1, 1-di -(4'-methoxyphenyl)methyl; silyl groups such as trimethylsilyl (TMS) and tert-
  • hydroxy protecting group refers to a protecting group suitable for use in preventing hydroxy side reactions.
  • Representative hydroxy protecting groups include, but are not limited to, alkyl groups such as methyl, ethyl and t-butyl groups; acyl groups such as alkanoyl groups (e.g., acetyl); arylmethyl groups such as benzyl (Bn), Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and the like.
  • alkyl groups such as methyl, ethyl and t-butyl groups
  • acyl groups such as alkanoyl groups (e.g., acetyl)
  • arylmethyl groups such as benzyl (Bn), Oxybenzyl (PMB), 9-fluoreny
  • haloalkyl groups include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl.
  • Alkoxy represents the above alkyl group having a specified number of carbon atoms attached through an oxygen bridge.
  • the C 1-6 alkoxy group includes a C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkoxy groups.
  • alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- Pentyloxy.
  • Cycloalkyl includes saturated cyclic groups such as cyclopropyl, cyclobutyl or cyclopentyl.
  • the 3-7 cycloalkyl group includes C 3 , C 4 , C 5 , C 6 and C 7 cycloalkyl groups.
  • Alkenyl includes hydrocarbon chains in a straight or branched configuration wherein one or more carbon-carbon double bonds, such as vinyl and propylene groups, are present at any stable site on the chain.
  • halo or “halogen” refers to fluoro, chloro, bromo and iodo.
  • heterocycle or “heterocyclyl” means a stable monocyclic or bicyclic or bicyclic heterocycle which may be saturated, partially unsaturated or unsaturated (aromatic) which contain a carbon atom and 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein any of the above heterocyclic rings may be fused to a phenyl ring to form a bicyclic ring.
  • the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p).
  • the nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein).
  • the heterocyclic ring can be attached to the side groups of any hetero atom or carbon atom to form a stable structure. If the resulting compound is stable, the heterocycles described herein can undergo substitutions at the carbon or nitrogen sites.
  • the nitrogen atom in the heterocycle is optionally quaternized.
  • a preferred embodiment is that when the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. Another preferred embodiment is that the total number of S and O atoms in the heterocycle does not exceed one.
  • aromatic heterocyclic group or "heteroaryl” as used herein means a stable 5, 6, or 7 membered monocyclic or bicyclic or aromatic ring of a 7, 8, 9 or 10 membered bicyclic heterocyclic group, It Containing a carbon atom and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S.
  • the nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein).
  • the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p). It is worth noting that the total number of S and O atoms on the aromatic heterocycle does not exceed one.
  • Bridged rings are also included in the definition of heterocycles.
  • a bridged ring is formed when one or more atoms (ie, C, O, N, or S) join two non-adjacent carbon or nitrogen atoms.
  • Preferred bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and one carbon-nitrogen group. It is worth noting that a bridge always converts a single ring into a three ring. In the bridged ring, a substituent on the ring can also be present on the bridge.
  • heterocyclic compounds include, but are not limited to, acridinyl, octanoyl, benzimidazolyl, benzofuranyl, benzofuranylfuranyl, benzindenylphenyl, benzoxazolyl, benzimidin Oxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, oxazolyl, 4aH-carbazolyl, Porphyrin, chroman, chromene, porphyrin-decahydroquinolinyl, 2H, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b] Tetrahydrofuranyl, furyl, furfuryl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-carbazolyl, nonenyl,
  • the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments set forth below, combinations thereof with other chemical synthetic methods, and those well known to those skilled in the art. Equivalent alternatives, preferred embodiments include, but are not limited to, embodiments of the invention.
  • the present invention employs the following abbreviations: aq for water; HATU for O-7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; EDC stands for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; m-CPBA stands for 3-chloroperoxybenzoic acid; eq stands for equivalent, equivalent; CDI stands for carbonyl Diimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DIAD stands for diisopropyl azodicarboxylate; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOAc stands for ethyl acetate EtOH stands for ethanol; MeOH stands for methanol; CBz stands for benzyloxycarbonyl and is an amine protecting group; BOC
  • High performance liquid chromatography was performed using a Shimadzu LC20AB system equipped with a Shimadzu SIL-20A autosampler and a Shimadzu DAD: SPD-M20A detector using a Xtimate C18 (3 m packing, size 2.1 x 300 mm) column.
  • 0-60AB_6 min method Apply a linear gradient, start elution with 100% A (A is 0.0675% TFA in water), and end the elution with 60% B (B is 0.0625% TFA in MeCN solution). The whole process is 4.2 minutes, then eluted with 60% B for 1 minute. The column was equilibrated for 0.8 minutes to reach 100:0 with a total run time of 6 minutes.
  • 10-80AB_6 min method Apply a linear gradient, start elution with 90% A (A is 0.0675% TFA in water), and end the elution with 80% B (B in 0.0625% TFA in acetonitrile). 4.2 minutes, then eluted with 80% B for 1 minute.
  • the column was equilibrated for 0.8 minutes to 90:10 with a total run time of 6 minutes.
  • the column temperature was 50 ° C and the flow rate was 0.8 mL/min.
  • the diode array detector has a scanning wavelength of 200-400 nm.
  • TLC Thin layer chromatography
  • a common solvent for flash column chromatography or thin layer chromatography is a mixture of dichloromethane/methanol, ethyl acetate/methanol and hexane/ethyl acetate.
  • AS-H_3_40_2.35ML Chromatographic conditions Chiralpak AS-H column (specification 250x 4.6mm ID, 5m packing); mobile phase 40% methanol (0.05% DEA)-CO 2 ; flow rate 2.35mL/min, detection wavelength It is 220 nm.
  • OD-H_3_40_2.35M Chromatographic conditions Chiralcel OD-H column (specification 250x 4.6mm ID, 5m packing), mobile phase 40% methanol (0.05% DEA)-CO 2 , flow rate 2.35mL / min, detection wavelength It is 220 nm.
  • AD-H_2_50_2.35ML Chromatographic conditions Chiralpak AD-H column (specification 250x 4.6mm ID, 5mm packing), mobile phase 50% methanol (0.1% MEA)-CO 2 , flow rate 2.35mL / min, detection wavelength It is 220 nm.
  • Preparative SFC analysis was performed on a Waters Thar 80 Pre-SFC system using a Gilson UV detector using Chiralcel OD-H (250x 4.6mm ID, 5m packing) or Chiralpak AD-H (250x size) 4.6mm ID, 5m filler).
  • Chiralcel OD-H 250x 4.6mm ID, 5m packing
  • Chiralpak AD-H 250x size 4.6mm ID, 5m filler
  • the compound is eluted with a low gradient of ethanol-carbon dioxide or methanol-carbon dioxide, with methanol or ethanol containing 0.05% NH 3 ⁇ H 2 O, 0.05% DEA or 0.1% MEA, total run
  • the time is 20-30 minutes.
  • the PARP-1 inhibitors provided by the present invention can be used to treat a wide range of diseases including cancer, stroke, myocardial ischemia, inflammation and diabetes. PARP-1 inhibitors can be used as a single dose or in combination with other chemotherapeutic agents to enhance the effectiveness of these standard chemotherapeutic agents.
  • Cancers treatable by PARP-1 inhibitors include, but are not limited to, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, clonal cancer, and leukemia.
  • Example 1A A mixture of Example 1A (19 g, 55.7 mmol), sodium cyanide (8.19 g, 167 mmol) in dimethyl sulfoxide (100 mL) was reacted at 100 ° C for 16 hours. After cooling to room temperature, it was diluted with H ⁇ The title compound (11 g) was obtained eluted directly to next step without further purification.
  • Example 1C A mixture of Example 1C (3.5 g, 13.87 mmol) and EXAMPLE 1D (3.94 g, 13.87 mmol) in ethanol (30 mL) was stirred at 80 ° C for 0.5 hour. After the solution was removed in vacuo, EtOAc m. LCMS (ESI) m/z: 519 (M+1).
  • Example 1F (2.4 g, 4.63 mmol), N1, N2-dimethylethane-1,2-diamine (40.83 mg, 0.463 mmol), cuprous iodide (88 mg, 0.463).
  • a mixture of millimolar) and potassium phosphate (983 mg, 4.63 mmol) in DMF (30 mL) was heated at 60 ° C for one hour. After cooling to rt, the mixture was evaporated EtOAc mjjjjjjjjj LCMS (ESI) m/z: 437, 437 (M, M+2).
  • Example 1G 200 mg, 0.457 mmol
  • palladium acetate (10.27 mg, 0.0457 mmol)
  • Pd(dppf)Cl2 33.46 mg, 0.0457 mmol
  • Xantphos 53 mg, 0.0914 mmol
  • DPPP DPPP (38) Mg, 0.0914 mmol
  • a mixed solution of triphenylphosphine 24 mg, 0.0914 mmol
  • triethylamine 232 mg, 2.29 mmol
  • DMF 40 mL
  • methanol 20 ml
  • Example 1H 100 mg, 0.24 mmol
  • ammonia / methanol 30 mL
  • DMF 100 mL
  • Example 1I The mixture of Example 1I (70 mg, 0.174 mmol) eluted with dichloromethane (3 mL) 25 mg, 49%).
  • 1 H NMR 400 MHz, METHANOL-d4) ppm 1.93-1.96 (m, 2H), 2.37 - 2.36 (d, 2H), 3.09 - 3.22 (m, 3H), 3.31 - 3.53 (t, 2H), 7.37-7.39 (m, 1H), 7.68-7.74 (m, 2H).
  • Example 1J 750 mg, 2.49 mmol
  • acetaldehyde 1.1 g, 24.9 mmol
  • sodium cyanoborohydride 3.13 g, 49.8 mmol
  • the resulting mixture was stirred at 50 ° C for 16 hours. After the solution was removed in vacuo, EtOAc m.
  • Example 1J (112 mg, 0.372 mmol), 1-bromo-2-methoxyethane (71 mg, 0.558 mmol) and potassium carbonate (154 mg, 1.116 mmol) in acetonitrile (20 mL) Stir at °C for 16 hours.
  • Example 1I A mixture of Example 1I (100 mg, 0.25 mmol), benzyl bromide (127 mg, 0.748 mmol) and potassium carbonate (103 mg, 0.748 mmol) in acetonitrile (4 mL) was stirred at 60 ° C for 4 hours. After cooling and filtration, EtOAcqqqqqqm LCMS (ESI) m/z: 495 (M+1).
  • Example 6A A mixed solution of Example 6A (112.6 mg, 0.229 mmol) of dichloromethane (10 ml) and trifluoroacetic acid (3 ml) was stirred at 12 ° C for 2 hours.
  • the title compound (115 mg, 100%) eluted elute LCMS (ESI) M/Z: ⁇ /RTI>
  • Example 6B (115 mg, 0.229 mmol), a mixture of 2,2-dimethyloxirane (50 mg, 0.690 mmol) and triethylamine (116 mg, 1.15 mmol) in ethanol (5 ml) The microwave was heated at ° C for 1 hour. After the solution was removed in vacuo to give crystall LCMS (ESI) m/z: 464 (M+1).
  • Example 6C 32 mg, 0.069 mmol
  • Pd/C 25 mg
  • the title compound (8.2 mg, 32.2%) was obtained.
  • 1 H NMR 400 MHz, METHANOL-d 4 ) ppm 1.38 (s, 6H), 2.10-2.30 (m, 4H), 3.12 (s, 5H), 3.57-3.73 (m, 2H), 7.29-7.39 (m, 1H), 7.61-7.69 (m, 1H), 7.69-7.75 (m, 1H), 8.54 (br.s., 1H).
  • LCMS m/z: 374 (M+1).
  • Example 7A A mixture of Example 7A (27 mg, 0.058 mmol) and Pd/C (30 mg) in methanol (20 ml) was hydrogenated at 45 ° C for 16 hours (1 atm). Filtration of the title compound (2.1 mg, 10%).
  • 1 H NMR 400MHz, METHANOL- d 4) ppm 1.42 (s, 3H), 1.48 (s, 3H), 1.90-2.03 (m, 2H), 2.04-2.16 (m, 2H), 2.51-2.67 (m, 2H), 2.72-2.90 (m, 3H), 3.23-3.31 (m, 2H), 7.32-7.41 (m, 1H), 7.63-7.75 (m, 2H), 8.27-8.59 (m, 1H).
  • LCMS ESI
  • Example 1J 52 mg, 0.125 mmol
  • cyclopropanecarboxylic acid 13 mg, 0.150 mmol
  • triethylamine 50.5 mg, 0.5 mmol
  • HATU 47.5 mg, 0.125 mmol
  • LCMS 370 [M + 1].
  • 1 H NMR 400 MHz, DMSO-d 6 ).
  • Example 18C A mixture of Example 18C (13 g, 48.27 mmol) and Pd / C (1 g) in methanol (130 mL) was hydrogenated at 15 ° C for 16 hours (1 atm). The mixture was filtered, and the filtrate was evaporated to crystalljjjjjjjjjj LCMS (ESI) m/z: 258 (M+1).
  • Lithium tetrahydroaluminum (1.48 g, 39 mmol) was added portionwise to a solution of EtOAc (EtOAc). After stirring at 0<0>C for 30 min, EtOAc (EtOAc)EtOAc. The mixture was filtered, and the filtrate was evaporated. LCMS (ESI) m/z: 230 (M+1).
  • Example 28D To a mixture of Example 28D (3.5 g, 16.43 mmol), DMAP (200 mg, 1.6 mmol) and triethylamine (5 mL, 36.14 mmol) in dichloromethane (100 mL) TosCl (3.7 g, 19.47 mmol) was added in portions. The mixture was stirred at 24 <0>C for 15 h then quenched with water (100 mL). The aqueous layer was extracted with EtOAc (EtOAc (EtOAc). , is a colorless oil.
  • EtOAc EtOAc
  • Example 28E A mixture of Example 28E (2.6 g, 11 mmol), sodium cyanide (1.57 g, 32 mmol) and EtOAc (1. After cooling to room temperature, the mixture was combined with EtOAc EtOAc EtOAc. It was dried, filtered and evaporated.
  • Example 28G (3.0 g, crude, 10.8 mmol) of a mixture of tetrahydrofuran / acetic acid / water (1/1/1) (45 ml) was stirred at 24 ° C for 5 hours. After the solution was removed in vacuo, EtOAc EtOAc (EtOAc) The mixture was washed with EtOAc (EtOAc m. LCMS (ESI) m/z:195 (M-55).
  • This example was prepared as described in Examples 1E-1J.
  • Example 33A (7.67 g, 25.5 mmol) was heated to 190 °C for 1 hour. The residue was purified by EtOAcqqqqqq LCMS (ESI) m/z: 274 (M+1).
  • Example 33C A mixture of Example 33C (1.42 g, 7.0 mmol), Boc 2 O (1.81 g, 8.4 mmol) and 10% Pd/C (200 mg) in methanol (80 mL) was hydrogenated at 25 ° C for 16 hours (1 atm). The mixture was filtered, and the title crystalljjjjjjjj LCMS (ESI) m/z: 214 (M+1).
  • Example 36A A mixed solution of Example 36A (3.9 g, 8.1 mmol) and lithium hydroxide (1 g, 24.2 mmol) in water (20 mL), methanol (5 mL) and tetrahydrofuran (20 mL) was stirred at 15 ° C for 16 hours. Dilute with water (50 mL) and adjust the pH to 4-5 with 1N hydrochloric acid. The aqueous layer was extracted with EtOAc (EtOAc EtOAc (EtOAc) Without further purification.
  • EtOAc EtOAc EtOAc
  • LCMS (ESI) m/z: 304 (M+1).
  • Example 1D A mixture of Example 1D (4 g, 14 mmol) and 2-ethoxymethylenemalononitrile (2.24 g, 18.31 mmol) in ethanol (30 ml) was stirred at ⁇ RTIgt; The mixture was evaporated in vacuo to give title crystall crystall
  • Example 37A (2.8 g, 7.78 mmol), N1, N2-dimethylethane-1,2-diamine (68 mg, 0.777 mmol), cuprous iodide (148 mg, 0.777).
  • a mixture of millimolar) and potassium phosphate (1.65 g, 7.78 mmol) in DMF (30 mL) was stirred at 60 ° C for 24 hours. The mixture was cooled to EtOAc (EtOAc m.)
  • Example 37B (1 g, 3.58 mmol), palladium acetate (161 mg, 0.72 mmol), Pd (dppf) Cl 2 , (526 mg, 0.72 mmol), Xantphos (420 mg, 0.72 mmol), DPPP (mixture 296 mg, 0.72 mmol), triphenylphosphine (188 mg, 0.72 mmol) and triethylamine (1.8 g, 18 mmol) in DMF (30 mL) and methanol (10 mL) Stir at 120 ° C for 12 hours at 3 MPa. After cooling to rt, EtOAc m.
  • Example 37D To a mixture of Example 37D (100 mg, 0.4 mmol) in dichloromethane (20 mL) and methanol (50 mL) was added portionwise mixture of nickel chloride hexahydrate (200 mg, 0.8 mmol) and sodium borohydride at 0 ° C. (47 mg, 1.2 mmol). After stirring at 0<0>C for 5 min, EtOAcqqqqm 1 H NMR (400 MHz, D 2 O) ppm 4.2 (S, 2H), 7. 279 - 7. ⁇ / RTI> (t, 2H), 7.796 (S, 1H), 8.399 (S, 1H). LCMS (ESI) m/z: 248 (M +1).
  • Example 39 (20 mg, 0.081 mmol), cyclopropanecarboxylic acid (8.36 mg, 0.098 mmol), HOBT (13.12 mg, 0.0979 mmol), EDCI (18.61 mg, 0.097 mmol) and triethylamine (25 mg)
  • a mixture of 0.242 mmol of DMF (5 mL) was stirred at 30 ° C for 6 hours. After removal of the residue in vacuo, EtOAc m.
  • Example 1D A mixture of Example 1D (5 g, 17.61 mmol) and ethyl 2-cyano-3-ethoxyethyl acrylate (2.98 g, 17.61 mmol) in ethanol (100 mL) was stirred at 78 ° C for 16 hours. After the solution was removed in vacuo, m ⁇
  • Example 41A (2.7 g, 6.63 mmol), cuprous iodide (252 mg, 1.33 mmol), N1, N2-dimethylethane-1,2-diamine (233.9 mg, 2.65).
  • a mixture of millimolar) and potassium phosphate (4.22 g, 19.9 mmol) in DMF (60 mL) was stirred at 70 ° C for 16 h. Cooled to room temperature, the mixture was filtered, and the solvent was evaporated in vacuo. No further purification (2.16 g) was required.
  • Example 41C A mixed solution of Example 41C (1.97 g, 6.61 mmol) of EtOAc (20 mL). After concentrating with concentrated aqueous ammonia, the mixture was filtered and filtered and washed with EtOAc EtOAc.
  • Example 41D A solution of Example 41D (1.58 g, 6.22 mmol) in tetrahydrofuran (20 mL) was added dropwise to a solution of NaH (0.746 g, 18.66 mmol) in THF (10 mL). After stirring at 0 ° C for 0.5 h, EtOAc (EtOAc m. The combined organic layer was dried with sodium sulfate, filtered and evaporated. LCMS (ESI) m/z: 384, 386 (M, M+2).
  • Example 41E (0.43 g, 1.12 mmol), palladium acetate (50 mg, 0.233 mmol), Pd (dppf) Cl 2 (164 mg, 0.233 mmol), Xantphos (194 mg, 0.335 mmol), DPPP ( 138 mg, 0.335 mmol, triphenylphosphine (88 mg, 0.335 mmol) and triethylamine (566 mg, 5.59 mmol) in a solution of DMF (10 mL) and methanol (10 ml) at 80 ° C in carbon monoxide atmosphere ( Stir under 24 atmospheres for 24 hours. After cooling to room temperature, the mixture was filtered, EtOAcjjjjjjjj LCMS (ESI) m/z: 364 (M+1).
  • Example 41F A mixture of Example 41F (0.265 g, 729 mmol) and m. After the solution was removed in vacuo, EtOAc m. LCMS (ESI) m/z: 442, 444 (M, M+2).
  • Example 41G A mixture of Example 41G (240 mg, 0.542 mmol) and sodium hydroxide (108 mg, 2.71 mmol) in methanol (6 mL) and water ( 1.5 mL) was stirred at 60 ° C for 0.5 hour. After cooling to room temperature, the pH of the mixture was adjusted to 4 with 1N aqueous hydrochloric acid, and the aqueous phase was extracted with ethyl acetate (20 ml ⁇ 3). The combined organic layers were washed w ⁇
  • Example 41H (0.196 g, 0.46 mmol), HATU (0.226 mg, 0.595 mmol), ammonium carbonate (0.439 g, 4.6 mmol) and triethylamine (0.138 g, 1.37 mmol) DMF.
  • Example 41I 50 mg, 0.117 mmol, Pd(dppf)Cl 2 (17 mg, 0.023 mmol), sodium carbonate (31 mg, 0.292 mmol) and (4-fluorophenyl)boronic acid under nitrogen. (24 mg, 0.175 mmol) of a mixture of DMF (3 mL) and water (0.5 mL) was stirred at 100 ° C for 16 h. After the solution was removed in vacuo, EtOAc EtOAc m. The title compound (40 mg, yield: 77%). LCMS (ESI) m/z: 443 (M+1).
  • Example 42A A mixture of Example 42A (1.47 g, 6.77 mmol), Boc 2 O (1.77 g, 8.12 mmol) and triethylamine (1.37 g, 13.54 mmol) in dichloromethane (15 mL) hour. After the solution was removed in vacuo, EtOAcqqqqqq LCMS (ESI) m/z: 319 (M+1).
  • Example 41I 100 mg, 0.23 mmol
  • Example 42C (85.7 mg, 0.23 mmol), sodium carbonate (50 mg, 0.47 mmol) and Pd (dppf) Cl 2 (17.1 mg, 0.023).
  • a mixture of mmol of DMF (5 mL) and water (1 mL) was stirred at 80 ° C for 15 hours. After cooling to room temperature, the mixture was filtered, EtOAcjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj The title compound (110 mg, yield: 97%).
  • This example was prepared as described in Example 42C.
  • Example 41B To a solution of Example 41B (3.2 g, 9.812 mol) in tetrahydrofuran (50 mL) was added NaH (785 mg, 19.625 mmol). After stirring at 15 ° C for 0.5 hour, the temperature was lowered to 0 ° C, and SEMCl (3.3 g, 19.625 mmol) was added dropwise. The mixture was stirred at 15 ° C for 16 h then EtOAc (EtOAc m. Drying and evaporation, EtOAc EtOAc m. LCMS (ESI) m/z: 456, 458 (M, M+2).
  • Example 49A A mixed solvent of Example 49A (2.16 g, 4.726 mmol) and sodium hydroxide (950 mg, 23.632 mmol) in methanol/water (2:1) (30 mL) was stirred at 80 ° C for 16 hours. The mixture was adjusted to pH 3-4 with EtOAc (EtOAc)EtOAc. g, yield: 85.22%) was used in the next step without further purification.
  • EtOAc EtOAc
  • Example 49C 400 mg, 0.671 mmol), zinc (87 mg, 1.341 mmol), zinc cyanide (158 mg, 1.341 mmol), DPPF (75 mg, 0.134 mmol) and Pd 2 under nitrogen.
  • a mixture of (DBA) 3 (61 mg, 0.0671 mmol) in DMF (10 mL) was stirred at 120 ° C for 10 hr. After cooling to room temperature, the mixture was diluted w ⁇ The title compound (350 mg, yield: 96.15%) was obtained.
  • Example 49D 400 mg, 0.737 mmol
  • potassium carbonate 510 mg, 3.685 mmol
  • DMSO DMSO
  • EtOAc EtOAc
  • Example 49E A mixture of Example 49E (100 mg, 0.178 mmol) eluted elute After the solution was removed in vacuo, EtOAc (EtOAc m. One step without further purification.
  • Example 1D (5.0 g, 17.6 mmol), EtOAc (EtOAc m. After the solution was removed in vacuo, EtOAc m.
  • Example 50B A mixture of Example 50B (3.6 g, 9.18 mmol) and sodium hydroxide (2.2 g, 55.1 mmol) in methanol (20mL) and water (2mL) was stirred at 20 ° C for one hour. After the solution was removed in vacuo, EtOAc EtOAc (EtOAc m. The title compound was used directly in the next step without further purification (3.2 g, 97.0%).
  • Example 50C (3.2 g, 8.82 mmol), O,N-dimethylhydroxylamine (1.7 g, 17.6 mmol), HATU (4.0 g, 10.6 mmol) and triethylamine (3.6 g, A mixture of 35.3 mmol of anhydrous DMF (2 mL) was stirred at 20 ° C for 16 h. After the solution was removed in vacuo, EtOAc m.
  • Example 50D To a mixture of Example 50D (3.2 g, 7.90 mmol) in anhydrous tetrahydrofurane (5 mL) was added dropwise n-butyllithium (2.8 mL, 7.11 mmol), and stirred at -78 ° C. After 0.5 h, the mixture was evaporated w ⁇ The title compound (1.5 g, yield: 71.4%).
  • Example 50E (1.3 g, 4.89 mmol), Pd(dppf)Cl 2 (0.71 g, 0.98 mmol), palladium acetic acid (0.22 g, 0.98 mmol), DPPP (0.81 g, 1.96 mmol), triphenyl a mixture of phosphine (0.51 g, 1.96 mmol), Xantphos (1.13 g, 1.96 mmol) and triethylamine (3 ml) in methanol (20 ml) and DMF (60 mL) at 80 ° C under carbon monoxide atmosphere (3 atmospheres) ) Stir for 16 hours. After cooling to 20 ° C, the mixture was evaporated. LCMS (ESI) m/z: 247 (M+1).
  • Example 50F (0.9 g, 3.66 mmol), 2-ethanedithiol (0.69 g, 7.32 mmol) and boron trifluoride diethyl ether (1.0 g, 7.32 mmol). 30 mL) The mixture was stirred at 50 ° C for 24 hours. After cooling to room temperature, it was diluted with m ⁇ The title compound (0.5 g, yield: 42.4%). LCMS (ESI) m/z: 323 (M+1).
  • Example 50G 500 mg, 1.55 mmol
  • N.sub.2 276 mg, 1.55 mmol
  • THF 20 mL
  • Example 50IA (200 mg, 0.499 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3 , 6-Dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (185 mg, 0.598 mmol), Pd(DPPF)Cl2 (37 mg, 0.050 mmol) and potassium carbonate (138 mg, 0.997 mmol)
  • DMF 9 ml
  • water 3 mL
  • Example 50J (220 mg, 0.51 mmol), ammonium carbonate (97 mg, 1.01 mmol), triethylamine (0.2 mL, 1.53 mmol) and EtOAc (252 mg, 0.66 mmol) DMF (8 mL) The mixture was stirred at 20 ° C for 16 hours. Concentration in vacuo, EtOAc EtOAc m. LCMS (ESI) m/z: 435 (M+1).
  • Example 50M (30 mg, 0.069 mmol), cyclopropane (10 mg, 0.138 mmol), tetraisopropoxytitanium (39 mg, 0.138 mmol) and sodium cyanoborohydride A mixture of 13 mg, 0.207 mmol of methanol (8 mL) was stirred at 60 ° C for 16 h. The reaction was quenched with EtOAc (EtOAc (EtOAc). : 18.5%).
  • Example 51A 50 mg, 0.121 mmol
  • 10% ⁇ RTI ID 0.0> ⁇ /RTI> ⁇ /RTI> ⁇ RTIgt; The mixture was filtered, EtOAc mjjjjjjjjjj
  • This example was prepared as described in Example 50M.
  • Example 51C A mixture of Example 51C (25 mg, 0.079 mmol), 40% EtOAc (EtOAc) (EtOAc) . The resulting mixture was diluted with H.sub.2 (EtOAc (EtOAc) (EtOAc). %), as a white solid.
  • Example 1I A mixture of Example 1I (30 mg, 0.075 mmol), EtOAc (EtOAc (EtOAc) The reaction was quenched with EtOAc (EtOAc)EtOAc. Further purification.
  • This example was prepared in the manner described in Examples 1A-1B.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Disclosed is a series of analogues of 4H-pyrazolo[1,5-α]benzimidazole compound as PARP inhibitors. In particular, disclosed in the invention is a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.

Description

作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物Analogue of 4H-pyrazolo[1,5-α]benzimidazole compound as a PARP inhibitor 技术领域Technical field
本发明涉及一系列作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物。具体地，本发明涉及作为PARP抑制剂的式(I)所示化合物或其药学上可接受的盐。The present invention relates to a series of analogs of 4H-pyrazolo[1,5-alpha]benzimidazole compounds as PARP inhibitors. Specifically, the present invention relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof as a PARP inhibitor.
背景技术Background technique
PARP是一个酶家族，其催化加成ADP-核糖残基到各种靶蛋白上。到目前为止，已鉴定和表征了多达18个亚型。尽管该家族中酶的数量众多，PARP-1负责了细胞内90％以上的ADP-核糖基化。PARP is a family of enzymes that catalyze the addition of ADP-ribose residues to various target proteins. Up to now, up to 18 subtypes have been identified and characterized. Despite the large number of enzymes in this family, PARP-1 is responsible for more than 90% of ADP-ribosylation in cells.
PARP-1一直与DNA修复和基因组功能维护相关联。DNA损伤后，PARP-1通过结合到DNA断裂处被瞬间激活。结构发生变化后，它开始利用NAD+合成聚(ADP)核糖作为其他修复酶(如DNA连接酶III、DNA聚合酶β)的信号。PARP-1的结合和激活(称为碱基切除修复)这一过程有助于扩增修复过程，其目标是单链DNA断裂(SSB)。SSB是通常由氧化损伤所启动，该氧化性损伤由细胞本身的代谢过程，以及外源化学治疗剂和辐射所引起。众所周知地，许多类型的抗癌疗法例如DNA烷化剂、铂类药物、拓扑异构酶抑制剂和放射治疗都会伴随着DNA损伤。耐药性的出现给这些疗法带来了阴影，特别是在PARP-1主导的DNA修复路径中。最近的研究证实，选择性PARP-1抑制剂大大提高了TMZ和顺铂的抗肿瘤功效。PARP-1 has been associated with DNA repair and maintenance of genomic functions. After DNA damage, PARP-1 is transiently activated by binding to DNA breaks. After the structure changes, it begins to use NAD+ synthetic poly(ADP) ribose as a signal for other repair enzymes (such as DNA ligase III, DNA polymerase β). The process of binding and activation of PARP-1 (called base excision repair) facilitates the amplification of the repair process with the goal of single-stranded DNA breaks (SSB). SSB is usually initiated by oxidative damage caused by the metabolic processes of the cell itself, as well as by exogenous chemotherapeutic agents and radiation. It is well known that many types of anticancer therapies such as DNA alkylating agents, platinum drugs, topoisomerase inhibitors, and radiation therapy are associated with DNA damage. The emergence of drug resistance has cast a shadow on these therapies, especially in the PARP-1-dominated DNA repair pathway. Recent studies have demonstrated that selective PARP-1 inhibitors greatly enhance the anti-tumor efficacy of TMZ and cisplatin.
BRCA1和BRCA2在同源重组中发挥重要作用(HR)。DNA复制过程中所产生的DNA断裂只能通过HR来修复。在2005年，Bryant和Farmer(Nature,2005,913and 917)独立地发现缺乏BACA1和BACA2的细胞株对PARP-1抑制剂非常敏感，这导致了细胞死亡。乳腺癌基因BRCA1/2早已被定性为抑癌基因，其在DNA双链断裂的修复中起到了不可或缺的作用。卵巢癌和前列腺癌中BRCA1/2的突变载体也处于高风险。因此，对于已缺乏某些类型的DNA修复机制的肿瘤类型而言，PARP-1抑制剂也可作为一个独立的疗法。BRCA1 and BRCA2 play important roles in homologous recombination (HR). DNA breaks generated during DNA replication can only be repaired by HR. In 2005, Bryant and Farmer (Nature, 2005, 913 and 917) independently found that cell lines lacking BACA1 and BACA2 were very sensitive to PARP-1 inhibitors, which led to cell death. The breast cancer gene BRCA1/2 has long been characterized as a tumor suppressor gene, which plays an indispensable role in the repair of DNA double-strand breaks. Mutation vectors for BRCA1/2 in ovarian and prostate cancers are also at high risk. Therefore, PARP-1 inhibitors can also be used as an independent therapy for tumor types that are already deficient in certain types of DNA repair mechanisms.
作为抗肿瘤的靶点，PARP-1已被积极探索了30年，Ferraris完整总结了这一领域的进展(J.Med.Chem.2010,4561)。一系列的化合物正处于临床研究中，无论是作为单剂还是增效剂，比如veliparib(ABT-888)，niraparib(MK-4827)，BMN-673，CEP-977，BGP-15，E-7016MP-124和IND-1022。最近，一些专利公开了可以有效治疗多种癌症的某些杂环化合物，比如WO2014009872(A1)，WO2014019468(A1)，WO2014023390(A2)，WO2013182580，WO2013164061(A1)，EP2656843(A1)。As an anti-tumor target, PARP-1 has been actively explored for 30 years, and Ferraris has fully summarized the progress in this field (J. Med. Chem. 2010, 4561). A range of compounds are in clinical research, either as a single dose or as a potentiator, such as veliparib (ABT-888), niraparib (MK-4827), BMN-673, CEP-977, BGP-15, E-7016MP -124 and IND-1022. Recently, some patents disclose certain heterocyclic compounds which are effective in the treatment of various cancers, such as WO2014009872 (A1), WO2014019468 (A1), WO2014023390 (A2), WO2013182580, WO2013164061 (A1), EP2656843 (A1).
此外，PARP-1抑制一直是被积极探索的药物靶标，治疗领域围绕中风、心肌缺血、炎症和糖尿病(Pharmacol.Rev.2002,54,375.)。In addition, PARP-1 inhibition has been a drug target that has been actively explored, with treatments surrounding stroke, myocardial ischemia, inflammation, and diabetes (Pharmacol. Rev. 2002, 54, 375.).
虽然开发PARP-1抑制剂用于治疗癌症和其他疾病的努力一直持续，但令人满意的治疗一直没有实现，因此需要开发新的PARP-1抑制剂。Although efforts to develop PARP-1 inhibitors for the treatment of cancer and other diseases have continued, satisfactory treatment has not been achieved, and new PARP-1 inhibitors need to be developed.
发明内容Summary of the invention
本发明的目的在于提供式(I)所示化合物或其药学上可接受的盐， It is an object of the present invention to provide a compound of the formula (I) or a pharmaceutically acceptable salt thereof,
Figure PCTCN2015075363-appb-000001
Figure PCTCN2015075363-appb-000001
其中，among them,
D选自-C(Rd1)(Rd2)-、-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、-C(＝O)O-、-C(＝O)-、-C(＝S)-、-S(＝O)-或-S(＝O)2-；D is selected from -C(R d1 )(R d2 )-, -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(=O 2 N(R d6 )-, -S(=O)N(R d7 )-, -O-, -S-, -C(=O)O-, -C(=O)-, -C( =S)-, -S(=O)- or -S(=O) 2 -;
R1-3、Rd1、Rd2分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2，或选自任选被R01取代的C1-10烷基或杂烷基、C3-10环烃基或杂环烃基、被C3-10环烃基或杂环烃基取代的C1-10烷基或杂烷基；R 1-3 , R d1 , R d2 are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 or a C 1-10 alkyl group optionally substituted by R 01 Or a heteroalkyl group, a C 3-10 cycloalkyl or heterocycloalkyl group, a C 1-10 alkyl or heteroalkyl group substituted by a C 3-10 cycloalkyl or heterocycloalkyl;
R01选自F、Cl、Br、I、CN、OH、SH、NH2、R02；R 01 is selected from the group consisting of F, Cl, Br, I, CN, OH, SH, NH 2 , R 02 ;
R02选自C1-10烷基、C1-10烷氨基、N,N-二(C1-10烷基)氨基、C1-10烷氧基、C1-10烷酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷氨基、C3-10杂环烷氨基、C3-10环烷氧基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 02 is selected from C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1 -10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 cycloalkoxy, C 3-10 cycloalkyl acyl, C 3-10 cycloalkoxycarbonyl, C 3-10 cycloalkylsulfonyl, C 3-10 cycloalkylsulfinyl;
杂原子或杂原子团分别独立地选自-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、-C(＝O)O-、-C(＝O)-、-C(＝S)-、-S(＝O)-和/或-S(＝O)2-；The heteroatoms or heteroatoms are independently selected from -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(=O) 2 N(R D6 )-, -S(=O)N(R d7 )-, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)- and/or -S(=O) 2 -;
Rd3-d7分别独立地选自H、R03；R d3 - d7 are each independently selected from H, R 03 ;
R03选自C1-10烷基、C1-10烷基酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 03 is selected from C 1-10 alkyl, C 1-10 alkyl acyl, C 1-10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 a cycloalkyl group, a C 3-10 cycloalkyl acyl group, a C 3-10 cycloalkoxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
R02、R03任选地被R001取代；R 02 and R 03 are optionally substituted by R 001 ;
R001选自F、Cl、Br、I、CN、OH、N(CH3)2、NH(CH3)、NH2、三氟甲基、氨甲基、羟甲基、甲基、甲氧基、甲酰基、甲氧羰基、甲磺酰基、甲基亚磺酰基；R 001 is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH 3 ) 2 , NH(CH 3 ), NH 2 , trifluoromethyl, aminomethyl, hydroxymethyl, methyl, methoxy Base, formyl group, methoxycarbonyl group, methylsulfonyl group, methylsulfinyl group;
R01、R001、杂原子或杂原子团的数目分别独立地选自0、1、2或3。The number of R 01 , R 001 , heteroatoms or heteroatoms is independently selected from 0, 1, 2 or 3.
本发明的一个方案中，所述D选自-NH-、-N(CH3)-、-C(F)2-、-C(H)(F)-、-C(H)(OH)-。In one aspect of the invention, the D is selected from the group consisting of -NH-, -N(CH 3 )-, -C(F) 2 -, -C(H)(F)-, -C(H)(OH) -.
本发明的一个方案中，所述R1-3分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2、C1-6烷基、C1-6烷氧基、苄氧基、-CH2N(R21)(R22)、
Figure PCTCN2015075363-appb-000002
其中，In one embodiment of the invention, the R 1-3 are independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-6 alkyl, C 1-6 alkoxy Base, benzyloxy, -CH 2 N(R 21 )(R 22 ),
Figure PCTCN2015075363-appb-000002
among them,
L、D21分别独立地选自-C(Rd1)(Rd2)-、-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、-C(＝O)-、-C(＝O)O-、-C(＝S)-、-S(＝O)-或-S(＝O)2-；L and D 21 are each independently selected from -C(R d1 )(R d2 )-, -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )- , -S(=O) 2 N(R d6 )-, -S(=O)N(R d7 )-, -O-, -S-, -C(=O)-, -C(=O) O-, -C(=S)-, -S(=O)- or -S(=O) 2 -;
L还可以是仅起连接作用的单键；L can also be a single bond that only serves as a connection;
T21-22分别独立地选自C(Rt)、N；T 21-22 are independently selected from C(R t ), N;
X选自任选被R01取代的(CH2)n,n选自0、1、2或3，优选0、1、或2；X is selected from (CH2) n optionally substituted by R 01 , and n is selected from 0, 1, 2 or 3, preferably 0, 1, or 2;
Y选自任选被R01取代的(CH2)m，m选自0、1、2或3，优选1、2、或3； Y is selected from (CH2) m optionally substituted by R 01 , and m is selected from 0, 1, 2 or 3, preferably 1, 2, or 3;
R21-23、Rd3-d7分别独立地选自H、R03；R 21-23 , R d3 - d7 are each independently selected from H, R 03 ;
R24-27、Rd1、Rd2、Rt分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2，或选自任选被R01取代的C1-10烷基或杂烷基、C3-10环烃基或杂环烃基、被C3-10环烃基或杂环烃基取代的C1-10烷基或杂烷基；R 24-27 , R d1 , R d2 , R t are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 or C 1- optionally substituted by R 01 a 10 alkyl or heteroalkyl group, a C 3-10 cycloalkyl or heterocycloalkyl group, a C 1-10 alkyl or heteroalkyl group substituted by a C 3-10 cycloalkyl or heterocycloalkyl;
R01选自F、Cl、Br、I、CN、OH、SH、NH2、R02；R 01 is selected from the group consisting of F, Cl, Br, I, CN, OH, SH, NH 2 , R 02 ;
R02选自C1-10烷基、C1-10烷氨基、N,N-二(C1-10烷基)氨基、C1-10烷氧基、C1-10烷酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷氨基、C3-10杂环烷氨基、C3-10环烷氧基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 02 is selected from C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1 -10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 cycloalkoxy, C 3-10 cycloalkyl acyl, C 3-10 cycloalkoxycarbonyl, C 3-10 cycloalkylsulfonyl, C 3-10 cycloalkylsulfinyl;
杂原子或杂原子团分别独立地选自-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、C(＝O)O、-C(＝O)-、-C(＝S)-、-S(＝O)-和/或-S(＝O)2-；The heteroatoms or heteroatoms are independently selected from -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(=O) 2 N(R D6 )-, -S(=O)N(R d7 )-, -O-, -S-, C(=O)O, -C(=O)-, -C(=S)-, -S (=O)- and / or -S(=O) 2 -;
Rd3-d7分别独立地选自H、R03；R d3 - d7 are each independently selected from H, R 03 ;
R03选自C1-10烷基、C1-10烷基酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 03 is selected from C 1-10 alkyl, C 1-10 alkyl acyl, C 1-10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 a cycloalkyl group, a C 3-10 cycloalkyl acyl group, a C 3-10 cycloalkoxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
R02、R03任选地被R001取代；R 02 and R 03 are optionally substituted by R 001 ;
R001选自F、Cl、Br、I、CN、OH、N(CH3)2、NH(CH3)、NH2、三氟甲基、氨甲基、羟甲基、甲基、甲氧基、甲酰基、甲氧羰基、甲磺酰基、甲基亚磺酰基；R 001 is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH 3 ) 2 , NH(CH 3 ), NH 2 , trifluoromethyl, aminomethyl, hydroxymethyl, methyl, methoxy Base, formyl group, methoxycarbonyl group, methylsulfonyl group, methylsulfinyl group;
R01、R001、杂原子或杂原子团的数目分别独立地选自0、1、2或3。The number of R 01 , R 001 , heteroatoms or heteroatoms is independently selected from 0, 1, 2 or 3.
本发明的一个方案中，所述R1、R3分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2、C1-3烷基、C1-3烷氧基、苄氧基或
Figure PCTCN2015075363-appb-000003
R101选自H、甲基、乙基、正丙基或异丙基。In one embodiment of the invention, the R 1 and R 3 are each independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-3 alkyl, C 1-3 alkane. Oxyl, benzyloxy or
Figure PCTCN2015075363-appb-000003
R 101 is selected from H, methyl, ethyl, n-propyl or isopropyl.
本发明的一个方案中，所述R1选自H、甲基、甲氧基、苄氧基、
Figure PCTCN2015075363-appb-000004
In one embodiment of the invention, the R 1 is selected from the group consisting of H, methyl, methoxy, benzyloxy,
Figure PCTCN2015075363-appb-000004
本发明的一个方案中，R3选自H、F、Cl、Br、CN、甲基。In one embodiment of the invention, R 3 is selected from the group consisting of H, F, Cl, Br, CN, methyl.
本发明的一个方案中，所述R2选自-CH2N(R201)(R202)，R201、R202分别独立地选自H、C1-3烷基、C1-3烷基酰基、C3-6环烷基酰基或C3-6环烷基；In one embodiment of the invention, the R 2 is selected from -CH 2 N(R 201 )(R 202 ), and R 201 and R 202 are each independently selected from H, C 1-3 alkyl, C 1-3 alkane. a acyl group, a C 3-6 cycloalkyl acyl group or a C 3-6 cycloalkyl group;
本发明的一个方案中，所述R201、R202分别独立地选自H或环丙酰基。In one embodiment of the invention, the R 201 and R 202 are each independently selected from H or a cyclopropionyl group.
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000005
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000005
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000006
Figure PCTCN2015075363-appb-000007
R203、R204、R217、R218分别独立地选自H、任选被取代的C1-3烷基、环丙基或环丙基亚甲基，取代基选自F、Cl、Br、I、CN、OH、NH2、甲基或甲氧基，取代基的数目为0、1、2或3。 In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000006
Figure PCTCN2015075363-appb-000007
R 203 , R 204 , R 217 , R 218 are each independently selected from H, optionally substituted C 1-3 alkyl, cyclopropyl or cyclopropyl methylene, and the substituent is selected from the group consisting of F, Cl, Br. , I, CN, OH, NH 2 , methyl or methoxy, the number of substituents is 0, 1, 2 or 3.
本发明的一个方案中，所述R203选自甲基、乙基、正丙基、异丙基、-CH2C(CH3)(CH3)(OH)、环丙基亚甲基。In one embodiment of the invention, the R 203 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, -CH 2 C(CH 3 )(CH 3 )(OH), cyclopropylmethylene.
本发明的一个方案中，所述R204选自甲基、乙基、正丙基、异丙基。In one embodiment of the invention, the R 204 is selected from the group consisting of methyl, ethyl, n-propyl, and isopropyl.
本发明的一个方案中，所述R217-219分别独立选自乙基、甲基。In one embodiment of the invention, the R 217-219 are each independently selected from the group consisting of an ethyl group and a methyl group.
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000008
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000008
Figure PCTCN2015075363-appb-000009
Figure PCTCN2015075363-appb-000009
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000010
R205、R206分别独立地选自H、任选被取代的C1-3烷基、环丙基或环丙基亚甲基，取代基选自F、Cl、Br、I、CN、OH、NH2、甲基或甲氧基，取代基的数目为0、1、2或3。In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000010
R 205 and R 206 are each independently selected from H, optionally substituted C 1-3 alkyl, cyclopropyl or cyclopropyl methylene, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl or methoxy, the number of substituents is 0, 1, 2 or 3.
本发明的一个方案中，所述R205、R206分别独立地优选H、甲基、乙基、正丙基、异丙基，R206还可优选F、Cl、Br、I、CN、OH、NH2。In one embodiment of the present invention, the R 205 and R 206 are each independently preferably H, methyl, ethyl, n-propyl or isopropyl, and R 206 may also preferably be F, Cl, Br, I, CN, OH. , NH 2 .
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000011
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000011
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000012
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000012
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000013
R207选自H、任选被取代的C1-3烷基、环丙基、环丙基亚甲基、环丁基、环丁基亚甲基、氧杂环丁基或氧杂环丁基亚甲基，取代基选自F、Cl、Br、I、CN、OH、NH2、甲基、三氟甲基、甲氧基、甲磺酰基，取代基的数目为0、1、2或3。In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000013
R 207 is selected from H, optionally substituted C 1-3 alkyl, cyclopropyl, cyclopropylmethylene, cyclobutyl, cyclobutyl methylene, oxetanyl or oxetane a methylidene group, the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, trifluoromethyl, methoxy, methylsulfonyl, and the number of substituents is 0, 1, 2 Or 3.
本发明的一个方案中，所述R207选自H、甲基、乙基、正丙基、异丙基、-CH2CF3、-CH2CH2CF3、-CH2CH2F、-CH2CH2S(＝O)2CH3、-CH2CH2CN、
Figure PCTCN2015075363-appb-000014
In one embodiment of the invention, the R 207 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, -CH 2 CF 3 , -CH 2 CH 2 CF 3 , -CH 2 CH 2 F, -CH 2 CH 2 S(=O) 2 CH 3 , -CH 2 CH 2 CN,
Figure PCTCN2015075363-appb-000014
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000015
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000015
Figure PCTCN2015075363-appb-000016
Figure PCTCN2015075363-appb-000016
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000017
或
Figure PCTCN2015075363-appb-000018
R208选自H、任选被取代的C1-4烷基,取代基选自F、Cl、Br、I、CN、OH、NH2、甲基、三氟甲基、甲氧基、甲磺酰基，取代基的数目为0、1、2或3。In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000017
or
Figure PCTCN2015075363-appb-000018
R 208 is selected from H, optionally substituted C 1-4 alkyl, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, trifluoromethyl, methoxy, A Sulfonyl, the number of substituents is 0, 1, 2 or 3.
本发明的一个方案中，所述R208选自H、甲基、乙基、正丙基、异丙基、环丙基亚甲基、环丁基。In one embodiment of the invention, the R 208 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethylene, cyclobutyl.
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000019
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000019
Figure PCTCN2015075363-appb-000020
Figure PCTCN2015075363-appb-000020
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000021
R209选自-C(Rd1)(Rd2)-、-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、C(＝O)O、-C(＝O)-、-C(＝S)-、-S(＝O)-或-S(＝O)2-,Rd1-d7如权利要求1所定义；In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000021
R 209 is selected from -C(R d1 )(R d2 )-, -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(= O) 2 N(R d6 )-, -S(=O)N(R d7 )-, -O-, -S-, C(=O)O, -C(=O)-, -C(= S)-, -S(=O)- or -S(=O) 2 -, R d1-d7 are as defined in claim 1;
本发明的一个方案中，所述R209选自O、S(＝O)2。In one embodiment of the invention, the R 209 is selected from the group consisting of O, S(=O) 2 .
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000022
R210选自H、F、Cl、Br、I、CN、OH、NH2、N,N-二(C1-3烷基)氨基、C1-3烷基氨基。In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000022
R 210 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , N,N-di(C 1-3 alkyl)amino, C 1-3 alkylamino.
本发明的一个方案中，所述R210选自二甲基氨基、甲氨基、H、F、Cl、Br、I、CN、OH、NH2。In one embodiment of the invention, the R 210 is selected from the group consisting of dimethylamino, methylamino, H, F, Cl, Br, I, CN, OH, NH 2 .
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000023
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000023
R211-214选自H或任选被R215取代的C1-4烷氧羰基、C1-4烷基、3-6元环烷基、3-6元环烷基亚甲基或5-6元不饱和杂环烃基，R211-213还选自F、Cl、Br、I、CN、OH、NH2， R 211-214 is selected from H or C 1-4 alkoxycarbonyl, C 1-4 alkyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkylmethylene or 5 optionally substituted by R 215 a -6 member unsaturated heterocyclic hydrocarbon group, R 211-213 is also selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 ,
所述环烷基或不饱和杂环烃基上含有0、1或2个O、S或NR216，The cycloalkyl or unsaturated heterocyclic hydrocarbon group contains 0, 1 or 2 O, S or NR 216 ,
R216选自任选H、R215取代的C1-4烷基，R 216 is selected from C 1-4 alkyl optionally substituted by H, R 215 ,
R215选自F、Cl、Br、I、CN、OH、NH2、甲基、乙基、甲氧基、乙氧基、甲酰基、乙酰基、甲磺酰基、乙磺酰基、甲氧羰基、乙氧羰基、二甲基氨基、二乙基氨基、二甲基氨基羰基、二乙基氨基羰基、氧代，R215的数目为1、1、2或3，R 215 is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, ethyl, methoxy, ethoxy, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl , ethoxycarbonyl, dimethylamino, diethylamino, dimethylaminocarbonyl, diethylaminocarbonyl, oxo, the number of R 215 is 1, 1, 2 or 3,
任选地，R212与R213共同形成连接键-CH2-、-CH2CH2-或-CH2CH2CH2-；Optionally, R 212 and R 213 together form a linkage -CH 2 -, -CH 2 CH 2 - or -CH 2 CH 2 CH 2 -;
本发明的一个方案中，所述In an aspect of the invention, the
R211选自H、F、Cl、Br、I、CN、OH、NH2、甲基、乙基、羟甲基、甲氧羰基，R 211 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , methyl, ethyl, hydroxymethyl, methoxycarbonyl,
R212选自H、F、Cl、Br、I、CN、OH、NH2、甲基，R 212 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , methyl,
R213选自H、F、Cl、Br、I、CN、OH、NH2，R 213 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 ,
R214选自H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、-CH2C(OH)(CH3)2、-CH2C(F)(CH3)2、-CH2CH2F、-CH2CF3、-CH2CH2CF3、-CH2CH2NH2、-CH2CH2OH、-CH2CH2CN、-CH2CH2OCH3、-CH2CH2CH2OCH3、-CH2CH2N(CH3)2、-S(＝O)2CH3、-CH2CH2S(＝O)2CH3、
Figure PCTCN2015075363-appb-000024
环丙基、环丙基亚甲基、
Figure PCTCN2015075363-appb-000025
R 214 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -CH 2 C(OH)(CH 3 ) 2 , -CH 2 C ( F) (CH 3 ) 2 , -CH 2 CH 2 F, -CH 2 CF 3 , -CH 2 CH 2 CF 3 , -CH 2 CH 2 NH 2 , -CH 2 CH 2 OH, -CH 2 CH 2 CN , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 CH 2 OCH 3 , -CH 2 CH 2 N(CH 3 ) 2 , -S(=O) 2 CH 3 , -CH 2 CH 2 S(=O ) 2 CH 3 ,
Figure PCTCN2015075363-appb-000024
Cyclopropyl, cyclopropylmethylene,
Figure PCTCN2015075363-appb-000025
Figure PCTCN2015075363-appb-000026
Figure PCTCN2015075363-appb-000026
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000027
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000027
Figure PCTCN2015075363-appb-000028
Figure PCTCN2015075363-appb-000028
Figure PCTCN2015075363-appb-000029
Figure PCTCN2015075363-appb-000029
Figure PCTCN2015075363-appb-000030
Figure PCTCN2015075363-appb-000030
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000031
T22选自N或C(R224)；R220-224分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2、C1-3烷氨基C1-3烷基、
Figure PCTCN2015075363-appb-000032
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000031
T 22 is selected from N or C (R 224 ); R 220-224 are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-3 alkylamino C 1-3 alkyl,
Figure PCTCN2015075363-appb-000032
本发明的一个方案中，所述C1-3烷氨基C1-3烷基选自甲氨基亚甲基。In one embodiment of the invention, the C 1-3 alkylamino C 1-3 alkyl group is selected from the group consisting of methylaminomethylene.
本发明的一个方案中，所述R2选自
Figure PCTCN2015075363-appb-000033
In one aspect of the invention, the R 2 is selected from
Figure PCTCN2015075363-appb-000033
Figure PCTCN2015075363-appb-000034
Figure PCTCN2015075363-appb-000034
本发明的一个方案中，所述所述化合物或其药学上可接受的盐选自：In one embodiment of the invention, the compound or a pharmaceutically acceptable salt thereof is selected from the group consisting of
1)6-氟代-3-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；1) 6-fluoro-3-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
2)3-(1-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；2) 3-(1-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
3)6-氟-3-(1-(2-氟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；3) 6-Fluoro-3-(1-(2-fluoroethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
4)3-(1-环丙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；4) 3-(1-Cyclopropylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
5)3-(1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；5) 3-(1-(Cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
6)6-氟-3-(1-(2-羟基-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；6) 6-Fluoro-3-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridinium Azole-8-carboxamide;
7)6-氟-3-(1-(2-氟-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；7) 6-Fluoro-3-(1-(2-fluoro-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridinium Azole-8-carboxamide;
8)3-(1-(环丙基甲酰基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；8) 3-(1-(Cyclopropylformyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Amide
9)6-氟-3-(1-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；9) 6-fluoro-3-(1-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
10)6-氟-3-(1-异丙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；10) 6-fluoro-3-(1-isopropylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
11)6-氟-3-(1-(氧杂环丁烷-3-基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；11) 6-Fluoro-3-(1-(oxetan-3-yl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-formamide;
12)6-氟-3-(1-丙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；12) 6-fluoro-3-(1-propylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
13)6-氟-3-(1-(2-氨乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；13) 6-Fluoro-3-(1-(2-aminoethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
14)3-(1-(2-(二甲胺基)乙基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；14) 3-(1-(2-(Dimethylamino)ethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
15)6-氟-3-(1-(2-甲氧基乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；15) 6-Fluoro-3-(1-(2-methoxyethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide;
16)6-氟-3-(1-(2-羟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺； 16) 6-Fluoro-3-(1-(2-hydroxyethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
17)3-(1-乙基哌啶-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；17) 3-(1-ethylpiperidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
18)3-(1-乙基氮杂环庚烷-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；18) 3-(1-Ethylazepane-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
19)6-氟-3-(1-甲基氮杂环庚烷-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；19) 6-fluoro-3-(1-methylazepane-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
20)6-氟-3-(1-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；20) 6-fluoro-3-(1-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
21)3-(1-乙基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；21) 3-(1-ethylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
22)6-氟-3-(1-异丙基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；22) 6-fluoro-3-(1-isopropylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
23)6-氟-3-(吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；23) 6-fluoro-3-(pyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
24)6-氟-3-(1-甲基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；24) 6-fluoro-3-(1-methylpyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
25)3-(1-乙基吡咯烷-2-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；25) 3-(1-ethylpyrrolidin-2-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
26)3-(1-乙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；26) 3-(1-ethylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
27)6-氟-3-(1-丙基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；27) 6-fluoro-3-(1-propylpyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
28)6-氟-3-(3-甲基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；28) 6-Fluoro-3-(3-methyl-3-azabicyclo[3.1.0]hexane-1-yl)-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
29)3-(3-乙基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；29) 3-(3-Ethyl-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
30)3-(3-环丁基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；30) 3-(3-Cyclobutyl-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
31)3-(3-环丙亚甲基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；31) 3-(3-Cyclopropione-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide;
32)6-氟-3-(3-异丙基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；32) 6-Fluoro-3-(3-isopropyl-3-azabicyclo[3.1.0]hexane-1-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
33)3-(3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；33) 3-(3-Azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
34)3-(3-乙基-3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；34) 3-(3-Ethyl-3-azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
35)3-(8-乙基-8-氮杂双环[3.2.1]辛-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；35) 3-(8-Ethyl-8-azabicyclo[3.2.1]oct-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
36)6-氟-3-(4-羟基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；36) 6-fluoro-3-(4-hydroxypyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
37)3-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；37) 3-cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
38)3-氰基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；38) 3-cyano-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
39)3-氨甲基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；39) 3-aminomethyl-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
40)3-(环丙甲酰胺亚甲基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；40) 3-(cyclopropanecartamethylene)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
41)6-氟-3-(4-氟苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；41) 6-fluoro-3-(4-fluorophenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
42)6-氟-3-(2-氟-4-((甲胺亚甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；42) 6-Fluoro-3-(2-fluoro-4-((methylaminomethylene)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
43)6-氟-3-(4-((甲基氨基)甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；43) 6-fluoro-3-(4-((methylamino)methyl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
44)6-氟-3-(2-氟-5-((甲基氨基)甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；44) 6-Fluoro-3-(2-fluoro-5-((methylamino)methyl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide;
45)6-氟-3-(吡啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；45) 6-fluoro-3-(pyridin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
46)6-氟-3-(4-(哌啶-3-基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；46) 6-fluoro-3-(4-(piperidin-3-yl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
47)6-氟-3-(四氢-2H-吡喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；47) 6-fluoro-3-(tetrahydro-2H-pyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
48)3-(4-(二甲基氨基)环己基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；48) 3-(4-(Dimethylamino)cyclohexyl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
49)6-氟-3-(4-甲基哌嗪-1-羰基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；49) 6-fluoro-3-(4-methylpiperazine-1-carbonyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
50)3-(1-(环丙基甲基)哌啶-4-基)-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-8-甲酰胺；50) 3-(1-(Cyclopropylmethyl)piperidin-4-yl)-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indole-8-carboxamide ;
51)3-(1-乙基哌啶-4-基)-6-氟-4-羟基-4H-吡唑并[1,5-a]吲哚-8-甲酰胺； 51) 3-(1-ethylpiperidin-4-yl)-6-fluoro-4-hydroxy-4H-pyrazolo[1,5-a]indole-8-carboxamide;
52)3-(1-乙基哌啶-4-基)-6-氟-4-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；52) 3-(1-Ethylpiperidin-4-yl)-6-fluoro-4-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
53)6-氟-3-(4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；53) 6-fluoro-3-(4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
54)3-(1-乙基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；54) 3-(1-Ethyl-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
55)3-(1-环丙基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；55) 3-(1-Cyclopropyl-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
56)6-氟-3-(1-(2-羟基-2-甲基丙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；56) 6-Fluoro-3-(1-(2-hydroxy-2-methylpropyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
57)3-(1-环丙基亚甲基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；57) 3-(1-Cyclopropylmethylene-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-formamide;
58)3-(1-(4,4-二氟环己基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；58) 3-(1-(4,4-Difluorocyclohexyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2- b] pyrazole-8-carboxamide;
59)6-氟-3-(4-甲基-1-(四氢-2H-吡喃-4-基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；59) 6-Fluoro-3-(4-methyl-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
60)6-氟-3-(1-(2-氟乙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；60) 6-Fluoro-3-(1-(2-fluoroethyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
61)6-氟-3-(4-甲基-1-(2,2,2-三氟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；61) 6-Fluoro-3-(4-methyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
62)6-氟-3-(4-甲基-1-(2,2,2-三氟丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；62) 6-Fluoro-3-(4-methyl-1-(2,2,2-trifluoropropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
63)3-(1-((1-氰基环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；63) 3-(1-((1-Cyanocyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
64)3-(1-((1-氰基环丁基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；64) 3-(1-((1-Cyanocyclobutyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
65)6-氟-3-(4-甲基-1-(2-(甲基磺酰基)乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；65) 6-Fluoro-3-(4-methyl-1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
66)6-氟-3-(4-甲基-1-((四氢-2H-吡喃-4-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；66) 6-Fluoro-3-(4-methyl-1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
67)3-(1-((1-氨基环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；67) 3-(1-((1-Aminocyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
68)6-氟-3-(4-甲基-1-(氧杂环丁烷-3-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；68) 6-Fluoro-3-(4-methyl-1-(oxetan-3-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
69)6-氟-3-(1-(2-甲氧基乙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；69) 6-Fluoro-3-(1-(2-methoxyethyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
70)6-氟-3-(1-((1-羟基环丙基)甲基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；70) 6-Fluoro-3-(1-((1-hydroxycyclopropyl)methyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
71)6-氟-3-(4-甲基-1-((3-甲基氧杂环丁烷-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；71) 6-Fluoro-3-(4-methyl-1-((3-methyloxetan-3-yl)methyl)piperidin-4-yl)-4H-benzo[4, 5] imidazo[1,2-b]pyrazole-8-carboxamide;
72)6-氟-3-(1-(3-甲氧基丙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；72) 6-Fluoro-3-(1-(3-methoxypropyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
73)6-氟-3-(4-甲基-1-((1-(甲基磺酰基)环丙基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；73) 6-Fluoro-3-(4-methyl-1-((1-(methylsulfonyl)cyclopropyl)methyl)piperidin-4-yl)-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
74)6-氟-3-(4-甲基-1-(噻唑-2-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；74) 6-Fluoro-3-(4-methyl-1-(thiazol-2-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
75)6-氟-3-(4-甲基-1-(甲磺酰基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；75) 6-Fluoro-3-(4-methyl-1-(methylsulfonyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide;
76)6-氟-3-(1-(3-氟环丁基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；76) 6-Fluoro-3-(1-(3-fluorocyclobutyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
77)6-氟-3-(4-甲基-1-(噻吩-2-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；77) 6-Fluoro-3-(4-methyl-1-(thiophen-2-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
78)3-(1-((1-乙基哌啶-4-基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；78) 3-(1-((1-ethylpiperidin-4-yl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazole And [1,2-b]pyrazole-8-carboxamide;
79)6-氟-3-(4-甲基-1-((1-甲基氮杂环丁烷-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；79) 6-Fluoro-3-(4-methyl-1-((1-methylazetidin-3-yl)methyl)piperidin-4-yl)-4H-benzo[4, 5] imidazo[1,2-b]pyrazole-8-carboxamide;
80)2-((4-(8-氨基甲酰基-6-氟-4H苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-基)甲基)环丙烷羧酸乙酯；80) 2-((4-(8-carbamoyl-6-fluoro-4Hbenzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine Ethyl-1-methyl)methyl)cyclopropanecarboxylate;
81)3-(1-((2-(二甲基氨基甲基)环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b] 吡唑-8-甲酰胺；81) 3-(1-((2-(Dimethylaminomethyl)cyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4, 5]Imidazo[1,2-b] Pyrazole-8-carboxamide;
82)6-氟-3-(1-异丁基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺82) 6-Fluoro-3-(1-isobutyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
83)6-氟-3-(4-甲基-1-((4-甲基噻唑-5-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；83) 6-Fluoro-3-(4-methyl-1-((4-methylthiazol-5-yl)methyl)piperidin-4-yl)-4H-benzo[4,5]imidazolium [1,2-b]pyrazole-8-carboxamide;
84)6-氟-3-(4-甲基-1-((1-甲基-1H-咪唑-2-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；84) 6-Fluoro-3-(4-methyl-1-((1-methyl-1H-imidazol-2-yl)methyl)piperidin-4-yl)-4H-benzo[4,5 Imidazo[1,2-b]pyrazole-8-carboxamide;
85)3-(1-((1,2-二甲基-1H-咪唑-5-基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；85) 3-(1-((1,2-Dimethyl-1H-imidazol-5-yl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[ 4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
86)3-(1'-乙基-4-甲基-[1,4'-联哌啶]-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；86) 3-(1'-Ethyl-4-methyl-[1,4'-bipiperidino]-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
87)6-氟-3-(4-甲基-1-((6-氧代-1,6-二氢哒嗪-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；87) 6-Fluoro-3-(4-methyl-1-((6-oxo-1,6-dihydropyridazin-3-yl)methyl)piperidin-4-yl)-4H-benzene And [4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
88)3-(1-(2-氰基乙基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；88) 3-(1-(2-Cyanoethyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
89)6-氯-3-(1-乙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；89) 6-Chloro-3-(1-ethyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
90)3-(1-乙基-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；90) 3-(1-Ethyl-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
91)3-(1,3-二甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；91) 3-(1,3-Dimethylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
92)6-氟-3-(1-异丙基-3-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；92) 6-Fluoro-3-(1-isopropyl-3-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
93)3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；93) 3-(1-(Cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
94)6-氟-3-(3-甲基-1-(氧杂环丁烷-3-基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；94) 6-Fluoro-3-(3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide;
95)6-氟-3-(1-(2-氟乙基)-3-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；95) 6-Fluoro-3-(1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
96)3-(1-((2,2-二氟环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；96) 3-(1-((2,2-Difluorocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo [1,2-b]pyrazole-8-carboxamide;
97)6-氟-3-(3-甲基-1-(2,2,2-三氟乙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；97) 6-Fluoro-3-(3-methyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
98)6-氟-3-(3-甲基-1-(2-(甲基磺酰基)乙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；98) 6-Fluoro-3-(3-methyl-1-(2-(methylsulfonyl)ethyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
99)6-氟-3-(3-甲基-1-(3,3,3-三氟丙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；99) 6-fluoro-3-(3-methyl-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
100)3-(1-((1-氨基环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；100) 3-(1-((1-Aminocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
101)3-(1-((1-氰基环丁基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；101) 3-(1-((1-Cyanocyclobutyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
102)3-(1-((1-氰基环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；102) 3-(1-((1-Cyanocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
103)3-(1-(2-氰基异基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；103) 3-(1-(2-Cyanoisoyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
104)3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；104) 3-(1-(Cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
105)6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；105) 6-Fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
106)6-氟-3-(4-甲基-1,1-二氧-2H-噻喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；106) 6-Fluoro-3-(4-methyl-1,1-dioxo-2H-thiopyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrr Azole-8-carboxamide;
107)3-(1,4-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；107) 3-(1,4-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
108)3-(4-氰基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；108) 3-(4-Cyano-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
109)3-(4-羟甲基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；109) 3-(4-Hydroxymethyl-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
110)4-(8-甲酰氨-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-1-(环丙基甲基)哌啶-4-羧酸乙酯； 110) 4-(8-Formylamino-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-1-(cyclopropylmethyl) Ethyl piperidine-4-carboxylate;
111)3-(1-(环丙基甲基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；111) 3-(1-(Cyclopropylmethyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
112)3-(1-乙基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；112) 3-(1-Ethyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
113)3-(1-异丁基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；113) 3-(1-Isobutyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
114)3-(1-异丙基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；114) 3-(1-Isopropyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
115)3-(1,4-二甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；115) 3-(1,4-Dimethylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide;
116)3-(1-(2-羟基-2-甲基丙基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；116) 3-(1-(2-Hydroxy-2-methylpropyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
117)3-(1-乙基-2,4-二甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；117) 3-(1-Ethyl-2,4-dimethylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2- b] pyrazole-8-carboxamide;
118)3-(1-乙基-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；118) 3-(1-Ethyl-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
119)3-(1-异丙基-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；119) 3-(1-Isopropyl-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
120)3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；120) 3-(1-(Cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
121)3-(1,3-二甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；121) 3-(1,3-Dimethylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide;
122)3-(1-乙基-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；122) 3-(1-Ethyl-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
123)3-(1-异丙基-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；123) 3-(1-Isopropyl-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
124)3-(1-(环丙基甲基)-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；124) 3-(1-(Cyclopropylmethyl)-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
125)3-(1-(2-羟基-2-甲基丙基)-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；125) 3-(1-(2-Hydroxy-2-methylpropyl)-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
126)6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；126) 6-Fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-2-methoxy-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
127)2-苄甲氧基-6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；127) 2-Benzyloxy-6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b] pyrazole-8-carboxamide;
128)6-氟-2-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；和128) 6-fluoro-2-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
129)2-(1-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺。129) 2-(1-Ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide.
有关定义：Related definitions:
C1-10选自C1、C2、C3、C4、C5、C6、C7、C8、C9和C10；C3-10选自C3、C4、C5、C6、C7、C8、C9和C10。C 1-10 is selected from C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 ; C 3-10 is selected from C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 .
C1-10烷基或杂烷基、C3-10环基或杂环烃基、被C3-10环烃基或杂环烃基取代的C1-10烷基或杂烷基包括但不限于：C 1-10 alkyl or heteroalkyl, C 3-10 cyclo or heterocycloalkyl, C 1-10 alkyl or heteroalkyl substituted by C 3-10 cycloalkyl or heterocycloalkyl includes, but is not limited to:
C1-10烷基、C1-10烷氨基、N,N-二(C1-10烷基)氨基、C1-10烷氧基、C1-10烷酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷氨基、C3-10杂环烷氨基、C3-10环烷氧基、C3-10环烷基酰基、C3-10环烷基氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1-10 alkoxy Carbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 a cycloalkoxy group, a C 3-10 cycloalkyl group, a C 3-10 cycloalkyloxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
甲基、乙基、正丙基、异丙基、-CH2C(CH3)(CH3)(OH)、环丙基、环丁基、丙基亚甲基、环丙酰基、苄氧基、三氟甲基、氨甲基、羟甲基、甲氧基、甲酰基、甲氧羰基、甲磺酰基、甲基亚磺酰基、乙氧基、乙酰基、乙磺酰基、乙氧羰基、二甲基氨基、二乙基氨基、二甲基氨基羰基、二乙基氨基羰基；Methyl, ethyl, n-propyl, isopropyl, -CH2C(CH3)(CH3)(OH), cyclopropyl, cyclobutyl, propylmethylene, cyclopropionyl, benzyloxy, trifluoro Methyl, aminomethyl, hydroxymethyl, methoxy, formyl, methoxycarbonyl, methylsulfonyl, methylsulfinyl, ethoxy, acetyl, ethylsulfonyl, ethoxycarbonyl, dimethyl Amino group, diethylamino group, dimethylaminocarbonyl group, diethylaminocarbonyl group;
N(CH3)2、NH(CH3)、-CH2CF3、-CH2CH2CF3、-CH2CH2F、-CH2CH2S(＝O)2CH3、-CH2CH2CN、
Figure PCTCN2015075363-appb-000035
Figure PCTCN2015075363-appb-000036
-CH2CH(OH)(CH3)2、-CH2CH(F)(CH3)2、-CH2CH2F、-CH2CF3、-CH2CH2CF3、-CH2CH2NH2、-CH2CH2OH、-CH2CH2OCH3、-CH2CH2CH2OCH3、-CH2CH2N(CH3)2、-S(＝O)2CH3、-CH2CH2S(＝O)2CH3,
Figure PCTCN2015075363-appb-000037
 N (CH 3) 2, NH (CH 3), - CH 2 CF 3, -CH2CH 2 CF 3, -CH 2 CH 2 F, -CH 2 CH 2 S (= O) 2 CH 3, -CH 2 CH 2 CN,
Figure PCTCN2015075363-appb-000035
Figure PCTCN2015075363-appb-000036
-CH 2 CH(OH)(CH3) 2 , -CH 2 CH(F)(CH 3 ) 2 , -CH 2 CH 2 F, -CH 2 CF 3 , -CH 2 CH 2 CF 3 , -CH 2 CH 2 NH 2 , -CH 2 CH 2 OH, -CH 2 CH 2 OCH 3 , -CH 2 CH 2 CH 2 OCH 3 , -CH 2 CH 2 N(CH 3 ) 2 , -S(=O) 2 CH 3 , -CH 2 CH 2 S(=O) 2 CH 3 ,
Figure PCTCN2015075363-appb-000037
Figure PCTCN2015075363-appb-000038
Figure PCTCN2015075363-appb-000038
Figure PCTCN2015075363-appb-000039
Figure PCTCN2015075363-appb-000039
Figure PCTCN2015075363-appb-000040
Figure PCTCN2015075363-appb-000040
苯基、噻唑基、联苯基、萘基、环戊基、呋喃基、3-吡咯啉基、吡咯烷基、1,3-氧五环基、吡唑基、2-吡唑啉基、吡唑烷基、咪唑基、恶唑基、噻唑基、1,2,3-唑基、1,2,3-三唑基、1,2,4-三唑基、1,3,4-噻二唑基、4H-吡喃基、吡啶基、哌啶基、1,4-二氧六环基、吗啉基、哒嗪基、嘧啶基、吡嗪基、哌嗪基、1,3,5-三噻烷基、1,3,5-三嗪基、苯并呋喃基、苯并噻吩基、吲哚基、苯并咪唑基、苯并噻唑基、嘌呤基、喹啉基、异喹啉基、噌啉基或喹喔啉基；Phenyl, thiazolyl, biphenyl, naphthyl, cyclopentyl, furyl, 3-pyrrolyl, pyrrolidinyl, 1,3-oxapentacyclyl, pyrazolyl, 2-pyrazolyl, Pyrazolidinyl, imidazolyl, oxazolyl, thiazolyl, 1,2,3-oxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4- Thiadiazolyl, 4H-pyranyl, pyridyl, piperidinyl, 1,4-dioxolyl, morpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 1,3 , 5-trithiazide, 1,3,5-triazinyl, benzofuranyl, benzothienyl, fluorenyl, benzimidazolyl, benzothiazolyl, fluorenyl, quinolinyl, iso a quinolyl group, a porphyrin group or a quinoxaline group;
这里所采用的术语“药学上可接受的”，是针对那些化合物、材料、组合物和/或剂型而言，它们在可靠的医学判断的范围之内，适用于与人类和动物的组织接触使用，而没有过多的毒性、刺激性、过敏性反应或其它问题或并发症，与合理的利益/风险比相称。The term "pharmaceutically acceptable" as used herein is intended to mean that those compounds, materials, compositions and/or dosage forms are within the scope of sound medical judgment and are suitable for use in contact with human and animal tissues. Without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.
术语“药学上可接受的盐”是指本发明化合物的盐，由本发明发现的具有特定取代基的化合物与相对无毒的酸或碱制备。当本发明的化合物中含有相对酸性的功能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式获得碱加成盐。药学上可接受的碱加成盐包括钠、钾、钙、铵、有机氨或镁盐或类似的盐。当本发明的化合物中含有相对碱性的官能团时，可以通过在纯的溶液或合适的惰性溶剂中用足够量的酸与这类化合物的中性形式接触的方式获得酸加成盐。药学上可接受的酸加成盐的实例包括无机酸盐，所述无机酸包括例如盐酸、氢溴酸、硝酸、碳酸，碳酸氢根，磷酸、磷酸一氢根、磷酸二氢根、硫酸、硫酸氢根、氢碘酸、亚磷酸等；以及有机酸盐，所述有机酸包括如乙酸、丙酸、异丁酸、马来酸、丙二酸、苯甲酸、琥珀酸、辛二酸、反丁烯二酸、乳酸、扁桃酸、邻苯二甲酸、苯磺酸、对甲苯磺酸、柠檬酸、酒石酸和甲磺酸等类似的酸；还包括氨基酸(如精氨酸等)的盐，以及如葡 糖醛酸等有机酸的盐(参见Berge et al.,"Pharmaceutical Salts",Journal of Pharmaceutical Science 66:1-19(1977))。本发明的某些特定的化合物含有碱性和酸性的官能团，从而可以被转换成任一碱或酸加成盐。The term "pharmaceutically acceptable salt" refers to a salt of a compound of the invention prepared from a compound having a particular substituent found in the present invention and a relatively non-toxic acid or base. When a relatively acidic functional group is contained in the compound of the present invention, a base addition salt can be obtained by contacting a neutral amount of such a compound with a sufficient amount of a base in a neat solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts. When a relatively basic functional group is contained in the compound of the present invention, an acid addition salt can be obtained by contacting a neutral form of such a compound with a sufficient amount of an acid in a neat solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, hydrogencarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, Hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and an organic acid salt, such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, Similar acids such as fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; and salts of amino acids (such as arginine, etc.) And as Portugal A salt of an organic acid such as uronic acid (see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the invention contain both basic and acidic functional groups which can be converted to any base or acid addition salt.
优选地，以常规方式使盐与碱或酸接触，再分离母体化合物，由此再生化合物的中性形式。化合物的母体形式与其各种盐的形式的不同之处在于某些物理性质，例如在极性溶剂中的溶解度不同。Preferably, the salt is contacted with a base or acid in a conventional manner, and the parent compound is separated, thereby regenerating the neutral form of the compound. The parent form of the compound differs from the form of its various salts by certain physical properties, such as differences in solubility in polar solvents.
本文所用的“药学上可接受的盐”属于本发明化合物的衍生物，其中，通过与酸成盐或与碱成盐的方式修饰所述母体化合物。药学上可接受的盐的实例包括但不限于：碱基比如胺的无机酸或有机酸盐、酸根比如羧酸的碱金属或有机盐等等。药学上可接受的盐包括常规的无毒性的盐或母体化合物的季铵盐，例如无毒的无机酸或有机酸所形成的盐。常规的无毒性的盐包括但不限于那些衍生自无机酸和有机酸的盐，所述的无机酸或有机酸选自2-乙酰氧基苯甲酸、2-羟基乙磺酸、乙酸、抗坏血酸、苯磺酸、苯甲酸、碳酸氢根、碳酸、柠檬酸、依地酸、乙烷二磺酸、乙烷磺酸、富马酸、葡庚糖、葡糖酸、谷氨酸、乙醇酸、氢溴酸、盐酸、氢碘酸盐、羟基、羟萘、羟乙磺酸、乳酸、乳糖、十二烷基磺酸、马来酸、苹果酸、扁桃酸、甲烷磺酸、硝酸、草酸、双羟萘酸、泛酸、苯乙酸、磷酸、多聚半乳糖醛、丙酸、水杨酸、硬脂酸、亚乙酸、琥珀酸、氨基磺酸、对氨基苯磺酸、硫酸、单宁、酒石酸和对甲苯磺酸。As used herein, a "pharmaceutically acceptable salt" is a derivative of a compound of the invention wherein the parent compound is modified by salt formation with an acid or with a base. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic salts of acid groups such as carboxylic acids, and the like. Pharmaceutically acceptable salts include the conventional non-toxic salts or quaternary ammonium salts of the parent compound, for example salts formed from non-toxic inorganic or organic acids. Conventional non-toxic salts include, but are not limited to, those derived from inorganic acids and organic acids selected from the group consisting of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, Benzenesulfonic acid, benzoic acid, hydrogencarbonate, carbonic acid, citric acid, edetic acid, ethane disulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid, Hydrobromic acid, hydrochloric acid, hydroiodide, hydroxyl, hydroxynaphthalene, isethionethane, lactic acid, lactose, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, nitric acid, oxalic acid, Pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturaldehyde, propionic acid, salicylic acid, stearic acid, acrylic acid, succinic acid, sulfamic acid, p-aminobenzenesulfonic acid, sulfuric acid, tannin, Tartaric acid and p-toluenesulfonic acid.
本发明的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下，这样的盐的制备方法是：在水或有机溶剂或两者的混合物中，经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。一般地，优选醚、乙酸乙酯、乙醇、异丙醇或乙腈等非水介质。The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing an acid group or a base by conventional chemical methods. In general, such salts are prepared by reacting these compounds in water or an organic solvent or a mixture of the two via a free acid or base form with a stoichiometric amount of a suitable base or acid. Generally, a nonaqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile is preferred.
除了盐的形式，本发明所提供的化合物还存在前药形式。本文所描述的化合物的前药容易地在生理条件下发生化学变化从而转化成本发明的化合物。此外，前体药物可以在体内环境中通过化学或生化方法被转换到本发明的化合物。In addition to the form of the salt, the compounds provided herein also exist in the form of prodrugs. Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the invention. Furthermore, prodrugs can be converted to the compounds of the invention by chemical or biochemical methods in an in vivo setting.
本发明的某些化合物可以以非溶剂化形式或者溶剂化形式存在，包括水合物形式。一般而言，溶剂化形式与非溶剂化的形式相当，都包含在本发明的范围之内。本发明的某些化合物可以以多晶或无定形形式存在。Certain compounds of the invention may exist in unsolvated or solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are included within the scope of the invention. Certain compounds of the invention may exist in polycrystalline or amorphous form.
本发明的某些化合物可以具有不对称碳原子(光学中心)或双键。外消旋体、非对映异构体、几何异构体和单个的异构体都包括在本发明的范围之内。Certain compounds of the invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the invention.
本文中消旋体、ambiscalemic and scalemic或者对映体纯的化合物的图示法来自Maehr,J.Chem.Ed.1985,62:114-120。1985年，62：114-120。除非另有说明，用楔形键和虚线键表示一个立体中心的绝对构型。当本文所述化合物含有烯属双键或其它几何不对称中心，除非另有规定，它们包括E、Z几何异构体。同样地，所有的互变异构形式均包括在本发明的范围之内。Graphical representations of racemates, ambiscalemic and scalemic or enantiomerically pure compounds herein are from Maehr, J. Chem. Ed. 1985, 62: 114-120. 1985, 62: 114-120. The absolute configuration of a stereocenter is indicated by a wedge key and a dashed key unless otherwise stated. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, they include the E and Z geometric isomers unless otherwise specified. Likewise, all tautomeric forms are included within the scope of the invention.
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物，包括顺式和反式异构体、(-)-和(+)-对对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体，及其外消旋混合物和其他混合物，例如对映异构体或非对映体富集的混合物，所有这些混合物都属于本发明的范围之内。烷基等取代基中可存在另外的不对称碳原子。所有这些异构体以及它们的混合物，均包括在本发明的范围之内。The compounds of the invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including the cis and trans isomers, the (-)- and (+)-p-enantiomers, the (R)- and (S)-enantiomers, and the diastereomeric a conformation, a (D)-isomer, a (L)-isomer, and a racemic mixture thereof, and other mixtures, such as enantiomerically or diastereomeric enriched mixtures, all of which belong to It is within the scope of the invention. Additional asymmetric carbon atoms may be present in the substituents such as alkyl groups. All such isomers, as well as mixtures thereof, are included within the scope of the invention.
可以通过的手性合成或手性试剂或者其他常规技术制备光学活性的(R)-和(S)-异构体以及D和L异构体。如果想得到本发明某化合物的一种对映体，可以通过不对称合成或者具有手性助剂的衍生作用来制备， 其中将所得非对映体混合物分离，并且辅助基团裂开以提供纯的所需对映异构体。或者，当分子中含有碱性官能团(如氨基)或酸性官能团(如羧基)时，与适当的光学活性的酸或碱形成非对映异构体的盐，然后通过本领域所公知的分步结晶法或色谱法进行非对映异构体拆分，然后回收得到纯的对映体。此外，对映异构体和非对映异构体的分离通常是通过使用色谱法完成的，所述色谱法采用手性固定相，并任选地与化学衍生法相结合(例如由胺生成氨基甲酸盐)。The optically active (R)- and (S)-isomers as well as the D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary. Wherein the resulting mixture of diastereomers is separated and the auxiliary group cleaved to provide the pure desired enantiomer. Alternatively, when a molecule contains a basic functional group (e.g., an amino group) or an acidic functional group (e.g., a carboxyl group), a salt of a diastereomer is formed with a suitable optically active acid or base, followed by stepping as is known in the art. The diastereomeric resolution is carried out by crystallization or chromatography, and then the pure enantiomer is recovered. Furthermore, the separation of enantiomers and diastereomers is generally accomplished by the use of chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (eg, formation of an amino group from an amine). Formate).
本发明的化合物可以在一个或多个构成该化合物的原子上包含非天然比例的原子同位素。例如，可用放射性同位素标记化合物，比如氚(3H)，碘-125(125I)或C-14(14C)。本发明的化合物的所有同位素组成的变换，无论放射性与否，都包括在本发明的范围之内。The compounds of the present invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, radiolabeled compounds can be used, such as tritium (3 H), iodine -125 (125 I) or C-14 (14 C). Alterations of all isotopic compositions of the compounds of the invention, whether radioactive or not, are included within the scope of the invention.
术语“药学上可接受的载体”是指能够递送本发明有效量活性物质、不干扰活性物质的生物活性并且对宿主或者患者无毒副作用的任何制剂或载体介质代表性的载体包括水、油、蔬菜和矿物质、膏基、洗剂基质、软膏基质等。这些基质包括悬浮剂、增粘剂、透皮促进剂等。它们的制剂为化妆品领域或局部药物领域的技术人员所周知。关于载体的其他信息，可以参考Remington:The Science and Practice of Pharmacy,21st Ed.,Lippincott,Williams&Wilkins(2005)，该文献的内容通过引用的方式并入本文。The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium that is capable of delivering an effective amount of an active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects to the host or patient, including water, oil, Vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, tackifiers, transdermal enhancers and the like. Their formulations are well known to those skilled in the cosmetic or topical pharmaceutical arts. For additional information on vectors, reference is made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are hereby incorporated by reference.
术语“赋形剂”通常是指配制有效的药物组合物所需要载体、稀释剂和/或介质。The term "excipient" generally refers to the carrier, diluent and/or vehicle required to formulate an effective pharmaceutical composition.
针对药物或药理学活性剂而言，术语“有效量”或“治疗有效量”是指无毒的但能达到预期效果的药物或药剂的足够用量。对于本发明中的口服剂型，组合物中一种活性物质的“有效量”是指与该组合物中另一种活性物质联用时为了达到预期效果所需要的用量。有效量的确定因人而异，取决于受体的年龄和一般情况，也取决于具体的活性物质，个案中合适的有效量可以由本领域技术人员根据常规试验确定。The term "effective amount" or "therapeutically effective amount" with respect to a pharmaceutical or pharmacologically active agent refers to a sufficient amount of a drug or agent that is non-toxic but that achieves the desired effect. For oral dosage forms in the present invention, an "effective amount" of an active substance in a composition refers to the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount will vary from person to person, depending on the age and general condition of the recipient, and also on the particular active substance, and a suitable effective amount in a case can be determined by one skilled in the art based on routine experimentation.
术语“活性成分”、“治疗剂”，“活性物质”或“活性剂”是指一种化学实体，它可以有效地治疗目标紊乱、疾病或病症。The term "active ingredient", "therapeutic agent", "active substance" or "active agent" refers to a chemical entity that is effective in treating a target disorder, disease or condition.
术语“被取代的”是指特定原子上的任意一个或多个氢原子被取代基取代，包括重氢和氢的变体，只要特定原子的价态是正常的并且取代后的化合物是稳定的。当取代基为酮基(即＝O)时，意味着两个氢原子被取代。酮取代不会发生在芳香基上。术语“任选被取代的”是指可以被取代，也可以不被取代，除非另有规定，取代基的种类和数目在化学上可以实现的基础上可以是任意的。The term "substituted" means that any one or more hydrogen atoms on a particular atom are replaced by a substituent, including variants of heavy hydrogen and hydrogen, as long as the valence of the particular atom is normal and the substituted compound is stable. . When the substituent is a keto group (ie, =0), it means that two hydrogen atoms are substituted. Ketone substitution does not occur on the aryl group. The term "optionally substituted" means that it may or may not be substituted, and unless otherwise specified, the kind and number of substituents may be arbitrary on the basis of chemically achievable.
当任何变量(例如R)在化合物的组成或结构中出现一次以上时，其在每一种情况下的定义都是独立的。因此，例如，如果一个基团被0-2个R所取代，则所述基团可以任选地至多被两个R所取代，并且每种情况下的R都有独立的选项。此外，取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。When any variable (eg, R) occurs more than once in the composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2 R, the group may optionally be substituted with at most two R, and each case has an independent option. Furthermore, combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
当一个取代基的键可以交叉连接到一个环上的两个原子时，这种取代基可以与这个环上的任意原子相键合。当所列举的取代基中没有指明其通过哪一个原子连接到化学结构通式中包括但未具体提及的化合物时，这种取代基可以通过其任何原子相键合。取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。When a bond of a substituent can be cross-linked to two atoms on a ring, the substituent can be bonded to any atom on the ring. When the recited substituents do not indicate which atom is attached to a compound included in the chemical structural formula including but not specifically mentioned, such a substituent may be bonded through any atomic phase thereof. Combinations of substituents and/or variants thereof are permissible only if such combinations result in stable compounds.
烷基和杂烷基原子团(包括通常被称为亚烷基、链烯基、亚杂烷基、杂烯基、炔基、环烷基、杂环烷基、环烯基和杂环烯基的那些基团)的取代基一般被称为“烷基取代基”，它们可以选自但不限于下列基团中的一个或多个：-R’、-OR’、＝O、＝NR’、＝N-OR’、-NR’R”、-SR’、卤素、-SiR’R”R”’、OC(O)R’、-C(O)R’、 -CO2R’、-CONR’R”、-OC(O)NR’R”、-NR”C(O)R’、NR’C(O)NR”R”’、-NR”C(O)2R’、-NR””’-C(NR’R”R’”)＝NR””、NR””C(NR’R”)＝NR’”、-S(O)R’、-S(O)2R’、-S(O)2NR’R”、NR”SO2R’、-CN、–NO2、-N3、-CH(Ph)2和氟代(C1-C4)烷基,取代基的数目为0～(2m’+1),其中m’是这类原子团中碳原子的总数。R'、R”、R”'、R””和R””’各自独立地优选氢、被取代或未被取代的杂烷基、被取代或未被取代的芳基(例如被1～3个卤素取代芳基)、被取代或未被取代的烷基、烷氧基、硫代烷氧基基团或芳烷基。当本发明的化合物包括一个以上的R基团时，例如，每一个R基团是独立地加以选择的，如同当存在一个以上的R'、R”、R”'、R””和R””’基团时的每个这些基团。当R'和R”附着于同一个氮原子时，它们可与该氮原子结合形成5-，6-或7-元环。例如，-NR'R“意在包括但不仅限于1-吡咯烷基和4-吗啉基。根据上述关于取代基的讨论中，本领域技术人员可以理解，术语“烷基”意在包括碳原子键合于非氢基团所构成的基团，如卤代烷基(例如-CF3、-CH2CF3)和酰基(例如-C(O)CH3、-C(O)CF3、-C(O)CH2OCH3等)。Alkyl and heteroalkyl radicals (including what are commonly referred to as alkylene, alkenyl, heteroalkyl, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl and heterocycloalkenyl) Substituents for those groups are generally referred to as "alkyl substituents" which may be selected from, but are not limited to, one or more of the following groups: -R', -OR', =O, =NR' , =N-OR', -NR'R", -SR', halogen, -SiR'R"R"', OC(O)R', -C(O)R', -CO 2 R', - CONR'R", -OC(O)NR'R", -NR"C(O)R', NR'C(O)NR"R"', -NR"C(O) 2 R', -NR "-C(NR'R"R'")=NR"", NR""C(NR'R")=NR'", -S(O)R', -S(O) 2 R' , -S(O) 2 NR'R", NR"SO 2 R', -CN, -NO 2 , -N 3 , -CH(Ph) 2 and fluoro(C 1 -C 4 )alkyl, substituted The number of radicals is 0 to (2m'+1), where m' is the total number of carbon atoms in such radicals. R', R", R"', R"" and R""' are each independently preferably hydrogen, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted aryl group (for example, an aryl group substituted by 1 to 3 halogens), a substituted or unsubstituted alkyl group, an alkoxy group, or a thioalkyl group oxygen a group or an aralkyl group. When a compound of the invention includes more than one R group, for example, each R group is independently selected, as when more than one R', R", R"' Each of these groups, R"" and R""' groups. When R' and R" are attached to the same nitrogen atom, they can form a 5-, 6- or 7-member with the nitrogen atom. ring. For example, -NR'R" is intended to include, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. In light of the above discussion of substituents, those skilled in the art will appreciate that the term "alkyl" is intended to include carbon. A group bonded to a non-hydrogen group such as a haloalkyl group (e.g., -CF 3 , -CH 2 CF 3 ) and an acyl group (e.g., -C(O)CH 3 , -C(O)CF 3 ,- C(O)CH 2 OCH 3 , etc.).
与烷基原子团所述取代基相似，芳基和杂芳基取代基一般统称为“芳基取代基”，选自例如-R’、-OR’、-NR’R”、-SR’、-卤素,-SiR’R”R”’、OC(O)R’、-C(O)R’、-CO2R’、-CONR’R”、-OC(O)NR’R”、-NR”C(O)R’、NR’C(O)NR”R”’、-NR”C(O)2R’、-NR””’-C(NR’R”R’”)＝NR””、NR””C(NR’R”)＝NR’”、-S(O)R’、-S(O)2R’、-S(O)2NR’R”、NR”SO2R’、-CN、–NO2、-N3、-CH(Ph)2、氟(C1-C4)烷氧基和氟(C1-C4)烷基等，取代基的数量为0到芳香环上开放化合价的总数之间；其中R’、R”、R”’、R””和R””’独立地优选自氢、被取代或未被取代的烷基、被取代或未被取代的杂烷基、被取代或未被取代的芳基和被取代或未被取代的杂芳基。当本发明的化合物包括一个以上的R基团时，例如，每个R基团是独立地加以选择的，如同当存在一个以上R’、R”、R”’、R””和R””’基团时的每个这些基团。Similar to the substituents of the alkyl group, the aryl and heteroaryl substituents are generally collectively referred to as "aryl substituents" and are selected, for example, from -R', -OR', -NR'R", -SR', - Halogen, -SiR'R"R"', OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR'R", -NR"C (O) R', NR'C(O)NR"R"', -NR"C(O)2R', -NR""'-C(NR'R"R'")=NR"", NR ""C(NR'R")=NR'", -S(O)R', -S(O) 2 R', -S(O) 2 NR'R", NR"SO 2 R',- CN, -NO 2 , -N 3 , -CH(Ph) 2 , fluorine (C 1 -C 4 ) alkoxy, and fluorine (C 1 -C 4 ) alkyl, etc., the number of substituents is 0 to an aromatic ring Between the total number of open valencies; wherein R', R", R"', R"" and R""' are independently preferred from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted a heteroalkyl group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group. When the compound of the present invention includes more than one R group, for example, each R group is independently added. Each of these groups is selected as when more than one R', R", R"', R"" and R"" group are present.
芳基或杂芳基环的相邻原子上的两个取代基可以任选地被通式为–T-C(O)-(CRR’)q-U-的取代基所取代，其中T和U独立地选自-NR-、-O-、CRR'-或单键，q是0到3的整数。作为替代选择，芳基或杂芳基环的相邻原子上的两个取代基可以任选地被通式为–A(CH2)r B-的取代基所取代，其中A和B独立的选自–CRR’-、-O-、-NR-、-S-、-S(O)-、S(O)2-、-S(O)2NR’-或单键，r是1～4的整数。任选地，由此形成的新环上的一个单键可以替换为双键。作为替代选择，芳基或杂芳基环的相邻原子上的两个取代基可以任选地被通式为–A(CH2)r B-的取代基所取代，其中s和d分别独立的选自0～3的整数，X是–O-、-NR’、-S-、-S(O)-、-S(O)2-或–S(O)2NR’-。取代基R、R’、R”和R”’分别独立地优选自氢和被取代或未被取代的(C1-C6)烷基。Two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a substituent of the formula -TC(O)-(CRR')qU-, wherein T and U are independently selected From -NR-, -O-, CRR'- or a single bond, q is an integer from 0 to 3. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a substituent of the formula -A(CH2)r B-, wherein A and B are independently selected From -CRR'-, -O-, -NR-, -S-, -S(O)-, S(O) 2 -, -S(O) 2 NR'- or a single bond, r is 1 to 4 The integer. Optionally, a single bond on the new ring thus formed can be replaced with a double bond. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally substituted with a substituent of the formula -A(CH2)r B-, wherein s and d are each independently An integer selected from 0 to 3, X is -O-, -NR', -S-, -S(O)-, -S(O) 2 - or -S(O) 2 NR'-. The substituents R, R', R" and R"' are each independently preferably selected from hydrogen and substituted or unsubstituted (C 1 -C 6 )alkyl.
除非另有规定，术语“烃基”或者其下位概念(比如烷基、烯基、炔基、苯基等等)本身或者作为另一取代基的一部分表示直链的、支链的或环状的烃原子团或其组合，可以是完全饱和的、单元或多元不饱和的，可以是单取代、二取代或多取代的，可以包括二价或多价原子团，具有指定数量的碳原子(如C1-C10表示1至10个碳)。“烃基”包括但不限于脂肪烃基和芳香烃基，所述脂肪烃基包括链状和环状，具体包括但不限于烷基、烯基、炔基，所述芳香烃基包括但不限于6-12元的芳香烃基，例如苯、萘等。在一些实施例中，术语“烷基”表示直链的或支链的原子团或它们的组合，可以是完全饱和的、单元或多元不饱和的，可以包括二价和多价原子团。饱和烃原子团的实例包括但不限于甲基、乙基、正丙基、异丙基、正丁基、叔丁基、异丁基、仲丁基、异丁基、环己基、(环己基)甲基、环丙基甲基，以及正戊基、正己基、正庚基、正辛基等原子团的同系物或异构体。不饱和烷基具有一个或多个双键或三键，其实例包括但不限于乙 烯基、2-丙烯基、丁烯基、巴豆基、2-异戊烯基、2-(丁二烯基)、2，4-戊二烯基、3-(1，4-戊二烯基)、乙炔基、1-和3-丙炔基，3-丁炔基，以及更高级的同系物和异构体。Unless otherwise specified, the term "hydrocarbyl" or its subordinate concept (such as alkyl, alkenyl, alkynyl, phenyl, etc.) by itself or as part of another substituent means straight-chain, branched or cyclic The hydrocarbon radical or a combination thereof may be fully saturated, unitary or polyunsaturated, may be monosubstituted, disubstituted or polysubstituted, and may include divalent or polyvalent radicals having a specified number of carbon atoms (eg, C1 ) -C 10 represents 1 to 10 carbons). "Hydrocarbyl" includes, but is not limited to, aliphatic hydrocarbyl groups including chain and cyclic, including but not limited to alkyl, alkenyl, alkynyl groups including, but not limited to, 6-12 members. An aromatic hydrocarbon group such as benzene, naphthalene or the like. In some embodiments, the term "alkyl" refers to a straight or branched chain of atoms or a combination thereof, which may be fully saturated, unitary or polyunsaturated, and may include divalent and multivalent radicals. Examples of saturated hydrocarbon radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, isobutyl, cyclohexyl, (cyclohexyl). A homolog or isomer of a methyl group, a cyclopropylmethyl group, and an atomic group such as n-pentyl, n-hexyl, n-heptyl, n-octyl. The unsaturated alkyl group has one or more double or triple bonds, and examples thereof include, but are not limited to, a vinyl group, a 2-propenyl group, a butenyl group, a crotyl group, a 2-isopentenyl group, and a 2-(butadienyl group). ), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and Structure.
除非另有规定，术语“杂烃基”或者其下位概念(比如杂烷基、杂烯基、杂炔基、杂芳基等等)本身或者与另一术语联合表示稳定的直链的、支链的或环状的烃原子团或其组合，有一定数目的碳原子和至少一个杂原子组成。在一些实施例中，术语“杂烷基”本身或者与另一术语联合表示稳定的直链的、支链的烃原子团或其组合物，有一定数目的碳原子和至少一个杂原子组成。在一个典型实施例中，杂原子选自B、O、N和S，其中氮和硫原子任选地被氧化，氮杂原子任选地被季铵化。杂原子B、O、N和S可以位于杂烃基的任何内部位置(除该烃基基附着于分子其余部分的位置之外)。实例包括但不限于-CH2-CH2-O-CH3、-CH2-CH2-NH-CH3、-CH2-CH2-N(CH3)-CH3、-CH2-S-CH2-CH3、-CH2-CH2、-S(O)-CH3、-CH2-CH2-S(O)2-CH3、-CH＝CH-O-CH3、-CH2-CH＝N-OCH3和–CH＝CH-N(CH3)-CH3。至多两个杂原子可以是连续的，例如-CH2-NH-OCH3。Unless otherwise specified, the term "heterohydrocarbyl" or its subordinate concept (such as heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, etc.), by itself or in combination with another term, means a stable straight chain, branched chain. Or a cyclic hydrocarbon radical or a combination thereof having a number of carbon atoms and at least one heteroatom. In some embodiments, the term "heteroalkyl" by itself or in conjunction with another term refers to a stable straight chain, branched hydrocarbon radical or combination thereof, having a number of carbon atoms and at least one heteroatom. In a typical embodiment, the heteroatoms are selected from the group consisting of B, O, N, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatoms are optionally quaternized. The heteroatoms B, O, N and S may be located at any internal position of the heterohydrocarbyl group (except where the hydrocarbyl group is attached to the rest of the molecule). Examples include, but are not limited to, -CH 2 -CH 2 -O-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -CH 2 -N(CH 3 )-CH 3 , -CH 2 -S -CH 2 -CH 3 , -CH 2 -CH 2 , -S(O)-CH 3 , -CH 2 -CH 2 -S(O) 2 -CH 3 , -CH=CH-O-CH 3 ,- CH 2 -CH=N-OCH 3 and -CH=CH-N(CH 3 )-CH 3 . Up to two heteroatoms may be consecutive, for example, -CH 2 -NH-OCH 3.
术语“烷氧基”、“烷氨基”和“烷硫基”(或硫代烷氧基)属于惯用表达，是指分别通过一个氧原子、氨基或硫原子连接到分子的其余部分的那些烷基基团。The terms "alkoxy", "alkylamino" and "alkylthio" (or thioalkoxy) are customary expressions and refer to those alkane which are attached to the remainder of the molecule through an oxygen atom, an amino group or a sulfur atom, respectively. Base group.
除非另有规定，术语“环烃基”、“杂环烃基”、“环烃杂基”或者其下位概念(比如芳基、杂芳基、芳杂基、环烷基、杂环烷基、环烷杂基、环烯基、杂环烯基、环烯杂基、环炔基、杂环炔基、环炔杂基等等)本身或与其他术语联合分别表示环化的“烃基”、“杂烃基”或“烃杂基”。此外，就杂烃基或杂环烃基(比如杂烷基、杂环烷基)而言，杂原子可以占据该杂环附着于分子其余部分的位置。环烷基的实例包括但不限于环戊基、环己基、1-环己烯基、3-环己烯基、环庚基等。杂环基的非限制性实例包括1-(1,2,5,6-四氢吡啶基)、1-哌啶基、2-哌啶基，3-哌啶基、4-吗啉基、3-吗啉基、四氢呋喃-2-基、四氢呋喃吲哚-3-基、四氢噻吩-2-基、四氢噻吩-3-基，1-哌嗪基和2-哌嗪基。Unless otherwise specified, the terms "cycloalkyl", "heterocycloalkyl", "cyclohetero" or subordinates thereof (such as aryl, heteroaryl, aryl, cycloalkyl, heterocycloalkyl, ring) Alkyl, cycloalkenyl, heterocycloalkenyl, cycloalkenyl, cycloalkynyl, heterocycloalkynyl, cycloalkynyl, and the like, by themselves or in combination with other terms, respectively denote a cyclized "hydrocarbyl group", Heterohydrocarbyl" or "hydrocarbyl". Further, in the case of a heterohydrocarbyl group or a heterocycloalkyl group (such as a heteroalkyl group or a heterocycloalkyl group), a hetero atom may occupy a position at which the hetero ring is attached to the rest of the molecule. Examples of cycloalkyl groups include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Non-limiting examples of heterocyclic groups include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl and 2-piperazinyl.
除非另有规定，术语“卤代素”或“卤素”本身或作为另一取代基的一部分表示氟、氯、溴或碘原子。此外，术语“卤代烷基”意在包括单卤代烷基和多卤代烷基。例如，术语“卤代(C1-C4)烷基”意在包括但不仅限于三氟甲基、2，2，2-三氟乙基、4-氯丁基和3-溴丙基等等。Unless otherwise specified, the term "halo" or "halogen", by itself or as part of another substituent, denotes a fluorine, chlorine, bromine or iodine atom. Further, the term "haloalkyl" is intended to include both monohaloalkyl and polyhaloalkyl. For example, the term "halo(C 1 -C 4 )alkyl" is intended to include, but is not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. Wait.
除非另有规定，术语“芳基”表示多不饱和的芳族烃取代基，可以是单取代、二取代或多取代的，它可以是单环或多环(优选1至3个环)，它们稠合在一起或共价连接。术语“杂芳基”是指含有一至四个杂原子的芳基(或环)。在一个示范性实例中，杂原子选自B、N、O和S，其中氮和硫原子任选地被氧化，氮原子任选地被季铵化。杂芳基可通过杂原子连接到分子的其余部分。芳基或杂芳基的非限制性实施例包括苯基、1-萘基、2-萘基、4-联苯基、1-吡咯基、2-吡咯基、3-吡咯基、3-吡唑基、2-咪唑基、4-咪唑基、吡嗪基、2-恶唑基、4-恶唑基、2-苯基-4-恶唑基、5-恶唑基、3-异恶唑基、4-异恶唑基、5-异恶唑基、2-噻唑基、4-噻唑基、5-噻唑基、2-呋喃基、3-呋喃基、2-噻吩基、3-噻吩基、2-吡啶基、3-吡啶基、4-吡啶基、2-嘧啶基、4-嘧啶基、5-苯并噻唑基、嘌呤基、2-苯并咪唑基、5-吲哚基、1-异喹啉基、5-异喹啉基、2-喹喔啉基、5-喹喔啉基、3-喹啉基和6-喹啉基。上述任意一个芳基和杂芳基环系的取代基选自下文所述的可接受的取代基。Unless otherwise specified, the term "aryl" denotes a polyunsaturated, aromatic hydrocarbon substituent which may be monosubstituted, disubstituted or polysubstituted, which may be monocyclic or polycyclic (preferably 1 to 3 rings), They are fused together or covalently linked. The term "heteroaryl" refers to an aryl (or ring) containing one to four heteroatoms. In an illustrative example, the heteroatoms are selected from the group consisting of B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom is optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl or heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyridyl Azyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxan Azyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thiophene , 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, indolyl, 2-benzimidazolyl, 5-indenyl, 1-isoquinolyl, 5-isoquinolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl and 6-quinolinyl. The substituents of any of the above aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
为简便起见，芳基在与其他术语联合使用时(例如芳氧基、芳硫基、芳烷基)包括如上定义的芳基和杂芳基环。因此，术语“芳烷基”意在包括芳基附着于烷基的那些原子团(例如苄基、苯乙基、吡啶基甲基 等)，包括其中碳原子(如亚甲基)已经被例如氧原子代替的那些烷基，例如苯氧基甲基、2-吡啶氧甲基3-(1-萘氧基)丙基等。For simplicity, aryl groups, when used in conjunction with other terms (eg, aryloxy, arylthio, aralkyl), include aryl and heteroaryl rings as defined above. Thus, the term "aralkyl" is intended to include those radicals to which an aryl group is attached to an alkyl group (eg, benzyl, phenethyl, pyridylmethyl) And the like, including those in which a carbon atom such as a methylene group has been replaced by, for example, an oxygen atom, such as a phenoxymethyl group, a 2-pyridyloxymethyl 3-(1-naphthyloxy)propyl group or the like.
“环”表示被取代或未被取代的环烷基、被取代或未被取代的杂环烷基、被取代或未被取代的芳基或被取代或未被取代的杂芳基。所谓的环包括稠环。环上原子的数目通常被定义为环的元数，例如，“5～7元环”是指环绕排列5～7个原子。除非另有规定，该环任选地包含1～3个杂原子。因此，“5～7元环”包括例如苯基吡啶和哌啶基；另一方面，术语“5～7元杂环烷基环”包括吡啶基和哌啶基，但不包括苯基。术语“环”还包括含有至少一个环的环系，其中的每一个“环”均独立地符合上述定义。"Ring" means a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted heterocycloalkyl group, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group. The so-called ring includes a fused ring. The number of atoms on the ring is usually defined as the number of elements of the ring. For example, "5 to 7-membered ring" means 5 to 7 atoms arranged in a circle. Unless otherwise specified, the ring optionally contains from 1 to 3 heteroatoms. Thus, "5- to 7-membered ring" includes, for example, phenylpyridine and piperidinyl; on the other hand, the term "5- to 7-membered heterocycloalkyl ring" includes pyridyl and piperidinyl, but does not include phenyl. The term "ring" also includes ring systems containing at least one ring, each of which "ring" independently conforms to the above definition.
本文所用术语“杂原子”包括碳(C)和氢(H)以外的原子，例如包括氧(O)、氮(N)、硫(S)、硅(Si)、锗(Ge)、铝(Al)和硼(B)等。The term "heteroatom" as used herein includes atoms other than carbon (C) and hydrogen (H), including, for example, oxygen (O), nitrogen (N), sulfur (S), silicon (Si), germanium (Ge), aluminum ( Al) and boron (B) and the like.
术语“离去基团”是指可以被另一种官能团或原子通过取代反应(例如亲和取代反应)所取代的官能团或原子。例如，代表性的离去基团包括三氟甲磺酸酯；氯、溴、碘；磺酸酯基，如甲磺酸酯、甲苯磺酸酯、对溴苯磺酸酯、对甲苯磺酸酯等；酰氧基，如乙酰氧基、三氟乙酰氧基等等。The term "leaving group" refers to a functional group or atom which may be substituted by another functional group or atom by a substitution reaction (for example, an affinity substitution reaction). For example, representative leaving groups include triflate; chlorine, bromine, iodine; sulfonate groups such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonic acid Esters and the like; acyloxy groups such as acetoxy, trifluoroacetoxy and the like.
术语“保护基”包括但不限于“氨基保护基”、“羟基保护基”或“巯基保护基”。术语“氨基保护基”是指适合用于阻止氨基氮位上副反应的保护基团。代表性的氨基保护基包括但不限于：甲酰基；酰基，例如链烷酰基(如乙酰基、三氯乙酰基或三氟乙酰基)；烷氧基羰基，如叔丁氧基羰基(Boc)；芳基甲氧羰基，如苄氧羰基(Cbz)和9-芴甲氧羰基(Fmoc)；芳基甲基，如苄基(Bn)、三苯甲基(Tr)、1,1-二-(4'-甲氧基苯基)甲基；甲硅烷基，如三甲基甲硅烷基(TMS)和叔丁基二甲基甲硅烷基(TBS)等等。术语“羟基保护基”是指适合用于阻止羟基副反应的保护基。代表性羟基保护基包括但不限于：烷基，如甲基、乙基和叔丁基；酰基，例如链烷酰基(如乙酰基)；芳基甲基，如苄基(Bn)，对甲氧基苄基(PMB)、9-芴基甲基(Fm)和二苯基甲基(二苯甲基，DPM)；甲硅烷基，如三甲基甲硅烷基(TMS)和叔丁基二甲基甲硅烷基(TBS)等等。The term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "thiol protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the amino nitrogen position. Representative amino protecting groups include, but are not limited to, formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, e.g., tert-butoxycarbonyl (Boc) Arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethoxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1, 1-di -(4'-methoxyphenyl)methyl; silyl groups such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS) and the like. The term "hydroxy protecting group" refers to a protecting group suitable for use in preventing hydroxy side reactions. Representative hydroxy protecting groups include, but are not limited to, alkyl groups such as methyl, ethyl and t-butyl groups; acyl groups such as alkanoyl groups (e.g., acetyl); arylmethyl groups such as benzyl (Bn), Oxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (diphenylmethyl, DPM); silyl groups such as trimethylsilyl (TMS) and tert-butyl Dimethylsilyl (TBS) and the like.
卤代烷基的实例包括但不仅限于：三氟甲基、三氯甲基、五氟乙基，和五氯乙基。“烷氧基”代表通过氧桥连接的具有特定数目碳原子的上述烷基。C1-6烷氧基包括C1、C2、C3、C4、C5和C6的烷氧基。烷氧基的例子包括但不限于：甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、仲丁氧基、叔丁氧基、正戊氧基和S-戊氧基。“环烷基”包括饱和环基，如环丙基、环丁基或环戊基。3-7环烷基包括C3、C4、C5、C6和C7环烷基。“链烯基”包括直链或支链构型的烃链，其中该链上任何的稳定位点上存在一个或多个碳-碳双键，例如乙烯基和丙烯基。术语“卤”或“卤素”是指氟、氯、溴和碘。Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents the above alkyl group having a specified number of carbon atoms attached through an oxygen bridge. The C 1-6 alkoxy group includes a C 1 , C 2 , C 3 , C 4 , C 5 and C 6 alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S- Pentyloxy. "Cycloalkyl" includes saturated cyclic groups such as cyclopropyl, cyclobutyl or cyclopentyl. The 3-7 cycloalkyl group includes C 3 , C 4 , C 5 , C 6 and C 7 cycloalkyl groups. "Alkenyl" includes hydrocarbon chains in a straight or branched configuration wherein one or more carbon-carbon double bonds, such as vinyl and propylene groups, are present at any stable site on the chain. The term "halo" or "halogen" refers to fluoro, chloro, bromo and iodo.
术语“杂环”或“杂环基”意指稳定的单环或双环或双环杂环，它们可以是饱和的、部分不饱和的或不饱和的(芳族的)，它们包含碳原子和1、2、3或4个独立地选自N、O和S的环杂原子，其中上述任意杂环可以稠合到一个苯环上形成双环。氮和硫杂原子可任选被氧化(即NO和S(O)p)。氮原子可以是被取代的或未取代的(即N或NR，其中R是H或本文已经定义过的其他取代基)。该杂环可以附着到任何杂原子或碳原子的侧基上从而形成稳定的结构。如果产生的化合物是稳定的，本文所述的杂环可以发生碳位或氮位上的取代。杂环中的氮原子任选地被季铵化。一个优选方案是，当杂环中S及O原子的总数超过1时，这些杂原子彼此不相邻。另一个优选方案是，杂环中S及O原子的总数不超过1。如本文所用，术语“芳族杂环基团”或“杂芳基”意指稳定的5、6、7元单环或双环或7、8、9或10元双环杂环基的芳香环，它 包含碳原子和1、2、3或4个独立地选自N、O和S的环杂原子。氮原子可以是被取代的或未取代的(即N或NR，其中R是H或本文已经定义过的其他取代基)。氮和硫杂原子可任选被氧化(即NO和S(O)p)。值得注意的是，芳香杂环上S和O原子的总数不超过1。桥环也包含在杂环的定义中。当一个或多个原子(即C、O、N或S)连接两个不相邻的碳原子或氮原子时形成桥环。优选的桥环包括但不限于：一个碳原子、两个碳原子、一个氮原子、两个氮原子和一个碳-氮基。值得注意的是，一个桥总是将单环转换成三环。桥环中，环上的取代基也可以出现在桥上。The term "heterocycle" or "heterocyclyl" means a stable monocyclic or bicyclic or bicyclic heterocycle which may be saturated, partially unsaturated or unsaturated (aromatic) which contain a carbon atom and 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein any of the above heterocyclic rings may be fused to a phenyl ring to form a bicyclic ring. The nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p). The nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein). The heterocyclic ring can be attached to the side groups of any hetero atom or carbon atom to form a stable structure. If the resulting compound is stable, the heterocycles described herein can undergo substitutions at the carbon or nitrogen sites. The nitrogen atom in the heterocycle is optionally quaternized. A preferred embodiment is that when the total number of S and O atoms in the heterocycle exceeds 1, these heteroatoms are not adjacent to each other. Another preferred embodiment is that the total number of S and O atoms in the heterocycle does not exceed one. The term "aromatic heterocyclic group" or "heteroaryl" as used herein means a stable 5, 6, or 7 membered monocyclic or bicyclic or aromatic ring of a 7, 8, 9 or 10 membered bicyclic heterocyclic group, It Containing a carbon atom and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S. The nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein). The nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p). It is worth noting that the total number of S and O atoms on the aromatic heterocycle does not exceed one. Bridged rings are also included in the definition of heterocycles. A bridged ring is formed when one or more atoms (ie, C, O, N, or S) join two non-adjacent carbon or nitrogen atoms. Preferred bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and one carbon-nitrogen group. It is worth noting that a bridge always converts a single ring into a three ring. In the bridged ring, a substituent on the ring can also be present on the bridge.
杂环化合物的实例包括但不限于：吖啶基、吖辛因基、苯并咪唑基、苯并呋喃基、苯并巯基呋喃基、苯并巯基苯基、苯并恶唑基、苯并恶唑啉基、苯并噻唑基、苯并三唑基、苯并四唑基、苯并异恶唑基、苯并异噻唑基、苯并咪唑啉基、咔唑基、4aH-咔唑基、咔啉基、苯并二氢吡喃基、色烯、噌啉基十氢喹啉基、2H,6H-1,5,2-二噻嗪基、二氢呋喃并[2,3-b]四氢呋喃基、呋喃基、呋咱基、咪唑烷基、咪唑啉基、咪唑基、1H-吲唑基、吲哚烯基、二氢吲哚基、中氮茚基、吲哚基、3H-吲哚基、isatino基、异苯并呋喃基、吡喃、异吲哚基、异二氢吲哚基、异吲哚基、吲哚基、异喹啉基、异噻唑基、异恶唑基、亚甲二氧基苯基、吗啉基、萘啶基，八氢异喹啉基、恶二唑基、1,2,3-恶二唑基、1,2,4-恶二唑基、1,2,5-恶二唑基、1,3,4-恶二唑基、恶唑烷基、恶唑基、异恶唑基、羟吲哚基、嘧啶基、菲啶基、菲咯啉基、吩嗪、吩噻嗪、苯并黄嘌呤基、酚恶嗪基、酞嗪基、哌嗪基、哌啶基、哌啶酮基、4-哌啶酮基、胡椒基、蝶啶基、嘌呤基、吡喃基、吡嗪基、吡唑烷基、吡唑啉基、吡唑基、哒嗪基、吡啶并恶唑、吡啶并咪唑、吡啶并噻唑、吡啶基、嘧啶基、吡咯烷基、吡咯啉基、2H-吡咯基、吡咯基、吡唑基、喹唑啉基、喹啉基、4H-喹嗪基、喹喔啉基、奎宁环基、四氢呋喃基、四氢异喹啉基、四氢喹啉基、四唑基，6H-1,2,5-噻二嗪基、1,2,3-噻二唑基、1,2,4-噻二唑基、1,2,5-噻二唑基、1,3,4-噻二唑基、噻蒽基、噻唑基、异噻唑基噻吩基、噻吩基、噻吩并恶唑基、噻吩并噻唑基、噻吩并咪唑基、噻吩基、三嗪基、1,2,3-三唑基、1,2,4-三唑基、1,2,5-三唑基、1,3,4-三唑基和呫吨基。还包括稠环和螺环化合物。Examples of heterocyclic compounds include, but are not limited to, acridinyl, octanoyl, benzimidazolyl, benzofuranyl, benzofuranylfuranyl, benzindenylphenyl, benzoxazolyl, benzimidin Oxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, oxazolyl, 4aH-carbazolyl, Porphyrin, chroman, chromene, porphyrin-decahydroquinolinyl, 2H, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b] Tetrahydrofuranyl, furyl, furfuryl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-carbazolyl, nonenyl, indanyl, mesoindolyl, fluorenyl, 3H-indole Sulfhydryl, isatino, isobenzofuranyl, pyran, isodecyl, isoindoline, isodecyl, decyl, isoquinolyl, isothiazolyl, isoxazolyl, Methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, isoxazolyl, oxindole , pyrimidinyl, phenanthryl, phenanthroline, phenazine, phenothiazine, benzoxanthyl, phenolzinyl, pyridazinyl, piperazinyl, piperidinyl, piperidinone, 4 -piperidone, piperonyl, pteridinyl, fluorenyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole , pyridothiazole, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, pyrazolyl, quinazolinyl, quinolyl, 4H-quinazinyl, quinoxalinyl , quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thioxyl, thiazolyl, isothiazolylthiophenyl, thienyl, thiophene And oxazolyl, thienothiazolyl, thienoimidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazole Base, 1,3,4-triazolyl and xanthene. Also included are fused ring and spiro compounds.
本发明的化合物可以通过本领域技术人员所熟知的多种合成方法来制备，包括下面列举的具体实施方式、其与其他化学合成方法的结合所形成的实施方式以及本领域技术上人员所熟知的等同替换方式，优选的实施方式包括但不限于本发明的实施例。The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments set forth below, combinations thereof with other chemical synthetic methods, and those well known to those skilled in the art. Equivalent alternatives, preferred embodiments include, but are not limited to, embodiments of the invention.
本发明所使用的所有溶剂是市售的，无需进一步纯化即可使用。反应一般是在惰性氮气下、无水溶剂中进行的。质子核磁共振数据记录在Bruker Avance III 400(400MHz)分光仪上，化学位移以四甲基硅烷低场处的(ppm)表示。质谱是在安捷伦1200系列加6110(&1956A)上测定。LC/MS或Shimadzu MS包含一个DAD：SPD-M20A(LC)和Shimadzu Micromass 2020检测器。质谱仪配备有一个正或负模式下操作的电喷雾离子源(ESI)。All solvents used in the present invention are commercially available and can be used without further purification. The reaction is generally carried out under an inert nitrogen atmosphere in an anhydrous solvent. Proton nuclear magnetic resonance data was recorded on a Bruker Avance III 400 (400 MHz) spectrometer with chemical shifts expressed in ppm at the low field of tetramethylsilane. Mass spectra were measured on an Agilent 1200 Series Plus 6110 (&1956A). LC/MS or Shimadzu MS contains a DAD: SPD-M20A (LC) and Shimadzu Micromass 2020 detector. The mass spectrometer is equipped with an electrospray ionization source (ESI) operating in either positive or negative mode.
本发明采用下述缩略词：aq代表水；HATU代表O-7-氮杂苯并三唑-1-基)-N，N，N'，N'-四甲基脲六氟磷酸盐；EDC代表N-(3-二甲基氨基丙基)-N'-乙基碳二亚胺盐酸盐；m-CPBA代表3-氯过氧苯甲酸；eq代表当量、等量；CDI代表羰基二咪唑；DCM代表二氯甲烷；PE代表石油醚；DIAD代表偶氮二羧酸二异丙酯；DMF代表N，N-二甲基甲酰胺；DMSO代表二甲亚砜；EtOAc代表乙酸乙酯；EtOH代表乙醇；MeOH代表甲醇；CBz代表苄氧羰基，是一种胺保护基团；BOC代表叔丁基羰基是一种胺保护基团；HOAc代表乙酸；NaCNBH3代表氰基硼氢化钠；r.t.代表室温；O/N代表过夜；THF代表四氢呋喃；Boc2O 代表二-叔丁基二碳酸酯；TFA代表三氟乙酸；DIPEA代表二异丙基乙基胺；SOCl2代表氯化亚砜；CS2代表二硫化碳；TsOH代表对甲苯磺酸；NFSI代表N-氟-N-(苯磺酰基)苯磺酰胺；NCS代表1-氯吡咯烷-2,5-二酮；n-Bu4NF代表氟化四丁基铵；iPrOH代表2-丙醇；mp代表熔点。The present invention employs the following abbreviations: aq for water; HATU for O-7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; EDC stands for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; m-CPBA stands for 3-chloroperoxybenzoic acid; eq stands for equivalent, equivalent; CDI stands for carbonyl Diimidazole; DCM stands for dichloromethane; PE stands for petroleum ether; DIAD stands for diisopropyl azodicarboxylate; DMF stands for N,N-dimethylformamide; DMSO stands for dimethyl sulfoxide; EtOAc stands for ethyl acetate EtOH stands for ethanol; MeOH stands for methanol; CBz stands for benzyloxycarbonyl and is an amine protecting group; BOC stands for t-butylcarbonyl which is an amine protecting group; HOAc stands for acetic acid; and NaCNBH 3 stands for sodium cyanoborohydride; Rt stands for room temperature; O/N stands for overnight; THF stands for tetrahydrofuran; Boc 2 O stands for di-tert-butyldicarbonate; TFA stands for trifluoroacetic acid; DIPEA stands for diisopropylethylamine; SOCl 2 stands for thionyl chloride CS 2 stands for carbon disulfide; TsOH stands for p-toluenesulfonic acid; NFSI stands for N-fluoro-N-(phenylsulfonyl)benzenesulfonamide; NCS stands for 1-chloropyrrolidine-2,5-dione; n-Bu 4 NF Representative fluorine Tetrabutylammonium; iPrOH represents 2-propanol; mp representative of melting point.
化合物经手工或者
Figure PCTCN2015075363-appb-000041
软件命名，市售化合物采用供应商目录名称。Compound by hand or
Figure PCTCN2015075363-appb-000041
Software naming, commercially available compounds using the supplier catalog name.
用配有Shimadzu SIL-20A自动进样器和日本岛津DAD：SPD-M20A探测器的岛津LC20AB系统进行高效液相色谱分析，采用Xtimate C18(3m填料，规格为2.1x 300mm)色谱柱。0-60AB_6分钟的方法：应用线性梯度，以100％A(A为0.0675％TFA的水溶液)开始洗脱，并以60％B(B为0.0625％TFA的MeCN溶液)结束洗脱，整个过程为4.2分钟，然后以60％B洗脱1分钟。将色谱柱再平衡0.8分钟达到100:0，总运行时间为6分钟。10-80AB_6分钟的方法：应用线性梯度，以90％A(A为0.0675％TFA的水溶液)开始洗脱，并以80％B(B为0.0625％TFA的乙腈溶液)结束洗脱，整个过程为4.2分钟，然后以80％B洗脱1分钟。将色谱柱再平衡0.8分钟达到90:10，总运行时间为6分钟。柱温为50℃，流速为0.8mL/min。二极管阵列检测器扫描波长为200-400nm。High performance liquid chromatography was performed using a Shimadzu LC20AB system equipped with a Shimadzu SIL-20A autosampler and a Shimadzu DAD: SPD-M20A detector using a Xtimate C18 (3 m packing, size 2.1 x 300 mm) column. 0-60AB_6 min method: Apply a linear gradient, start elution with 100% A (A is 0.0675% TFA in water), and end the elution with 60% B (B is 0.0625% TFA in MeCN solution). The whole process is 4.2 minutes, then eluted with 60% B for 1 minute. The column was equilibrated for 0.8 minutes to reach 100:0 with a total run time of 6 minutes. 10-80AB_6 min method: Apply a linear gradient, start elution with 90% A (A is 0.0675% TFA in water), and end the elution with 80% B (B in 0.0625% TFA in acetonitrile). 4.2 minutes, then eluted with 80% B for 1 minute. The column was equilibrated for 0.8 minutes to 90:10 with a total run time of 6 minutes. The column temperature was 50 ° C and the flow rate was 0.8 mL/min. The diode array detector has a scanning wavelength of 200-400 nm.
在Sanpont-group的硅胶GF254上进行薄层色谱分析(TLC)，常用紫外光灯照射检出斑点，在某些情况下也采用其他方法检视斑点，在这些情况下，用碘(10g硅胶中加入约1g碘并彻底混合而成)、香草醛(溶解大约1g香草醛于100mL 10％H2SO4中制得)、茚三酮(从Aldrich购得)或特殊显色剂(彻底混合(NH4)6Mo7O24·4H2O、5g(NH4)2Ce(IV)(NO3)6、450mL H2O和50mL浓H2SO4而制得)展开薄层板，检视化合物。采用Still,W.C.；Kahn,M.；and Mitra,M.Journal of Organic Chemistry,1978,43,2923-2925.中所公开技术的类似方法，在Silicycle的40-63μm(230-400目)硅胶上进行快速柱色谱。快速柱色谱或薄层色谱的常用溶剂是二氯甲烷/甲醇、乙酸乙酯/甲醇和己烷/乙酸乙酯的混合物。Thin layer chromatography (TLC) was performed on silica gel GF254 of Sanpont-group. Spots were detected by ultraviolet light irradiation. In some cases, spots were also observed by other methods. In these cases, iodine (10 g silica gel was added). About 1 g of iodine and thoroughly mixed), vanillin (dissolved in about 1 g of vanillin in 100 mL of 10% H 2 SO 4 ), ninhydrin (purchased from Aldrich) or special developer (completely mixed (NH) 4 ) 6 Mo 7 O 24 · 4H 2 O, 5 g (NH 4 ) 2 Ce(IV)(NO 3 ) 6 , 450 mL of H 2 O and 50 mL of concentrated H 2 SO 4 were prepared to develop a thin layer plate and examine the compound. A similar method of the technique disclosed in Still, WC; Kahn, M.; and Mitra, M. Journal of Organic Chemistry, 1978, 43, 2923-2925. on Silicycle 40-63 μm (230-400 mesh) silica gel. Perform a fast column chromatography. A common solvent for flash column chromatography or thin layer chromatography is a mixture of dichloromethane/methanol, ethyl acetate/methanol and hexane/ethyl acetate.
在Gilson-281Prep LC 322系统上采用吉尔森UV/VIS-156探测器进行制备色谱分析,所采用的色谱柱是Agella Venusil ASB Prep C18,5m、150x 21.2mm；Phenomenex Gemini C18、5m、150x 30mm；Boston Symmetrix C18,5m、150x 30mm；或者Phenomenex Synergi C18、4m、150x 30mm。在流速约为25mL/min时，用低梯度的乙腈/水洗脱化合物，其中水中含有0.05％HCl、0.25％HCOOH或0.5％NH3·H2O，总运行时间为8-15分钟。Preparative chromatographic analysis was performed on a Gilson-281Prep LC 322 system using a Gilson UV/VIS-156 detector using Agella Venusil ASB Prep C18, 5 m, 150 x 21.2 mm; Phenomenex Gemini C18, 5 m, 150 x 30 mm; Boston Symmetrix C18, 5m, 150x 30mm; or Phenomenex Synergi C18, 4m, 150x 30mm. When a flow rate of about 25mL / min, with a low gradient of acetonitrile / water elution compound, wherein water containing 0.05% HCl, 0.25% HCOOH or 0.5% NH 3 · H 2 O , the total run time of 8-15 minutes.
用带有Agilent1260自动进样器和Agilent DAD：1260检测器的Agilent 1260Infinity SFC系统进行SFC分析。色谱柱采用Chiralcel OD-H 250x 4.6mm I.D.,5um或者Chiralpak AS-H 250x 4.6mm I.D.,5m或者Chiralpak AD-H 250x 4.6mm I.D.,5m。OD-H_5_40_2.35ML的色谱条件：Chiralcel OD-H色谱柱(规格为250x 4.6mm I.D.,m填料)，流动相为40％乙醇(0.05％DEA)-CO2；流速为2.35mL/min；检测波长为220nm。AS-H_3_40_2.35ML色谱条件：Chiralpak AS-H色谱柱(规格为250x 4.6mm I.D.,5m填料)；流动相为40％甲醇(0.05％DEA)-CO2；流速为2.35mL/min，检测波长为220nm。OD-H_3_40_2.35M色谱条件：Chiralcel OD-H色谱柱(规格为250x 4.6mm I.D，5m填料)，流动相为40％甲醇(0.05％DEA)-CO2，流速为2.35mL/min，检测波长为220nm。AD-H_2_50_2.35ML色谱条件：Chiralpak AD-H色谱柱(规格为250x 4.6mm I.D，5mm填料),流动相为50％甲醇(0.1％MEA)-CO2，流速为2.35mL/min，检测波长为220nm。SFC analysis was performed using an Agilent 1260 Infinity SFC system with an Agilent 1260 autosampler and an Agilent DAD: 1260 detector. The column was Chiralcel OD-H 250x 4.6 mm ID, 5 um or Chiralpak AS-H 250x 4.6 mm ID, 5 m or Chiralpak AD-H 250x 4.6 mm ID, 5 m. Chromatographic conditions for OD-H_5_40_2.35ML: Chiralcel OD-H column (specification 250x 4.6mm ID, m packing), mobile phase 40% ethanol (0.05% DEA)-CO 2 ; flow rate 2.35mL/min; detection The wavelength is 220 nm. AS-H_3_40_2.35ML Chromatographic conditions: Chiralpak AS-H column (specification 250x 4.6mm ID, 5m packing); mobile phase 40% methanol (0.05% DEA)-CO 2 ; flow rate 2.35mL/min, detection wavelength It is 220 nm. OD-H_3_40_2.35M Chromatographic conditions: Chiralcel OD-H column (specification 250x 4.6mm ID, 5m packing), mobile phase 40% methanol (0.05% DEA)-CO 2 , flow rate 2.35mL / min, detection wavelength It is 220 nm. AD-H_2_50_2.35ML Chromatographic conditions: Chiralpak AD-H column (specification 250x 4.6mm ID, 5mm packing), mobile phase 50% methanol (0.1% MEA)-CO 2 , flow rate 2.35mL / min, detection wavelength It is 220 nm.
在使用Gilson UV检测器的Waters Thar 80Pre-SFC系统上进行制备型SFC分析，所采用的色谱柱为 Chiralcel OD-H(规格为250x 4.6mm I.D，5m填料)或者Chiralpak AD-H(规格为250x 4.6mm I.D，5m填料)。在流速约为40-80mL/min时，用低梯度的乙醇-二氧化碳或者甲醇-二氧化碳洗脱化合物，其中甲醇或乙醇含有0.05％NH3·H2O、0.05％DEA或者0.1％MEA，总运行时间为20-30分钟。Preparative SFC analysis was performed on a Waters Thar 80 Pre-SFC system using a Gilson UV detector using Chiralcel OD-H (250x 4.6mm ID, 5m packing) or Chiralpak AD-H (250x size) 4.6mm ID, 5m filler). At a flow rate of approximately 40-80 mL/min, the compound is eluted with a low gradient of ethanol-carbon dioxide or methanol-carbon dioxide, with methanol or ethanol containing 0.05% NH 3 ·H 2 O, 0.05% DEA or 0.1% MEA, total run The time is 20-30 minutes.
本发明所提供的PARP-1抑制剂可以用于治疗广泛的疾病，包括癌症、中风、心肌缺血、炎症和糖尿病。PARP-1抑制剂可以用作单剂，或与其他化学治疗剂联用，以增强这些标准化学治疗剂的效果。The PARP-1 inhibitors provided by the present invention can be used to treat a wide range of diseases including cancer, stroke, myocardial ischemia, inflammation and diabetes. PARP-1 inhibitors can be used as a single dose or in combination with other chemotherapeutic agents to enhance the effectiveness of these standard chemotherapeutic agents.
PARP-1抑制剂可以治疗的癌症包括但不限于乳腺癌、卵巢癌、胰腺癌、前列腺癌、克隆癌以及白血病等。Cancers treatable by PARP-1 inhibitors include, but are not limited to, breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, clonal cancer, and leukemia.
具体实施方式Detailed ways
为了更详细地说明本发明，给出下列实例，但本发明的范围并非限定于此。In order to explain the present invention in more detail, the following examples are given, but the scope of the invention is not limited thereto.
流程AProcess A
Figure PCTCN2015075363-appb-000042
Figure PCTCN2015075363-appb-000042
实施例1Example 1
6-氟-3-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000043
Figure PCTCN2015075363-appb-000043
实施例1AExample 1A
4-(对甲苯磺酰氧甲基)哌啶-1-甲酸叔丁酯4-(p-toluenesulfonyloxymethyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000044
Figure PCTCN2015075363-appb-000044
0℃氮气保护下,向4-(羟甲基)哌啶-1-甲酸叔丁酯(10克，46.5毫摩尔)，三乙胺(5.64克，55.8毫摩尔)和DMAP(1.13克，9.3毫摩尔)的二氯甲烷(100毫升)溶液中分批加入TosCl(9.73克，51.2毫摩尔)，在17℃下搅拌2小时后，加入水(100毫升)淬灭，水层用二氯甲烷(100毫升×2)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，残余物通过柱色谱纯化得到标题化合物(白色固体，17克，99％产率)。LCMS(ESI)m/z:370(M+1).To a solution of 4-(hydroxymethyl)piperidine-1-carboxylic acid tert-butyl ester (10 g, 46.5 mmol), triethylamine (5.64 g, 55.8 mmol) and DMAP (1.13 g, 9.3) To a solution of 1 ml of dichloromethane (100 ml) was added to a solution of EtOAc (m. The mixture was extracted with EtOAc (EtOAc m. LCMS (ESI) m/z: 370 (M+1).
实施例1B Example 1B
4-(氰基甲基)哌啶-1-甲酸叔丁酯4-(cyanomethyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000045
Figure PCTCN2015075363-appb-000045
实施例1A(19克，55.7毫摩尔)，氰化钠(8.19克，167毫摩尔)的二甲基亚砜(100毫升)混合物在100℃反应16小时。冷却至室温后，用水(200ml)稀释，水层用乙酸乙酯(100毫升×3)萃取，合并的有机层用水(50毫升)，盐水(50mL)洗涤后，经硫酸钠干燥，过滤并蒸发，提供标题化合物(11克)可直接用于下一步骤而无需进一步纯化。LCMS(ESI)m/z:225(M+1)A mixture of Example 1A (19 g, 55.7 mmol), sodium cyanide (8.19 g, 167 mmol) in dimethyl sulfoxide (100 mL) was reacted at 100 ° C for 16 hours. After cooling to room temperature, it was diluted with H~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The title compound (11 g) was obtained eluted directly to next step without further purification. LCMS (ESI) m/z: 225 (M+1)
实施例1CExample 1C
4-(1-氰基-2-氧代乙基)哌啶-1-甲酸叔丁酯4-(1-Cyano-2-oxoethyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000046
Figure PCTCN2015075363-appb-000046
-10℃氮气保护下，向实施例1B(11克，49毫摩尔)，叔丁醇钾(32.9克，294毫摩尔)的DMF(80mL)混合物中滴加甲酸乙酯(21.7克，294毫摩尔)的DMF(50mL)溶液。滴加完毕后在17℃下搅拌16小时后，1N盐酸中和，水层用乙酸乙酯(100毫升×4)萃取。将合并的有机层用硫酸钠干燥，过滤并蒸发，提供标题化合物(11g，89％)可直接用于下一步骤而无需进一步纯化。LCMS(ESI)m/z:253(M+1)To a mixture of Example 1B (11 g, 49 mmol), potassium tert-butoxide (32.9 g, 294 mmol) in DMF <RTI ID=0.0> Mole) of DMF (50 mL) solution. After the completion of the dropwise addition, the mixture was stirred at 17 ° C for 16 hours, then 1N hydrochloric acid was evaporated, and the aqueous layer was extracted with ethyl acetate (100 ml × 4). The combined organic layers were dried with EtOAc EtOAcjjjjjjjj LCMS (ESI) m/z: 253 (M+1)
实施例1DExample 1D
(2,6-二溴-4-氟苯基)肼(2,6-dibromo-4-fluorophenyl)indole
Figure PCTCN2015075363-appb-000047
Figure PCTCN2015075363-appb-000047
零下5℃，向2,6-二溴-4-氟苯胺(5克，18.6毫摩尔)的35毫升20％盐酸水溶液滴加溶有亚硝酸钠(1.41克，20.45毫摩尔)的水(40mL)溶液。滴加速度保持内温低于5℃，0.5小时后，在-15℃将上述溶液滴加到氯化亚锡(10.49克，46毫摩尔)的浓盐酸(40mL)溶液中，滴加完毕混合物加热至35℃并搅拌12小时，冷却至0℃并用浓氨水调Ph＝9，水层用乙酸乙酯(150毫升×3)萃取，合并有机层用水(100毫升)洗，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱纯化得到标题化合物(4克，收率：76％)。1H NMR(400MHz,CDCl3-d):δppm 3.91(br.s.,1H),5.37(br.s.,1H),7.31(d,J＝7.37Hz,2H). To a solution of 2,6-dibromo-4-fluoroaniline (5 g, 18.6 mmol) in 35 ml of 20% aqueous hydrochloric acid was added dropwise a solution of sodium nitrite (1.41 g, 20.45 mmol) in water (40 mL). ) solution. The dropping temperature was maintained at an internal temperature of less than 5 ° C. After 0.5 hours, the solution was added dropwise to a solution of stannous chloride (10.49 g, 46 mmol) in concentrated hydrochloric acid (40 mL) at -15 ° C. The mixture was stirred for 15 hours at 35 ° C, and cooled to 0 ° C. EtOAc (EtOAc) (EtOAc) Evaporation, and the residue was purified tojjjjjjjj 1 H NMR (400 MHz, CDCl3-d): δ ppm 3.91 (br.s., 1H), 5.37 (br.s., 1H), 7.31 (d, J = 7.37 Hz, 2H).
实施例1EExample 1E
4-(1-氰基-2-(2-(2,6-二溴-4-氟苯基)亚肼基)乙基)哌啶-1-甲酸叔丁酯4-(1-Cyano-2-(2-(2,6-dibromo-4-fluorophenyl)phosphonium)ethyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000048
Figure PCTCN2015075363-appb-000048
实施例1C(3.5克，13.87毫摩尔)和实施例1D(3.94克，13.87毫摩尔)的乙醇(30mL)混合物80℃搅拌0.5小时。真空除去溶液后，残余物通过柱色谱纯化得到标题化合物，为白色固体(3.8克，53％)。LCMS(ESI)m/z:519(M+1). A mixture of Example 1C (3.5 g, 13.87 mmol) and EXAMPLE 1D (3.94 g, 13.87 mmol) in ethanol (30 mL) was stirred at 80 ° C for 0.5 hour. After the solution was removed in vacuo, EtOAc m. LCMS (ESI) m/z: 519 (M+1).
实施例1FExample 1F
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-1H-吡唑-4-基)哌啶-1-甲酸叔丁酯4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazol-4-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000049
Figure PCTCN2015075363-appb-000049
实施例1E的(3.8克，7.33毫摩尔)和三乙胺(1.48克，14.67毫摩尔)的乙醇(30mL)混合物在80℃下搅拌16小时。真空除去溶液后，提供标题化合物(3.8克，100％)可直接用于下一步骤而无需进一步纯化。A mixture of (3.8 g, 7.33 mmol) and triethylamine (1.48 g, 14.67 mmol) in EtOAc (30 mL). The title compound (3.8 g, 100%) elute
实施例1GExample 1G
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000050
Figure PCTCN2015075363-appb-000050
氮气保护下，实施例1F(2.4克，4.63毫摩尔)，N1，N2-二甲基乙烷-1,2-二胺(40.83毫克，0.463毫摩尔)，碘化亚铜(88毫克，0.463毫摩尔)和磷酸钾(983毫克，4.63毫摩尔)的DMF(30mL)混合物60℃用微波加热1小时。冷却至室温后将混合物通过硅藻土过滤，真空除去溶液后，残余物通过柱色谱纯化得到标题化合物，为白色固体(0.4克，15％)。LCMS(ESI)m/z:437,439(M,M+2).Example 1F (2.4 g, 4.63 mmol), N1, N2-dimethylethane-1,2-diamine (40.83 mg, 0.463 mmol), cuprous iodide (88 mg, 0.463). A mixture of millimolar) and potassium phosphate (983 mg, 4.63 mmol) in DMF (30 mL) was heated at 60 ° C for one hour. After cooling to rt, the mixture was evaporated EtOAc mjjjjjjjjj LCMS (ESI) m/z: 437, 437 (M, M+2).
实施例1HExample 1H
3-(1-(叔丁氧羰基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-羧酸甲酯Methyl 3-(1-(tert-butoxycarbonyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxylate
Figure PCTCN2015075363-appb-000051
Figure PCTCN2015075363-appb-000051
实施例1G(200毫克，0.457毫摩尔)，钯醋酸(10.27毫克，0.0457毫摩尔)，Pd(dppf)Cl2(33.46毫克，0.0457毫摩尔)，Xantphos(53毫克，0.0914毫摩尔)，DPPP(38毫克，0.0914毫摩尔)，三苯基膦(24毫克，0.0914毫摩尔)和三乙胺(232毫克，2.29毫摩尔)的DMF(40mL)和甲醇(20ml)混合溶液在120℃一氧化碳氛围(3兆帕)下搅拌12小时。冷却至室温后，硅藻土垫过滤，将滤液蒸发，残余物通过柱色谱纯化得到标题化合物，为白色固体(100毫克，52％)。LCMS(ESI)m/z:417(M+1).Example 1G (200 mg, 0.457 mmol), palladium acetate (10.27 mg, 0.0457 mmol), Pd(dppf)Cl2 (33.46 mg, 0.0457 mmol), Xantphos (53 mg, 0.0914 mmol), DPPP (38) Mg, 0.0914 mmol), a mixed solution of triphenylphosphine (24 mg, 0.0914 mmol) and triethylamine (232 mg, 2.29 mmol) in DMF (40 mL) and methanol (20 ml) at 120 ° C carbon monoxide atmosphere (3 Stir for 12 hours under MPa. After cooling to rt, EtOAc (EtOAc m.) LCMS (ESI) m/z: 417 (M+1).
实施例1IExample 1I
4-(8-氨基甲酰基-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)哌啶-1-甲酸叔丁酯 4-(8-carbamoyl-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000052
Figure PCTCN2015075363-appb-000052
实施例1H(100毫克，0.24毫摩尔)和氨气/甲醇(30毫升)的DMF(100mL)混合物在120℃闷罐反应16小时。冷却后真空除去溶液，残余物通过柱色谱纯化得到标题化合物，为白色固体(70毫克，73％)。LCMS(ESI)m/z:402(M+1).A mixture of Example 1H (100 mg, 0.24 mmol) and ammonia / methanol (30 mL) in DMF (100 mL) was stirred at 120 ° C for 16 hours. After cooling, the solution was evaporated in vacuo. LCMS (ESI) m/z: 402 (M+1).
实施例1JExample 1J
6-氟-3-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000053
Figure PCTCN2015075363-appb-000053
将实施例1I(70毫克，0.174毫摩尔)的二氯甲烷(3mL)和三氟乙酸(1mL)混合溶液在15℃搅拌1小时，真空除去溶液，残余物通过制备型HPLC纯化得到标题化合物(25mg，49％)。1H NMR(400MHz,METHANOL-d4)ppm 1.93-1.96(m,2H),2.37–2.36(d,2H),3.09–3.22(m,3H),3.31–3.53(t,2H),7.37-7.39(m,1H),7.68-7.74(m,2H).LCMS(ESI)m/z:302(M+1).The mixture of Example 1I (70 mg, 0.174 mmol) eluted with dichloromethane (3 mL) 25 mg, 49%). 1 H NMR (400 MHz, METHANOL-d4) ppm 1.93-1.96 (m, 2H), 2.37 - 2.36 (d, 2H), 3.09 - 3.22 (m, 3H), 3.31 - 3.53 (t, 2H), 7.37-7.39 (m, 1H), 7.68-7.74 (m, 2H). LCMS (ESI) m/z: 302 (M+1).
实施例2Example 2
3-(1-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000054
Figure PCTCN2015075363-appb-000054
实施例1J(750毫克，2.49毫摩尔)和乙醛(1.1克，24.9毫摩尔)的甲醇(15mL)混合物在50℃搅拌0.5小时后，加入氰基硼氢化钠(3.13克，49.8毫摩尔)。将所得混合物在50℃搅拌16小时。真空除去溶液后，残余物通过柱色谱纯化得到标题化合物，为白色固体(563.1克，69％)。1H NMR(400MHz,METHANOL-d4)ppm 1.31-1.34(t,3H),1.94-1.97(m,2H),2.27-2.31(d,2H),2.82(t,2H),2.97-3.02(m,3H),3.47-3.48(d,2H),7.34-7.37(m,1H),7.67-7.72(m,2H).LCMS(ESI)m/z:330(M+1).A mixture of Example 1J (750 mg, 2.49 mmol) and acetaldehyde (1.1 g, 24.9 mmol) in methanol (15 mL) was stirred at 50 ° C for 0.5 h then sodium cyanoborohydride (3.13 g, 49.8 mmol) . The resulting mixture was stirred at 50 ° C for 16 hours. After the solution was removed in vacuo, EtOAc m. 1 H NMR (400 MHz, METHANOL-d4) ppm 1.31-1.34 (t, 3H), 1.94-1.97 (m, 2H), 2.27-2.31 (d, 2H), 2.82 (t, 2H), 2.97-3.02 (m) , 3H), 3.47-3.48 (d, 2H), 7.34-7.37 (m, 1H), 7.67-7.72 (m, 2H). LCMS (ESI) m/z: 330 (M+1).
实施例3Example 3
6-氟-3-(1-(2-氟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(1-(2-fluoroethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000055
Figure PCTCN2015075363-appb-000055
实施例1J(112毫克，0.372毫摩尔)，1-溴-2-甲氧基乙烷(71毫克，0.558毫摩尔)和碳酸钾(154毫克，1.116毫摩尔)的乙腈(20mL)混合物在40℃下搅拌16个小时。冷却过滤，真空除去溶液后，残余物通过制备型HPLC纯化得到标题化合物(4.6毫克，3.6％)。1H NMR(400MHz,METHANOL-d4)ppm 1.94-2.15(m,2H),2.17-2.37(m,2H),2.86-3.07(m,3H),3.27-3.32(m,1H),3.35-3.39(m,1H),3.46-3.61(m,2H),4.71-4.80(m,1H),4.89(br.s.,1H),7.28-7.41(m,1H),7.60-7.76(m,2H),8.24-8.69(m,1H).LCMS(ESI)m/z:348(M+1).Example 1J (112 mg, 0.372 mmol), 1-bromo-2-methoxyethane (71 mg, 0.558 mmol) and potassium carbonate (154 mg, 1.116 mmol) in acetonitrile (20 mL) Stir at °C for 16 hours. After cooling and filtration, EtOAc~~~~~ 1 H NMR (400MHz, METHANOL- d 4) ppm 1.94-2.15 (m, 2H), 2.17-2.37 (m, 2H), 2.86-3.07 (m, 3H), 3.27-3.32 (m, 1H), 3.35- 3.39 (m, 1H), 3.46-3.61 (m, 2H), 4.71-4.80 (m, 1H), 4.89 (br.s., 1H), 7.28-7.41 (m, 1H), 7.60-7.76 (m, 2H), 8.24-8.69 (m, 1H). LCMS (ESI) m/z: 348 (M+1).
实施例4Example 4
3-(1-环丙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-Cyclopropylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000056
Figure PCTCN2015075363-appb-000056
将(1-乙氧基环丙氧基)三甲基硅烷(115毫克，0.663毫摩尔)，实施例1J(40毫克，0.133毫摩尔)，乙酸(79毫克，1.33毫摩尔)和氰基硼氢化钠(83毫克，1.33毫摩尔)的甲醇(10mL)混合物在66℃下搅拌7小时。冷却真空除去溶液后，残余物通过制备型HPLC纯化得到标题化合物(19.6毫克，43％)。1H NMR(400MHz,METHANOL-d4)ppm 0.70-0.79(m,4H),1.84-1.92(m,2H),2.18-2.28(t,3H),2.85-2.94(m,3H),3.42-3.45(d,2H),7.33-7.35(m,1H),7.65-7.68(m,2H),8.395(s,1H).LCMS(ESI)m/z:342(M+1).(1-Ethoxycyclopropoxy)trimethylsilane (115 mg, 0.663 mmol), Example 1J (40 mg, 0.133 mmol), acetic acid (79 mg, 1.33 mmol) and cyano boron A mixture of sodium hydride (83 mg, 1.33 mmol) in methanol (10 mL) was stirred at <RTIgt; The title compound (19.6 mg, 43%) was obtained. 1 H NMR (400 MHz, METHANOL-d4) ppm 0.70-0.79 (m, 4H), 1.84-1.92 (m, 2H), 2.18-2.28 (t, 3H), 2.85-2.94 (m, 3H), 3.42-3.45 (d, 2H), 7.33-7.35 (m, 1H), 7.65-7.68 (m, 2H), 8.395 (s, 1H). LCMS (ESI) m/z: 342 (M+1).
实施例5Example 5
3-(1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000057
Figure PCTCN2015075363-appb-000057
实施例1J的(12毫克，0.04毫摩尔)，环丙烷甲醛(5.58毫克，0.08mmol)，氰基硼氢化钠(50毫克，0.8毫摩尔)的甲醇(2mL)混合物在10℃下搅拌16小时后，加入四异丙氧基钛(17毫克，0.06毫摩尔)并继续搅拌1小时。真空除去溶液后，残余物通过制备型HPLC纯化得到提供标题化合物(5.2毫克，37％)。1H NMR(400MHz,METHANOL-d4)ppm 0.40-0.44(m,2H),0.75-0.79(m,1H),1.12-1.13 (m,1H),2.04(s,2H),2.32-2.36(d,2H),2.9-3.12(m,5H),3.68(s,2H),7.36-7.39(m,1H),7.68-7.73(m,2H),8.50(s,1H).LCMS(ESI)m/z:356(M+1).A mixture of (12 mg, 0.04 mmol), cyclopropanecarboxaldehyde (5.58 mg, 0.08 mmol), EtOAc (EtOAc, m. Thereafter, titanium tetraisopropoxide (17 mg, 0.06 mmol) was added and stirring was continued for 1 hour. After the solution was removed in vacuo, EtOAcqqqqqqq 1 H NMR (400MHz, METHANOL- d4) ppm 0.40-0.44 (m, 2H), 0.75-0.79 (m, 1H), 1.12-1.13 (m, 1H), 2.04 (s, 2H), 2.32-2.36 (d , 2H), 2.9-3.12 (m, 5H), 3.68 (s, 2H), 7.36-7.39 (m, 1H), 7.68-7.73 (m, 2H), 8.50 (s, 1H). LCMS (ESI) m /z:356(M+1).
实施例6Example 6
6-氟-3-(1-(2-羟基-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000058
Figure PCTCN2015075363-appb-000058
实施例6AExample 6A
4-(4-苄基-8-氨基甲酰基-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)哌啶-1-甲酸叔丁酯4-(4-Benzyl-8-carbamoyl-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)piperidine-1-carboxylic acid Butyl ester
Figure PCTCN2015075363-appb-000059
Figure PCTCN2015075363-appb-000059
实施例1I(100毫克，0.25毫摩尔)，苄溴(127毫克，0.748毫摩尔)和碳酸钾(103毫克，0.748毫摩尔)的乙腈(4mL)混合物在60℃下搅拌4小时。冷却过滤，真空除去溶液后，残余物通过硅胶色谱法纯化得到标题化合物(112.6毫克，91.8％)。LCMS(ESI)m/z:492(M+1).A mixture of Example 1I (100 mg, 0.25 mmol), benzyl bromide (127 mg, 0.748 mmol) and potassium carbonate (103 mg, 0.748 mmol) in acetonitrile (4 mL) was stirred at 60 ° C for 4 hours. After cooling and filtration, EtOAcqqqqqqm LCMS (ESI) m/z: 495 (M+1).
实施例6BExample 6B
4-苄基-6-氟-3-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺4-benzyl-6-fluoro-3-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000060
Figure PCTCN2015075363-appb-000060
实施例6A(112.6毫克，0.229毫摩尔)的二氯甲烷(10毫升)和三氟乙酸(3毫升)混合溶液中12℃下搅拌2小时。真空除去溶液后，提供标题化合物(115毫克，100％)可直接用于下一步骤而无需进一步纯化，为黄色固体。LCMS(ESI)M/Z：392(M+1)。A mixed solution of Example 6A (112.6 mg, 0.229 mmol) of dichloromethane (10 ml) and trifluoroacetic acid (3 ml) was stirred at 12 ° C for 2 hours. The title compound (115 mg, 100%) eluted elute LCMS (ESI) M/Z: </RTI>
实施例6CExample 6C
4-苄基-6-氟-3-(1-(2-羟基-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺4-benzyl-6-fluoro-3-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000061
Figure PCTCN2015075363-appb-000061
实施例6B(115毫克，0.229毫摩尔)，2,2-二甲基环氧乙烷(50毫克，0.690毫摩尔)和三乙胺(116毫克，1.15mmol)的乙醇(5ml)混合物在120℃下微波加热1小时。冷却真空除去溶液后，残余物通过硅胶色谱法纯化得到标题化合物。LCMS(ESI)m/z:464(M+1).Example 6B (115 mg, 0.229 mmol), a mixture of 2,2-dimethyloxirane (50 mg, 0.690 mmol) and triethylamine (116 mg, 1.15 mmol) in ethanol (5 ml) The microwave was heated at ° C for 1 hour. After the solution was removed in vacuo to give crystall LCMS (ESI) m/z: 464 (M+1).
实施例6DExample 6D
6-氟-3-(1-2-羟基-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-2-hydroxy-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide
Figure PCTCN2015075363-appb-000062
Figure PCTCN2015075363-appb-000062
实施例6C(32毫克，0.069mmol)和Pd/C(25毫克)的甲醇(30mL)混合物在50℃下氢化4小时(1大气压)。冷却过滤，真空除去溶液后，残余物通过制备型HPLC纯化得到标题化合物(8.2毫克，32.2％)。1H NMR(400MHz,METHANOL-d4)ppm 1.38(s,6H),2.10-2.30(m,4H),3.12(s,5H),3.57-3.73(m,2H),7.29-7.39(m,1H),7.61-7.69(m,1H),7.69-7.75(m,1H),8.54(br.s.,1H).LCMS(ESI)m/z:374(M+1).A mixture of Example 6C (32 mg, 0.069 mmol) and Pd/C (25 mg) in methanol (30 mL) was hydrogenated at 50 ° C for 4 hours (1 atm). The title compound (8.2 mg, 32.2%) was obtained. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.38 (s, 6H), 2.10-2.30 (m, 4H), 3.12 (s, 5H), 3.57-3.73 (m, 2H), 7.29-7.39 (m, 1H), 7.61-7.69 (m, 1H), 7.69-7.75 (m, 1H), 8.54 (br.s., 1H). LCMS (ESI) m/z: 374 (M+1).
实施例7Example 7
6-氟-3-(1-(2-氟-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-fluoro-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000063
Figure PCTCN2015075363-appb-000063
实施例7AExample 7A
4-苄基-6-氟-3-(1-(2-氟-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺4-benzyl-6-fluoro-3-(1-(2-fluoro-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000064
Figure PCTCN2015075363-appb-000064
0℃下氮气保护下，向实施例6C(32毫克，0.069毫摩尔)的二氯甲烷(10mL)溶液中逐滴加入DAST(33毫克，0.207毫摩尔)的二氯甲烷(2毫升)溶液。滴加完毕后在17℃搅拌16小时后，用饱和碳酸氢钠溶液(10mL)淬灭反应，水层用乙酸乙酯(10毫升×2)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，残余物通过硅胶色谱法得到标题化合物(27mg，84.4％)。LCMS(ESI)m/z:466(M+1).A solution of DAST (33 mg, 0.207 mmol) in dichloromethane (2 mL) was added dropwise EtOAc. After the completion of the dropwise addition, the mixture was stirred at 17 ° C for 16 hr then EtOAc EtOAc (EtOAc) The title compound (27 mg, 84.4%). LCMS (ESI) m/z: 466 (M+1).
实施例7BExample 7B
6-氟-3-(1-(2-氟-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(1-(2-fluoro-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000065
Figure PCTCN2015075363-appb-000065
实施例7A(27毫克，0.058mmol)和Pd/C(30毫克)的甲醇(20毫升)混合物在45℃下氢化16小时(1大气压)。冷却过滤，将滤液蒸发，残余物通过制备型HPLC纯化得到标题化合物(2.1毫克，10％)。1H NMR(400MHz,METHANOL-d4)ppm 1.42(s,3H),1.48(s,3H),1.90-2.03(m,2H),2.04-2.16(m,2H),2.51-2.67(m,2H),2.72-2.90(m,3H),3.23-3.31(m,2H),7.32-7.41(m,1H),7.63-7.75(m,2H),8.27-8.59(m,1H).LCMS(ESI)m/z:376(M+1)A mixture of Example 7A (27 mg, 0.058 mmol) and Pd/C (30 mg) in methanol (20 ml) was hydrogenated at 45 ° C for 16 hours (1 atm). Filtration of the title compound (2.1 mg, 10%). 1 H NMR (400MHz, METHANOL- d 4) ppm 1.42 (s, 3H), 1.48 (s, 3H), 1.90-2.03 (m, 2H), 2.04-2.16 (m, 2H), 2.51-2.67 (m, 2H), 2.72-2.90 (m, 3H), 3.23-3.31 (m, 2H), 7.32-7.41 (m, 1H), 7.63-7.75 (m, 2H), 8.27-8.59 (m, 1H). LCMS ( ESI)m/z: 376(M+1)
实施例8Example 8
3-(1-(环丙基甲酰基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylformyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000066
Figure PCTCN2015075363-appb-000066
实施例1J(52毫克，0.125毫摩尔)，环丙烷甲酸(13毫克，0.150毫摩尔)，三乙胺(50.5毫克，0.5毫摩尔)和HATU(47.5毫克，0.125毫摩尔)的乙腈(5mL)混合物在50℃下搅拌3小时。冷却真空除去溶液后，残余物通过制备型HPLC纯化得到标题化合物(12.7毫克，27.3％)。LCMS:370[M+1].1HNMR(400MHz,DMSO-d6)ppm 0.72(d,J＝7.53Hz,4H),1.42-1.69(m,2H),1.88-2.07(m,3H),2.65-2.77(m,1H),2.86-2.98(m,1H),3.14-3.29(m,1H),4.26-4.50(m,2H),7.43-7.50(m,1H),7.51-7.59(m,1H),7.76(s,1H).LCMS(ESI)m/z:370(M+1).Example 1J (52 mg, 0.125 mmol), cyclopropanecarboxylic acid (13 mg, 0.150 mmol), triethylamine (50.5 mg, 0.5 mmol) and HATU (47.5 mg, 0.125 mmol) of acetonitrile (5 mL) The mixture was stirred at 50 ° C for 3 hours. The title compound (12.7 mg, 27.3%) was obtained. LCMS: 370 [M + 1]. 1 H NMR (400 MHz, DMSO-d 6 ). 2.65-2.77(m,1H),2.86-2.98(m,1H),3.14-3.29(m,1H), 4.26-4.50(m,2H),7.43-7.50(m,1H),7.51-7.59(m , 1H), 7.76 (s, 1H). LCMS (ESI) m/z: 370 (M+1).
实施例9Example 9
6-氟-3-(1-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000067
Figure PCTCN2015075363-appb-000067
这个实施例如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.98-2.01(d,2H),2.29-2.31(d,2H),2.83(s,1H),3.01-3.04(d,2H),3.48(d,2H),7.36-7.39(m,1H),7.68-7.73(m,2H),8.49(s,1H).LCMS(ESI)m/z:316(M+1).This embodiment was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d4) ppm 1.98-2.01 (d, 2H), 2.29-2.31 (d, 2H), 2.83 (s, 1H), 3.01-3.04 (d, 2H), 3.48 (d, 2H) ), 7.36-7.39 (m, 1H), 7.68-7.73 (m, 2H), 8.49 (s, 1H). LCMS (ESI) m/z: 316 (M+1).
实施例10Example 10
6-氟-3-(1-异丙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(1-isopropylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000068
Figure PCTCN2015075363-appb-000068
这个实施例如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.38-1.40(d,6H),2.02-2.05(d,2H),2.36-2.40(d,2H),3.06(m,1H),3.19-3.22(t,2H),3.51-3.55(m,3H),7.35-7.38(m,1H),7.66-7.72(m,2H),8.51(s,1H).LCMS(ESI)m/z:344(M+1).This embodiment was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d4) ppm 1.38-1.40 (d, 6H), 2.02-2.05 (d, 2H), 2.36-2.40 (d, 2H), 3.06 (m, 1H), 3.19-3.22 (t , 2H), 3.51-3.55 (m, 3H), 7.35-7.38 (m, 1H), 7.66-7.72 (m, 2H), 8.51 (s, 1H). LCMS (ESI) m/z: 344 (M+ 1).
实施例11Example 11
6-氟-3-(1-(氧杂环丁烷-3-基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(oxetan-3-yl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide
Figure PCTCN2015075363-appb-000069
Figure PCTCN2015075363-appb-000069
这个实施例如实施例2中描述的方法制备。1H NMR(400MHz,DMSO-d6)ppm 1.66-1.79(m,2H),1.82-1.99(m,4H),2.58-2.69(m,1H),2.70-2.81(m,2H),3.36-3.45(m,1H),4.45(s,2H),4.51-4.58(m,2H),7.36-7.44(m,1H),7.45-7.53(m,1H),7.65-7.75(m,1H).LCMS(ESI)m/z:358(M+1).This embodiment was prepared as described in Example 2. 1 H NMR (400MHz, DMSO- d 6) ppm 1.66-1.79 (m, 2H), 1.82-1.99 (m, 4H), 2.58-2.69 (m, 1H), 2.70-2.81 (m, 2H), 3.36- 3.45 (m, 1H), 4.45 (s, 2H), 4.51-4.58 (m, 2H), 7.36-7.44 (m, 1H), 7.45-7.53 (m, 1H), 7.65-7.75 (m, 1H). LCMS (ESI) m/z: 358 (M+1).
实施例12Example 12
6-氟-3-(1-丙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-propylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000070
Figure PCTCN2015075363-appb-000070
这个实施例如实施例2中描述的方法制备。1H-NMR(400MHz,METHANOL-d4)ppm 1.02-1.06(t,3H),1.76-1.82(m,2H),2.00-2.03(d,2H),2.31-2.34(d,2H),3.01-3.05(m,5H),3.57-3.58(d,2H),7.36-7.39(m,1H),7.68-7.73(m,2H),8.51(s,1H).LCMS(ESI)m/z:344(M+1).This embodiment was prepared as described in Example 2. 1 H-NMR (400 MHz, METHANOL-d4) ppm 1.02-1.06 (t, 3H), 1.76-1.82 (m, 2H), 2.00-2.03 (d, 2H), 2.31-2.34 (d, 2H), 3.01 3.05 (m, 5H), 3.57-3.58 (d, 2H), 7.36-7.39 (m, 1H), 7.68-7.73 (m, 2H), 8.51 (s, 1H). LCMS (ESI) m/z: 344 (M+1).
实施例13Example 13
6-氟-3-(1-(2-氨乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-aminoethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000071
Figure PCTCN2015075363-appb-000071
这个实施例如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.80-1.98(m,2H),2.06-2.17(m,2H),2.30-2.46(m,2H),2.68-2.85(m,3H),3.05-3.19(m,4H),7.30-7.38(m,1H),7.69(br.s.,2H),8.28-8.67(m,1H).LCMS(ESI)m/z:345(M+1).This embodiment was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.80-1.98 (m, 2H), 2.06-2.17 (m, 2H), 2.30-2.46 (m, 2H), 2.68-2.85 (m, 3H), 3.05- 3.19 (m, 4H), 7.30-7.38 (m, 1H), 7.69 (br.s., 2H), 8.28-8.67 (m, 1H). LCMS (ESI) m/z: 345 (M+1).
实施例14Example 14
3-(1-(2-(二甲胺基)乙基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(2-(Dimethylamino)ethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000072
Figure PCTCN2015075363-appb-000072
这个实施例如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.83-1.98(m,2H),2.05-2.18(m,2H),2.36-2.48(m,2H),2.68(s,6H),2.80(t,J＝6.46Hz,3H),2.97-3.07(m,2H),3.11-3.25(m,2H),7.25-7.40(m,1H),7.57-7.75(m,2H).LCMS(ESI)m/z:373(M+1).This embodiment was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.83-1.98 (m, 2H), 2.05-2.18 (m, 2H), 2.36-2.48 (m, 2H), 2.68 (s, 6H), 2.80 (t, J=6.46 Hz, 3H), 2.97-3.07 (m, 2H), 3.11-3.25 (m, 2H), 7.25-7.40 (m, 1H), 7.57-7.75 (m, 2H). LCMS (ESI) m/ z: 373 (M+1).
实施例15Example 15
6-氟-3-(1-(2-甲氧基乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-methoxyethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
Figure PCTCN2015075363-appb-000073
Figure PCTCN2015075363-appb-000073
这个实施例如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 2.00-2.18(m,2H),2.22-2.38(m,2H),2.94-3.08(m,1H),3.08-3.22(m,2H),3.33-3.38(m,2H),3.44(s,3H),3.56-3.70(m,2H),3.71-3.82(m,2H),7.19-7.38(m,1H),7.53-7.64(m,1H),7.68(s,1H),8.42-8.66(m,1H).LCMS(ESI)m/z:360(M+1).This embodiment was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d4) ppm 2.00-2.18 (m, 2H), 2.22-2.38 (m, 2H), 2.94-3.08 (m, 1H), 3.08-3.22 (m, 2H), 3.33-3.38 (m, 2H), 3.44 (s, 3H), 3.56-3.70 (m, 2H), 3.71-3.82 (m, 2H), 7.19-7.38 (m, 1H), 7.53-7.64 (m, 1H), 7.68 (s, 1H), 8.42 - 8.66 (m, 1H). LCMS (ESI) m/z: 360 (M+1).
实施例16Example 16
6-氟-3-(1-(2-羟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-hydroxyethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000074
Figure PCTCN2015075363-appb-000074
这个实施例如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 2.04-2.20(m,2H),2.25-2.37(m,2H),2.98-3.10(m,1H),3.12-3.24(m,2H),3.25-3.31(m,2H),3.62-3.75(m,2H),3.89-3.99(m,2H),7.25-7.38(m,1H),7.57-7.66(m,1H),7.69(s,1H),8.50-8.62(m,1H).LCMS(ESI)m/z:346(M+1). This embodiment was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) ppm 2.04-2.20 (m, 2H), 2.25-2.37 (m, 2H), 2.98-3.10 (m, 1H), 3.12-3.24 (m, 2H), 3.25- 3.31 (m, 2H), 3.62-3.75 (m, 2H), 3.89-3.99 (m, 2H), 7.25-7.38 (m, 1H), 7.57-7.66 (m, 1H), 7.69 (s, 1H), 8.50-8.62 (m, 1H). LCMS (ESI) m/z: 346 (M+1).
实施例17Example 17
3-(1-乙基哌啶-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpiperidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000075
Figure PCTCN2015075363-appb-000075
本实施例中如实施例1和2中所述制备，其中用3-(羟甲基)哌啶-1-羧酸叔丁酯替代4-(羟基甲基)哌啶-1-甲酸叔丁酯。1H-NMR(MeOD,400MHz)δ:1.38(t,3H),1.85-2.00(m,2H),2.13-2.26(m,2H),2.94-3.03(m,2H),3.21-3.24(m,3H),3.59-3.73(m,2H),7.37-7.39(dd,1H),7.66-7.69(dd,1H),7.76(s,1H),8.52(bs,1H).LCMS(ESI)m/z:331(M+1).Prepared as described in Examples 1 and 2 in this example, in which tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate was substituted for tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate ester. 1 H-NMR (MeOD, 400MHz ) δ: 1.38 (t, 3H), 1.85-2.00 (m, 2H), 2.13-2.26 (m, 2H), 2.94-3.03 (m, 2H), 3.21-3.24 (m , 3H), 3.59-3.73 (m, 2H), 7.37-7.39 (dd, 1H), 7.66-7.69 (dd, 1H), 7.76 (s, 1H), 8.52 (bs, 1H). LCMS (ESI) m /z:331(M+1).
实施例18Example 18
3-(1-乙基氮杂环庚烷-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylazepane-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000076
Figure PCTCN2015075363-appb-000076
实施例18AExample 18A
1-叔丁基-4-乙基-5-氧代氮杂环庚烷-14-二羧酸二酯1-tert-butyl-4-ethyl-5-oxoazepane-14-dicarboxylic acid diester
Figure PCTCN2015075363-appb-000077
Figure PCTCN2015075363-appb-000077
-40℃氮气保护下，向4-氧代哌啶-1-甲酸叔丁酯(50克，251毫摩尔)和三氟化硼乙醚(49.86克，351毫摩尔)的THF(500毫升)溶液中滴加乙基-2-重氮基(40.09克，351毫摩尔)。滴加完毕后在-40℃搅拌2小时后，升温至15℃下搅拌16小时，反应完毕后用碳酸钾水溶液(500mL)淬灭，水层用乙酸乙酯(500毫升×2)萃取，将合并的有机层用水和盐水洗涤后，无水硫酸钠干燥，过滤并蒸发，残余物通过硅胶柱色谱法纯化得到标题化合物(45克，产率：63％)。LCMS(ESI)m/z:286(M+1).a solution of tert-butyl 4-oxopyridin-1-carboxylate (50 g, 251 mmol) and boron trifluoride diethyl ether (49.86 g, 351 mmol) in THF (500 mL) Ethyl-2-diazo (40.09 g, 351 mmol) was added dropwise. After the completion of the dropwise addition, the mixture was stirred at -40 ° C for 2 hours, and then heated to 15 ° C for 16 hours. After completion of the reaction, it was quenched with aqueous potassium carbonate (500 mL). The combined organic layer was washed with w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ LCMS (ESI) m/z: 286 (M+1).
实施例18BExample 18B
1-叔丁基-4-乙基-5-羟基氮杂-1,4-二羧酸二酯1-tert-butyl-4-ethyl-5-hydroxyaza-1,4-dicarboxylic acid diester
Figure PCTCN2015075363-appb-000078
Figure PCTCN2015075363-appb-000078
在0℃下，向实施例18A(45克，157.7毫摩尔)的甲醇(420毫升)溶液中分批加入硼氢化钠(7.16x克，189毫摩尔)。0℃下搅拌1小时后，将得到的混合物用水(400毫升)淬灭，水相用乙酸乙酯(400 毫升×2)萃取，将合并的有机层，用水,盐水洗涤，无水硫酸钠干燥，过滤并蒸发，残余物通过硅胶柱色谱法纯化以提供标题化合物(22.3g，收率：49％)。LCMS(ESI)m/z:288(M+1).Sodium borohydride (7.16 x g, 189 mmol) was added portionwise to a solution of <RTI ID=0.0>#</RTI> </RTI> <RTIgt; After stirring at 0 ° C for 1 hour, the resulting mixture was quenched with water (400 mL). The mixture was extracted with EtOAc (EtOAc m. LCMS (ESI) m/z: 288 (M+1).
实施例18CExample 18C
1-叔丁基-4-乙基2,3,6,7-四氢-1H-吖庚因-1,4-二羧酸二酯1-tert-butyl-4-ethyl 2,3,6,7-tetrahydro-1H-azepine-1,4-dicarboxylic acid diester
Figure PCTCN2015075363-appb-000079
Figure PCTCN2015075363-appb-000079
室温下向实施例18B(21克，73毫摩尔)，DBU(22克，146毫摩尔)的甲苯(200mL)溶液中滴加入MsCl(14.56克，128毫摩尔)，滴加完毕后在110℃下搅拌2小时。冷却至室温后，加入水(200毫升)淬灭，水层用乙酸乙酯(200毫升×2)萃取，将合并的有机层，用水，盐水洗涤，无水硫酸钠干燥，过滤并蒸发，残余物通过硅胶柱色谱纯化以提供标题化合物(13克，产率：66％)。LCMS(ESI)m/z:270(M+1).MsCl (14.56 g, 128 mmol) was added dropwise to a solution of EXAMPLE 18B (21 g, 73 mmol), DBU (22 g, 146 mmol) in toluene (200 mL) at 110 ° C. Stir under 2 hours. After cooling to rt, EtOAc (EtOAc)EtOAc. Purification by silica gel column chromatography afforded titled LCMS (ESI) m/z: 270 (M+1).
实施例18DExample 18D
1-叔丁基-4-甲基氮杂环庚烷-1,4-二羧酸二酯1-tert-butyl-4-methylazepane-1,4-dicarboxylic acid diester
Figure PCTCN2015075363-appb-000080
Figure PCTCN2015075363-appb-000080
实施例18C(13克，48.27毫摩尔)和Pd/C(1克)的甲醇(130毫升)混合物在15℃氢化16小时(1大气压)。将混合物过滤，将滤液蒸发，得到标题化合物(10.7g，收率：82％)可直接用于下一步骤而无需纯化。LCMS(ESI)m/z:258(M+1).A mixture of Example 18C (13 g, 48.27 mmol) and Pd / C (1 g) in methanol (130 mL) was hydrogenated at 15 ° C for 16 hours (1 atm). The mixture was filtered, and the filtrate was evaporated to crystalljjjjjjjjjjjjjj LCMS (ESI) m/z: 258 (M+1).
实施例18EExample 18E
4-(羟甲基)氮杂环庚烷-1-羧酸叔丁酯4-(hydroxymethyl)azetidin-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000081
Figure PCTCN2015075363-appb-000081
在0℃下，向实施例18D(10.7克，39毫摩尔)的THF(200毫升)溶液中分批加入四氢铝锂(1.48克，39毫摩尔)。在0℃下搅拌30分钟后，将得到的混合物用水(10毫升)，15％NaOH水溶液(10毫升)，水(30毫升)淬灭。将混合物过滤，滤液蒸发，残余物通过硅胶柱色谱法纯化得到标题化合物(7克，收率：77％)。LCMS(ESI)m/z:230(M+1).Lithium tetrahydroaluminum (1.48 g, 39 mmol) was added portionwise to a solution of EtOAc (EtOAc). After stirring at 0&lt;0&gt;C for 30 min, EtOAc (EtOAc)EtOAc. The mixture was filtered, and the filtrate was evaporated. LCMS (ESI) m/z: 230 (M+1).
实施例18FExample 18F
3-(1-乙基氮杂环庚烷-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-(1-ethylazepane-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000082
Figure PCTCN2015075363-appb-000082
本实施例中如实施例1和2中所述制备，其中用4-(羟甲基)氮杂环庚烷-1-羧酸叔丁酯替代4-(羟甲基)哌啶-1-羧酸叔丁酯。1H-NMR(MeOD,400MHz)δ:1.38-1.42(t,3H),1.93-1.96(m,2H),1.99-2.12(m,2H),2.32-2.34(m,2H),3.15-3.30(m,1H),3.32-3.33(m,2H),3.33-3.53(m,4H),7.38-7.40(dd,1H),7.69-7.73(dd,1H),7.74(s,1H),8.50(bs,1H).LCMS(ESI)m/z:344(M+1).Prepared as described in Examples 1 and 2 in this example, wherein 4-(hydroxymethyl)azetidin-1-carboxylic acid tert-butyl ester was substituted for 4-(hydroxymethyl)piperidine-1- Tert-butyl carboxylate. 1 H-NMR (MeOD, 400 MHz) δ: 1.38-1.42 (t, 3H), 1.93-1.96 (m, 2H), 1.99-2.12 (m, 2H), 2.32-2.34 (m, 2H), 3.15-3.30 (m, 1H), 3.32-3.33 (m, 2H), 3.33-3.53 (m, 4H), 7.38-7.40 (dd, 1H), 7.69-7.73 (dd, 1H), 7.74 (s, 1H), 8.50 (bs, 1H). LCMS (ESI) m/z: 344 (M+1).
实施例19Example 19
6-氟-3-(1-甲基氮杂环庚烷-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-methylazepane-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000083
Figure PCTCN2015075363-appb-000083
本实施例中如实施例18中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.95-2.10(m,3H),2.26-2.35(m,3H),2.96(s,1H),3.14-3.17(m,1H),3.36-3.49(m,4H),7.38-7.40(dd,1H),7.69-7.72(dd,1H),7.74(s,1H),8.47(bs,1H).LCMS(ESI)m/z:330(M+1).This example was prepared as described in Example 18. 1 H-NMR (MeOD, 400MHz) δ: 1.95-2.10 (m, 3H), 2.26-2.35 (m, 3H), 2.96 (s, 1H), 3.14 - 3.17 (m, 1H), 3.36-3.49 (m , 4H), 7.38-7.40 (dd, 1H), 7.69-7.72 (dd, 1H), 7.74 (s, 1H), 8.47 (bs, 1H). LCMS (ESI) m/z: 330 (M+1) .
实施例20Example 20
6-氟-3-(1-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000084
Figure PCTCN2015075363-appb-000084
本实施例中如实施例1和2中所述制备，其中用3-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟甲基)哌啶-1-羧酸叔丁酯。1H-NMR(MeOD,400MHz)δ:2.29-2.35(m,1H),2.59-2.62(m,1H),2.99(s,3H),3.32-3.36(m,1H),3.53-3.55(m,2H),3.76-3.81(m,2H),7.40-7.42(dd,1H),7.70-7.73(dd,1H),7.80(s,1H),8.50(bs,1H).LCMS(ESI)m/z:302(M+1).Prepared as described in Examples 1 and 2 in this example, in which tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate was substituted for 4-(hydroxymethyl)piperidine-1-carboxylic acid. Butyl ester. 1 H-NMR (MeOD, 400 MHz) δ: 2.29-2.35 (m, 1H), 2.59-2.62 (m, 1H), 2.99 (s, 3H), 3.32-3.36 (m, 1H), 3.53-3.55 (m) , 2H), 3.76-3.81 (m, 2H), 7.40-7.42 (dd, 1H), 7.70-7.73 (dd, 1H), 7.80 (s, 1H), 8.50 (bs, 1H). LCMS (ESI) m /z:302(M+1).
实施例21Example 21
3-(1-乙基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000085
Figure PCTCN2015075363-appb-000085
本实施例中如实施例20中所述制备，其中用3-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟基甲基)哌 啶-1-甲酸叔丁酯。1H-NMR(MeOD,400MHz)δ:2.29-2.35(m,1H),2.59-2.62(m,1H),2.99(s,3H),3.32-3.36(m,1H),3.53-3.55(m,2H),3.76-3.81(m,2H),7.40-7.42(dd,1H),7.70-7.73(dd,1H),7.80(s,1H),8.50(bs,1H).LCMS(ESI)m/z:316(M+1).This example was prepared as described in Example 20, in which tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was replaced with tert-butyl 3-(hydroxymethyl)pyrrolidin-1-carboxylate. 1 H-NMR (MeOD, 400 MHz) δ: 2.29-2.35 (m, 1H), 2.59-2.62 (m, 1H), 2.99 (s, 3H), 3.32-3.36 (m, 1H), 3.53-3.55 (m) , 2H), 3.76-3.81 (m, 2H), 7.40-7.42 (dd, 1H), 7.70-7.73 (dd, 1H), 7.80 (s, 1H), 8.50 (bs, 1H). LCMS (ESI) m /z:316(M+1).
实施例22Example 22
6-氟-3-(1-异丙基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isopropylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000086
Figure PCTCN2015075363-appb-000086
本实施例中如实施例20中所述制备，其中用3-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟基甲基)哌啶-1-甲酸叔丁酯。1H-NMR(MeOD,400MHz)δ:1.42-1.44(d,6H),2.25-2.31(m,1H),2.57-2.60(m,1H),3.32-3.33(m,1H),3.44-3.55(m,3H),3.68-3.71(m,1H),7.41-7.43(dd,1H),7.71-7.74(dd,1H),7.82(s,1H),8.55(bs,1H).LCMS(ESI)m/z:330(M+1).This example was prepared as described in Example 20, in which tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was replaced with tert-butyl 3-(hydroxymethyl)pyrrolidin-1-carboxylate. 1 H-NMR (MeOD, 400MHz) δ: 1.42-1.44 (d, 6H), 2.25-2.31 (m, 1H), 2.57-2.60 (m, 1H), 3.32-3.33 (m, 1H), 3.44-3.55 (m, 3H), 3.68-3.71 (m, 1H), 7.41-7.43 (dd, 1H), 7.71-7.74 (dd, 1H), 7.82 (s, 1H), 8.55 (bs, 1H). LCMS (ESI) ) m / z: 330 (M + 1).
实施例23Example 23
6-氟-3-(吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(pyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000087
Figure PCTCN2015075363-appb-000087
本实施例中如实施例1中所述制备，其中用-2-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟基甲基)哌啶-1-甲酸叔丁酯。1H-NMR(400MHz,MethanoL-d4)δppm 2.17-2.31(m,1H),2.33-2.51(m,2H),2.52-2.67(m,1H),3.48(t,J＝7.28Hz,2H),7.40(dd,J＝8.03,2.26Hz,1H),7.65(dd,J＝10.79,2.26Hz,1H),7.94(s,1H),8.55(br.s.,1H).LCMS(ESI)m/z:288(M+1).Prepared as described in Example 1 in this example, in which tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was replaced with tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate. . 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 2.17-2.31 (m, 1H), 2.33-2.51 (m, 2H), 2.52-2.67 (m, 1H), 3.48 (t, J = 7.28 Hz, 2H) ), 7.40 (dd, J = 8.03, 2.26 Hz, 1H), 7.65 (dd, J = 10.79, 2.26 Hz, 1H), 7.94 (s, 1H), 8.55 (br.s., 1H). LCMS (ESI) ) m / z: 288 (M + 1).
实施例24Example 24
6-氟-3-(1-丙基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-propylpyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000088
Figure PCTCN2015075363-appb-000088
这个实施例如实施例2中所述制备，其中用-2-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟基甲基)哌啶-1-甲酸叔丁酯。1H-NMR(400MHz,MethanoL-d4)δppm 0.93(t,J＝7.34Hz,3H),1.54-1.79(m,2H),2.23(d,J＝5.02Hz,2H),2.37-2.53(m,2H),2.76(br.s.,1H),3.05(br.s.,2H),3.65(br.s.,1H),4.31(br.s.,1H),7.44(dd,J＝8.09,2.32Hz,1H),7.73(dd,J＝10.92,2.38Hz,1H),7.94(s,1H),8.54(br.s.,1H).LCMS(ESI)m/z:330(M+1). This was prepared as described in Example 2, in which tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was replaced with tert-butyl 2-(hydroxymethyl)pyrrolidin-1-carboxylate. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 0.93 (t, J = 7.34 Hz, 3H), 1.54-1.79 (m, 2H), 2.23 (d, J = 5.02 Hz, 2H), 2.37-2.53 ( m, 2H), 2.76 (br.s., 1H), 3.05 (br.s., 2H), 3.65 (br.s., 1H), 4.31 (br.s., 1H), 7.44 (dd, J = 8.09, 2.32 Hz, 1H), 7.73 (dd, J = 10.92, 2.38 Hz, 1H), 7.94 (s, 1H), 8.54 (br.s., 1H). LCMS (ESI) m/z: 330 ( M+1).
实施例25Example 25
6-氟-3-(1-甲基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-methylpyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000089
Figure PCTCN2015075363-appb-000089
这个实施例如实施例2中所述制备，其中用2-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟基甲基)哌啶-1-甲酸叔丁酯。1H-NMR(400MHz,MethanoL-d4)δppm 2.25-2.41(m,2H),2.47-2.67(m,2H),2.82(s,3H),3.23-3.30(m,1H),3.66-3.79(m,1H),4.50-4.58(m,1H),7.43(dd,J＝8.16,2.51Hz,1H),7.64(dd,J＝10.73,2.57Hz,1H),7.95-8.02(m,1H),8.52(br.s.,1H).LCMS(ESI)m/z:302(M+1).This was prepared as described in Example 2, in which tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was replaced with tert-butyl 2-(hydroxymethyl)pyrrolidin-1-carboxylate. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 2.25-2.41 (m, 2H), 2.47-2.67 (m, 2H), 2.82 (s, 3H), 3.23-3.30 (m, 1H), 3.66-3.79 (m, 1H), 4.50-4.58 (m, 1H), 7.43 (dd, J = 8.16, 2.51 Hz, 1H), 7.64 (dd, J = 10.73, 2.57 Hz, 1H), 7.95-8.02 (m, 1H) ), 8.52 (br.s., 1H). LCMS (ESI) m/z: 302 (M + 1).
实施例26Example 26
3-(1-乙基吡咯烷-2-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpyrrolidin-2-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000090
Figure PCTCN2015075363-appb-000090
这个实施例如实施例2中所述制备，其中用2-(羟甲基)吡咯烷-1-羧酸叔丁酯替代4-(羟基甲基)哌啶-1-甲酸叔丁酯。1H-NMR(400MHz,MethanoL-d4)δppm 1.30(t,J＝7.28Hz,3H),2.26-2.37(m,2H),2.46-2.61(m,2H),2.98-3.09(m,1H),3.25(d,J＝10.29Hz,2H),3.68-3.80(m,1H),4.55(t,J＝8.78Hz,1H),7.42(dd,J＝8.16,2.26Hz,1H),7.64(dd,J＝10.73,2.32Hz,1H),7.97(s,1H),8.54(br.s.,1H).LCMS(ESI)m/z:316(M+1).This was prepared as described in Example 2, in which tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was replaced with tert-butyl 2-(hydroxymethyl)pyrrolidin-1-carboxylate. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 1.30 (t, J = 7.28 Hz, 3H), 2.26-2.37 (m, 2H), 2.46-2.61 (m, 2H), 2.98-3.09 (m, 1H) ), 3.25 (d, J = 10.29 Hz, 2H), 3.68-3.80 (m, 1H), 4.55 (t, J = 8.78 Hz, 1H), 7.42 (dd, J = 8.16, 2.26 Hz, 1H), 7.64 (dd, J = 10.73, 2.32 Hz, 1H), 7.97 (s, 1H), 8.54 (br.s., 1H). LCMS (ESI) m/z: 316 (M+1).
实施例27Example 27
3-(1-乙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000091
Figure PCTCN2015075363-appb-000091
这个实施例是如在实施例1中所述制备，用2,6-二溴苯基肼替代2,6-二溴-4-氟苯基肼制备。1H-NMR(400MHz,METHANOL-d4)ppm 1.16-1.20(t,3H),1.84-1.87(m,2H),2.07-2.11(d,2H),2.16-2.19(d,2H),2.51-2.56(q,2H),2.70-2.75(m,1H),3.11-3.13(d,2H),7.40-7.44(t,1H),7.61-7.63(m,1H),7.70(s,1H),7.99-8.02(m,1H).LCMS(ESI)m/z:312(M+1).This example was prepared as described in Example 1, using 2,6-dibromophenylphosphonium instead of 2,6-dibromo-4-fluorophenylhydrazine. 1H-NMR (400MHz, METHANOL-d4) ppm 1.16-1.20 (t, 3H), 1.84-1.87 (m, 2H), 2.07-2.11 (d, 2H), 2.16-2.19 (d, 2H), 2.51-2.56 (q, 2H), 2.70-2.75 (m, 1H), 3.11-3.13 (d, 2H), 7.40-7.44 (t, 1H), 7.61-7.63 (m, 1H), 7.70 (s, 1H), 7.99 -8.02 (m, 1H). LCMS (ESI) m/z: 312 (M+1).
实施例28Example 28
6-氟-3-(3-甲基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(3-methyl-3-azabicyclo [3.1.0]hexane-1 -yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000092
Figure PCTCN2015075363-appb-000092
实施例28AExample 28A
1-苄基-2,5-二氢-1H-吡咯-3-羧酸乙酯Ethyl 1-benzyl-2,5-dihydro-1H-pyrrole-3-carboxylate
Figure PCTCN2015075363-appb-000093
Figure PCTCN2015075363-appb-000093
在0℃，向N-苄基-1-甲氧基-N-((三甲基硅烷基)甲基)甲胺(4.5克，61毫摩尔)和丙炔酸乙酯(5.0克，51毫摩尔)的二氯甲烷(150mL)溶液中滴加入三乙胺(0.4毫升，5.2毫摩尔)。滴加完毕之后，在0℃下搅拌1小时，升温至20℃搅拌24h，反应混合物用饱和NaHCO 3(100mL)淬灭，水相用二氯甲烷(250毫升×2)萃取，将合并的有机层用盐水(150毫升×2)洗涤并用无水硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化以提供标题化合物(10g，收率：80％)，为黄色油状物。LCMS(ESI)m/z:232(M+1).To N-benzyl-1-methoxy-N-((trimethylsilyl)methyl)methylamine (4.5 g, 61 mmol) and ethyl propiolate (5.0 g, 51) Triethylamine (0.4 mL, 5.2 mmol) was added dropwise to a solution of dichloromethane (150 mL). After the completion of the dropwise addition, the mixture was stirred at 0 ° C for 1 hour, warmed to 20 ° C and stirred for 24 h. The mixture was quenched with saturated NaHCO 3 (100 mL). The layers were washed with EtOAc EtOAc EtOAc. LCMS (ESI) m/z: 232 (M+1).
实施例28BExample 28B
3-苄基-3-氮杂双环[3.1.0]己烷-1-羧酸乙酯3-benzyl-3-azabicyclo[3.1.0]hexane-1-carboxylic acid ethyl ester
Figure PCTCN2015075363-appb-000094
Figure PCTCN2015075363-appb-000094
在0℃-5℃下氮气保护下，向(CH 3)3SOI(21.5克，97.7毫摩尔)的DMSO(150毫升)混合物中分批加入60％氢化钠(3.5克，87.5毫摩尔)，加完后在19℃下搅拌2小时后，0℃-5℃分批加入实施例28A(9克，38.9毫摩尔)。混合反应液在19℃下搅拌15小时后，用饱和碳酸氢钠(300毫升)淬灭，水相用二氯甲烷(500毫升×2)萃取，将合并的有机层用盐水(200毫升×2)洗涤并用无水硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化以提供的标题化合物(5.4g，收率：32％)，为黄色油状物。LCMS(ESI)m/z:246(M+1).Add 60% sodium hydride (3.5 g, 87.5 mmol) to a mixture of (CH 3 ) 3 SOI (21.5 g, 97.7 mmol) in DMSO (150 mL) at 0 ° C - 5 ° C. After stirring at 19 ° C for 2 hours, Example 28A (9 g, 38.9 mmol) was added portionwise from 0 °C to 5 °C. The mixture was stirred at 19 ° C for 15 hr then EtOAc (EtOAc)EtOAc. The organic layer was washed with EtOAc EtOAc EtOAc. LCMS (ESI) m/z: 246 (M+1).
实施例28CExample 28C
3-叔丁基-1-乙基-3-氮杂双环[3.1.0]己烷-1,3-二羧酸二酯3-tert-Butyl-1-ethyl-3-azabicyclo[3.1.0]hexane-1,3-dicarboxylic acid diester
Figure PCTCN2015075363-appb-000095
Figure PCTCN2015075363-appb-000095
将实施例28B的(5.4克，22毫摩尔)，BOC 2O(10克，46毫摩尔)和10％的Pd/C(600毫克)的甲醇(100毫升)混合液在19℃氢化15小时(1大气压)。将混合物过滤，滤液蒸发，残余物通过柱 色谱纯化得到标题化合物(5.3g，收率：94％)，为无色油状物。1H-NMR(400MHz,CDCl3)δppm 0.83(t,J＝4.96Hz,1H),1.25(t,J＝7.15Hz,3H),1.39-1.48(m,9H),1.56(dd,J＝8.34,4.58Hz,1H),1.79(s,1H),1.94-2.10(m,1H),3.41(dd,J＝10.73,3.45Hz,1H),3.50-3.82(m,3H),4.07-4.19(m,2H),4.25(d,J＝7.15Hz,1H),5.05(s,1H),6.61(t,J＝1.88Hz,1H),7.14(s,1H),7.28-7.38(m,1H)A mixture of (5.4 g, 22 mmol) of EXAMPLE 28B, EtOAc (10 g, 46 mmol) and 10% of EtOAc (EtOAc) 1 atmosphere). The mixture was filtered, and the residue was evaporated. 1 H-NMR (400 MHz, CDCl 3 ) δ ppm 0.83 (t, J = 4.96 Hz, 1H), 1.25 (t, J = 7.15 Hz, 3H), 1.39-1.48 (m, 9H), 1.56 (dd, J = 8.34, 4.58 Hz, 1H), 1.79 (s, 1H), 1.94-2.10 (m, 1H), 3.41 (dd, J = 10.73, 3.45 Hz, 1H), 3.50-3.82 (m, 3H), 4.07-4.19 (m, 2H), 4.25 (d, J = 7.15 Hz, 1H), 5.05 (s, 1H), 6.61 (t, J = 1.88 Hz, 1H), 7.14 (s, 1H), 7.28-7.38 (m, 1H)
实施例28DExample 28D
1-(羟甲基)-3-氮杂双环[3.1.0]己烷-3-甲酸叔丁基酯1-(Hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000096
Figure PCTCN2015075363-appb-000096
实施例28C的(5.3克，20.7毫摩尔)和1N氢氧化锂(50毫升，50毫摩尔)的四氢呋喃(25mL)和甲醇(50mL)混合溶液在60℃下搅拌2小时。冷却至室温，将混合物用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水(50毫升×2)，盐水(50毫升×2)洗涤，无水硫酸钠干燥，蒸发得到残余物溶解在四氢呋喃(100毫升)中，在0℃下氮气保护下滴加10M硼烷二甲硫醚(10毫升，100毫摩尔)，滴加完毕后混合物在19℃下搅拌15小时，反应完毕后用甲醇(100mL)淬灭，真空蒸发溶液，残余物通过柱色谱法纯化得到标题化合物(3.5g，收率：89％)，为无色油状物。1H-NMR(400MHz,CDCl3)δppm0.51(br.s.,1H,0.78(dd,J＝8.09,5.08Hz,1H),1.37-1.47(m,10H),3.42(d,J＝10.29Hz,2H,3.48-3.78(m,4H).A mixed solution of (5.3 g, 20.7 mmol) and 1N lithium hydroxide (50 ml, 50 mmol) of tetrahydrofuran (25 mL) and methanol (50 mL) was stirred at 60 ° C for 2 hours. After cooling to room temperature, the mixture was extracted with EtOAc (EtOAc m. Dissolved in tetrahydrofuran (100 ml), 10 M borane dimethyl sulfide (10 ml, 100 mmol) was added dropwise under a nitrogen atmosphere at 0 ° C. After the addition was completed, the mixture was stirred at 19 ° C for 15 hours. The title compound (3.5 g, yield: ield: 89%). 1 H-NMR (400 MHz, CDCl 3 ) δ ppm 0.51 (br.s., 1H, 0.78 (dd, J = 8.09, 5.08 Hz, 1H), 1.37-1.47 (m, 10H), 3.42 (d, J = 10.29Hz, 2H, 3.48-3.78 (m, 4H).
实施例28EExample 28E
1-(氯甲基)-3-氮杂双环[3.1.0]己烷-3-甲酸叔丁基酯1-(Chloromethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000097
Figure PCTCN2015075363-appb-000097
在0℃下，向实施例28D(3.5克，16.43毫摩尔)，DMAP(200毫克，1.6毫摩尔)和三乙胺(5毫升，36.14毫摩尔)的二氯甲烷中(100毫升)混合物中分批加入TosCl(3.7克，19.47毫摩尔)。混合物在24℃下搅拌15小时后，用水(100毫升)淬灭。水层用二氯甲烷(250毫升×2)萃取，将合并的有机层用盐水洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(2.6克收率：68％)，为无色油状物。1H-NMR(400MHz,CDCl3)δppm 0.68(t,J＝4.64Hz,1H),0.90(dd,J＝8.16,5.27Hz,1H),1.39-1.55(m,10H),3.36-3.46(m,2H),3.48-3.77(m,4H).To a mixture of Example 28D (3.5 g, 16.43 mmol), DMAP (200 mg, 1.6 mmol) and triethylamine (5 mL, 36.14 mmol) in dichloromethane (100 mL) TosCl (3.7 g, 19.47 mmol) was added in portions. The mixture was stirred at 24 &lt;0&gt;C for 15 h then quenched with water (100 mL). The aqueous layer was extracted with EtOAc (EtOAc (EtOAc). , is a colorless oil. 1 H-NMR (400 MHz, CDCl 3 ) δ ppm 0.68 (t, J = 4.64 Hz, 1H), 0.90 (dd, J = 8.16, 5.27 Hz, 1H), 1.39-1.55 (m, 10H), 3.36-3.46 ( m, 2H), 3.48-3.77 (m, 4H).
实施例28FExample 28F
1-(氰基甲基)-3-氮杂双环[3.1.0]己烷-3-甲酸叔丁基酯1-(cyanomethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000098
Figure PCTCN2015075363-appb-000098
实施例28E(2.6克，11毫摩尔)，氰化钠(1.57克，32毫摩尔)和碘化钾(1.87克，11毫摩尔)的DMSO(40mL)混合物在100-120℃搅拌2小时。冷却至室温后，将混合物分散在乙酸乙酯(200mL)和碳酸钠水溶液(120毫升)中，水层用乙酸乙酯(100毫升×2)萃取，将合并的有机层用盐水洗涤，硫酸钠干 燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(2.4g，收率：96％)，为无色油状物。1H-NMR(400MHz,CDCl3)δppm 0.47-0.72(m,1H),0.81-0.96(m,1H),1.34-1.55(m,10H),2.53-2.80(m,2H),3.30(d,J＝10.54Hz,1H),3.38-3.84(m,1H).LCMS(ESI)m/z:167(M-55).A mixture of Example 28E (2.6 g, 11 mmol), sodium cyanide (1.57 g, 32 mmol) and EtOAc (1. After cooling to room temperature, the mixture was combined with EtOAc EtOAc EtOAc. It was dried, filtered and evaporated. 1 H-NMR (400 MHz, CDCl 3 ) δ ppm 0.47-0.72 (m, 1H), 0.81 - 0.96 (m, 1H), 1.34-1.55 (m, 10H), 2.53 - 2.80 (m, 2H), 3.30 (d) , J=10.54 Hz, 1H), 3.38-3.84 (m, 1H). LCMS (ESI) m/z: 167 (M-55).
实施例28GExample 28G
1-(1-氰基-2-(二甲基氨基)乙烯基)-3-氮杂二环[3.1.0]己烷-3-甲酸叔丁基酯1-(1-Cyano-2-(dimethylamino)vinyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000099
Figure PCTCN2015075363-appb-000099
1-叔丁氧基-N，N，N'，N'-四甲基甲二胺(3.8克，21.8毫摩尔)和实施例28F(2.4克，10.8毫摩尔)的DMF(20mL)混合物在70℃搅拌约10小时。冷却至室温后，真空蒸除溶剂，提供标题化合物可直接用于下一步骤而无需进一步纯化。a mixture of 1-tert-butoxy-N,N,N',N'-tetramethylformamide (3.8 g, 21.8 mmol) and Example 28F (2.4 g, 10.8 mmol) in DMF (20 mL) Stir at 70 ° C for about 10 hours. After cooling to rt.
实施例28HExample 28H
1-(1-氰基-2-羟基乙烯基)-3-氮杂双环[3.1.0]己烷-3-甲酸叔丁基酯1-(1-Cyano-2-hydroxyvinyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000100
Figure PCTCN2015075363-appb-000100
实施例28G(3.0克，粗，10.8毫摩尔)的四氢呋喃/乙酸/水(1/1/1)(45毫升)混合溶液中在24℃搅拌5小时。真空除去溶液后，将残余物分散在饱和碳酸氢钠(100毫升)和乙酸乙酯(100mL)中，水相用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水(100毫升×2)，盐水(100毫升×2)洗涤，无水硫酸钠干燥，过滤并蒸发，残余物通过柱色谱纯化得到标题化合物(1.4g，收率：52％)，为黄色油状物。LCMS(ESI)m/z:195(M-55).Example 28G (3.0 g, crude, 10.8 mmol) of a mixture of tetrahydrofuran / acetic acid / water (1/1/1) (45 ml) was stirred at 24 ° C for 5 hours. After the solution was removed in vacuo, EtOAc EtOAc (EtOAc) The mixture was washed with EtOAc (EtOAc m. LCMS (ESI) m/z:195 (M-55).
实施例28IExample 28I
3-(3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-Azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000101
Figure PCTCN2015075363-appb-000101
这个实施例如实施例1E-1J中所述制备。This example was prepared as described in Examples 1E-1J.
实施例28JExample 28J
6-氟-3-(3-甲基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(3-methyl-3-azabicyclo[3.1.0]hexane-1-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000102
Figure PCTCN2015075363-appb-000102
这个实施例如实施例2中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)δppm 1.32(d,J＝6.40Hz,2H),2.05(td,J＝6.37,3.95Hz,1H),2.93(s,3H),3.47(d,J＝11.04Hz,1H),3.59(dd,J＝11.11,3.83Hz,1H),3.67-3.76(m,1H),3.85(d,J＝11.04Hz,1H),7.32(dd,J＝8.16,2.51Hz,1H),7.58(dd,J＝10.79,2.51Hz,1H),7.77(s,1H),8.52(s,1H).LCMS(ESI)m/z:314(M+1).This embodiment was prepared as described in Example 2. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 1.32 (d, J = 6.40 Hz, 2H), 2.05 (td, J = 6.37, 3.95 Hz, 1H), 2.93 (s, 3H), 3.47 (d, J=11.04 Hz, 1H), 3.59 (dd, J=11.11, 3.83 Hz, 1H), 3.67-3.76 (m, 1H), 3.85 (d, J=11.04 Hz, 1H), 7.32 (dd, J=8.16) , 2.51 Hz, 1H), 7.58 (dd, J = 10.79, 2.51 Hz, 1H), 7.77 (s, 1H), 8.52 (s, 1H). LCMS (ESI) m/z: 314 (M+1).
实施例29Example 29
3-(3-乙基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-ethyl-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000103
Figure PCTCN2015075363-appb-000103
本实施例中如实施例28中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)δppm 1.27-1.37(m,5H),1.95-2.11(m,1H),3.22(q,J＝7.19Hz,2H),3.41(d,J＝10.92Hz,1H),3.48-3.57(m,1H),3.69(s,1H),3.86(d,J＝10.92Hz,1H),7.33(dd,J＝8.16,2.51Hz,1H),7.64(dd,J＝10.85,2.57Hz,1H),7.79(s,1H),8.51(s,1H).LCMS(ESI)m/z:328(M+1).This example was prepared as described in Example 28. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 1.27-1.37 (m, 5H), 1.95-2.11 (m, 1H), 3.22 (q, J = 7.19 Hz, 2H), 3.41 (d, J = 10.92) Hz, 1H), 3.48-3.57 (m, 1H), 3.69 (s, 1H), 3.86 (d, J = 10.92 Hz, 1H), 7.33 (dd, J = 8.16, 2.51 Hz, 1H), 7.64 (dd , J = 10.85, 2.57 Hz, 1H), 7.79 (s, 1H), 8.51 (s, 1H). LCMS (ESI) m/z: 328 (M+1).
实施例30Example 30
3-(3-环丁基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-Cyclobutyl-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridinium Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000104
Figure PCTCN2015075363-appb-000104
本实施例中如实施例28中描述的方法制备。1H-NMR(400MHz,DMSO-d6+D2O)0.77(dd,J＝7.91,4.14Hz,1H),1.22(t,J＝4.14Hz,1H),1.51-1.68(m,3H),1.77-1.96(m,4H),2.47(br.s.,2H),2.88(d,J＝8.78Hz,1H),2.98-3.13(m,2H),7.44(dd,J＝8.41,2.51Hz,1H),7.52(dd,J＝10.98,2.57Hz,1H),7.71(s,1H).LCMS(ESI)m/z:354(M+1).This example was prepared as described in Example 28. 1 H-NMR (400 MHz, DMSO-d 6 + D 2 O) 0.77 (dd, J = 7.91, 4.14 Hz, 1H), 1.22 (t, J = 4.14 Hz, 1H), 1.51-1.68 (m, 3H) , 1.77-1.96 (m, 4H), 2.47 (br.s., 2H), 2.88 (d, J = 8.78 Hz, 1H), 2.98-3.13 (m, 2H), 7.44 (dd, J = 8.41, 2.51) Hz, 1H), 7.52 (dd, J = 10.98, 2.57 Hz, 1H), 7.71 (s, 1H). LCMS (ESI) m/z: 354 (M+1).
实施例31Example 31
3-(3-环丙亚甲基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-cyclopropionethylene-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000105
Figure PCTCN2015075363-appb-000105
本实施例中如实施例28中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 0.32-0.35(m,2 H),0.65-0.68(m,2H),1.06(m,1H),1.16-1.19(m,1H),1.39-1.42(t,1H),1.92–1.94(m,1H),2.84-2.85(d,2H),3.18-3.21(m,1H),3.56-3.59(d,2H),3.73-3.75(d,2H),7.35-7.39(dd,1H),7.68-7.71(dd,1H),7.78(s,1H),8.55(s,1H).LCMS(ESI)m/z:354(M+1).This example was prepared as described in Example 28. 1 H NMR (400MHz, METHANOL- d4) ppm 0.32-0.35 (m, 2 H), 0.65-0.68 (m, 2H), 1.06 (m, 1H), 1.16-1.19 (m, 1H), 1.39-1.42 ( t,1H), 1.92–1.94 (m, 1H), 2.84-2.85 (d, 2H), 3.18-3.21 (m, 1H), 3.56-3.59 (d, 2H), 3.73-3.75 (d, 2H), 7.35-7.39 (dd, 1H), 7.68-7.71 (dd, 1H), 7.78 (s, 1H), 8.55 (s, 1H). LCMS (ESI) m/z: 354 (M+1).
实施例32Example 32
6-氟-3-(3-异丙基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(3-isopropyl-3-azabicyclo[3.1.0]hexane-1-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000106
Figure PCTCN2015075363-appb-000106
本实施例中如实施例28中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)1.25-1.43(m,8H),2.00-2.15(m,1H),3.39(s,1H),3.49(d,J＝11.04Hz,1H),3.62(d,J＝3.89Hz,1H),3.71(s,1H),3.90(d,J＝10.92Hz,1H),7.29-7.40(m,1H),7.64(dd,J＝10.85,2.57Hz,1H),7.79(s,1H),8.52(br.s.,1H).LCMS(ESI)m/z:342(M+1).This example was prepared as described in Example 28. 1 H-NMR (400 MHz, Methano L-d 4 ) 1.25-1.43 (m, 8H), 2.00-2.15 (m, 1H), 3.39 (s, 1H), 3.49 (d, J = 11.04 Hz, 1H), 3.62 (d, J = 3.89 Hz, 1H), 3.71 (s, 1H), 3.90 (d, J = 10.92 Hz, 1H), 7.29-7.40 (m, 1H), 7.64 (dd, J = 10.85, 2.57 Hz, 1H), 7.79 (s, 1H), 8.52 (br.s., 1H). LCMS (ESI) m/z: 342 (M+1).
实施例33Example 33
3-(3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-Azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000107
Figure PCTCN2015075363-appb-000107
实施例33AExample 33A
5-苄基-4,6-二氧代-1，4,5,6,6a-六氢[3,4-c]吡唑-3-羧酸乙酯Ethyl 5-benzyl-4,6-dioxo-1,4,5,6,6a-hexahydro[3,4-c]pyrazole-3-carboxylate
Figure PCTCN2015075363-appb-000108
Figure PCTCN2015075363-appb-000108
1-苄基-1H-吡咯--2,5-二酮(5.0克，26.7毫摩尔)和2-propionyldiazenecarbaldehyde(2.9毫升，28.0毫摩尔)的甲苯(30mL)混合物在30℃搅拌5h。真空除去溶液后，残余物用硅胶色谱纯化得到标题化合物(7.67克，产率95.4％)。LCMS(ESI)m/z:302(M+1).A mixture of 1-benzyl-1H-pyrrole-2,5-dione (5.0 g, 26.7 mmol) and 2-propionyldiazenecarbaldehyde (2.9 mL, 28.0 mmol) in toluene (30 mL) was stirred at 30 ° C for 5 h. After the solution was removed in vacuo, EtOAc m. LCMS (ESI) m/z: 302 (M+1).
实施例33BExample 33B
3-苄基-2,4-二氧代-3-氮杂双环[3.1.0]己烷-6-羧酸乙酯Ethyl 3-benzyl-2,4-dioxo-3-azabicyclo[3.1.0]hexane-6-carboxylate
Figure PCTCN2015075363-appb-000109
Figure PCTCN2015075363-appb-000109
实施例33A(7.67克，25.5毫摩尔)加热至190℃1小时。残余物通过色谱法纯化得到标题化合物(5.353克，76.9％)，为白色固体。LCMS(ESI)m/z:274(M+1). Example 33A (7.67 g, 25.5 mmol) was heated to 190 °C for 1 hour. The residue was purified by EtOAcqqqqqq LCMS (ESI) m/z: 274 (M+1).
实施例33CExample 33C
(3-苄基-3-氮杂双环[3.1.0]己-6-基)甲醇(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)methanol
Figure PCTCN2015075363-appb-000110
Figure PCTCN2015075363-appb-000110
0℃在氮气保护下，向四氢铝锂(3.055克，80.4毫摩尔)的四氢呋喃(50mL)悬浮液中逐滴加入实施例33B(5.353克，19.6毫摩尔)的30毫升四氢呋喃溶液。回流16小时后，反应混合物用饱和硫酸钠水溶液(5mL)淬灭，将有机层用硫酸钠干燥，过滤并蒸发，得到残余物通过色谱法纯化得到标题化合物(1.42克，35.8％)。LCMS(ESI)m/z:204(M+1).To a suspension of lithium tetrahydroaluminum (3.055 g, 80.4 mmol) in tetrahydrofuran (50 mL) was added dropwise a solution of EXAMPLE 33B (5.353 g, 19.6 mmol) in 30 mL of THF. After refluxing for 16 h, EtOAcqqqqqqqqqqQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ LCMS (ESI) m/z: 204 (M+1).
实施例33DExample 33D
6-(羟甲基)-3-氮杂二环[3.1.0]己烷-3-甲酸叔丁基酯6-(Hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000111
Figure PCTCN2015075363-appb-000111
实施例33C(1.42克，7.0毫摩尔)，Boc 2O(1.81克，8.4毫摩尔)和10％Pd/C(200毫克)的甲醇(80mL)混合物在25℃氢化16小时(1大气压)。将混合物过滤，将滤液蒸发，得到残余物用色谱法纯化得到标题化合物4(1.14克，76％)。LCMS(ESI)m/z:214(M+1).A mixture of Example 33C (1.42 g, 7.0 mmol), Boc 2 O (1.81 g, 8.4 mmol) and 10% Pd/C (200 mg) in methanol (80 mL) was hydrogenated at 25 ° C for 16 hours (1 atm). The mixture was filtered, and the title crystalljjjjjjjjjjj LCMS (ESI) m/z: 214 (M+1).
实施例33EExample 33E
3-(3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-Azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000112
Figure PCTCN2015075363-appb-000112
这个实施例是如实施例1E-1J中所述制备。1H NMR(400MHz,METHANOL-d4)ppm 1.86-1.95(m,1H),2.12-2.22(m,2H),3.49-3.65(m,4H),7.34-7.42(m,1H),7.64-7.74(m,2H),8.42-8.61(m,1H).LCMS(ESI)m/z:300(M+1).This example was prepared as described in Examples 1E-1J. 1 H NMR (400 MHz, METHANOL-d4) ppm 1.86-1.95 (m, 1H), 2.12-2.22 (m, 2H), 3.49-3.65 (m, 4H), 7.34-7.42 (m, 1H), 7.64-7.74 (m, 2H), 8.42-8.61 (m, 1H). LCMS (ESI) m/z: 300 (M+1).
实施例34Example 34
3-(3-乙基-3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(3-ethyl-3-azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000113
Figure PCTCN2015075363-appb-000113
本实施例中如实施例28中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.26(s,3H),1.95-2.02(m,2H),2.11-2.18(m,1H),2.85-2.95(m,2H),2.96-3.08(m,2H),3.42-3.58(m,2H),7.30-7.38(m,1H),7.60-7.65(m,1H),7.65-7.70(m,1H).LCMS(ESI)m/z:328(M+1). This example was prepared as described in Example 28. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.26 (s, 3H), 1.95-2.02 (m, 2H), 2.11-2.18 (m, 1H), 2.85-2.95 (m, 2H), 2.96-3.08 ( m, 2H), 3.42-3.58 (m, 2H), 7.30-7.38 (m, 1H), 7.60-7.65 (m, 1H), 7.65-7.70 (m, 1H). LCMS (ESI) m/z: 328 (M+1).
实施例35Example 35
3-(8-乙基-8-氮杂双环[3.2.1]辛-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000114
Figure PCTCN2015075363-appb-000114
实施例35AExample 35A
3-氰基-8-氮杂双环[3.2.1]辛烷-8-甲酸叔丁酯3-cyano-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000115
Figure PCTCN2015075363-appb-000115
在0℃氮气保护下，向3-氧代-8-氮杂双环[3.2.1]辛烷-8-羧酸叔丁基酯(10克，44.389毫摩尔)的二甲基乙二醇(300mL)和乙醇(6.7毫升)混合液中分批加入叔丁醇钾(20克，177.557毫摩尔)和TOSMIC(17.33克，88.778毫摩尔)。在60℃下搅拌16小时后，混合物用水(100毫升)淬灭，水层用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(6.08g，收率：57.96％)，为白色固体。LCMS(ESI)m/z:327(M+1).To a 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (10 g, 44.389 mmol) of dimethylglycol (under 10 ° C under nitrogen) Potassium tert-butoxide (20 g, 177.557 mmol) and TOSMIC (17.33 g, 88.778 mmol) were added portionwise in a mixture of 300 mL) and ethanol (6.7 mL). After stirring at 60 ° C for 16 hours, the mixture was evaporated w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The residue was purified by EtOAc EtOAcqqqqq LCMS (ESI) m/z: 327 (M+1).
实施例35BExample 35B
8-(叔-丁氧基羰基)-8-氮杂双环[3.2.1]辛烷-3-羧酸8-(tert-Butoxycarbonyl)-8-azabicyclo[3.2.1]octane-3-carboxylic acid
Figure PCTCN2015075363-appb-000116
Figure PCTCN2015075363-appb-000116
实施例35A的(6.58克，27.845毫摩尔)和氢氧化钾(9.36克，167.069毫摩尔)的乙醇/水(1:1，200mL)混合溶液在80℃下搅拌4小时。将得到的混合物用水稀释(100毫升)，水相用2N盐酸调节pH至3～4后用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥，过滤并蒸发，得到标题化合物(6.01克，收率：84.53％)，为白色固体，将其直接用于用于下一步骤而无需进一步纯化。A mixed solution of (6.58 g, 27.845 mmol) of Example 35A and potassium hydroxide (9.36 g, 167.069 mmol) in ethanol/water (1:1, 200 mL) was stirred at 80 ° C for 4 hours. The obtained mixture was diluted with water (100 ml), EtOAc (EtOAc m. The title compound (6.01 g, EtOAc:EtOAc:
实施例35CExample 35C
3-(羟甲基)-8-氮杂双环[3.2.1]辛烷-8-甲酸叔丁酯3-(Hydroxymethyl)-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000117
Figure PCTCN2015075363-appb-000117
在0℃下氮气保护下，向实施例35B(6克，23.529毫摩尔)的四氢呋喃中(60mL)溶液中加入硼烷二甲硫醚。在25℃下搅拌16小时后，加入甲醇(100mL)淬灭，将得到的混合物蒸发，残余物通过柱色谱法纯化得到标题化合物(5.2g，收率：92.69％)。LCMS(ESI)m/z:242(M+1).Borane dimethyl sulfide was added to a solution of Example 35B (6 g, 23.529 mmol) in tetrahydrofuran (60 mL). After stirring for 16 hours at 25 ° C, EtOAc (EtOAc) (EtOAc) LCMS (ESI) m/z: 242 (M+1).
实施例35DExample 35D
3-(8-乙基-8-氮杂双环[3.2.1]辛-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(8-ethyl-8-azabicyclo[3.2.1]oct-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000118
Figure PCTCN2015075363-appb-000118
这个实施例是如实施例1E-1J&2中所述制备。1H-NMR(MeOD,400MHz)δ:1.42-1.45(t,3H),2.18-2.36(m,8H),3.16-3.18(m,2H),3.36-3.42(m,1H),4.13(s,2H),7.36-7.37(dd,1H),7.61-7.66(dd,1H),7.68(s,1H),8.62(bs,1H).LCMS(ESI)m/z:356(M+1).This example was prepared as described in Examples 1E-1J&2. 1 H-NMR (MeOD, 400MHz ) δ: 1.42-1.45 (t, 3H), 2.18-2.36 (m, 8H), 3.16-3.18 (m, 2H), 3.36-3.42 (m, 1H), 4.13 (s , 2H), 7.36-7.37 (dd, 1H), 7.61-7.66 (dd, 1H), 7.68 (s, 1H), 8.62 (bs, 1H). LCMS (ESI) m/z: 356 (M+1) .
实施例36Example 36
6-氟-3-(4-羟基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-hydroxypyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000119
Figure PCTCN2015075363-appb-000119
实施例36AExample 36A
1-(叔丁基)-2-甲基4-((叔丁基二苯基硅烷基)氧基)吡咯烷-1,2-二羧酸二酯1-(tert-butyl)-2-methyl 4-((tert-butyldiphenylsilyl)oxy)pyrrolidine-1,2-dicarboxylic acid diester
Figure PCTCN2015075363-appb-000120
Figure PCTCN2015075363-appb-000120
0℃氮气保护下，向1-叔丁基2-甲基4-羟基吡咯烷-1,2-二羧酸二酯(2克，8.13毫摩尔)，咪唑(1.1克，16.26毫摩尔)的无水二氯甲烷(50mL)混合物中分批加入TBDPSCl(2.68克，9.76毫摩尔)。在15℃下搅拌4小时后，将反应液用水(10毫升×2)洗涤，无水硫酸钠干燥，过滤并蒸发以提供标题化合物(3.9g，收率：99％)，为无色油状物，可直接使用无需进一步纯化。To a 1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylic acid diester (2 g, 8.13 mmol), imidazole (1.1 g, 16.26 mmol) at 0 ° C under N2 TBDPSCl (2.68 g, 9.76 mmol) was added portionwise over anhydrous dichloromethane (50 mL). After stirring for 4 hours at 15 ° C, EtOAc (EtOAc m. It can be used directly without further purification.
实施例36BExample 36B
1-(叔丁氧基羰基)-4-((叔丁基二苯基硅烷基)氧基)吡咯烷-2-羧酸1-(tert-Butoxycarbonyl)-4-((tert-butyldiphenylsilyl)oxy)pyrrolidine-2-carboxylic acid
Figure PCTCN2015075363-appb-000121
Figure PCTCN2015075363-appb-000121
实施例36A(3.9克，8.1毫摩尔)和氢氧化锂(1克，24.2毫摩尔)的水(20mL),甲醇(5mL)和四氢呋喃(20mL)混合溶液在15℃下搅拌16小时。用水(50mL)稀释并用1N盐酸调节pH至4-5， 水层用乙酸乙酯萃取(50mL×3)，将合并的有机层用盐水洗涤，硫酸钠干燥，过滤并蒸发,以提供标题化合物(3.7g，收率：97％)直接用于下一步骤而无需进一步纯化。A mixed solution of Example 36A (3.9 g, 8.1 mmol) and lithium hydroxide (1 g, 24.2 mmol) in water (20 mL), methanol (5 mL) and tetrahydrofuran (20 mL) was stirred at 15 ° C for 16 hours. Dilute with water (50 mL) and adjust the pH to 4-5 with 1N hydrochloric acid. The aqueous layer was extracted with EtOAc (EtOAc EtOAc (EtOAc) Without further purification.
实施例36CExample 36C
4-((叔丁基二苯基硅烷基)氧基)-2-(羟甲基)吡咯烷-1-甲酸叔丁酯4-((tert-Butyldiphenylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000122
Figure PCTCN2015075363-appb-000122
在0℃下氮气保护下，向实施例36B的(3.7克，7.89毫摩尔)，三乙胺(2.2克，15.8毫摩尔)的四氢呋喃(100毫升)混合溶液中加入异丙基碳酰氯(1.2克，9.5毫摩尔)。在15℃搅拌4小时后，降温至0℃，硼氢化钠(1.2克，31.56毫摩尔)加入，该反应混合物在15℃搅拌64小时。真空除去溶液后，将残余物分散在水(50mL)和二氯甲烷(50mL)中，水层用二氯甲烷(50毫升×2)萃取，合并的有机层，用盐水洗涤，硫酸钠干燥，过滤并蒸发，残余物通过在柱色谱法纯化得到标题化合物(3.5g，收率：100％)。LCMS(ESI)m/z:456(M+1).To a mixed solution of (36 g, 7.89 mmol) of triethylamine (2.2 g, 15.8 mmol) in tetrahydrofuran (100 ml) was added isopropyl carbonyl chloride (1.2). Gram, 9.5 mmol). After stirring at 15 ° C for 4 hours, the temperature was lowered to 0 ° C, sodium borohydride (1.2 g, 31.56 mmol) was added, and the mixture was stirred at 15 ° C for 64 hours. After the solution was removed in vacuo, EtOAc EtOAc m. Filtration and evaporation. LCMS (ESI) m/z: 456 (M+1).
实施例36DExample 36D
4-((叔丁基二苯基硅烷基)氧基)-2(8-甲酰胺-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-1-吡咯烷甲酸叔丁酯4-((tert-Butyldiphenylsilyl)oxy)-2(8-carboxamide-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-3 -yl)-1-pyrrolidinecarboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000123
Figure PCTCN2015075363-appb-000123
这个实施例是如实施例1E-1J描述制备。LCMS(ESI)m/z:642(M+1).This example was prepared as described in Examples 1E-1J. LCMS (ESI) m/z: 642 (M+1).
实施例36EExample 36E
6-氟-3-(4-羟基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-hydroxypyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000124
Figure PCTCN2015075363-appb-000124
实施例36D(50毫克，0.078毫摩尔)的溴化氢/乙酸(0.5毫升)混合物在15℃下搅拌6小时。将得到的混合物蒸发，残余物通过制备型HPLC纯化得到标题化合物(10mg，收率：43％)。1H NMR(400MHz,DMSO-d6)＝8.36(br.s.,1H),8.06-7.86(m,1H),7.53(d,J＝9.9Hz,2H),4.91(dd,J＝6.1,11.5Hz,1H),4.56(br.s.,1H),3.45(d,J＝8.8Hz,1H),3.06(d,J＝12.7Hz,1H),2.48-2.41(m,1H),2.21(dd,J＝5.8,13.0Hz,1H).LCMS(ESI)m/z:304(M+1).A mixture of Example 36D (50 mg, 0.078 mmol) of hydrogen bromide / acetic acid (0.5 mL) was stirred at 15 ° C for 6 hours. The obtained mixture was evaporated, the crystallijjjjjjjjj 1 H NMR (400MHz, DMSO- d 6) = 8.36 (br.s., 1H), 8.06-7.86 (m, 1H), 7.53 (d, J = 9.9Hz, 2H), 4.91 (dd, J = 6.1 , 11.5 Hz, 1H), 4.56 (br.s., 1H), 3.45 (d, J = 8.8 Hz, 1H), 3.06 (d, J = 12.7 Hz, 1H), 2.48-2.41 (m, 1H), 2.21 (dd, J = 5.8, 13.0 Hz, 1H). LCMS (ESI) m/z: 304 (M+1).
实施例37Example 37
3-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000125
Figure PCTCN2015075363-appb-000125
实施例37AExample 37A
5-氨基-1-(2,6-二溴-4-氟苯基)-1H-吡唑-4-甲腈5-amino-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazole-4-carbonitrile
Figure PCTCN2015075363-appb-000126
Figure PCTCN2015075363-appb-000126
实施例1D(4克，14毫摩尔)和2-乙氧亚甲基丙二腈(2.24克，18.31mmol)的乙醇(30毫升)混合液在80℃下搅拌1.5小时。真空将混合物蒸发，以提供标题化合物可直接用于下一步骤的而无需进一步纯化(2.8g，56％)。A mixture of Example 1D (4 g, 14 mmol) and 2-ethoxymethylenemalononitrile (2.24 g, 18.31 mmol) in ethanol (30 ml) was stirred at <RTIgt; The mixture was evaporated in vacuo to give title crystall crystall
实施例37BExample 37B
8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-甲腈8-bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-3-carbonitrile
Figure PCTCN2015075363-appb-000127
Figure PCTCN2015075363-appb-000127
氮气保护下，实施例37A(2.8克，7.78毫摩尔)，N1，N2-二甲基乙烷-1,2-二胺(68毫克，0.777毫摩尔)，碘化亚铜(148毫克，0.777毫摩尔)和磷酸钾(1.65克，7.78毫摩尔)的DMF(30mL)混合物在60℃下搅拌在24小时。冷却至室温，混合物过滤，将滤液蒸发得到残余物用甲醇和水洗涤，真空干燥后以提供标题化合物直接用于下一步骤而无需进一步纯化(1.7克，78％)。Example 37A (2.8 g, 7.78 mmol), N1, N2-dimethylethane-1,2-diamine (68 mg, 0.777 mmol), cuprous iodide (148 mg, 0.777). A mixture of millimolar) and potassium phosphate (1.65 g, 7.78 mmol) in DMF (30 mL) was stirred at 60 ° C for 24 hours. The mixture was cooled to EtOAc (EtOAc m.)
实施例37CExample 37C
甲基3-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-羧酸乙酯Ethyl 3-cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxylate
Figure PCTCN2015075363-appb-000128
Figure PCTCN2015075363-appb-000128
实施例37B(1克，3.58毫摩尔)，钯醋酸(161毫克，0.72毫摩尔)，Pd(dppf)Cl2，(526毫克，0.72毫摩尔)，Xantphos(420毫克，0.72毫摩尔)，DPPP(的混合物296毫克，0.72毫摩尔)，三苯基膦(188毫克，0.72毫摩尔)和三乙胺(1.8克，18毫摩尔)的DMF(30mL)和甲醇(10ml)溶液在CO氛围(3兆帕)下120℃搅拌12小时。冷却至室温后，将混合物过滤，滤液蒸发得到残余物用二氯甲烷洗涤，干燥，所得标题化合物直接用于下一步骤而无需进一步纯化(0.5克，54％)。Example 37B (1 g, 3.58 mmol), palladium acetate (161 mg, 0.72 mmol), Pd (dppf) Cl 2 , (526 mg, 0.72 mmol), Xantphos (420 mg, 0.72 mmol), DPPP (mixture 296 mg, 0.72 mmol), triphenylphosphine (188 mg, 0.72 mmol) and triethylamine (1.8 g, 18 mmol) in DMF (30 mL) and methanol (10 mL) Stir at 120 ° C for 12 hours at 3 MPa. After cooling to rt, EtOAc m.
实施例37DExample 37D
3-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000129
Figure PCTCN2015075363-appb-000129
实施例37C(20毫克，0.077毫摩尔)，氨水(5mL)的DMF(1mL)和甲醇(1毫升)混合物在120℃搅拌4小时。真空除去溶液后，所得残余物通过制备型HPLC纯化，得到标题化合物(2.99毫克，16％)。1H-NMR(400MHz,MeOD-d4)δppm 7.52(dd,J＝7.91Hz,1H),7.80(dd,J＝10.67Hz,1H),8.19(s,1H).LCMS(ESI)m/z:244(M+1).A mixture of DMF (1 mL) and methanol (1 mL), EtOAc (EtOAc) After the solution was removed in vacuo, EtOAcqqqqqqq 1 H-NMR (400 MHz, MeOD-d4) δ ppm 7.52 (dd, J = 7.91 Hz, 1H), 7.80 (dd, J = 10.67 Hz, 1H), 8.19 (s, 1H). LCMS (ESI) m/z :244(M+1).
实施例38Example 38
3-氰基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-cyano-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000130
Figure PCTCN2015075363-appb-000130
本实施例中如实施例37中所述制备。1H NMR(400MHz,D2O)ppm 7.54-7.58(t,1H),7.75-7.77(d,1H),8.10-8.12(d,1H),8.23(S,1H).LCMS(ESI)m/z:226(M+1).Prepared as described in Example 37 in this example. 1 H NMR (400 MHz, D2O) ppm 7.54-7.58 (t, 1H), 7.75-7.77 (d, 1H), 8.10-8.12 (d, 1H), 8.23 (S, 1H). LCMS (ESI) m/z :226(M+1).
实施例39Example 39
3-(氨甲基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(Aminomethyl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000131
Figure PCTCN2015075363-appb-000131
0℃下，向实施例37D(100毫克，0.4毫摩尔)的二氯甲烷(20mL)和甲醇(50mL)混合物中分批加入六水合氯化镍(200毫克，0.8毫摩尔)和硼氢化钠(47毫克，1.2毫摩尔)。在0℃进行5分钟搅拌后，反应混合物蒸发，得到残余物通过制备型HPLC纯化得到标题化合物(45mg，45％)。1H NMR(400MHz,D2O)ppm 4.2(S,2H),7.269-7.318(t,2H),7.796(S,1H),8.399(S,1H).LCMS(ESI)m/z:248(M+1).To a mixture of Example 37D (100 mg, 0.4 mmol) in dichloromethane (20 mL) and methanol (50 mL) was added portionwise mixture of nickel chloride hexahydrate (200 mg, 0.8 mmol) and sodium borohydride at 0 ° C. (47 mg, 1.2 mmol). After stirring at 0&lt;0&gt;C for 5 min, EtOAcqqqqm 1 H NMR (400 MHz, D 2 O) ppm 4.2 (S, 2H), 7. 279 - 7. </ RTI> (t, 2H), 7.796 (S, 1H), 8.399 (S, 1H). LCMS (ESI) m/z: 248 (M +1).
实施例40Example 40
3-(环丙甲酰胺亚甲基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(cyclopropymidamide methylene)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000132
Figure PCTCN2015075363-appb-000132
实施例39(20毫克，0.081毫摩尔)，环丙烷甲酸(8.36毫克，0.098毫摩尔)，HOBT(13.12毫克，0.0979毫摩尔)，EDCI(18.61毫克，0.097毫摩尔)和三乙胺(25毫克，0.242毫摩尔)的DMF(5毫升)混合物在30℃搅拌6小时。真空除去在溶液后，残余物通过制备型HPLC纯化以提供标题化合物(11.9mg，48％)。1H NMR(400MHz,DMSO-d6)ppm 0.64-0.72(m,4H),1.52-1.57(m,1H),4.25-2.50(d,2H),7.57-7.61(m,2H),7.82(s,1H),8.13(s,1H),8.44-8.46(t,1H),10.46(s,1H),11.93(br,1 H).LCMS(ESI)m/z:316(M+1).Example 39 (20 mg, 0.081 mmol), cyclopropanecarboxylic acid (8.36 mg, 0.098 mmol), HOBT (13.12 mg, 0.0979 mmol), EDCI (18.61 mg, 0.097 mmol) and triethylamine (25 mg) A mixture of 0.242 mmol of DMF (5 mL) was stirred at 30 ° C for 6 hours. After removal of the residue in vacuo, EtOAc m. 1 H NMR (400MHz, DMSO- d6) ppm 0.64-0.72 (m, 4H), 1.52-1.57 (m, 1H), 4.25-2.50 (d, 2H), 7.57-7.61 (m, 2H), 7.82 (s , 1H), 8.13 (s, 1H), 8.44-8.46 (t, 1H), 10.46 (s, 1H), 11.93 (br, 1 H). LCMS (ESI) m/z: 316 (M+1).
流程BProcess B
Figure PCTCN2015075363-appb-000133
Figure PCTCN2015075363-appb-000133
实施例41Example 41
6-氟-3-(4-氟苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-fluorophenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000134
Figure PCTCN2015075363-appb-000134
实施例41AExample 41A
5-氨基-1-(2,6-二溴-4-氟苯基)-1H-吡唑-4-羧酸乙酯Ethyl 5-amino-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazole-4-carboxylate
Figure PCTCN2015075363-appb-000135
Figure PCTCN2015075363-appb-000135
实施例1D(5克，17.61毫摩尔)和2-氰基-3-乙氧基丙烯酸乙酯(2.98克，17.61毫摩尔)的乙醇(100mL)的混合物在78℃下搅拌16小时。真空除去溶液后，残余物用柱色谱纯化得到标题化合物(2.7g，收率：38％)，可直接用于下一步骤而无需进一步纯化。A mixture of Example 1D (5 g, 17.61 mmol) and ethyl 2-cyano-3-ethoxyethyl acrylate (2.98 g, 17.61 mmol) in ethanol (100 mL) was stirred at 78 ° C for 16 hours. After the solution was removed in vacuo, m~~~~~~~~~~~~~~~~~~~~~~~
实施例41BExample 41B
8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-羧酸乙酯Ethyl 8-bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-3-carboxylate
Figure PCTCN2015075363-appb-000136
Figure PCTCN2015075363-appb-000136
氮气保护下，实施例41A(2.7克，6.63毫摩尔)，碘化亚铜(252毫克，1.33毫摩尔)，N1，N2-二甲基乙烷-1,2-二胺(233.9毫克，2.65毫摩尔)和磷酸钾(4.22克，19.9毫摩尔)的DMF(60mL)混合物在70℃下搅拌16小时。冷却至室温，混合物过滤，真空蒸除溶剂，所得残余物可直接用于下一步 骤而无需进一步纯化(2.16克)。Example 41A (2.7 g, 6.63 mmol), cuprous iodide (252 mg, 1.33 mmol), N1, N2-dimethylethane-1,2-diamine (233.9 mg, 2.65). A mixture of millimolar) and potassium phosphate (4.22 g, 19.9 mmol) in DMF (60 mL) was stirred at 70 ° C for 16 h. Cooled to room temperature, the mixture was filtered, and the solvent was evaporated in vacuo. No further purification (2.16 g) was required.
实施例41CExample 41C
8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-羧酸8-bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-3-carboxylic acid
Figure PCTCN2015075363-appb-000137
Figure PCTCN2015075363-appb-000137
向实施例41B的(2.16克，6.62毫摩尔)和氢氧化钠(1.06克，26.49毫摩尔)的甲醇(40mL)和水(10毫升)混合物在70℃搅拌16小时。真空蒸除溶剂，所得残余物可直接用于下一步骤而无需进一步纯化。To a mixture of (2.16 g, 6.62 mmol) of EtOAc (EtOAc m. The solvent was evaporated in vacuo and the residue was takenjjjjjjj
实施例41DExample 41D
8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑8-bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole
Figure PCTCN2015075363-appb-000138
Figure PCTCN2015075363-appb-000138
实施例41C(1.97克，6.61毫摩尔)的浓盐酸(20毫升)和水(20毫升)混合溶液在80℃下搅拌16小时。用浓氨水中和后，将所得混合物过滤，滤饼用甲醇洗涤并在真空下干燥，所得固体(1.58克)可直接用于下一步骤而无需进一步纯化。A mixed solution of Example 41C (1.97 g, 6.61 mmol) of EtOAc (20 mL). After concentrating with concentrated aqueous ammonia, the mixture was filtered and filtered and washed with EtOAc EtOAc.
实施例41EExample 41E
8-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑8-bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole
Figure PCTCN2015075363-appb-000139
Figure PCTCN2015075363-appb-000139
0℃氮气下，向NaH(0.746克，18.66毫摩尔)的四氢呋喃(10mL)溶液中滴加入实施例41D(1.58克，6.22毫摩尔)的四氢呋喃溶液(20mL)。在0℃下搅拌0.5小时后，滴加入SEMCl(1.56克，9.33毫摩尔)，混合物在0℃下再搅拌1小时后，用水(20mL)淬灭，水层用二氯甲烷(20毫升×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(0.43g，四步收率：17％，)。LCMS(ESI)m/z:384,386(M,M+2).A solution of Example 41D (1.58 g, 6.22 mmol) in tetrahydrofuran (20 mL) was added dropwise to a solution of NaH (0.746 g, 18.66 mmol) in THF (10 mL). After stirring at 0 ° C for 0.5 h, EtOAc (EtOAc m. The combined organic layer was dried with sodium sulfate, filtered and evaporated. LCMS (ESI) m/z: 384, 386 (M, M+2).
实施例41FExample 41F
6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-羧酸甲酯6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxylate Methyl ester
Figure PCTCN2015075363-appb-000140
Figure PCTCN2015075363-appb-000140
实施例41E(0.43克，1.12毫摩尔)，钯醋酸(50毫克，0.233毫摩尔)，Pd(dppf)Cl2(164毫克，0.233 毫摩尔)，Xantphos(194毫克，0.335毫摩尔)，DPPP(138毫克，0.335毫摩尔)，三苯基膦(88毫克，0.335毫摩尔)和三乙胺(566毫克，5.59毫摩尔)的DMF(10mL)和甲醇(10ml)溶液中在80℃一氧化碳氛围(3大气压)下搅拌24小时。冷却至室温后，将混合物过滤，将滤液蒸发，残余物通过柱色谱法纯化得到标题化合物(0.265克，产率：63％)。LCMS(ESI)m/z:364(M+1).Example 41E (0.43 g, 1.12 mmol), palladium acetate (50 mg, 0.233 mmol), Pd (dppf) Cl 2 (164 mg, 0.233 mmol), Xantphos (194 mg, 0.335 mmol), DPPP ( 138 mg, 0.335 mmol, triphenylphosphine (88 mg, 0.335 mmol) and triethylamine (566 mg, 5.59 mmol) in a solution of DMF (10 mL) and methanol (10 ml) at 80 ° C in carbon monoxide atmosphere ( Stir under 24 atmospheres for 24 hours. After cooling to room temperature, the mixture was filtered, EtOAcjjjjjjjjj LCMS (ESI) m/z: 364 (M+1).
实施例41GExample 41G
3-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-羧酸甲酯3-bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole Methyl-8-carboxylate
Figure PCTCN2015075363-appb-000141
Figure PCTCN2015075363-appb-000141
实施例41F(0.265克，729毫摩尔)和NBS(117毫克，656毫摩尔)的二氯甲烷(20毫升)混合物在10℃搅拌20分钟。真空除去溶液后，残余物通过柱色谱法纯化得到标题化合物(75％0.24克，产率)。LCMS(ESI)m/z:442,444(M,M+2).A mixture of Example 41F (0.265 g, 729 mmol) and m. After the solution was removed in vacuo, EtOAc m. LCMS (ESI) m/z: 442, 444 (M, M+2).
实施例41HExample 41H
3-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-羧酸3-bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxylic acid
Figure PCTCN2015075363-appb-000142
Figure PCTCN2015075363-appb-000142
实施例41G(240毫克，0.542毫摩尔)和氢氧化钠(108毫克，2.71毫摩尔)的甲醇(6mL)和水(1.5mL)混合液在60℃搅拌0.5小时。冷却至室温后，混合物的PH值用1N盐酸调节至4，水相用乙酸乙酯(20毫升×3)萃取。将合并的有机层用盐水洗涤，硫酸钠干燥并蒸发得到标题化合物(196mg，收率：84％),直接用于下一步骤而无需进一步纯化。A mixture of Example 41G (240 mg, 0.542 mmol) and sodium hydroxide (108 mg, 2.71 mmol) in methanol (6 mL) and water ( 1.5 mL) was stirred at 60 ° C for 0.5 hour. After cooling to room temperature, the pH of the mixture was adjusted to 4 with 1N aqueous hydrochloric acid, and the aqueous phase was extracted with ethyl acetate (20 ml × 3). The combined organic layers were washed w~~~~~~~~~~~~~~~~~~~~~
实施例41IExample 41I
3-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰氨3-bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-formamide
Figure PCTCN2015075363-appb-000143
Figure PCTCN2015075363-appb-000143
氮气保护下，实施例41H(0.196克，0.46毫摩尔)，HATU(0.226毫克，0.595毫摩尔)，碳酸铵(0.439克，4.6毫摩尔)和三乙胺(0.138克，1.37毫摩尔)的DMF(8毫升)混合液在40℃下搅拌16小时。真空除去溶液后，残余物用水稀释(10mL)，水层用乙酸乙酯(15毫升×3)萃取，将合并的有机层用盐水洗涤，硫酸钠干燥并蒸发，残余物通过柱色谱法纯化得到标题化合物(0.125g，收率：64％)。LCMS(ESI)m/z:427,429(M,M+2).Example 41H (0.196 g, 0.46 mmol), HATU (0.226 mg, 0.595 mmol), ammonium carbonate (0.439 g, 4.6 mmol) and triethylamine (0.138 g, 1.37 mmol) DMF. The mixture (8 ml) was stirred at 40 ° C for 16 hours. After the solution was removed in vacuo <RTI ID=0.0>(~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The title compound (0.125 g, yield: 64%). LCMS (ESI) m/z: 427, 429 (M, M+2).
实施例41J Example 41J
6-氟-3-(4-氟苯基)-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰氨6-fluoro-3-(4-fluorophenyl)-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-formamide
Figure PCTCN2015075363-appb-000144
Figure PCTCN2015075363-appb-000144
氮气保护下，实施例41I(50毫克，0.117毫摩尔)，Pd(dppf)Cl2(17毫克，0.023毫摩尔)，碳酸钠(31毫克，0.292毫摩尔)和(4-氟苯基)硼酸(24毫克，0.175毫摩尔)的DMF(3mL)和水(0.5mL)的混合物在100℃搅拌16小时。真空除去溶液后，将残余物用水(10mL)稀释，水层用乙酸乙酯(10毫升×3)萃取，将合并的有机层用盐水洗涤，经硫酸钠干燥，过滤并蒸发，残余物通过制备型TLC纯化得到标题化合物(40mg，收率：77％)。LCMS(ESI)m/z:443(M+1).Example 41I (50 mg, 0.117 mmol), Pd(dppf)Cl 2 (17 mg, 0.023 mmol), sodium carbonate (31 mg, 0.292 mmol) and (4-fluorophenyl)boronic acid under nitrogen. (24 mg, 0.175 mmol) of a mixture of DMF (3 mL) and water (0.5 mL) was stirred at 100 ° C for 16 h. After the solution was removed in vacuo, EtOAc EtOAc m. The title compound (40 mg, yield: 77%). LCMS (ESI) m/z: 443 (M+1).
实施例41KExample 41K
6-氟-3-(4-氟苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-fluorophenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000145
Figure PCTCN2015075363-appb-000145
实施例41J(40毫克，0.090毫摩尔)的三氟乙酸(0.5毫升)和二氯甲烷(0.5mL)混合物在10℃搅拌5小时。真空除去溶液后，残余物中加入甲醇(3毫升)和碳酸钾(0.037克，0.271毫摩尔)在10℃搅拌2小时，混合物过滤，真空蒸除溶剂，残余物通过制备型HPLC纯化得到标题化合物(6.3毫克，收率：24％)。1H NMR(400MHz,DMSO-d6)δ:8.32(s,1H),7.67-7.71(m,2H),7.59-7.61(d,1H),7.55-7.57(d,1H),7.22-7.27(t,2H).LCMS(ESI)m/z:313(M+1).A mixture of Example 41J (40 mg, EtOAc) (EtOAc) After the solution was removed in vacuo, EtOAc EtOAc m. (6.3 mg, yield: 24%). 1 H NMR (400MHz, DMSO- d6) δ: 8.32 (s, 1H), 7.67-7.71 (m, 2H), 7.59-7.61 (d, 1H), 7.55-7.57 (d, 1H), 7.22-7.27 ( t, 2H). LCMS (ESI) m / z: 313 (M + 1).
实施例42Example 42
6-氟-3-(2-氟-4-((甲胺亚甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(2-fluoro-4-((methylaminomethylene)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000146
Figure PCTCN2015075363-appb-000146
实施例42AExample 42A
1-(4-溴-3-氟苯基)-N-甲基甲胺 1-(4-bromo-3-fluorophenyl)-N-methylmethylamine
Figure PCTCN2015075363-appb-000147
Figure PCTCN2015075363-appb-000147
4-溴-3-氟苯甲醛(2克，9.8毫摩尔)和甲胺(在EtOH中30％-40％)(10毫升，16.7毫摩尔)的乙醇(10mL)混合物在75℃下搅拌15小时。冷却至室温后，一次性加入硼氢化钠(745毫克，19.6毫摩尔)后再搅拌30分钟。真空除去溶液后，将残余物用饱和碳酸氢钠(20mL)稀释，水层用乙酸乙酯(50毫升×3)萃取。将合并的有机层，用水(50毫升)，盐水(50mL)洗涤，经硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化以提供标题化合物(1.47g，收率：74％)。LCMS(ESI)m/z:218,220(M,M+2).A mixture of 4-bromo-3-fluorobenzaldehyde (2 g, 9.8 mmol) and methylamine (30%-40% in EtOH) (10 mL, 16.7 mmol) in ethanol (10 mL) was stirred at 75 ° C 15 hour. After cooling to room temperature, sodium borohydride (745 mg, 19.6 mmol) was added in one portion and stirred for 30 minutes. After the solution was removed in vacuo, EtOAc m. The combined organic layers were washed w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ LCMS (ESI) m/z: 218, 220 (M, M+2).
实施例42BExample 42B
(4-溴-3-氟苄基)(甲基)氨基甲酸叔丁酯(4-Bromo-3-fluorobenzyl)(methyl)carbamic acid tert-butyl ester
Figure PCTCN2015075363-appb-000148
Figure PCTCN2015075363-appb-000148
实施例42A(1.47克，6.77毫摩尔)，Boc 2O(1.77克，8.12毫摩尔)和三乙胺的(1.37克，13.54毫摩尔)的二氯甲烷(15毫升)混合物于18℃下搅拌2小时。真空去除溶液后，残余物通过柱色谱法纯化以提供标题化合物(85％1.83克，收率)。LCMS(ESI)m/z:319(M+1).A mixture of Example 42A (1.47 g, 6.77 mmol), Boc 2 O (1.77 g, 8.12 mmol) and triethylamine (1.37 g, 13.54 mmol) in dichloromethane (15 mL) hour. After the solution was removed in vacuo, EtOAcqqqqqq LCMS (ESI) m/z: 319 (M+1).
实施例42CExample 42C
(3-氟-4-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)苄基)(甲基)氨基甲酸叔丁酯(3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)(methyl)carbamic acid tert-butyl ester
Figure PCTCN2015075363-appb-000149
Figure PCTCN2015075363-appb-000149
N 2保护下，4,4,4'，4'，5,5,5'，5'-八甲基-2,2'-双(1,3,2-二氧硼戊环)(1.76克，6.92毫摩尔)，实施例42B(1.83克，5.77毫摩尔)，醋酸钾(1.13克，11.54毫摩尔)和Pd(dppf)Cl2(422毫克，0.577毫摩尔)的DMSO(15mL)混合物在80℃下搅拌在15小时。冷却至室温后，将混合物过滤，滤液用水(20毫升)稀释，水层用乙酸乙酯(50毫升×2)萃取，将合并的有机层，用水(30毫升)，盐水(30mL)洗涤，无水硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化以提供标题化合物(2克，收率：95％)，为无色油。Under the protection of N 2 , 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxaborolan) (1.76克, 6.92 mmol), a mixture of Example 42B (1.83 g, 5.77 mmol), potassium acetate (1.13 g, 11.54 mmol) and Pd (dppf) Cl 2 (422 mg, 0.577 mmol) in DMSO (15 mL) Stir at 80 ° C for 15 hours. After cooling to room temperature, the mixture was filtered, EtOAcjjjjjjjjjjjjjjjjjjjjj The residue was dried with EtOAc EtOAc EtOAc.
实施例42DExample 42D
(4-(-8-甲酰氨-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-3-氟甲苯基)(甲基)氨基甲酸叔丁酯 (4-(-8-formylamino-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1 ,2-b]pyrazol-3-yl)-3-fluoromethylphenyl)(methyl)carbamic acid tert-butyl ester
Figure PCTCN2015075363-appb-000150
Figure PCTCN2015075363-appb-000150
氮气保护下，实施例41I(100毫克，0.23毫摩尔)，实施例42C(85.7毫克，0.23毫摩尔)，碳酸钠(50毫克，0.47毫摩尔)和Pd(dppf)Cl2(17.1毫克，0.023毫摩尔)的DMF(5mL)和水(1毫升)混合物在80℃下搅拌在15小时。冷却至室温后，将混合物过滤，滤液用水(20毫升)稀释，水层用乙酸乙酯(50毫升×2)萃取，将合并的有机层，用水(30毫升)，盐水(30mL)洗涤，无水硫酸钠干燥，过滤并蒸发，得到残余物通过制备型TLC纯化提供标题化合物(110mg，收率：97％)。LCMS(ESI)m/z:586(M+1).Example 41I (100 mg, 0.23 mmol), Example 42C (85.7 mg, 0.23 mmol), sodium carbonate (50 mg, 0.47 mmol) and Pd (dppf) Cl 2 (17.1 mg, 0.023). A mixture of mmol of DMF (5 mL) and water (1 mL) was stirred at 80 ° C for 15 hours. After cooling to room temperature, the mixture was filtered, EtOAcjjjjjjjjjjjjjjjjjjjjj The title compound (110 mg, yield: 97%). LCMS (ESI) m/z: 586 (M+1).
实施例42EExample 42E
6-氟-3-(2-氟-4-((甲胺亚甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(2-fluoro-4-((methylaminomethylene)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000151
Figure PCTCN2015075363-appb-000151
实施例42D(110毫克，0.19毫摩尔)的三氟乙酸(5mL)和二氯甲烷(5mL)混合液在10℃下搅拌15小时。真空除去溶液后，残余物中加入甲醇(15mL)和碳酸钾(53毫克，0.38毫摩尔)。混合物在18℃搅拌15小时。将混合物过滤，将滤液蒸发，残余物分散在水(10mL)和乙酸乙酯(10毫升)之间。水层用乙酸乙酯/四氢呋喃＝3/1(20毫升×2)萃取。将合并的有机层用盐水(20mL)洗涤，用无水硫酸钠干燥，过滤并蒸发，得到残余物通过制备型HPLC纯化得到标题化合物(22.45毫克，收率：34％)，为白色固体。1H NMR(400MHz,METHANOL-d4)ppm 2.79(s,3H),4.24(s,2H),4.48-5.29(m,27H),7.37-7.43(m,2H),7.52(d,J＝7.78Hz,1H),7.72(d,J＝9.79Hz,1H),7.78(t,J＝7.78Hz,1H),8.23(s,1H),8.49(br.s.,1H).LCMS(ESI)m/z:356(M+1).A mixture of Example 42D (110 mg, 0.19 mmol) of trifluoroacetic acid (5mL) and dichloromethane (5mL) was stirred at 10 ° C for 15 hours. After the solution was removed in vacuo, methanol (15 mL) and potassium carbonate (53 mg, 0.3 The mixture was stirred at 18 ° C for 15 hours. The mixture was filtered, and the filtrate was evaporated,jjjjjjjjj The aqueous layer was extracted with ethyl acetate / tetrahydrofuran = 3 / 1 (20 mL × 2). The combined organic layers were washed w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 1 H NMR (400MHz, METHANOL- d 4) ppm 2.79 (s, 3H), 4.24 (s, 2H), 4.48-5.29 (m, 27H), 7.37-7.43 (m, 2H), 7.52 (d, J = 7.78 Hz, 1H), 7.72 (d, J = 9.79 Hz, 1H), 7.78 (t, J = 7.78 Hz, 1H), 8.23 (s, 1H), 8.49 (br.s., 1H). LCMS (ESI) ) m / z: 356 (M + 1).
实施例43Example 43
6-氟-3-(4-((甲基氨基)甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-((methylamino)methyl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000152
Figure PCTCN2015075363-appb-000152
本实施例中如实施例42中描述的方法制备。1H-NMR(400MHz,MethanoL-d4+D2O)2.77(s,3H),4.21(s,2H),7.46-7.62(m,3H),7.75(d,J＝8.16Hz,3H),8.26(s,1H),8.53(br.s.,1H).LCMS(ESI)m/z:338(M+1). This example was prepared as described in Example 42. 1 H-NMR (400 MHz, Methano L-d 4 + D 2 O) 2.77 (s, 3H), 4.21 (s, 2H), 7.46-7.62 (m, 3H), 7.75 (d, J = 8.16 Hz, 3H) , 8.26(s, 1H), 8.53 (br.s., 1H). LCMS (ESI) m/z: 338 (M+1).
实施例44Example 44
6-氟-3-2-氟-5-((甲基氨基)甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-2-fluoro-5-((methylamino)methyl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000153
Figure PCTCN2015075363-appb-000153
本实施例中如实施例42中描述的方法制备。1H-NMR(400MHz,DMSO-d6+D2O)2.59(br.s.,3H),4.13(br.s.,2H),7.15-7.41(m,2H),7.47-7.68(m,2H),7.95-8.09(m,1H),8.16-8.27(m,1H),8.36(br.s.,1H).LCMS(ESI)m/z:356(M+1).This example was prepared as described in Example 42. 1 H-NMR (400 MHz, DMSO-d 6 + D 2 O) 2.59 (br.s., 3H), 4.13 (br.s., 2H), 7.15-7.41 (m, 2H), 7.47-7.68 (m) , 2H), 7.95-8.09 (m, 1H), 8.16-8.27 (m, 1H), 8.36 (br.s., 1H). LCMS (ESI) m/z: 356 (M+1).
实施例45Example 45
6-氟-3-(吡啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(pyridin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000154
Figure PCTCN2015075363-appb-000154
本实施例中如实施例42中描述的方法制备。1H-NMR(MeOD,400MHz)δ:7.55-7.63(m,2H),7.73-7.79(m,1H),8.11-8.14(m,1H),8.15-8.19(m,1H),8.48-8.54(m,2H),8.55-8.59(m,1H),10.28-10.36(m,1H).LCMS(ESI)m/z:296(M+1).This example was prepared as described in Example 42. 1 H-NMR (MeOD, 400 MHz) δ: 7.55-7.63 (m, 2H), 7.73-7.79 (m, 1H), 8.11-8.14 (m, 1H), 8.15-8.19 (m, 1H), 8.48-8.54 (m, 2H), 8.55-8.59 (m, 1H), 10.28-10.36 (m, 1H). LCMS (ESI) m/z: 296 (M+1).
实施例46Example 46
6-氟-3-(4-(哌啶-3-基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-(piperidin-3-yl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000155
Figure PCTCN2015075363-appb-000155
实施例46AExample 46A
3-(4-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)苯基)哌啶-1-甲酸叔丁酯tert-Butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine-1-carboxylate
Figure PCTCN2015075363-appb-000156
Figure PCTCN2015075363-appb-000156
在N2保护下，3-(4-氨基苯基)哌啶-1-羧酸叔丁酯(0.1克，0.362毫摩尔)，4,4,4'，4'，5,5,5'，5'-八甲基-2,2'-双(1,3,2-二氧硼戊环)(0.101克，0.398毫摩尔)，BPO(1.75克，0.00724毫摩尔)和t-BuONO(0.056克，0.542毫摩尔)的乙腈(3mL)混合物在10℃搅拌16小时。真空蒸除溶剂，残余物通过制备型TLC纯化得到标题化合物(0.095克，收率：68％)。3-(4-Aminophenyl)piperidine-1-carboxylic acid tert-butyl ester (0.1 g, 0.362 mmol), 4,4,4',4',5,5,5', under N2 protection 5'-octamethyl-2,2'-bis(1,3,2-dioxaborolan) (0.101 g, 0.398 mmol), BPO (1.75 g, 0.00724 mmol) and t-BuONO (0.056 A mixture of acetonitrile (0.54 mmol) in acetonitrile (3 mL) was stirred at 10 ° C for 16 h. The solvent was evaporated in vacuo tolululululululu
实施例46B Example 46B
6-氟-3-(4-(哌啶-3-基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-(piperidin-3-yl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000157
Figure PCTCN2015075363-appb-000157
本实施例中如实施例42中描述的方法制备。1H NMR(300MHz,METHANOL-d4)ppm 1.189(m,2H),2.10-2.01(m,2H),3.03-3.14(m,3H),3.45-3.49(m,2H),7.37–7.40(d,2H),7.44-7.47(dd,1H),7.66-7.68(d,2H),7.74-7.79(dd,1H),8.22(s,1H),8.53(s,1H).LCMS(ESI)m/z:378(M+1).This example was prepared as described in Example 42. 1 H NMR (300MHz, METHANOL- d4) ppm 1.189 (m, 2H), 2.10-2.01 (m, 2H), 3.03-3.14 (m, 3H), 3.45-3.49 (m, 2H), 7.37-7.40 (d , 2H), 7.44-7.47 (dd, 1H), 7.66-7.68 (d, 2H), 7.74-7.79 (dd, 1H), 8.22 (s, 1H), 8.53 (s, 1H). LCMS (ESI) m /z:378(M+1).
实施例47Example 47
6-氟-3-(四氢-2H-吡喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(tetrahydro-2H-pyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000158
Figure PCTCN2015075363-appb-000158
实施例47AExample 47A
3,6-二氢-2H-吡喃-4-基三氟甲磺酸酯3,6-dihydro-2H-pyran-4-yl trifluoromethanesulfonate
Figure PCTCN2015075363-appb-000159
Figure PCTCN2015075363-appb-000159
-78℃氮气保护下，向二氢-2H-吡喃-4(3H)-酮(1.8克，18.0摩尔)的四氢呋喃(20ml)溶液滴加入LiHMDS(1M，21.6毫升，21.6毫摩尔)。在-78摄氏度下搅拌1小时后，(CF3SO2)2NPh(6.4克，18.0毫摩尔)分批加入，混合物在15℃搅拌16小时后，用氯化铵水溶液(20mL)淬灭。水层用乙酸乙酯(30毫升×2)萃取，将合并的有机层用水，盐水洗涤，硫酸钠干燥并在真空下浓缩，残余物通过柱色谱纯化得到标题化合物，为无色油状物(1.5克，收率：35.7％)。LCMS(ESI)m/z:233(M+1).To a solution of dihydro-2H-pyran-4(3H)-one (1.8 g, 18.0 mol) in tetrahydrofuran (20 ml) was added dropwise EtOAc (1M, 21.6 mL, 21.6 mmol). After stirring at -78 ° C for 1 hour, (CF3SO2) 2 NPh (6.4 g, 18.0 mmol) was added portionwise, and the mixture was stirred at 15 ° C for 16 hours and then quenched with aqueous ammonium chloride (20 mL). The aqueous layer was extracted with EtOAc (EtOAc EtOAc. Gram, yield: 35.7%). LCMS (ESI) m/z: 233 (M+1).
实施例47BExample 47B
2-(3,6-二氢-2H-吡喃-4-基)-4,4,5,5-四甲基-1,3,2-二氧硼戊环2-(3,6-Dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan
Figure PCTCN2015075363-appb-000160
Figure PCTCN2015075363-appb-000160
本实施例中如实施例42C描述的方法制备。This example was prepared as described in Example 42C.
实施例47CExample 47C
6-氟-3-(四氢-2H-吡喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(tetrahydro-2H-pyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000161
Figure PCTCN2015075363-appb-000161
本实施例中如实施例46B所述的方法制备。1H-NMR(MeOD,400MHz)δ:1.82-2.03(m,4H),2.93-3.04(m,1 H),3.62(td,J＝11.70,2.45Hz,2H),4.04-4.11(m,2H),7.32-7.39(m,1H),7.66-7.75(m,2H),8.51-8.55(m,1H).LCMS(ESI)m/z:303(M+1).This example was prepared as described in Example 46B. 1 H-NMR (MeOD, 400MHz ) δ: 1.82-2.03 (m, 4H), 2.93-3.04 (m, 1 H), 3.62 (td, J = 11.70,2.45Hz, 2H), 4.04-4.11 (m, 2H), 7.32-7.39 (m, 1H), 7.66-7.75 (m, 2H), 8.51 - 8.55 (m, 1H). LCMS (ESI) m/z: 303 (M+1).
实施例48Example 48
3-(4-(二甲基氨基)环己基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-(Dimethylamino)cyclohexyl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000162
Figure PCTCN2015075363-appb-000162
实施例48AExample 48A
4-((叔丁氧基羰基)氨基)环己-1-烯-1-基三氟甲磺酸酯4-((tert-Butoxycarbonyl)amino)cyclohex-1-en-1-yl trifluoromethanesulfonate
Figure PCTCN2015075363-appb-000163
Figure PCTCN2015075363-appb-000163
-78℃下氮气保护下,向(4-氧环己基)氨基甲酸叔丁酯(1克，4.689摩尔)的四氢呋喃(20mL)溶液中滴加入LiHMDS(1M，9.4毫升，9.378毫摩尔)。在-78摄氏度下搅拌1小时后，滴加(CF3SO2)2NPh(1.84克，5.158毫摩尔)的四氢呋喃(5mL)溶液。将混合物在15摄氏度下搅拌16小时后，用氯化铵水溶液(20mL)淬灭，水层用乙酸乙酯(20毫升×2)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥，过滤并蒸发，残余物用硅胶柱色谱纯化得到标题化合物，为白色固体(1.16克，收率：71.60％)。LCMS(ESI)m/z:347(M+1).To a solution of tert-butyl (4-oxocyclohexyl)carbamate (1 g, 4.689 mol) in tetrahydrofuran (20 mL) was added dropwise EtOAc (1M, EtOAc, After stirring at -78 ° C for 1 hour, a solution of (CF3SO2) 2 NPh (1.84 g, 5.158 mmol) in tetrahydrofuran (5 mL) was added dropwise. The mixture was stirred at 15 ° C for 16 h then EtOAc (EtOAc)EtOAc. The title compound was obtained as a white solid (1.16 g, yield: 71.60%). LCMS (ESI) m/z: 347 (M+1).
实施例48BExample 48B
(4-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)环己-3-烯-1-基)氨基甲酸叔丁酯(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)carbamic acid tert-butyl ester
Figure PCTCN2015075363-appb-000164
Figure PCTCN2015075363-appb-000164
本实施例中如实施例47B所述的方法制备.This method is prepared as described in Example 47B.
实施例48CExample 48C
3-(4-(二甲基氨基)环己基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-(Dimethylamino)cyclohexyl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000165
Figure PCTCN2015075363-appb-000165
这个实施例是为在实施例47C和实施例2描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.63-1.87(m,3H),1.91-2.10(m,2H),2.20-2.46(m,3H),2.81(s,4H),2.90(s,3H),3.19-3.30(m,1H),7.34-7.44(m,1H),7.64-7.75(m,2H),7.78-7.85(m,1H),8.38-8.73(m,3H).LCMS(ESI)m/z:344(M+1).This example was prepared for the methods described in Example 47C and Example 2. 1 H-NMR (MeOD, 400 MHz) δ: 1.63-1.87 (m, 3H), 1.91-2.10 (m, 2H), 2.20-2.46 (m, 3H), 2.81 (s, 4H), 2.90 (s, 3H) ), 3.19-3.30 (m, 1H), 7.34-7.44 (m, 1H), 7.64-7.75 (m, 2H), 7.78-7.85 (m, 1H), 8.38-8.73 (m, 3H). LCMS (ESI) ) m / z: 344 (M + 1).
实施例49Example 49
6-氟-3-(4-甲基哌嗪-1-羰基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methylpiperazine-1-carbonyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000166
Figure PCTCN2015075363-appb-000166
实施例49AExample 49A
8-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-甲酸乙酯8-bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole Ethyl 3-carboxylate
Figure PCTCN2015075363-appb-000167
Figure PCTCN2015075363-appb-000167
在0℃下氮气保护下,向实施例41B(3.2克，9.812摩尔)的四氢呋喃(50mL)溶液溶液中分批加入NaH(785毫克，19.625毫摩尔)。在15℃下搅拌0.5小时后降温至0℃，滴加入SEMCl(3.3克，19.625毫摩尔)。将混合物在15摄氏度下搅拌16小时后用饱和氯化铵水溶液(30mL)淬灭，水层用乙酸乙酯(30毫升×3)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥并蒸发，残余物通过柱色谱法纯化以提供标题化合物，为黄色固体(2.16克收率：48.21％)。LCMS(ESI)m/z:456,458(M,M+2).To a solution of Example 41B (3.2 g, 9.812 mol) in tetrahydrofuran (50 mL) was added NaH (785 mg, 19.625 mmol). After stirring at 15 ° C for 0.5 hour, the temperature was lowered to 0 ° C, and SEMCl (3.3 g, 19.625 mmol) was added dropwise. The mixture was stirred at 15 ° C for 16 h then EtOAc (EtOAc m. Drying and evaporation, EtOAc EtOAc m. LCMS (ESI) m/z: 456, 458 (M, M+2).
实施例49BExample 49B
8-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-甲酸8-bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole 3-carboxylic acid
Figure PCTCN2015075363-appb-000168
Figure PCTCN2015075363-appb-000168
实施例49A(2.16克，4.726毫摩尔)和氢氧化钠(950毫克，23.632毫摩尔)的甲醇/水(2:1)(30mL)混合溶剂在80摄氏度搅拌16小时。将所得混合物用1N盐酸调节pH至3～4，水层用乙酸乙酯(30毫升×2)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥，蒸发，得到标题化合物(1.73g，收率：85.22％)可用于下一步骤而无需进一步纯化。A mixed solvent of Example 49A (2.16 g, 4.726 mmol) and sodium hydroxide (950 mg, 23.632 mmol) in methanol/water (2:1) (30 mL) was stirred at 80 ° C for 16 hours. The mixture was adjusted to pH 3-4 with EtOAc (EtOAc)EtOAc. g, yield: 85.22%) was used in the next step without further purification.
实施例49CExample 49C
4-(8-溴-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-羰基)哌嗪-1-羧酸叔丁酯4-(8-Bromo-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-3-carbonyl)piperazine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000169
Figure PCTCN2015075363-appb-000169
N 2保护下,哌嗪-1-羧酸叔丁酯(415毫克，2.241毫摩尔)，实施例49B(800毫克，1.868毫摩尔)，HATU(1.42克，3.735毫摩尔)和三乙胺(567毫克，5.603毫摩尔)的DMF(15毫升)混合物在15摄氏度下搅拌16小时。混合物用水(10mL)淬灭，水层用乙酸乙酯(20毫升×2)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥并蒸发，残余物通过柱色谱法纯化得到标题化合物(1克，收率： 90％)。LCMS(ESI)m/z:596,598(M,M+2).Tert-butyl piperazine-1-carboxylate (415 mg, 2.241 mmol), N.sub.2, Example 49B (800 mg, 1.868 mmol), HATU (1.42 g, 3.735 mmol) and triethylamine A mixture of 567 mg, 5.603 mmol of DMF (15 mL) was stirred at 15 ° C for 16 hours. The mixture was quenched with EtOAc (EtOAc)EtOAc. (1 g, yield: 90%). LCMS (ESI) m/z: 596, 598 (M, M+2).
实施例49DExample 49D
4-(8-氰基-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-羰基)哌嗪-1-羧酸叔丁酯4-(8-Cyano-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-3-carbonyl)piperazine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000170
Figure PCTCN2015075363-appb-000170
氮气保护下,实施例49C(400毫克，0.671毫摩尔)，锌(87毫克，1.341毫摩尔)，氰化锌(158毫克，1.341毫摩尔)，DPPF(75毫克，0.134毫摩尔)和Pd 2(DBA)3(61毫克，0.0671毫摩尔)的DMF(10mL)混合物在120℃下搅拌10小时。冷却至室温后，将所得混合物用水(20mL)稀释，水层用乙酸乙酯(30毫升×3)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(350mg，收率：96.15％)。LCMS(ESI)m/z:543(M+1).Example 49C (400 mg, 0.671 mmol), zinc (87 mg, 1.341 mmol), zinc cyanide (158 mg, 1.341 mmol), DPPF (75 mg, 0.134 mmol) and Pd 2 under nitrogen. A mixture of (DBA) 3 (61 mg, 0.0671 mmol) in DMF (10 mL) was stirred at 120 ° C for 10 hr. After cooling to room temperature, the mixture was diluted w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The title compound (350 mg, yield: 96.15%) was obtained. LCMS (ESI) m/z: 543 (M+1).
实施例49EExample 49E
4-(8-氨基甲酰-6-氟-4-((2-(三甲基甲硅烷基)乙氧基)甲基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-羰基)哌嗪-1-羧酸叔丁酯4-(8-carbamoyl-6-fluoro-4-((2-(trimethylsilyl)ethoxy)methyl)-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-3-carbonyl)piperazine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000171
Figure PCTCN2015075363-appb-000171
0-5℃下,向实施例49D(400毫克，0.737毫摩尔)和碳酸钾(510毫克，3.685毫摩尔)的DMSO(10毫升)混合物滴加入过氧化氢(5mL)。滴加完毕在15℃下搅拌1小时后，用亚硫酸钠水溶液(20mL)淬灭，水层用乙酸乙酯(30毫升×3)萃取，将合并的有机层用水，盐水洗涤，无水硫酸钠干燥并蒸发，残余物通过柱色谱法纯化得到标题化合物(400mg，产率：96.85％)。LCMS(ESI)m/z:561(M+1).To a mixture of Example 49D (400 mg, 0.737 mmol) and potassium carbonate (510 mg, 3.685 mmol) in DMSO (10 mL) was added dropwise hydrogen peroxide (5 mL). After the completion of the dropwise addition, the mixture was stirred at 15 ° C for 1 hr, then EtOAc (EtOAc) After evaporation, the residue was purifiedjjjjjlilili LCMS (ESI) m/z: 564 (M+1).
实施例49FExample 49F
6-氟-3-(哌嗪-1-羰基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(piperazin-1-carbonyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000172
Figure PCTCN2015075363-appb-000172
实施例49E(100毫克，0.178毫摩尔)的三氟乙酸(1毫升)和二氯甲烷(1毫升)混合物在15℃下搅拌16小时。真空除去溶液后，残余物中加入碳酸钾(123毫克，0.892毫摩尔)和甲醇(2毫升)，混合物在15℃下搅拌2小时，将混合物过滤，滤液蒸发，得到标题化合物可直接用于下一步骤而无需进一步纯化。A mixture of Example 49E (100 mg, 0.178 mmol) eluted elute After the solution was removed in vacuo, EtOAc (EtOAc m. One step without further purification.
实施例49G Example 49G
6-氟-3-(4-甲基哌嗪-1-羰基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methylpiperazine-1-carbonyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000173
Figure PCTCN2015075363-appb-000173
实施例49F(59毫克，0.179毫摩尔),甲醛(40毫克，0.358毫摩尔),氰基硼氢化钠(56毫克，0.894毫摩尔)的甲醇(2mL)混合物在15℃下搅拌16小时。真空蒸除溶剂，残余物通过制备型HPLC纯化得到标题化合物(8.14毫克，收率：13.23％)，为白色固体。1H-NMR(MeOD,400MHz)δ:2.68(s,3H),2.99(d,J＝4.64Hz,4H),4.00(br.s.,4H),7.46-7.54(m,1H),7.74-7.84(m,1H),8.12-8.20(m,1H),8.24-8.35(m,2H).LCMS(ESI)m/z:345(M+1).A mixture of 49F (59 mg, 0.179 mmol), EtOAc (EtOAc, m. The solvent was evaporated in vacuo tolululululululululu 1 H-NMR (MeOD, 400MHz ) δ: 2.68 (s, 3H), 2.99 (d, J = 4.64Hz, 4H), 4.00 (br.s., 4H), 7.46-7.54 (m, 1H), 7.74 - 7.84 (m, 1H), 8.12-8.20 (m, 1H), 8.24 - 8.35 (m, 2H). LCMS (ESI) m/z: 345 (M+1).
实施例50Example 50
3-(1-(环丙基甲基)哌啶-4-基)-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-8-甲酰胺3-(1-(cyclopropylmethyl)piperidin-4-yl)-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indole-8-carboxamide
Figure PCTCN2015075363-appb-000174
Figure PCTCN2015075363-appb-000174
实施例50AExample 50A
(E)-4-(二甲基氨基)-2-氧代丁-3-烯酸乙酯(E)-4-(Dimethylamino)-2-oxobut-3-enoate
Figure PCTCN2015075363-appb-000175
Figure PCTCN2015075363-appb-000175
乙基-2-氧代丙酸乙酯(5.0克，43.1毫摩尔)的DMF-DMA(5.0克，42.0毫摩尔)溶液在20℃搅拌16小时。将所得混合物蒸发，得到标题化合物(7.0克，粗产物)，为棕色油状物，可直接用于下一步骤而无需进一步纯化。A solution of ethyl ethyl-2-oxopropanoate (5.0 g, 43.1 mmol) in DMF-DMA (5.0 g, 42.0 mmol) was stirred at 20 ° C for 16 hours. The mixture was evaporated to give the title compound (jjjjjjjjj
实施例50BExample 50B
1-(2,6-二溴-4-氟苯基)-1H-吡唑-5-甲酸乙酯Ethyl 1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazole-5-carboxylate
Figure PCTCN2015075363-appb-000176
Figure PCTCN2015075363-appb-000176
实施例1D(5.0克，17.6毫摩尔)，实施例50A(6.0克，35.2毫摩尔)的乙醇(100毫升)和浓盐酸(2.4毫升)混合物在80℃搅拌16小时。真空除去溶液后，残余物用柱色谱法纯化以提供标题化合物(3.6克，收率：46.8％)，为黄色固体。Example 1D (5.0 g, 17.6 mmol), EtOAc (EtOAc m. After the solution was removed in vacuo, EtOAc m.
实施例50C Example 50C
1-(2,6-二溴-4-氟苯基)-1H-吡唑-5-甲酸1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazole-5-carboxylic acid
Figure PCTCN2015075363-appb-000177
Figure PCTCN2015075363-appb-000177
实施例50B(3.6克，9.18毫摩尔)和氢氧化钠(2.2克，55.1毫摩尔)的甲醇(20mL)和水(2mL)混合物在20℃搅拌1小时。真空除去溶液后，将残余物用水(50mL)稀释并用2N盐酸调节pH至3，水层用二氯甲烷(50mL×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，以提供标题化合物可直接用于下一步骤而无需进一步纯化(3.2克，97.0％)。A mixture of Example 50B (3.6 g, 9.18 mmol) and sodium hydroxide (2.2 g, 55.1 mmol) in methanol (20mL) and water (2mL) was stirred at 20 ° C for one hour. After the solution was removed in vacuo, EtOAc EtOAc (EtOAc m. The title compound was used directly in the next step without further purification (3.2 g, 97.0%).
实施例50DExample 50D
1-(2,6-二溴-4-氟苯基)-N-甲氧基-N-甲基-1H-吡唑-5-甲酰胺1-(2,6-Dibromo-4-fluorophenyl)-N-methoxy-N-methyl-1H-pyrazole-5-carboxamide
Figure PCTCN2015075363-appb-000178
Figure PCTCN2015075363-appb-000178
氮气保护下,实施例50C(3.2克，8.82毫摩尔)，O，N-二甲基羟胺(1.7克，17.6毫摩尔)，HATU(4.0克，10.6毫摩尔)和三乙胺(3.6克，35.3毫摩尔)的无水DMF(2mL)混合物在20℃搅拌16小时。真空除去溶液后，残余物通过柱色谱法纯化得到标题化合物(3.4克，收率：94.4％)，为黄色固体。Example 50C (3.2 g, 8.82 mmol), O,N-dimethylhydroxylamine (1.7 g, 17.6 mmol), HATU (4.0 g, 10.6 mmol) and triethylamine (3.6 g, A mixture of 35.3 mmol of anhydrous DMF (2 mL) was stirred at 20 ° C for 16 h. After the solution was removed in vacuo, EtOAc m.
实施例50EExample 50E
8-溴-6-氟-4H-吡唑并[1,5-a]吲哚-4-酮8-bromo-6-fluoro-4H-pyrazolo[1,5-a]indole-4-one
Figure PCTCN2015075363-appb-000179
Figure PCTCN2015075363-appb-000179
在-78℃氮气保护下，向实施例50D(3.2克，7.90毫摩尔)的无水四氢呋喃(5mL)混合物中在滴加正丁基锂(2.8毫升，7.11毫摩尔)，-78℃下搅拌0.5小时后，混合物用饱和氯化铵水溶液(30mL)淬灭，水层用二氯甲烷(50毫升×2)萃取，将合并的有机层蒸发，残留物用甲醇(30毫升)洗涤，所得亮黄色固体为标题化合物(1.5g，收率：71.4％)。LCMS(ESI)m/z:267,269(M,M+2).To a mixture of Example 50D (3.2 g, 7.90 mmol) in anhydrous tetrahydrofurane (5 mL) was added dropwise n-butyllithium (2.8 mL, 7.11 mmol), and stirred at -78 ° C. After 0.5 h, the mixture was evaporated w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The title compound (1.5 g, yield: 71.4%). LCMS (ESI) m/z: 266, 269 (M, M+2).
实施例50FExample 50F
6-氟-4-氧代-4H-吡唑并[1,5-a]吲哚-8-羧酸甲酯Methyl 6-fluoro-4-oxo-4H-pyrazolo[1,5-a]indole-8-carboxylate
Figure PCTCN2015075363-appb-000180
Figure PCTCN2015075363-appb-000180
实施例50E(1.3克，4.89毫摩尔)，Pd(dppf)Cl2(0.71克，0.98毫摩尔)，钯醋酸(0.22克，0.98毫摩尔)，DPPP(0.81克，1.96毫摩尔)，三苯基膦(的混合物0.51克，1.96毫摩尔)，Xantphos(1.13克，1.96毫摩尔)和三乙胺(3毫升)的甲醇(20ml)和DMF(60mL)混合物80℃在一氧化碳氛围下(3大气压)搅拌16小时。冷却至20℃后，将混合物过滤，将滤液蒸发，残余物通过柱色谱法纯化得到标题化合物(0.9克，收率：75.0％)，为黄色固体。LCMS(ESI)m/z:247(M+1).Example 50E (1.3 g, 4.89 mmol), Pd(dppf)Cl 2 (0.71 g, 0.98 mmol), palladium acetic acid (0.22 g, 0.98 mmol), DPPP (0.81 g, 1.96 mmol), triphenyl a mixture of phosphine (0.51 g, 1.96 mmol), Xantphos (1.13 g, 1.96 mmol) and triethylamine (3 ml) in methanol (20 ml) and DMF (60 mL) at 80 ° C under carbon monoxide atmosphere (3 atmospheres) ) Stir for 16 hours. After cooling to 20 ° C, the mixture was evaporated. LCMS (ESI) m/z: 247 (M+1).
实施例50GExample 50G
6-氟螺[吡唑并[1,5-a]吲哚-4,2'-[1,3]二硫戊环]-8-甲酸甲酯Methyl 6-fluorospiro[pyrazolo[1,5-a]indole-4,2'-[1,3]dithiolan]-8-carboxylate
Figure PCTCN2015075363-appb-000181
Figure PCTCN2015075363-appb-000181
氮气保护下，实施例50F(0.9克，3.66毫摩尔)，2-乙二硫醇(0.69克，7.32毫摩尔)和三氟化硼乙醚(1.0克，7.32毫摩尔)的干燥二氯甲烷(30mL)混合物50℃下搅拌下24小时。冷却至室温后，用二氯甲烷(30毫升)稀释，将合并的有机层用水,10％氢氧化钠(30mL)洗涤后，无水硫酸钠干燥，过滤并蒸发，残余物用硅胶柱色谱纯化得到标题化合物(0.5克，收率：42.4％)，为黄色固体。LCMS(ESI)m/z:323(M+1).Example 50F (0.9 g, 3.66 mmol), 2-ethanedithiol (0.69 g, 7.32 mmol) and boron trifluoride diethyl ether (1.0 g, 7.32 mmol). 30 mL) The mixture was stirred at 50 ° C for 24 hours. After cooling to room temperature, it was diluted with m~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The title compound (0.5 g, yield: 42.4%). LCMS (ESI) m/z: 323 (M+1).
实施例50HExample 50H
3-溴-6-氟螺[吡唑并[1,5-a]吲哚-4,2'-[1,3]二硫戊环]-8-甲酸甲酯Methyl 3-bromo-6-fluorospiro[pyrazolo[1,5-a]indole-4,2'-[1,3]dithiolan]-8-carboxylate
Figure PCTCN2015075363-appb-000182
Figure PCTCN2015075363-appb-000182
实施例50G(500毫克，1.55毫摩尔)和NBS(276毫克，1.55毫摩尔)的四氢呋喃(20mL)混合物在40℃下搅拌16小时。冷却至20℃后，将混合物蒸发，残余物通过柱色谱法纯化以提供标题化合物(470mg，收率：75.7％)，为浅黄色固体。LCMS(ESI)m/z:401,403(M,M+2).A mixture of Example 50G (500 mg, 1.55 mmol) and N.sub.2 (276 mg, 1.55 mmol) in THF (20 mL) was stirred at 40 ° C for 16 hours. After cooling to 20 ° C, the mixture was evaporated. mjjjjjjjjj LCMS (ESI) m/z: 399, 403 (M, M+2).
实施例50IExample 50I
3-溴-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-8-羧酸甲酯Methyl 3-bromo-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indole-8-carboxylate
3-溴-6-氟-4-氧代-4H-吡唑并[1,5-a]吲哚-8-羧酸甲酯Methyl 3-bromo-6-fluoro-4-oxo-4H-pyrazolo[1,5-a]indole-8-carboxylate
Figure PCTCN2015075363-appb-000183
Figure PCTCN2015075363-appb-000183
-78℃下氮气保护下,向NIS(2.1克，9.38毫摩尔)的DCM(20mL)溶液中滴加入HF.Py(3.5毫升)。在 -78℃下搅拌10分钟后，加入实施例50H(470毫克，1.17毫摩尔)。将所得混合物在-78℃搅拌16小时后，用饱和碳酸氢钠水溶液(30mL)淬灭，水层用乙酸乙酯(30毫升×2)萃取，将合并的有机层，用饱和亚硫酸钠水溶液(30mL)洗涤，真空蒸除溶剂，残余物通过柱色谱法纯化以提供实施例50IA，为黄色固体(250毫克，收率：61.6％)，并提供实施例50IB(110毫克，收率：27.2％)，为白色固体。HF.Py (3.5 ml) was added dropwise to a solution of NIS (2.1 g, 9.38 mmol) in DCM (20 mL). In After stirring at -78 °C for 10 minutes, Example 50H (470 mg, 1.17 mmol). After the mixture was stirred at -78 °C for EtOAc (EtOAc) (EtOAc) Washing, the solvent was evaporated in vacuo to give crystalljjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjJ , as a white solid.
实施例50JExample 50J
4-(8-甲酸基-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-3-基)-5,6-二氢吡啶-1(2H)-甲酸叔丁酯4-(8-carboxylic acid-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indol-3-yl)-5,6-dihydropyridine-1(2H)- Tert-butyl formate
Figure PCTCN2015075363-appb-000184
Figure PCTCN2015075363-appb-000184
N 2保护下，实施例50IA(200毫克，0.499毫摩尔)，4-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)-3,6-二氢吡啶-1(2H)-甲酸叔丁酯(185毫克，0.598毫摩尔)，Pd(DPPF)Cl2(37毫克，0.050毫摩尔)和碳酸钾(138毫克，0.997毫摩尔)的DMF(9毫升)和水(3mL)混合物在90℃下搅拌为16小时。冷却至室温后，真空浓缩，残余物溶解于水(20mL)并用1N HCl调节pH至3，水层用二氯甲烷(50毫升×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，提供标题化合物(220mg，粗品)无需进一步纯化.Under the protection of N 2 , Example 50IA (200 mg, 0.499 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3 , 6-Dihydropyridine-1(2H)-carboxylic acid tert-butyl ester (185 mg, 0.598 mmol), Pd(DPPF)Cl2 (37 mg, 0.050 mmol) and potassium carbonate (138 mg, 0.997 mmol) A mixture of DMF (9 ml) and water (3 mL) was stirred at 90 ° C for 16 hours. After being cooled to room temperature, EtOAc was evaporated. EtOAcjjjjjjjjjjjjj The title compound (220 mg, crude) was obtained.
实施例50KExample 50K
4-(8-氨基甲酰基-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-3-基)-5,6-二氢吡啶-1(2H)-甲酸叔丁酯4-(8-carbamoyl-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indol-3-yl)-5,6-dihydropyridine-1 (2H) - tert-butyl formate
Figure PCTCN2015075363-appb-000185
Figure PCTCN2015075363-appb-000185
实施例50J(220毫克，0.51毫摩尔)，碳酸铵(97毫克，1.01毫摩尔)，三乙胺(0.2毫升，1.53毫摩尔)和HATU(252毫克，0.66毫摩尔)的DMF(8毫升)混合物在20℃搅拌16小时。真空浓缩，残余物通过柱色谱法纯化得到标题化合物，为黄色固体(70mg，收率：32.0％)。LCMS(ESI)m/z:435(M+1).Example 50J (220 mg, 0.51 mmol), ammonium carbonate (97 mg, 1.01 mmol), triethylamine (0.2 mL, 1.53 mmol) and EtOAc (252 mg, 0.66 mmol) DMF (8 mL) The mixture was stirred at 20 ° C for 16 hours. Concentration in vacuo, EtOAc EtOAc m. LCMS (ESI) m/z: 435 (M+1).
实施例50LExample 50L
4-(8-氨基甲酰基-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-3-基)哌啶-1-甲酸叔丁酯4-(8-carbamoyl-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indol-3-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000186
Figure PCTCN2015075363-appb-000186
实施例50K(35毫克，0.08毫摩尔)和10％Pd/C(20毫克)的干燥二氯甲烷(20mL)和甲醇(10mL)混合物在50℃氢化16小时(1大气压)。将混合物过滤，将滤液蒸发，得到标题化合物(30mg，收率：85.7％)可直接用于下一步骤而无需进一步纯化。LCMS(ESI)m/z:437(M+1). A mixture of dry dichloromethane (20 mL) and methanol (10 mL), EtOAc (EtOAc) The mixture was filtered, and the filtrate was evaporatedjjjjjjjjjjj LCMS (ESI) m/z: 437 (M+1).
实施例50MExample 50M
4,4,6-三氟-3-(哌啶-4-基)-4H-吡唑并[1,5-a]吲哚-8-甲酰胺4,4,6-trifluoro-3-(piperidin-4-yl)-4H-pyrazolo[1,5-a]indole-8-carboxamide
Figure PCTCN2015075363-appb-000187
Figure PCTCN2015075363-appb-000187
实施例50L(200毫克，0.466毫摩尔)的三氟乙酸(2mL)和二氯甲烷(6mL)混合物在20℃下搅拌2小时。将得到的混合物蒸发，以提供标题化合物可直接用于下一步骤而无需进一步纯化(30毫克，粗品)。A mixture of Example 50L (200 mg, 0.466 mmol) eluted elute The resulting mixture was evaporated to give the title compound mjjjd
实施例50NExample 50N
3-(1-(环丙基甲基)哌啶-4-基)-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-8-甲酰胺3-(1-(cyclopropylmethyl)piperidin-4-yl)-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indole-8-carboxamide
Figure PCTCN2015075363-appb-000188
Figure PCTCN2015075363-appb-000188
N 2保护下，实施例50M(30毫克，0.069毫摩尔)，环丙烷(10毫克，0.138毫摩尔)，四异丙基氧钛(39毫克，0.138毫摩尔)和氰基硼氰化钠(13毫克，0.207毫摩尔)的甲醇(8mL)混合物在60℃下搅拌16小时。用水(10mL)淬灭反应，水层用二氯甲烷(20毫升×3)萃取，将合并的有机层，蒸发，残余物通过制备型HPLC纯化得到标题化合物，为白色固体(5毫克，收率：18.5％)。1H-NMR(400MHz,MethanoL-d4) ppm 0.41(d,J＝4.89Hz,2H),0.72-0.81(m,2H),1.13(br.s.,1H),1.93-2.13(m,2H),2.31(d,J＝13.93Hz,2H),2.87-3.12(m,5H),3.66(d,J＝11.17Hz,2H),7.78-7.82(m,1H),7.85(s,1H),7.97(dd,J＝9.91,2.64Hz,1H),8.07(s,1H).LCMS(ESI)m/z:391(M+1).Example 50M (30 mg, 0.069 mmol), cyclopropane (10 mg, 0.138 mmol), tetraisopropoxytitanium (39 mg, 0.138 mmol) and sodium cyanoborohydride A mixture of 13 mg, 0.207 mmol of methanol (8 mL) was stirred at 60 ° C for 16 h. The reaction was quenched with EtOAc (EtOAc (EtOAc). : 18.5%). 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 0.41 (d, J = 4.89 Hz, 2H), 0.72-0.81 (m, 2H), 1.13 (br.s., 1H), 1.93-2.13 (m, 2H), 2.31 (d, J = 13.93 Hz, 2H), 2.87-3.12 (m, 5H), 3.66 (d, J = 11.17 Hz, 2H), 7.78-7.82 (m, 1H), 7.85 (s, 1H) ), 7.97 (dd, J = 9.91, 2.64 Hz, 1H), 8.07 (s, 1H). LCMS (ESI) m/z: 391 (M+1).
实施例51Example 51
3-(1-乙基哌啶-4-基)-6-氟-4-羟基-4H-吡唑并[1,5-a]吲哚-8-甲酰胺3-(1-ethylpiperidin-4-yl)-6-fluoro-4-hydroxy-4H-pyrazolo[1,5-a]indole-8-carboxamide
Figure PCTCN2015075363-appb-000189
Figure PCTCN2015075363-appb-000189
实施例51AExample 51A
4-(8-氨基甲酰基-6-氟-4-氧代-4H-吡唑并[1,5-a]吲哚-3-基)-3,6-二氢吡啶-1(2H)-甲酸叔丁酯 4-(8-carbamoyl-6-fluoro-4-oxo-4H-pyrazolo[1,5-a]indol-3-yl)-3,6-dihydropyridine-1 (2H) - tert-butyl formate
Figure PCTCN2015075363-appb-000190
Figure PCTCN2015075363-appb-000190
这个实施例是为在实施例50K中所述制备。LCMS(ESI)m/z:413(M+1).This example was prepared as described in Example 50K. LCMS (ESI) m/z: 437 (M+1).
实施例51BExample 51B
4-(8-氨基甲酰基-6-氟-4-羟基-4H-吡唑并[1,5-a]吲哚-3-基)哌啶-1-甲酸叔丁酯4-(8-carbamoyl-6-fluoro-4-hydroxy-4H-pyrazolo[1,5-a]indol-3-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000191
Figure PCTCN2015075363-appb-000191
实施例51A(50毫克，0.121毫摩尔)和10％Pd/C(10毫克)的无水甲醇(10mL)混合物在50℃氢化16小时(1大气压)。将混合物过滤，将滤液蒸发，得到标题化合物(40mg，收率：80.0％)可直接用于下一步骤而无需进一步纯化.LCMS(ESI)m/z:417(M+1).A mixture of Example 51A (50 mg, 0.121 mmol) and 10% <RTI ID=0.0></RTI> </RTI> <RTIgt; The mixture was filtered, EtOAc mjjjjjjjjjjjjj
实施例51CExample 51C
6-氟-4-羟基-3-(哌啶-4-基)-4H-吡唑并[1,5-a]吲哚-8-甲酰胺6-fluoro-4-hydroxy-3-(piperidin-4-yl)-4H-pyrazolo[1,5-a]indole-8-carboxamide
Figure PCTCN2015075363-appb-000192
Figure PCTCN2015075363-appb-000192
这个实施例是为在实施例50M中描述制备。This example was prepared as described in Example 50M.
实施例51DExample 51D
3-(1-乙基哌啶-4-基)-6-氟-4-羟基-4H-吡唑并[1,5-a]吲哚-8-甲酰胺3-(1-ethylpiperidin-4-yl)-6-fluoro-4-hydroxy-4H-pyrazolo[1,5-a]indole-8-carboxamide
Figure PCTCN2015075363-appb-000193
Figure PCTCN2015075363-appb-000193
实施例51C(25毫克，0.079毫摩尔)，40％的乙醛(0.1毫升)和氰基硼氰化钠(20毫克，0.316毫摩尔)的甲醇(5毫升)混合物在10℃下搅拌16小时。将得到的混合物用水(10mL)稀释，水层用二氯甲烷(20毫升×3)萃取，将合并的有机层蒸发，得到残留物通过制备型HPLC纯化得到标题化合物(9.40毫克，收率：34.8％)，为白色固体。1H-NMR(400MHz,MethanoL-d4)ppm 1.11-1.18(m,3H),1.77-1.96(m,2H),2.01-2.16(m,2H),2.61(br.s.,2H),2.81(br.s.,3H),3.27(br.s.,2H),5.72(s,1H),7.59(dd,J＝7.22,2.45Hz,1H),7.70(d,J＝10.42Hz,1H),7.76(s,1H),7.99(br.s.,1H),8.32(br.s.,1H),10.09(br.s.,1H). LCMS(ESI)m/z:345(M+1).A mixture of Example 51C (25 mg, 0.079 mmol), 40% EtOAc (EtOAc) (EtOAc) . The resulting mixture was diluted with H.sub.2 (EtOAc (EtOAc) (EtOAc). %), as a white solid. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.11-1.18 (m, 3H), 1.77-1.96 (m, 2H), 2.01-2.16 (m, 2H), 2.61 (br.s., 2H), 2.81 (br.s., 3H), 3.27 (br.s., 2H), 5.72 (s, 1H), 7.59 (dd, J = 7.22, 2.45 Hz, 1H), 7.70 (d, J = 10.42 Hz, 1H), 7.76 (s, 1H), 7.99 (br.s., 1H), 8.32 (br.s., 1H), 10.09 (br.s., 1H). LCMS (ESI) m/z: 345 ( M+1).
实施例52Example 52
3-(1-乙基哌啶-4-基)-6-氟-4-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpiperidin-4-yl)-6-fluoro-4-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000194
Figure PCTCN2015075363-appb-000194
实施例52AExample 52A
4-(8-氨基甲酰基-6-氟-4-甲基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)哌啶-1-甲酸叔丁酯4-(8-carbamoyl-6-fluoro-4-methyl-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)piperidine-1-carboxylic acid Butyl ester
Figure PCTCN2015075363-appb-000195
Figure PCTCN2015075363-appb-000195
实施例1I(30毫克，0.075毫摩尔)，碳酸钾(31毫克，0.224毫摩尔)和碘甲烷(32毫克，0.224毫摩尔)的DMF(3mL)混合物在10℃下搅拌1小时。反应物用水(10mL)淬灭，水层用乙酸乙酯(10毫升×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，以提供标题化合物可直接用于下一步骤而无需进一步纯化.A mixture of Example 1I (30 mg, 0.075 mmol), EtOAc (EtOAc (EtOAc) The reaction was quenched with EtOAc (EtOAc)EtOAc. Further purification.
实施例52BExample 52B
6-氟-4-甲基-3-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-4-methyl-3-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000196
Figure PCTCN2015075363-appb-000196
实施例52A(31毫克，0.074毫摩尔)的二氯甲烷(1毫升)和三氟乙酸(0.2毫升)混合物在10℃下搅拌2小时。将混合物蒸发，以提供标题化合物可直接用于下一步骤而无需进一步纯化.A mixture of methylene chloride (1 ml) and trifluoroacetic acid (0.2 ml) was stirred at <RTIgt; The mixture was evaporated to give the title compound which was taken directly to the next step without further purification.
实施例52CExample 52C
3-(1-乙基哌啶-4-基)-6-氟-4-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethylpiperidin-4-yl)-6-fluoro-4-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000197
Figure PCTCN2015075363-appb-000197
本实施例中如实施例51D所述的方法制备。1H-NMR(400MHz,METHANOL-d4)ppm 1.23-1.26(t,3H), 1.91-1.97(m,2H),2.11-2.14(d,2H),2.55(t,2H),2.78-2.80(m,2H),3.04-3.07(m,2H),3.32(2H),3.87(s,2H),7.48-8.50(m,1H),7.64-7.67(m,1H),7.73(s,1H),8.54(s,1H).LCMS(ESI)m/z:344(M+1).This example was prepared as described in Example 51D. 1 H-NMR (400 MHz, METHANOL-d4) ppm 1.23-1.26 (t, 3H), 1.91-1.97 (m, 2H), 2.11-2.14 (d, 2H), 2.55 (t, 2H), 2.78-2.80 ( m, 2H), 3.04-3.07 (m, 2H), 3.32 (2H), 3.87 (s, 2H), 7.48-8.50 (m, 1H), 7.64-7.67 (m, 1H), 7.73 (s, 1H) , 8.54 (s, 1H). LCMS (ESI) m / z: 344 (M + 1).
流程CProcess C
Figure PCTCN2015075363-appb-000198
Figure PCTCN2015075363-appb-000198
实施例53Example 53
6-氟-3-(4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000199
Figure PCTCN2015075363-appb-000199
实施例53AExample 53A
1-(叔丁基)-4-甲基-4-甲基哌啶-1,4-二羧酸二甲酯Dimethyl 1-(tert-butyl)-4-methyl-4-methylpiperidine-1,4-dicarboxylate
Figure PCTCN2015075363-appb-000200
Figure PCTCN2015075363-appb-000200
-78℃N 2保护下，向1-叔丁基-4-甲基哌啶-1,4-二羧酸酯(36.5克，0.15摩尔)的无水四氢呋喃(400毫升)溶液中滴入LiHMDS(1M，300毫升)。在-78℃下搅拌30分钟后，滴加入碘甲烷(42.6克，0.3摩尔)的四氢呋喃(100mL)溶液，反应混合物在-78℃搅拌2小时后升温至15℃下再搅拌20小时。反应完毕后用饱和氯化铵水溶液(500mL)淬灭，水层用乙酸乙酯(500毫升×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(30克，收率：78％)。LCMS(ESI)m/z:258(M+1).To a solution of 1-tert-butyl-4-methylpiperidine-1,4-dicarboxylate (36.5 g, 0.15 mol) in dry tetrahydrofuran (400 mL) (1M, 300 ml). After stirring at -78 ° C for 30 minutes, a solution of methyl iodide (42.6 g, 0.3 mol) in tetrahydrofuran (100 mL) was added dropwise, and the mixture was stirred at -78 ° C for 2 hours and then warmed to 15 ° C and then stirred for 20 hours. After completion of the reaction, the mixture was evaporated to m~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The title compound was obtained (30 g, yield: 78%). LCMS (ESI) m/z: 258 (M+1).
实施例53BExample 53B
4-(羟基甲基)-4-甲基哌啶-1-甲酸叔丁酯4-(hydroxymethyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000201
Figure PCTCN2015075363-appb-000201
0℃在氮气保护下，向四氢铝锂(3.7克，97.5毫摩尔)的无水四氢呋喃(40mL)溶液中逐滴加入实施例53A(10克，39毫摩尔)的无水四氢呋喃(80mL)溶液。滴加完毕在0℃搅拌2.5小时后，将反应混合物用水(4mL)，15％氢氧化钠水溶液(4mL)和水(12毫升)淬灭，混合物在0℃再搅拌20分钟后过滤， 固体用乙酸乙酯(50ml×4)洗涤，将合并的有机层用硫酸钠干燥，过滤并蒸发，以提供标题化合物(9克,粗品)可直接用于下一步而无需进一步纯化。To a solution of lithium tetrahydroaluminum (3.7 g, 97.5 mmol) in anhydrous tetrahydrofuran (40 mL), EtOAc (EtOAc m. Solution. After the dropwise addition was completed at 0 ° C for 2.5 hours, the reaction mixture was quenched with water (4mL), 15% aqueous sodium hydroxide (4mL) and water (12 ml), and the mixture was stirred at 0 ° C for 20 minutes and then filtered. The solid was washed with EtOAc (EtOAc)EtOAc.
实施例53CExample 53C
4-(羟基甲基)-4-甲基哌啶-1-甲酸叔丁酯4-(hydroxymethyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000202
Figure PCTCN2015075363-appb-000202
这个实施例是在实施例1A-1B描述的方法制备。This example was prepared in the manner described in Examples 1A-1B.
实施例53DExample 53D
6-氟-3-(4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000203
Figure PCTCN2015075363-appb-000203
这个实施例是如实施例1E-1J中所述制备的。1H NMR(400MHz,MeOD)δ:8.51(s,1H),7.81(s,1H),7.69(dd,J＝2.4Hz/J＝10.2Hz,1H),7.45(dd,J＝2.4Hz/J＝8.0Hz,1H),3.33-3.39(m,2H),3.12-3.32(m,2H),2.42-2.46(m,2H),2.03-2.08(m,2H),1.46(s,3H).LCMS(ESI)m/z:316(M+1).This example was prepared as described in Examples 1E-1J. 1 H NMR (400MHz, MeOD) δ: 8.51 (s, 1H), 7.81 (s, 1H), 7.69 (dd, J = 2.4Hz / J = 10.2Hz, 1H), 7.45 (dd, J = 2.4Hz / J=8.0Hz,1H),3.33-3.39(m,2H),3.12-3.32(m,2H),2.42-2.46(m,2H),2.03-2.08(m,2H),1.46(s,3H) .LCMS (ESI) m / z: 316 (M + 1).
实施例54Example 54
3-(1-乙基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-Ethyl-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000204
Figure PCTCN2015075363-appb-000204
这个实施例是为在实施例52C(10毫克，38％产率)中所述制备。1H NMR(400MHz,DMSO)δ:10.58(s,1H),8.28(s,1H),8.13(s,1H),7.80(s,1H),7.61(dd,J＝2.8Hz/J＝7.2Hz,1H),7.49(t,J＝2.4Hz,1H),2.75-2.78(m,2H),2.50-2.54(m,4H),2.18-2.20(m,2H),1.73-1.78(m,2H),1.30(s,3H),1.05(t,J＝7.2Hz,3H).LCMS(ESI)m/z:344(M+1).This example was prepared as described in Example 52C (10 mg, 38% yield). 1 H NMR (400MHz, DMSO) δ: 10.58 (s, 1H), 8.28 (s, 1H), 8.13 (s, 1H), 7.80 (s, 1H), 7.61 (dd, J = 2.8Hz / J = 7.2 Hz, 1H), 7.49 (t, J = 2.4 Hz, 1H), 2.75-2.78 (m, 2H), 2.50-2.54 (m, 4H), 2.18-2.20 (m, 2H), 1.73-1.78 (m, 2H), 1.30 (s, 3H), 1.05 (t, J = 7.2 Hz, 3H). LCMS (ESI) m/z: 344 (M+1).
实施例55Example 55
3-(1-环丙基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-cyclopropyl-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000205
Figure PCTCN2015075363-appb-000205
本实施例中如实施例4中所述制备。1H-NMR(400MHz,MethanoL-d4)0.77(d,J＝5.40Hz,4H),1.41-1.45(m, 3H),1.90-2.01(m,2H),2.28-2.44(m,3H),3.03(br.s.,2H),3.27(br.s.,2H),7.39(dd,J＝8.16,2.51Hz,1H),7.73(dd,J＝10.92,2.38Hz,1H),7.79(s,1H),8.41(br.s.,1H).LCMS(ESI)m/z:356(M+1).It was prepared as described in Example 4 in this example. 1 H-NMR (400 MHz, Methano L-d 4 ) 0.77 (d, J = 5.40 Hz, 4H), 1.41-1.45 (m, 3H), 1.90-2.01 (m, 2H), 2.28-2.44 (m, 3H) , 3.03 (br.s., 2H), 3.27 (br.s., 2H), 7.39 (dd, J = 8.16, 2.51 Hz, 1H), 7.73 (dd, J = 10.92, 2.38 Hz, 1H), 7.79 (s, 1H), 8.41 (br.s., 1H). LCMS (ESI) m/z: 356 (M+1).
实施例56Example 56
6-氟-3-(1-(2-羟基-2-甲基丙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-hydroxy-2-methylpropyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000206
Figure PCTCN2015075363-appb-000206
本实施例中如实施例6中描述的方法制备。1H-NMR(400MHz,DMSO-d4)δppm 1.13(s,6H),1.28(s,3H),1.86(t,J＝10.23Hz,2H),2.20(d,J＝15.43Hz,2H),2.62(s,2H),2.76(br.s.,2H),3.04(d,J＝4.02Hz,2H),This example was prepared as described in Example 6. 1 H-NMR (400 MHz, DMSO-d 4 ) δ ppm 1.13 (s, 6H), 1.28 (s, 3H), 1.86 (t, J = 10.23 Hz, 2H), 2.20 (d, J = 15.43 Hz, 2H) , 2.62 (s, 2H), 2.76 (br.s., 2H), 3.04 (d, J = 4.02 Hz, 2H),
7.48(dd,J＝8.34,2.57Hz,1H),7.56(dd,J＝10.92,2.64Hz,1H),7.79(s,1H),8.31(s,1H).LCMS(ESI)m/z:388(M+1).7.48 (dd, J = 8.34, 2.57 Hz, 1H), 7.56 (dd, J = 10.92, 2.64 Hz, 1H), 7.79 (s, 1H), 8.31 (s, 1H). LCMS (ESI) m/z: 388 (M+1).
实施例57Example 57
3-(1-环丙基亚甲基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-cyclopropylmethylene-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide
Figure PCTCN2015075363-appb-000207
Figure PCTCN2015075363-appb-000207
本实施例中如实施例5中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)δppm 0.37(d,J＝3.89Hz,2H),0.73(d,J＝7.53Hz,2H),1.02-1.14(m,1H),1.44(br.s.,3H),2.08(d,J＝11.29Hz,2H),2.37-2.66(m,2H),2.94(br.s.,3H),3.34-3.63(m,3H),7.38(dd,J＝8.09,2.57Hz,1H),7.71(dd,J＝10.92,2.51Hz,1H),7.79(s,1H),7.77-7.81(m,1H),8.51(s,1H).LCMS(ESI)m/z:370(M+1).This example was prepared as described in Example 5. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 0.37 (d, J = 3.89 Hz, 2H), 0.73 (d, J = 7.53 Hz, 2H), 1.02-1.14 (m, 1H), 1.44 (br. s., 3H), 2.08 (d, J = 11.29 Hz, 2H), 2.37-2.66 (m, 2H), 2.94 (br.s., 3H), 3.34 - 3.63 (m, 3H), 7.38 (dd, J=8.09, 2.57 Hz, 1H), 7.71 (dd, J = 10.92, 2.51 Hz, 1H), 7.79 (s, 1H), 7.77-7.81 (m, 1H), 8.51 (s, 1H). LCMS (ESI) ) m / z: 370 (M + 1).
实施例58Example 58
3-(1-4,4-二氟环己基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-4,4-difluorocyclohexyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000208
Figure PCTCN2015075363-appb-000208
本实施例中如实施例5中描述的方法制备。1H-NMR(400MHz,DMSO-d4)δppm 1.22(s,3H),1.33-1.49(m,1H),1.70(br.s.,6H),1.92-2.12(m,1H),2.31-2.38(m,1H),2.59-2.64(m,1H),7.40-7.62(m,2H),This example was prepared as described in Example 5. 1 H-NMR (400MHz, DMSO-d 4 ) δ ppm 1.22 (s, 3H), 1.33-1.49 (m, 1H), 1.70 (br.s., 6H), 1.92-2.12 (m, 1H), 2.31 2.38 (m, 1H), 2.59-2.64 (m, 1H), 7.40-7.62 (m, 2H),
7.74(s,1H).LCMS(ESI)m/z:434(M+1).7.74 (s, 1H). LCMS (ESI) m /z: 434 (M + 1).
实施例59Example 59
6-氟-3-(4-甲基-1-(四氢-2H-吡喃-4-基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000209
Figure PCTCN2015075363-appb-000209
本实施例中如实施例5中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.05(t,J＝7.22Hz,1H),This example was prepared as described in Example 5. 1 H NMR (400 MHz, METHANOL-d 4 ) 1.05 (t, J = 7.22 Hz, 1H),
1.36(s,3H),1.50-1.60(m,1H),1.82(d,J＝11.92Hz,3H),2.21-2.27(m,1H),2.44-2.56(m,1H),2.79(br.s.,2H),3.35-3.42(m,1H),3.90-4.05(m,1H),7.32-7.38(m,1H),7.71(s,1H).LCMS(ESI)m/z:4001.36(s,3H),1.50-1.60(m,1H),1.82(d,J=11.92Hz,3H),2.21-2.27(m,1H),2.44-2.56(m,1H), 2.79(br. s., 2H), 3.35-3.42 (m, 1H), 3.90-4.05 (m, 1H), 7.32-7.38 (m, 1H), 7.71 (s, 1H). LCMS (ESI) m/z: 400
(M+1).(M+1).
实施例60Example 60
6-氟-3-(1-2-氟乙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-2-fluoroethyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide
Figure PCTCN2015075363-appb-000210
Figure PCTCN2015075363-appb-000210
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.45(s,3H),This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.45 (s, 3H),
2.01-2.05(m,2H),2.24-2.47(m,2H),3.05(m,2H),3.24-3.25(m,1H),3.26-3.27(m,1H),3.33-3.34(m,1H),4.70-4.72(m,1H),4.82-4.93(m,1H),7.37-7.39(m,1H),7.68-7.79(d,1H),7.81(s,1H),8.45(br.s.,1H).2.01-2.05(m,2H),2.24-2.47(m,2H),3.05(m,2H),3.24-3.25(m,1H), 3.26-3.27(m,1H),3.33-3.34(m,1H ), 4.70-4.72 (m, 1H), 4.82-4.93 (m, 1H), 7.37-7.39 (m, 1H), 7.68-7.79 (d, 1H), 7.81 (s, 1H), 8.45 (br.s) .,1H).
LCMS(ESI)m/z:362(M+1).LCMS (ESI) m/z: 356 (M+1).
实施例61Example 61
6-氟-3-(4-甲基-1-(2,2,2-三氟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000211
Figure PCTCN2015075363-appb-000211
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.37(s,3H),1.79-1.91(m,2H),2.16-2.27(m,2H),2.58-2.69(m,2H),2.79-2.89(m,2H),2.98-3.10(m,2H),7.33-7.39(m,1H),7.66-7.75(m,2H).LCMS(ESI)m/z:398(M+1).This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) ppm 1.37 (s, 3H), 1.79-1.91 (m, 2H), 2.16-2.27 (m, 2H), 2.58-2.69 (m, 2H), 2.79-2.89 ( m, 2H), 2.98-3.10 (m, 2H), 7.33-7.39 (m, 1H), 7.66-7.75 (m, 2H). LCMS (ESI) m/z: 398 (M+1).
实施例62Example 62
6-氟-3-(4-甲基-1-(2,2,2-三氟丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-(2,2,2-trifluoropropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000212
Figure PCTCN2015075363-appb-000212
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.42(s,3H),1.92-2.05(m,2H),2.38(d,J＝14.93Hz,2H),2.54-2.71(m,2H),2.86(d,J＝9.79Hz,2H),2.93-3.07(m,2H),3.14(d,This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) 1.42 (s, 3H), 1.92-2.05 (m, 2H), 2.38 (d, J = 14.93Hz, 2H), 2.54-2.71 (m, 2H), 2.86 ( d, J = 9.79 Hz, 2H), 2.93 - 3.07 (m, 2H), 3.14 (d,
J＝11.17Hz,2H),7.37(dd,J＝8.16,2.51Hz,1H),7.70(dd,J＝10.92,2.51Hz,1H),7.76(s,1H),8.37(br.s.,1J=11.17Hz, 2H), 7.37 (dd, J=8.16, 2.51 Hz, 1H), 7.70 (dd, J=10.92, 2.51 Hz, 1H), 7.76 (s, 1H), 8.37 (br.s., 1
H).LCMS(ESI)m/z:412(M+1).H). LCMS (ESI) m / z: 412 (M + 1).
实施例63Example 63
3-(1-((1-氰基环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-Cyanocyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000213
Figure PCTCN2015075363-appb-000213
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.05(d,J＝2.26Hz,2H),1.32-1.38(m,2H),1.40(s,3H),1.89-2.05(m,2H),2.33(d,J＝15.69Hz,2H),2.69(s,4H),3.02(br.s.,2H),7.38(dd,J＝8.09,2.57Hz,1H),7.68-7.83(m,2H),8.28(br.s.,1H).LCMS(ESI)m/z:395(M+1).This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.05 (d, J = 2.26 Hz, 2H), 1.32-1.38 (m, 2H), 1.40 (s, 3H), 1.89-2.05 (m, 2H), 2.33 (d, J=15.69 Hz, 2H), 2.69 (s, 4H), 3.02 (br.s., 2H), 7.38 (dd, J=8.09, 2.57 Hz, 1H), 7.68-7.83 (m, 2H) , 8.28 (br.s., 1H). LCMS (ESI) m / z: 395 (M + 1).
实施例64Example 64
3-(1-((1-氰基环丁基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-Cyanocyclobutyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000214
Figure PCTCN2015075363-appb-000214
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.38(s,3H),1.85-1.94(m,2H),2.00-2.09(m,1H),2.18-2.31(m,5H),2.42-2.52(m,2H),2.63(t,J＝9.22Hz,2H),2.81(s,2H),2.88(d,J＝5.65Hz,2H),7.36(dd,J＝8.03,2.26Hz,1H),7.69(d,J＝2.26Hz,1H),7.73(s,1H),8.30(br.s.,1H).This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) 1.38 (s, 3H), 1.85-1.94 (m, 2H), 2.00-2.09 (m, 1H), 2.18-2.31 (m, 5H), 2.42-2.52 (m , 2H), 2.63 (t, J = 9.22 Hz, 2H), 2.81 (s, 2H), 2.88 (d, J = 5.65 Hz, 2H), 7.36 (dd, J = 8.03, 2.26 Hz, 1H), 7.69 (d, J = 2.26 Hz, 1H), 7.73 (s, 1H), 8.30 (br.s., 1H).
LCMS(ESI)m/z:409(M+1).LCMS (ESI) m/z: 409 (M+1).
实施例65Example 65
6-氟-3-(4-甲基-1-(2-(甲基磺酰基)乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000215
Figure PCTCN2015075363-appb-000215
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.40(s,3H),1.87-This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.40 (s, 3H), 1.87-
1.98(m,2H),2.28-2.38(m,2H),2.63-2.80(m,2H),2.95-3.05(m,2H),3.07(s,3H),3.07-3.14(m,2H),3.38-3.47(m,2H),7.33-7.40(m,1H),7.66-7.73(m,1H),7.73-7.77(m,1H),8.20-8.37(m,1H).LCMS(ESI)m/z:422(M+1).1.98 (m, 2H), 2.28-2.38 (m, 2H), 2.63-2.80 (m, 2H), 2.95-3.05 (m, 2H), 3.07 (s, 3H), 3.07-3.14 (m, 2H), 3.38-3.47 (m, 2H), 7.33-7.40 (m, 1H), 7.66-7.73 (m, 1H), 7.73-7.77 (m, 1H), 8.20-8.37 (m, 1H). LCMS (ESI) m /z:422(M+1).
实施例66Example 66
6-氟-3-(4-甲基-1-((四氢-2H-吡喃-4-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)-4H-benzo[4,5]imidazolium [1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000216
Figure PCTCN2015075363-appb-000216
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.25-1.33(m,2H),1.37(s,3H),1.70(d,J＝13.30Hz,2H),1.80-1.89(m,3H),2.22(br.s.,2H),2.23(br.s.,2H),2.38(br.s.,2H),2.67(br.s.,2H),3.40-3.47(m,2H),3.94(dd,J＝11.67,2.89Hz,2H),7.36(dd,J＝8.16,2.51Hz,1H),7.69(d,J＝2.51This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) 1.25-1.33 (m, 2H), 1.37 (s, 3H), 1.70 (d, J = 13.30 Hz, 2H), 1.80-1.89 (m, 3H), 2.22 ( Br.s., 2H), 2.23 (br.s., 2H), 2.38 (br.s., 2H), 2.67 (br.s., 2H), 3.40-3.47 (m, 2H), 3.94 (dd , J=11.67, 2.89Hz, 2H), 7.36 (dd, J=8.16, 2.51Hz, 1H), 7.69(d, J=2.51
Hz,1H),7.72(br.s.,1H).LCMS(ESI)m/z:414(M+1).Hz, 1H), 7.72 (br.s., 1H). LCMS (ESI) m/z: 414 (M+1).
实施例67Example 67
3-(1-((1-氨基环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-Aminocyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000217
Figure PCTCN2015075363-appb-000217
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 0.72-0.82(m,2H),0.93-1.00(m,2H),1.40(s,3H),1.91-2.03(m,2H),2.26-2.37(m,2H),2.66(s,4H),2.94-3.06(m,2H),7.33-7.41(m,1H),7.67-7.73(m,1H),7.73-7.77(m,1H),8.22-8.48(m,2H).LCMS(ESI)m/z:385(M+1).This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 0.72-0.82 (m, 2H), 0.93-1.00 (m, 2H), 1.40 (s, 3H), 1.91-2.03 (m, 2H), 2.26-2.37 ( m, 2H), 2.66 (s, 4H), 2.94-3.06 (m, 2H), 7.33-7.41 (m, 1H), 7.67-7.73 (m, 1H), 7.73-7.77 (m, 1H), 8.22 8.48 (m, 2H). LCMS (ESI) m/z: 385 (M +1).
实施例68Example 68
6-氟-3-(4-甲基-1-(氧杂环丁烷-3-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-(oxetan-3-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000218
Figure PCTCN2015075363-appb-000218
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,CHLOROFORM-d)ppm 1.36(s,3H),1.78-1.88(m,2H),2.17-2.25(m,2H),2.36(br.s.,2H),2.57-2.68(m,2H),2.72(d,J＝7.03Hz,2H),4.38-4.47(m,2H),4.60-4.63(m,1H),4.80-4.82(m,2H),7.33-7.39(m,1H),7.68-7.76(m,2H).LCMS(ESI)m/z:386(M+1).This example was prepared as described in Example 3. 1 H NMR (400MHz, CHLOROFORM- d) ppm 1.36 (s, 3H), 1.78-1.88 (m, 2H), 2.17-2.25 (m, 2H), 2.36 (br.s., 2H), 2.57-2.68 ( m, 2H), 2.72 (d, J = 7.03 Hz, 2H), 4.38-4.47 (m, 2H), 4.60-4.63 (m, 1H), 4.80-4.82 (m, 2H), 7.33-7.39 (m, 1H), 7.68-7.76 (m, 2H). LCMS (ESI) m/z: 386 (M+1).
实施例69Example 69
6-氟-3-(1-(2-甲氧基乙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-methoxyethyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000219
Figure PCTCN2015075363-appb-000219
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.45(s,3H),2.07(ddd,This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) 1.45 (s, 3H), 2.07 (ddd,
J＝14.68,10.85,3.58Hz,2H),2.46(d,J＝14.81Hz,2H),3.12(br.s.,2H),3.23(t,J＝4.83Hz,2H),3.41(s,5H),3.66-3.73(m,2H),7.39(dd,J＝8.16,2.51Hz,1H),7.71(dd,J＝10.92,2.51Hz,1H),7.80(s,1H),8.52(s,1H).LCMS(ESI)m/z:374(M+1).J=14.68, 10.85, 3.58 Hz, 2H), 2.46 (d, J = 14.81 Hz, 2H), 3.12 (br.s., 2H), 3.23 (t, J = 4.83 Hz, 2H), 3.41 (s, 5H), 3.66-3.73 (m, 2H), 7.39 (dd, J = 8.16, 2.51 Hz, 1H), 7.71 (dd, J = 10.92, 2.51 Hz, 1H), 7.80 (s, 1H), 8.52 (s) , 1H). LCMS (ESI) m / z: 374 (M + 1).
实施例70Example 70
6-氟-3-(1-((1-羟基环丙基)甲基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-((1-hydroxycyclopropyl)methyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000220
Figure PCTCN2015075363-appb-000220
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 0.64-0.74(m,2H),0.84-0.93(m,2H),1.46(s,3H),2.04-2.18(m,2H),2.50(d,J＝15.18Hz,2H),3.16(br.s.,4H),3.47-3.68(m,2H),7.36-7.43(m,1H),7.68-7.75(m,1H),7.79-7.84(m,1H),8.48-8.65(m,1H).LCMS(ESI)m/z:386(M+1).This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) ppm 0.64-0.74 (m, 2H), 0.84-0.93 (m, 2H), 1.46 (s, 3H), 2.04-2.18 (m, 2H), 2.50 (d, J=15.18 Hz, 2H), 3.16 (br.s., 4H), 3.47-3.68 (m, 2H), 7.36-7.43 (m, 1H), 7.68-7.75 (m, 1H), 7.79-7.84 (m , 1H), 8.48-8.65 (m, 1H). LCMS (ESI) m/z: 386 (M+1).
实施例71Example 71
6-氟-3-(4-甲基-1-((3-甲基氧杂环丁烷-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-Fluoro-3-(4-methyl-1-((3-methyloxetan-3-yl)methyl)piperidin-4-yl)-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000221
Figure PCTCN2015075363-appb-000221
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.38(s,3H),1.46(s,3H),1.81-1.93(m,2H),2.18-2.29(m,2H),2.33-2.54(m,2H),2.54-2.84(m,4H),4.31-4.35(m,2H),4.49-4.54(m,2H),7.34-7.39(m,1H),7.68-7.75(m,2H).LCMS(ESI)m/z:400(M+1).This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.38 (s, 3H), 1.46 (s, 3H), 1.81-1.93 (m, 2H), 2.18-2.29 (m, 2H), 2.33 - 2.54 (m, 2H), 2.54-2.84 (m, 4H), 4.31-4.35 (m, 2H), 4.49-4.54 (m, 2H), 7.34-7.39 (m, 1H), 7.68-7.75 (m, 2H). LCMS ( ESI) m/z: 400 (M+1).
实施例72Example 72
6-氟-3-(1-(3-甲氧基丙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(3-methoxypropyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000222
Figure PCTCN2015075363-appb-000222
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.45(s,3H),1.94-2.01(m,2H),2.02-2.12(m,2H),2.47(d,J＝13.05Hz,2H),2.89-3.20(m,4H),3.34(s,3H),3.39(br.s.,2H),3.45-3.52(m,2H),7.38(dd,J＝8.09,2.57Hz,1H),7.71(dd,J＝10.92,2.51Hz,1H),7.79(s,1H),8.55(s,1H).LCMS(ESI)m/z:434(M+1).This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) 1.45 (s, 3H), 1.94-2.01 (m, 2H), 2.02-2.12 (m, 2H), 2.47 (d, J = 13.05Hz, 2H), 2.89- 3.20 (m, 4H), 3.34 (s, 3H), 3.39 (br.s., 2H), 3.45-3.52 (m, 2H), 7.38 (dd, J = 8.09, 2.57 Hz, 1H), 7.71 (dd , J = 10.092, 2.51 Hz, 1H), 7.79 (s, 1H), 8.55 (s, 1H). LCMS (ESI) m/z: 434 (M+1).
实施例73Example 73
6-氟-3-(4-甲基-1-((1-(甲基磺酰基)环丙基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-((1-(methylsulfonyl)cyclopropyl)methyl)piperidin-4-yl)-4H-benzo[4,5]imidazolium [1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000223
Figure PCTCN2015075363-appb-000223
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)0.95-1.01(m,2H),1.38(s,3H),1.41-1.49(m,2H),1.83-1.96(m,2H),2.27(d,J＝13.30Hz,2H),2.55(br.s.,2H),2.86(s,2H),2.92(br.s.,2H),3.24(s,3H),7.36(dd,J＝8.16,2.51Hz,1H),7.67-7.78(m,2H).LCMS(ESI)m/z:448(M+1).This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) 0.95-1.01 (m, 2H), 1.38 (s, 3H), 1.41-1.49 (m, 2H), 1.83-1.96 (m, 2H), 2.27 (d, J =13.30 Hz, 2H), 2.55 (br.s., 2H), 2.86 (s, 2H), 2.92 (br.s., 2H), 3.24 (s, 3H), 7.36 (dd, J = 8.16, 2.51) Hz, 1H), 7.67-7.78 (m, 2H). LCMS (ESI) m/z: 448 (M+1).
实施例74Example 74
6-氟-3-(4-甲基-1-(噻唑-2-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-(thiazol-2-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000224
Figure PCTCN2015075363-appb-000224
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.36-1.42(m,3H),1.86-1.97(m,2H),2.23-2.33(m,2H),2.63-2.73(m,2H),2.89-2.98(m,2H),4.02-4.07(m,2H),7.32-7.40(m,1H),7.58-7.63(m,1H),7.68-7.73(m,1H),7.74(s,1H),7.75-7.79(m,1H),8.25-8.35(m,1H).LCMS(ESI)m/z:413(M+1).This example was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.36-1.42 (m, 3H), 1.86-1.97 (m, 2H), 2.23-2.33 (m, 2H), 2.63-2.73 (m, 2H), 2.89- 2.98 (m, 2H), 4.02-4.07 (m, 2H), 7.32-7.40 (m, 1H), 7.58-7.63 (m, 1H), 7.68-7.73 (m, 1H), 7.74 (s, 1H), 7.75-7.79 (m, 1H), 8.25-8.35 (m, 1H). LCMS (ESI) m/z: 413 (M+1).
实施例75Example 75
6-氟-3-(4-甲基-1-(甲磺酰基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-(methylsulfonyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
Figure PCTCN2015075363-appb-000225
Figure PCTCN2015075363-appb-000225
本实施例中如实施例3中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.38-1.46(m,3H),1.88(ddd,J＝13.68,9.66,3.76Hz,2H),2.32(d,J＝15.06Hz,2H),2.78(s,3H),3.00-3.17(m,2H),3.46-3.53(m,2H),7.35-7.41(m,1H),7.69-7.75(m,1H),7.77-7.79(m,1H),8.46-8.53(m,1H).LCMS(ESI)m/z:394(M+1).This example was prepared as described in Example 3. 1 H-NMR (MeOD, 400 MHz) δ: 1.38-1.46 (m, 3H), 1.88 (ddd, J = 13.86, 9.66, 3.76 Hz, 2H), 2.32 (d, J = 15.06 Hz, 2H), 2.78 ( s, 3H), 3.00-3.17 (m, 2H), 3.46-3.53 (m, 2H), 7.35-7.41 (m, 1H), 7.69-7.75 (m, 1H), 7.77-7.79 (m, 1H), 8.46-8.53 (m, 1H). LCMS (ESI) m/z: 394 (M+1).
实施例76Example 76
6-氟-3-(1-(3-氟环丁基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(3-fluorocyclobutyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000226
Figure PCTCN2015075363-appb-000226
本实施例中如实施例2中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)δppm 1.45(s,3H),1.96-2.18(m,2H),2.38-2.74(m,6H),2.94(br.s.,4H),3.74-3.93(m,1H),5.12-5.32(m,1H),7.41(dd,J＝8.16,2.38Hz,1H),7.67(dd,J＝10.79,2.26Hz,1H),7.79(s,1H),8.52(br.s.,1H).LCMS(ESI)m/z:388(M+1).This example was prepared as described in Example 2. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 1.45 (s, 3H), 1.96-2.18 (m, 2H), 2.38-2.74 (m, 6H), 2.94 (br.s., 4H), 3.74 3.93 (m, 1H), 5.12-5.32 (m, 1H), 7.41 (dd, J = 8.16, 2.38 Hz, 1H), 7.67 (dd, J = 10.79, 2.26 Hz, 1H), 7.79 (s, 1H) , 8.52 (br.s., 1H). LCMS (ESI) m/z: 388 (M+1).
实施例77Example 77
6-氟-3-(4-甲基-1-(噻吩-2-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-(thiophen-2-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000227
Figure PCTCN2015075363-appb-000227
本实施例中如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.34(s,3H),1.82(ddd,J＝13.36,9.41,3.45Hz,2H),2.13-2.27(m,1H),2.32-2.53(m,1H),2.69(br.s.,2H),3.72(s,2H),6.87-7.01(m,2H),7.25-7.39(m,2H),7.62-7.75(m,2H).LCMS(ESI)m/z:412(M+1).This example was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d 4 ) 1.34 (s, 3H), 1.82 (ddd, J = 13.36, 9.41, 3.45 Hz, 2H), 2.13 - 2.27 (m, 1H), 2.32 - 2.53 (m, 1H) ), 2.69 (br.s., 2H), 3.72 (s, 2H), 6.87-7.01 (m, 2H), 7.25-7.39 (m, 2H), 7.62-7.75 (m, 2H). LCMS (ESI) m/z: 412 (M+1).
实施例78Example 78
3-(1-((1-乙基哌啶-4-基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-ethylpiperidin-4-yl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[ 1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000228
Figure PCTCN2015075363-appb-000228
本实施例中如实施例2中描述的方法制备。1H-NMR(400MHz,METHANOL-d4)ppm 1.32-1.35(t,3H),1.42(s,3H),1.47-1.51(d,2H),1.99-2.08(m,5H),2.35-2.38(d,2H),2.64-2.65(d,2H),2.89(m,2H),3.06(t,2H),3.11-3.15(m,4H),3.51-3.54(d,2H),7.37-7.39(m,1H),7.70-7.74(m,1H),7.77(s,1H),8.446(s,2H).LCMS(ESI)m/z:441(M+1).This example was prepared as described in Example 2. 1 H-NMR (400 MHz, METHANOL-d4) ppm 1.32-1.35 (t, 3H), 1.42 (s, 3H), 1.47-1.51 (d, 2H), 1.99-2.08 (m, 5H), 2.35-2.38 ( d, 2H), 2.64-2.65 (d, 2H), 2.89 (m, 2H), 3.06 (t, 2H), 3.11-3.15 (m, 4H), 3.51-3.54 (d, 2H), 7.37-7.39 ( m,1H), 7.70-7.74 (m, 1H), 7.77 (s, 1H), 8.446 (s, 2H). LCMS (ESI) m/z: 441 (M+1).
实施例79Example 79
6-氟-3-(4-甲基-1-((1-甲基氮杂环丁烷-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-((1-methylazetidin-3-yl)methyl)piperidin-4-yl)-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000229
Figure PCTCN2015075363-appb-000229
本实施例中如实施例2中描述的方法制备。1H-NMR(400MHz,METHANOL-d4)ppm 1.32(s,3H),1.89-1.95(m,2H),2.29-2.33(d,2H),2.60(d,2H),2.86-2.91,2.64-2.65(m,7H),3.18(m,1H),3.84-3.88(t,2H),4.15-4.20(t,2H),7.36-7.39(m,1H),7.70-7.73(m,1H),7.77(s,1H),8.41(s,2H).LCMS(ESI)m/z:399(M+1).This example was prepared as described in Example 2. 1 H-NMR (400MHz, METHANOL-d4) ppm 1.32 (s, 3H), 1.89-1.95 (m, 2H), 2.29-2.33 (d, 2H), 2.60 (d, 2H), 2.86-2.91, 2.64 2.65 (m, 7H), 3.18 (m, 1H), 3.84-3.88 (t, 2H), 4.15-4.20 (t, 2H), 7.36-7.39 (m, 1H), 7.70-7.73 (m, 1H), 7.77 (s, 1H), 8.41 (s, 2H). LCMS (ESI) m/z: 399 (M+1).
实施例80Example 80
2-((4-(8-氨基甲酰基-6-氟-4H苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-基)甲基)环丙烷羧酸乙酯 2-((4-(8-carbamoyl-6-fluoro-4Hbenzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine-1 -yl)methyl)ethyl cyclopropanecarboxylate
Figure PCTCN2015075363-appb-000230
Figure PCTCN2015075363-appb-000230
本实施例中如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)0.86-1.34(m,6H),1.35-1.49(m,2H),1.57-2.01(m,4H),2.09-2.28(m,2H),2.44-2.70(m,2H),2.99-3.27(m,2H),3.36-3.47(m,2H),3.53-3.75(m,2H),4.06-4.26(m,3H),7.50-7.65(m,1H),7.74-7.85(m,1H),8.05(br.s.,1H).LCMS(ESI)m/z:442(M+1).This example was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d 4 ) 0.86-1.34 (m, 6H), 1.35-1.49 (m, 2H), 1.57-2.01 (m, 4H), 2.09-2.28 (m, 2H), 2.44-2.70 (m, 2H), 2.99-3.27 (m, 2H), 3.36-3.47 (m, 2H), 3.53-3.75 (m, 2H), 4.06-4.26 (m, 3H), 7.50-7.65 (m, 1H) , 7.74-7.85 (m, 1H), 8.05 (br.s., 1H). LCMS (ESI) m/z: 442 (M+1).
实施例81Example 81
3-(1-((2-(二甲基氨基甲基)环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((2-(Dimethylaminomethyl)cyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000231
Figure PCTCN2015075363-appb-000231
本实施例中如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)0.97-1.29(m,2H),1.47(s,2H),1.65(s,1H),2.08-2.30(m,3H),2.63(d,J＝15.3Hz,1H),2.85(s,1H),2.92-3.01(m,3H),3.01-3.12(m,2H),3.12-3.27(m,2H),3.29(s,2H),3.34-3.47(m,2H),3.55-3.77(m,2H),7.56-7.70(m,1H),7.78-7.85(m,1H),8.12(d,J＝6.5Hz,1H).LCMS(ESI)m/z:441(M+1).This example was prepared as described in Example 2. 1 H NMR (400MHz, METHANOL- d 4) 0.97-1.29 (m, 2H), 1.47 (s, 2H), 1.65 (s, 1H), 2.08-2.30 (m, 3H), 2.63 (d, J = 15.3 Hz, 1H), 2.85 (s, 1H), 2.92-3.01 (m, 3H), 3.01-3.12 (m, 2H), 3.12-3.27 (m, 2H), 3.29 (s, 2H), 3.34 - 3.47 ( m, 2H), 3.55-3.77 (m, 2H), 7.56-7.70 (m, 1H), 7.78-7.85 (m, 1H), 8.12 (d, J = 6.5 Hz, 1H). LCMS (ESI) m/ z: 441 (M + 1).
实施例82Example 82
6-氟-3-(1-异丁基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isobutyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000232
Figure PCTCN2015075363-appb-000232
本实施例中如实施例2中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.00-1.02(d,6H),1.43(s,3H),2.03-2.07(m,3H),2.10-2.11(d,2H),2.81-2.83(d,2H),3.03(bs,2H),3.31(bs,2H),7.35-7.38(dd,1H),7.67-7.71(s,1H),7.77(s,1H),8.53(bs,1H).LCMS(ESI)m/z:372(M+1).This example was prepared as described in Example 2. 1 H-NMR (MeOD, 400 MHz) δ: 1.00-1.02 (d, 6H), 1.43 (s, 3H), 2.03-2.07 (m, 3H), 2.10-2.11 (d, 2H), 2.81-2.83 (d , 2H), 3.03 (bs, 2H), 3.31 (bs, 2H), 7.35-7.38 (dd, 1H), 7.67-7.71 (s, 1H), 7.77 (s, 1H), 8.53 (bs, 1H). LCMS (ESI) m/z: 372 (M+1).
实施例83Example 83
6-氟-3-(4-甲基-1-((4-甲基噻唑-5-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1-((4-methylthiazol-5-yl)methyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1 ,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000233
Figure PCTCN2015075363-appb-000233
本实施例中如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.41(s,3H),1.89-2.01(m,2H),2.30-2.39(m,2H),2.43(s,3H),2.73-2.86(m,2H),2.97-3.15(m,2H),4.01-4.20(m,2H),7.30-7.47(m,1H),7.65-7.86(m,2H),8.90-9.04(m,1H).LCMS(ESI)m/z:427(M+1).This example was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d4) ppm 1.41 (s, 3H), 1.89-2.01 (m, 2H), 2.30-2.39 (m, 2H), 2.43 (s, 3H), 2.73-2.86 (m, 2H) ), 2.97-3.15 (m, 2H), 4.01-4.20 (m, 2H), 7.30-7.47 (m, 1H), 7.65-7.86 (m, 2H), 8.90-9.04 (m, 1H). LCMS (ESI) ) m / z: 427 (M + 1).
实施例84Example 84
6-氟-3-(4-甲基-1-((1-甲基-1H-咪唑-2-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-((1-methyl-1H-imidazol-2-yl)methyl)piperidin-4-yl)-4H-benzo[4,5]imidazole And [1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000234
Figure PCTCN2015075363-appb-000234
本实施例中如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.32-1.44(m,3H),1.78-1.96(m,2H),2.18-2.33(m,2H),2.46-2.62(m,2H),2.71-2.88(m,2H),3.73-3.77(m,2H),3.81(s,3H),7.01-7.11(m,1H),7.18-7.23(m,1H),7.33-7.40(m,1H),7.73(s,2H),8.28-8.44(m,1H).LCMS(ESI)m/z:410(M+1).This example was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.32-1.44 (m, 3H), 1.78-1.96 (m, 2H), 2.18-2.33 (m, 2H), 2.46-2.62 (m, 2H), 2.71 2.88(m,2H),3.73-3.77(m,2H),3.81(s,3H),7.01-7.11(m,1H),7.18-7.23(m,1H),7.33-7.40(m,1H), 7.73 (s, 2H), 8.28-8.44 (m, 1H). LCMS (ESI) m/z: 410 (M+1).
实施例85Example 85
3-(1-((1,2-二甲基-1H-咪唑-5-基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4, 5]Imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000235
Figure PCTCN2015075363-appb-000235
本实施例中如实施例2中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.38(s,3H),1.83-1.92(m,2H),2.27(d,J＝13.80Hz,2H),2.54(s,5H),2.86(d,J＝10.92Hz,2H),3.70(s,2H),3.75(s,3H),7.17(s,1H),7.36(dd,J＝8.16,2.51Hz,1H),7.66-7.80(m,2H),8.38(br.s.,1H).LCMS(ESI)m/z:424(M+1).This example was prepared as described in Example 2. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.38 (s, 3H), 1.83-1.92 (m, 2H), 2.27 (d, J = 13.80 Hz, 2H), 2.54 (s, 5H), 2.86 (d) , J = 10.92 Hz, 2H), 3.70 (s, 2H), 3.75 (s, 3H), 7.17 (s, 1H), 7.36 (dd, J = 8.16, 2.51 Hz, 1H), 7.66-7.80 (m, 2H), 8.38 (br.s., 1H). LCMS (ESI) m/z: 424 (M+1).
实施例86Example 86
3-(1'-乙基-4-甲基-[1,4'-联哌啶]-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-(1'-ethyl-4-methyl-[1,4'-bipiperidinyl]-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000236
Figure PCTCN2015075363-appb-000236
本实施例中如实施例2中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)1.09(t,J＝7.09Hz,3H),1.27(s,3H),1.50-1.70(m,2H),1.72-1.85(m,2H),1.92(d,J＝11.54Hz,2H),2.34(br.s.,2H),2.75(d,J＝7.40Hz,7H),2.86(br.s.,2H),3.23(d,J＝10.42Hz,2H),7.49(d,J＝8.41Hz,1H),7.58(dd,J＝10.85,2.20Hz,1H),7.79(s,1H),8.28(s,2H).LCMS(ESI)m/z:427(M+1).This example was prepared as described in Example 2. 1 H-NMR (400 MHz, Methano L-d 4 ) 1.09 (t, J = 7.09 Hz, 3H), 1.27 (s, 3H), 1.50-1.70 (m, 2H), 1.72-1.85 (m, 2H), 1.92 (d, J = 11.54 Hz, 2H), 2.34 (br.s., 2H), 2.75 (d, J = 7.40 Hz, 7H), 2.86 (br.s., 2H), 3.23 (d, J = 10.42) Hz, 2H), 7.49 (d, J = 8.41 Hz, 1H), 7.58 (dd, J = 10.85, 2.20 Hz, 1H), 7.79 (s, 1H), 8.28 (s, 2H). LCMS (ESI) m /z:427(M+1).
实施例87Example 87
6-氟-3-(4-甲基-1-((6-氧代-1,6-二氢哒嗪-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1-((6-oxo-1,6-dihydropyridazin-3-yl)methyl)piperidin-4-yl)-4H-benzo[ 4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000237
Figure PCTCN2015075363-appb-000237
这个实施例如实施例2中描述的方法制备。1H NMR(400MHz,MeOD)δ:8.35(s,1H),7.70-7.74(m,2H),7.57-7.60(d,1H),7.36-7.38(t,1H),6.98-7.00(d,1H),3.63(s,2H),2.86(m,2H),2.61-2.63(m,2H),2.26-2.30(d,2H),1.87-1.94(m,2H),1.39(s,3H).LCMS(ESI)m/z:424(M+1).This embodiment was prepared as described in Example 2. 1 H NMR (400MHz, MeOD) δ: 8.35 (s, 1H), 7.70-7.74 (m, 2H), 7.57-7.60 (d, 1H), 7.36-7.38 (t, 1H), 6.98-7.00 (d, 1H), 3.63 (s, 2H), 2.86 (m, 2H), 2.61-2.63 (m, 2H), 2.26-2.30 (d, 2H), 1.87-1.94 (m, 2H), 1.39 (s, 3H) .LCMS (ESI) m / z: 424 (M + 1).
实施例88Example 88
3-(1-(2-氰基乙基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(2-cyanoethyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000238
Figure PCTCN2015075363-appb-000238
实施例53D(52毫克，0.125毫摩尔)，丙烯腈(66毫克，1.25毫摩尔)和碳酸钾(172毫克，1.25毫摩尔)的DMF(18mL)混合物在28℃下搅拌1小时。反应完毕后用水(10mL)淬灭，水层用乙酸乙酯(20毫升×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，残余物通过制备型HPLC纯化得到标题化合物(31毫克，产率66.0％)。1H NMR(400MHz,METHANOL-d4)ppm 1.39(s,3H),1.86-1.97(m,2H),2.25-2.36(m,2H),2.60-2.70(m,2H),2.74(s,2H),2.84-2.98(m,4H),7.33-7.41(m,1H),7.68-7.73(m,1H),7.74(s,1H),8.21-8.32(m,1H).LCMS(ESI)m/z:369(M+1).A mixture of Example 53D (52 mg, 0.125 mmol), EtOAc (EtOAc, EtOAc) After completion of the reaction, the title compound (31 m. Mg, yield 66.0%). 1 H NMR (400MHz, METHANOL- d 4) ppm 1.39 (s, 3H), 1.86-1.97 (m, 2H), 2.25-2.36 (m, 2H), 2.60-2.70 (m, 2H), 2.74 (s, 2H), 2.84-2.98 (m, 4H), 7.33-7.41 (m, 1H), 7.68-7.73 (m, 1H), 7.74 (s, 1H), 8.21-8.32 (m, 1H). LCMS (ESI) m/z: 369 (M+1).
实施例89Example 89
6-氯-3-(1-乙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-Chloro-3-(1-ethyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000239
Figure PCTCN2015075363-appb-000239
本实施例中如实施例53中所述，用2,6-二溴-4-氯苯基肼替代2,6-二溴-4-氟苯基肼制备。1H-NMR(MeOD,400MHz)δ:1.32-1.39(t,3H),1.46(m,1H),2.52-2.55(s,3H),2.06-2.08(m,2H),2.47-2.48(m,2H),3.09-3.11(m,3H),3.34-3.41(m,3H),7.63(s,1H),7.83(s,1H),7.97-7.97(d,1H),8.54(bs,1H).LCMS(ESI)m/z:360(M+1).In the present example, as described in Example 53, it was prepared by substituting 2,6-dibromo-4-chlorophenylhydrazine for 2,6-dibromo-4-fluorophenylhydrazine. 1 H-NMR (MeOD, 400 MHz) δ: 1.32-1.39 (t, 3H), 1.46 (m, 1H), 2.52-2.55 (s, 3H), 2.06-2.08 (m, 2H), 2.47-2.48 (m) , 2H), 3.09-3.11 (m, 3H), 3.34-3.41 (m, 3H), 7.63 (s, 1H), 7.83 (s, 1H), 7.97-7.97 (d, 1H), 8.54 (bs, 1H) ). LCMS (ESI) m / z: 360 (M + 1).
实施例90Example 90
3-(1-乙基-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethyl-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000240
Figure PCTCN2015075363-appb-000240
本实施例中如实施例53中所述制备，其中用3-(羟甲基)-3-甲基吡咯烷-1-羧酸叔丁酯替代4-(羟甲基)-4-甲基哌啶-1-甲酸叔丁酯。1H NMR(400MHz,METHANOL-d4)ppm 1.38(s,3H),1.64(s,3H),2.25-2.42(m,1H),2.59-2.76(m,1H),3.27-3.32(m,2H),3.39-3.53(m,1H),3.54-3.71(m,2H),3.71-3.88(m,1H),7.33-7.39(m,1H),7.57-7.70(m,1H),7.76-7.90(m,1H),8.28-8.80(m,1H).LCMS(ESI)m/z:330(M+1).Prepared as described in Example 53 in this example, wherein 4-(hydroxymethyl)-3-methylpyrrolidin-1-carboxylic acid tert-butyl ester was substituted for 4-(hydroxymethyl)-4-methyl Tert-butyl piperidine-1-carboxylate. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.38 (s, 3H), 1.64 (s, 3H), 2.25-2.42 (m, 1H), 2.59-2.76 (m, 1H), 3.27-3.32 (m, 2H), 3.39-3.53 (m, 1H), 3.54-3.71 (m, 2H), 3.71-3.88 (m, 1H), 7.33-7.39 (m, 1H), 7.57-7.70 (m, 1H), 7.76- 7.90 (m, 1H), 8.28-8.80 (m, 1H). LCMS (ESI) m/z: 330 (M+1).
实施例91Example 91
3-(1,3-二甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1,3-Dimethylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000241
Figure PCTCN2015075363-appb-000241
这个实施例如实施例90中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)δppm 8.52(br.s.,1H),7.84(s,1H),7.67(dd,J＝2.5,10.9Hz,1H),7.38(dd,J＝2.5,8.0Hz,1H),3.74(d,J＝11.3Hz,1H),3.67-3.49(m,2H),3.40(d,J＝11.3Hz,1H),2.96(s,3H),2.73-2.60(m,1H),2.34(td,J＝7.8,13.4Hz,1H),1.64(s,3H).LCMS(ESI)m/z:316(M+1).This embodiment was prepared as described in Example 90. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 8.52 (br.s., 1H), 7.84 (s, 1H), 7.67 (dd, J = 2.5, 10.9 Hz, 1H), 7.38 (dd, J = 2.5, 8.0 Hz, 1H), 3.74 (d, J = 11.3 Hz, 1H), 3.67-3.49 (m, 2H), 3.40 (d, J = 11.3 Hz, 1H), 2.96 (s, 3H), 2.73 2.60 (m, 1H), 2.34 (td, J = 7.8, 13.4 Hz, 1H), 1.64 (s, 3H). LCMS (ESI) m/z: 316 (M+1).
实施例92Example 92
6-氟-3-(1-异丙基-3-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isopropyl-3-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000242
Figure PCTCN2015075363-appb-000242
这个实施例如实施例90中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.38-1.52(m,6H),1.71(d,J＝2.26Hz,3H),2.32-2.46(m,1H),2.63-2.82(m,1H),3.38-3.70(m,3H),3.76-4.11(m,2H), 7.58-7.70(m,1H),7.76-7.86(m,1H),8.15-8.29(m,1H).LCMS(ESI)m/z:344(M+1).This embodiment was prepared as described in Example 90. 1 H NMR (400MHz, METHANOL- d 4) ppm 1.38-1.52 (m, 6H), 1.71 (d, J = 2.26Hz, 3H), 2.32-2.46 (m, 1H), 2.63-2.82 (m, 1H) , 3.38-3.70 (m, 3H), 3.76-4.11 (m, 2H), 7.58-7.70 (m, 1H), 7.76-7.86 (m, 1H), 8.15-8.29 (m, 1H). LCMS (ESI) m/z: 344 (M+1).
实施例93Example 93
3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000243
Figure PCTCN2015075363-appb-000243
这个实施例如实施例5中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 0.41-0.52(m,2H),0.70-0.82(m,2H),1.10-1.26(m,1H),1.66(s,3H),2.27-2.39(m,1H),2.63-2.75(m,1H),3.17(d,J＝7.15Hz,2H),3.44-3.58(m,1H),3.59-3.78(m,2H),3.79-3.94(m,1H),7.27-7.40(m,1H),7.55-7.67(m,1H),7.77-7.89(m,1H),8.43-8.69(m,1H).LCMS(ESI)m/z:356(M+1).This embodiment was prepared as described in Example 5. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 0.41-0.52 (m, 2H), 0.70-0.82 (m, 2H), 1.10-1.26 (m, 1H), 1.66 (s, 3H), 2.27-2.39 ( m,1H), 2.63-2.75 (m,1H), 3.17 (d, J=7.15 Hz, 2H), 3.44-3.58 (m, 1H), 3.59-3.78 (m, 2H), 3.79-3.94 (m, 1H), 7.27-7.40 (m, 1H), 7.55-7.67 (m, 1H), 7.77-7.89 (m, 1H), 8.43-8.69 (m, 1H). LCMS (ESI) m/z: 356 (M +1).
实施例94Example 94
6-氟-3-(3-甲基-1-(氧杂环丁烷-3-基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000244
Figure PCTCN2015075363-appb-000244
这个实施例如实施例5中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.58(s,3H),2.01-2.10(m,1H),2.26-2.35(m,1H),2.68-2.74(m,1H),2.79-2.87(m,1H),2.87-2.96(m,1H),2.96-3.03(m,1H),3.78-3.85(m,1H),4.62-4.72(m,1H),4.74-4.81(m,1H),7.31-7.40(m,1H),7.64-7.71(m,1H),7.72-7.77(m,1H).LCMS(ESI)m/z:358(M+1).This embodiment was prepared as described in Example 5. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.58 (s, 3H), 2.01-2.10 (m, 1H), 2.26-2.35 (m, 1H), 2.68-2.74 (m, 1H), 2.79-2. m,1H), 2.87-2.96 (m,1H), 2.96-3.03 (m,1H), 3.78-3.85 (m,1H), 4.62-4.72 (m,1H), 4.74-4.81 (m,1H), 7.31-7.40 (m, 1H), 7.64-7.71 (m, 1H), 7.72-7.77 (m, 1H). LCMS (ESI) m/z: 358 (M+1).
实施例95Example 95
6-氟-3-(1-(2-氟乙基)-3-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000245
Figure PCTCN2015075363-appb-000245
这个实施例如实施例3中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.635(s,1H),2.243-2.263(m,1H),2.522-2.554(m,1H),3.288-3.321(d,1H),3.325(s,2H),3.329-3.337(m,1H),3.391-3.414(m,1H),3.632-3.659(d,1H),4.730-4.860(dt,2H),7.291-7.317(dd,1H),7.586-7.619(dd,1H),7.788(s,1H),8.445(bs,1H),LCMS(ESI)m/z:348(M+1).This embodiment was prepared as described in Example 3. 1 H-NMR (MeOD, 400 MHz) δ: 1.635 (s, 1H), 2.243-2.263 (m, 1H), 2.522-2.554 (m, 1H), 3.288-3.321 (d, 1H), 3.325 (s, 2H) ), 3.329-3.337 (m, 1H), 3.391-3.414 (m, 1H), 3.632-3.659 (d, 1H), 4.730-4.860 (dt, 2H), 7.291-7.317 (dd, 1H), 7.586-7.619 (dd, 1H), 7.788 (s, 1H), 8.445 (bs, 1H), LCMS (ESI) m/z: 348 (M+1).
实施例96Example 96
3-(1-((2,2-二氟环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-(1-((2,2-difluorocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 ,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000246
Figure PCTCN2015075363-appb-000246
这个实施例如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.34-1.46(m,1H)1.64(s,3H)1.67-1.79(m,1H)2.03-2.11(m,1H)2.20-2.31(m,1H)2.52-2.63(m,1H)3.13-3.24(m,1H)3.24-3.31(m,2H)3.37-3.48(m,1H)3.48-3.58(m,1H)3.59-3.67(m,1H)7.29-7.39(m,1H)7.57-7.67(m,1H)7.76-7.84(m,1H)8.35-8.54(m,1H)LCMS(ESI)m/z:392(M+1).This embodiment was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.34-1.46 (m, 1H) 1.64 (s, 3H) 1.67-1.79 (m, 1H) 2.03-2.11 (m, 1H) 2.20-2.31 (m, 1H) 2.52-2.63(m,1H)3.13-3.24(m,1H)3.24-3.31(m,2H)3.37-3.48(m,1H)3.48-3.58(m,1H)3.59-3.67(m,1H)7.29- 7.39 (m, 1H) 7.57-7.67 (m, 1H) 7.76-7.84 (m, 1H) 8.35-8.54 (m, 1H) LCMS (ESI) m/z: 392 (M+1).
实施例97Example 97
6-氟-3-(3-甲基-1-(2,2,2-三氟乙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(3-methyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000247
Figure PCTCN2015075363-appb-000247
这个实施例如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.74(s,3H),2.39-2.54(m,1H),2.74-2.88(m,1H),3.69-3.82(m,1H),3.82-3.95(m,2H),3.97-4.14(m,1H),4.36-4.50(m,2H),7.55-7.64(m,1H),7.73-7.83(m,1H),8.12-8.20(m,1H).LCMS(ESI)m/z:384(M+1).This embodiment was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.74 (s, 3H), 2.39-2.54 (m, 1H), 2.74-2.88 (m, 1H), 3.69-3.82 (m, 1H), 3.82-3.95 ( m, 2H), 3.97-4.14 (m, 1H), 4.36-4.50 (m, 2H), 7.55-7.64 (m, 1H), 7.73-7.83 (m, 1H), 8.12-8.20 (m, 1H). LCMS (ESI) m/z: 384 (M+1).
实施例98Example 98
6-氟-3-(3-甲基-1-(2-(甲基磺酰基)乙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(3-methyl-1-(2-(methylsulfonyl)ethyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000248
Figure PCTCN2015075363-appb-000248
这个实施例如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 1.60(s,3H),2.05-2.15(m,1H),2.18-2.28(m,1H),2.63-2.69(m,1H),2.69-2.78(m,1H),3.01-3.10(m,1H),3.11(s,3H),3.26-3.31(m,1H),3.34-3.41(m,2H),3.41-3.50(m,1H),3.50-3.60(m,1H),7.35-7.45(m,1H),7.63-7.70(m,1H),7.72(s,1H),8.22(s,1H).LCMS(ESI)m/z:408(M+1).This embodiment was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) ppm 1.60 (s, 3H), 2.05-2.15 (m, 1H), 2.18-2.28 (m, 1H), 2.63-2.69 (m, 1H), 2.69-2.78 ( m, 1H), 3.01-3.10 (m, 1H), 3.11 (s, 3H), 3.26-3.31 (m, 1H), 3.34-3.41 (m, 2H), 3.41-3.50 (m, 1H), 3.50- 3.60 (m, 1H), 7.35-7.45 (m, 1H), 7.63-7.70 (m, 1H), 7.72 (s, 1H), 8.22 (s, 1H). LCMS (ESI) m/z: 408 (M) +1).
实施例99Example 99
6-氟-3-(3-甲基-1-(3,3,3-三氟丙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(3-methyl-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000249
Figure PCTCN2015075363-appb-000249
这个实施例如实施例3中描述的方法制备。1HNMR(400MHz,METHANOL-d4)ppm 1.62(s,3H),2.16-2.25(m,1H),2.43-2.53(m,1H),2.58-2.72(m,1H),3.08-3.14(m,1H),3.16-3.29(m,1H),3.34-3.39 (m,1H),3.41-3.47(m,1H),7.32-7.41(m,1H),7.63-7.71(m,1H),7.74-7.83(m,1H),8.24-8.34(m,1H).LCMS(ESI)m/z:398(M+1).This embodiment was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.62 (s, 3H), 2.16-2.25 (m, 1H), 2.43-2.53 (m, 1H), 2.58-2.72 (m, 1H), 3.08-3.14 (m , 1H), 3.16-3.29 (m, 1H), 3.34-3.39 (m, 1H), 3.41-3.47 (m, 1H), 7.32-7.41 (m, 1H), 7.63-7.71 (m, 1H), 7.74 - 7.83 (m, 1H), 8.24 - 8.34 (m, 1H). LCMS (ESI) m/z: 398 (M+1).
实施例100Example 100
3-(1-((1-氨基环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-aminocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000250
Figure PCTCN2015075363-appb-000250
这个实施例如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)ppm 0.85(s,1H),1.00(s,1H),1.62(s,3H),2.07-2.17(m,1H),2.34-2.44(m,1H),2.85(s,1H),2.94-3.01(m,1H),3.04-3.12(m,1H),3.20(d,J＝9.41Hz,1H),7.33-7.39(m,1H),7.64-7.70(m,1H),7.75-7.80(m,1H),7.83-7.85(m,1H),8.02-8.05(m,1H),8.34-8.47(m,1H).LCMS(ESI)m/z:371(M+1).This embodiment was prepared as described in Example 3. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 0.85 (s, 1H), 1.00 (s, 1H), 1.62 (s, 3H), 2.07-2.17 (m, 1H), 2.34-2.44 (m, 1H) , 2.85(s,1H), 2.94-3.01(m,1H),3.04-3.12(m,1H), 3.20(d,J=9.41Hz,1H),7.33-7.39(m,1H),7.64-7.70 (m, 1H), 7.75-7.80 (m, 1H), 7.83-7.85 (m, 1H), 8.02-8.05 (m, 1H), 8.34-8.47 (m, 1H). LCMS (ESI) m/z: 371 (M+1).
实施例101Example 101
3-(1-((1-氰基环丁基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-Cyanocyclobutyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000251
Figure PCTCN2015075363-appb-000251
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,METHANOL-d4)1.60(s,3H),2.00-2.11(m,2H),2.13-2.23(m,1H),2.25-2.40(m,3H),2.45-2.58(m,2H),2.65-2.70(m,1H),2.72-2.80(m,1H),2.93(s,1H),2.99-3.06(m,1H),3.14-3.23(m,2H),7.38-7.44(m,1H),7.69(dd,J＝10.85,2.57Hz,1H),7.74(s,1H),8.33(br.s.,1H).LCMS(ESI)m/z:395(M+1).This example was prepared as described in Example 3. 1 H NMR (400MHz, METHANOL- d 4) 1.60 (s, 3H), 2.00-2.11 (m, 2H), 2.13-2.23 (m, 1H), 2.25-2.40 (m, 3H), 2.45-2.58 (m , 2H), 2.65-2.70 (m, 1H), 2.72-2.80 (m, 1H), 2.93 (s, 1H), 2.99-3.06 (m, 1H), 3.14 - 3.23 (m, 2H), 7.38-7.44 (m, 1H), 7.69 (dd, J = 10.85, 2.57 Hz, 1H), 7.74 (s, 1H), 8.33 (br.s., 1H). LCMS (ESI) m/z: 395 (M+1) ).
实施例102Example 102
3-(1-((1-氰基环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-((1-Cyanocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000252
Figure PCTCN2015075363-appb-000252
本实施例中如实施例3中描述的方法制备。1H NMR(400MHz,DMSO-d6)ppm 0.92(d,J＝2.26Hz,2H),1.16-1.24(m,2H),1.48(s,3H),1.87-1.97(m,1H),2.05(s,1H),2.55(d,J＝7.53Hz,4H),2.91(s,2H),7.43-7.50(m,1H),7.51-7.61(m,1H),7.79(s,1H).LCMS(ESI)m/z:381(M+1).This example was prepared as described in Example 3. 1 H NMR (400 MHz, DMSO-d 6 ) ppm 0.92 (d, J = 2.26 Hz, 2H), 1.16-1.24 (m, 2H), 1.48 (s, 3H), 1.87-1.97 (m, 1H), 2.05 (s, 1H), 2.55 (d, J = 7.53 Hz, 4H), 2.91 (s, 2H), 7.43-7.50 (m, 1H), 7.51-7.61 (m, 1H), 7.79 (s, 1H). LCMS (ESI) m/z: 381 (M+1).
实施例103 Example 103
3-(1-(2-氰基异基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(2-Cyanoisoyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000253
Figure PCTCN2015075363-appb-000253
本实施例中如实施例88中描述的方法制备。1HNMR(400MHz,METHANOL-d4)ppm 1.61(s,3H),2.06-2.16(m,1H),2.23-2.33(m,1H),2.80(d,J＝6.40Hz,1H),2.83-2.91(m,1H),2.93-3.02(m,1H),3.03-3.12(m,1H),3.27(d,J＝9.29Hz,2H),7.37-7.44(m,1H),7.64-7.72(m,1H),7.76(s,1H),8.14-8.26(m,1H).LCMS(ESI)m/z:355(M+1).This example was prepared as described in Example 88. 1 H NMR (400 MHz, METHANOL-d 4 ) ppm 1.61 (s, 3H), 2.06-2.16 (m, 1H), 2.23 - 2.33 (m, 1H), 2.80 (d, J = 6.40 Hz, 1H), 2.83 2.91 (m, 1H), 2.93-3.02 (m, 1H), 3.03-3.12 (m, 1H), 3.27 (d, J = 9.29 Hz, 2H), 7.37-7.44 (m, 1H), 7.64 - 7.72 ( m, 1H), 7.76 (s, 1H), 8.14 - 8.26 (m, 1H). LCMS (ESI) m/z: 355 (M+1).
实施例104Example 104
3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000254
Figure PCTCN2015075363-appb-000254
本实施例中如实施例93中描述的方法制备。1H NMR(400MHz,MeOD)δ:8.51(s,1H),7.96(s,1H),7.70-7.73(dd,1H),7.39-7.41(dd,1H),4.39-4.32(d,2H),4.23-4.26(d,2H),3.15-3.17(d,2H),1.87(s,3H),1.06-1.08(m,1H),0.69-0.74(m,2H),0.42-0.46(m,2H).LCMS(ESI)m/z:342(M+1).This example was prepared as described in Example 93. 1 H NMR (400MHz, MeOD) δ: 8.51 (s, 1H), 7.96 (s, 1H), 7.70-7.73 (dd, 1H), 7.39-7.41 (dd, 1H), 4.39-4.32 (d, 2H) , 4.3-4.26 (d, 2H), 3.15-3.17 (d, 2H), 1.87 (s, 3H), 1.06-1.08 (m, 1H), 0.69-0.74 (m, 2H), 0.42-0.46 (m, 2H). LCMS (ESI) m / z: 342 (M + 1).
流程DProcess D
Figure PCTCN2015075363-appb-000255
Figure PCTCN2015075363-appb-000255
实施例105Example 105
6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000256
Figure PCTCN2015075363-appb-000256
实施例105AExample 105A
4-(1-氰基-2-乙氧基-2-氧代亚乙基)哌啶-1-甲酸叔丁酯 4-(1-Cyano-2-ethoxy-2-oxoethylidene)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000257
Figure PCTCN2015075363-appb-000257
4-氧代哌啶-1-羧酸叔丁酯(100克，0.5摩尔)，乙基-2-氰基乙酸酯(56.5克，0.5摩尔)，乙酸铵(19.2克，0.25摩尔)和乙酸(15克，0.25摩尔)的甲苯(1升)混合物在120℃下搅拌5-6小时，由Dean-Stark分水器以除去水。真空除去溶剂后，残余物溶解在乙酸乙酯(500mL)和水(500mL)中，水层用乙酸乙酯(500毫升×3)萃取，合并有机层用盐水(500毫升)洗涤，硫酸钠干燥，过滤并蒸发，残余物用石油醚/乙酸乙酯＝10/1(300mL)打浆纯化。白色固体通过过滤收集，得到标题化合物(90克，61％产率)。1H NMR(400MHz,CHLOROFORM-d)δppm 1.38(t,J＝7.15Hz,3H),1.50(s,9H),2.79(t,J＝5.90Hz,2H),3.15(t,J＝5.83Hz,2H),3.56(t,J＝5.71Hz,2H),3.63(t,J＝5.83Hz,2H),4.31(q,J＝7.15Hz,2H).LCMS(ESI)m/z:295(M+1).4-oxopiperidine-1-carboxylic acid tert-butyl ester (100 g, 0.5 mol), ethyl-2-cyanoacetate (56.5 g, 0.5 mol), ammonium acetate (19.2 g, 0.25 mol) and A mixture of acetic acid (15 g, 0.25 mol) in toluene (1 L) was stirred at 120 ° C for 5-6 hours, and water was removed from a Dean-Stark trap. After the solvent was removed in vacuo <~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Filtration and evaporation. The residue was purified with EtOAc EtOAc EtOAc The white solid was collected by EtOAc (EtOAc) 1 H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.38 (t, J = 7.15 Hz, 3H), 1.50 (s, 9H), 2.79 (t, J = 5.90 Hz, 2H), 3.15 (t, J = 5.83 Hz) , 2H), 3.56 (t, J = 5.71 Hz, 2H), 3.63 (t, J = 5.83 Hz, 2H), 4.31 (q, J = 7.15 Hz, 2H). LCMS (ESI) m/z: 295 ( M+1).
实施例105BExample 105B
4-(1-氰基-2-乙氧基-2-氧代乙基)-4-甲基哌啶-1-甲酸叔丁酯4-(1-Cyano-2-ethoxy-2-oxoethyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000258
Figure PCTCN2015075363-appb-000258
在-60-70℃氮气保护下,向碘化亚铜(86.3克，0.454摩尔)的无水四氢呋喃(1.7升)混合物中滴加入3M甲基溴化镁(378毫升，1.13摩尔)。在-10℃～0℃下搅拌1小时后，降温至-60-70℃，滴加实施例105A(133.5克，0.454摩尔)的四氢呋喃(300mL)溶液，混合物在20℃下搅拌15小时后，降温至0℃用饱和的氯化铵水溶液(1.2升)淬灭，硅藻土过滤后，水层用乙酸乙酯(600毫升×3)萃取，将合并的有机层用盐水(500毫升)洗涤，硫酸钠干燥，过滤并蒸发，得到粗标题化合物(142克)，为黄色油状物，将其直接用于下一步骤而无需进一步纯化。To a mixture of cuprous iodide (86.3 g, 0.454 mol) in anhydrous tetrahydrofuran (1.7 L) was added dropwise 3M methylmagnesium bromide (378 ml, 1.13 mol) under nitrogen atmosphere at -60-70 °C. After stirring at -10 ° C to 0 ° C for 1 hour, the temperature was lowered to -60-70 ° C, and a solution of Example 105A (133.5 g, 0.44 mol) in tetrahydrofuran (300 mL) was added dropwise, and the mixture was stirred at 20 ° C for 15 hours. The mixture was cooled to 0 ° C. EtOAc (EtOAc m. This was dried with EtOAc EtOAc EtOAc.
实施例105CExample 105C
2-(1-(叔丁氧基羰基)-4-甲基哌啶-4-基)-2-氰基乙酸2-(1-(tert-Butoxycarbonyl)-4-methylpiperidin-4-yl)-2-cyanoacetic acid
Figure PCTCN2015075363-appb-000259
Figure PCTCN2015075363-appb-000259
0℃下,向实施例105B(142克，粗，0.458摩尔)的四氢呋喃/甲醇＝10:1(1.2升)混合溶液中滴加入氢氧化钠(73.3克，1.82摩尔)的水(320毫升)溶液。滴加完毕在20℃搅拌2小时后，加入水(320毫升)稀释，水层用乙酸乙酯(500毫升×3)萃取，将合并的有机层用水(200毫升×2)洗涤。合并的水层用1N盐酸调节pH至3-4中并用二氯甲烷/甲醇＝10:1(300毫升×6)萃取。将合并的二氯甲烷/甲醇有机层用盐水(800毫升)洗后，硫酸钠干燥，过滤并蒸发，得到粗标题化合物(111.5克)，为黄色黄色，将其直接用于下一步骤而无需进一步纯化。Sodium hydroxide (73.3 g, 1.82 mol) in water (320 ml) was added dropwise to a mixed solution of Example 105B (142 g, crude, 0.458 mol) of tetrahydrofuran/methanol = 10:1 (1.2 L) at 0 °C. Solution. After the completion of the dropwise addition, the mixture was stirred at 20 ° C for 2 hours, then diluted with water (3 ml), and the aqueous layer was extracted with ethyl acetate (500 ml × 3), and the combined organic layer was washed with water (200 ml × 2). The combined aqueous layers were adjusted to pH 3-4 with 1N hydrochloric acid and extracted with dichloromethane/methanol = 10:1 (300 ml. The combined dichloromethane/methanol EtOAc (EtOAc m. Further purification.
实施例105D Example 105D
4-(氰基甲基)-4-甲基哌啶-1-甲酸叔丁酯4-(cyanomethyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000260
Figure PCTCN2015075363-appb-000260
实施例105C(111.5克，粗，0.395摩尔)和氧化亚铜(11.4克，79.08毫摩尔)的乙腈(900毫升)混合物在80℃下搅拌2小时。冷却至室温后，将混合物蒸发，残余物用乙酸乙酯(1L)溶解，硅藻土过滤滤除不溶物，滤渣用乙酸乙酯(250毫升×2)洗涤，滤液中加入四氢呋喃(150ml)溶解析出物。将有机层用水,水/盐水＝1:1(300mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物用石油醚/乙酸乙酯＝10/1(300mL)打浆纯化。白色固体通过过滤收集，得到标题化合物(98克)。LCMS(ESI)m/z:239(M+1).A mixture of Example 105C (111.5 g, EtOAc, EtOAc) After cooling to room temperature, the mixture was evaporated. EtOAc mjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj Precipitates. The organic layer was washed with EtOAc EtOAc EtOAc. The white solid was collected by filtration to give the title compound (98 g). LCMS (ESI) m/z: 239 (M+1).
实施例105EExample 105E
4-(1-氰基-2-氧代乙基)-4-甲基哌啶-1-甲酸叔丁酯4-(1-Cyano-2-oxoethyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000261
Figure PCTCN2015075363-appb-000261
-60-70℃在氮气保护下，向实施例105D(50克，0.21摩尔)的四氢呋喃(400mL)混合物中滴加2M LDA(160毫升，0.32摩尔)。在-60-70℃1小时搅拌后，滴加甲酸乙酯(32克，0.43摩尔)，滴加完毕后缓慢升温至15℃下再搅拌4小时。反应完毕后用氯化铵水溶液(500mL)淬灭，水层用乙酸乙酯(200毫升×3)萃取，合并的有机层用水(200mL)，1N盐酸(300毫升×3)，盐水(200毫升)洗涤后，硫酸钠干燥，过滤并蒸发，得到残余物用石油醚/乙酸乙酯＝10/1(200mL)打浆纯化。白色固体通过过滤收集，得到标题化合物(45克，80％产率)。LCMS(ESI)m/z:267(M+1).To a mixture of Example 105D (50 g, 0.21 mol) of THF (400 mL), &lt;RTI ID=0.0&gt;&gt; After stirring at -60-70 ° C for 1 hour, ethyl formate (32 g, 0.43 mol) was added dropwise, and after the completion of the dropwise addition, the temperature was slowly raised to 15 ° C and stirred for further 4 hours. After completion of the reaction, it was quenched with EtOAc EtOAc (EtOAc) (EtOAc) After washing, it was dried with sodium sulfate, filtered and evaporated. The white solid was collected by filtration to give the title compound (45 g, 80%). LCMS (ESI) m/z: 266 (M+1).
实施例105FExample 105F
(2,6-二溴-4-氟苯基)肼盐酸盐(2,6-dibromo-4-fluorophenyl)phosphonium hydrochloride
Figure PCTCN2015075363-appb-000262
Figure PCTCN2015075363-appb-000262
-5-0℃下,向2,6-二溴-4-氟苯胺(50克，0.186摩尔)的浓盐酸(190毫升)溶液中滴入亚硝酸钠(14.1克，0.205摩尔)的水(70毫升)溶液。在-5-0℃进行40分钟搅拌后，在-5-0℃下将上述反应混合物中滴加入二水合氯化亚锡(62.95克，0.279摩尔)的浓盐酸(240毫升)溶液中，所得混合物缓慢升温至20℃左右并搅拌12小时，固体通过过滤收集，用异丙醇(200毫升)洗涤后真空干燥，得到标题化合物(47克，78％产率)可用下一步骤而无需进一步纯化。1H NMR(400MHz,DMSO-d6)δppm 2.37-2.68(m,1H),6.94-7.28(m,1H),7.80(d,J＝8.03Hz,2H),10.13(br.s.,3H).To a solution of 2,6-dibromo-4-fluoroaniline (50 g, 0.186 mol) in concentrated hydrochloric acid (190 ml), sodium nitrite (14.1 g, 0.205 mol). 70 ml) solution. After stirring at -5 to 0 ° C for 40 minutes, a solution of stannous chloride dihydrate (62.95 g, 0.279 mol) in concentrated hydrochloric acid (240 ml) was added dropwise at -5 to 0 ° C. The mixture was slowly warmed to about 20 ° C and stirred for 12 h. EtOAc (EtOAc m. . 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 2.37-2.68 (m, 1H), 6.94-7.28 (m, 1H), 7.80 (d, J = 8.03 Hz, 2H), 10.13 (br.s., 3H) ).
实施例105GExample 105G
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-1H-吡唑-4-基)-4-甲基哌啶-1-甲酸叔丁酯 4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazol-4-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000263
Figure PCTCN2015075363-appb-000263
实施例105E(50克，187.73毫摩尔)，醋酸钾(27.64克，281.73毫摩尔)和实施例105F(72.17克，225.28毫摩尔)的乙醇(500ml)混合物在60℃下搅拌5小时。反应完成后向该混合物中加入NaHCO3(31.57克，375.78毫摩尔)，并在80℃下再搅拌15小时，冷却至室温后，将所得混合物蒸发，残余物用乙酸乙酯(200ml)和水(200mL)溶解，水层用乙酸乙酯(200毫升×3)萃取，将合并的有机层用盐水(200mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物用石油醚/乙酸乙酯＝10/1(200mL)打浆纯化。白色固体通过过滤收集，以提供标题化合物(75克，75％产率)可用于下一步骤而无需进一步纯化。A mixture of Example 105E (50 g, 187.73 mmol), potassium acetate (27.64 g, 281.73 mmol) and EtOAc (EtOAc) After completion of the reaction, NaHCO3 (31.57 g, 375.78 mmol) was added to the mixture, and the mixture was stirred at 80 ° C for further 15 hours. After cooling to room temperature, the mixture was evaporated. The mixture was dissolved with EtOAc (EtOAc (EtOAc)EtOAc. 1 (200 mL) was purified by beating. The white solid was collected by EtOAc (EtOAc) elute
实施例105HExample 105H
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000264
Figure PCTCN2015075363-appb-000264
氮气保护下,实施例105G(35克，65.78毫摩尔)，PD2(DBA)3(6.02克，6.57毫摩尔)，Xantphos(7.61克，13.16毫摩尔)和碳酸铯(42.77克，131.58毫摩尔)的DMF(300毫升)混合物在130℃下搅拌9小时。冷却至室温后，将所得混合物过滤，将滤液蒸发，残余物溶解在乙酸乙酯(500mL)中，用水(200毫升×2)，盐水(200毫升×2)洗涤，硫酸钠干燥，过滤并蒸发，提供粗品标题化合物可用于下一步骤而无需进一步纯化，为棕色油状物。LCMS(ESI)m/z:451,453(M,M+2).Example 105G (35 g, 65.78 mmol), PD2 (DBA) 3 (6.02 g, 6.57 mmol), Xantphos (7.61 g, 13.16 mmol) and cesium carbonate (42.77 g, 131.58 mmol). The mixture of DMF (300 mL) was stirred at 130 ° C for 9 hours. After cooling to room temperature, the mixture was filtered, EtOAcjjjjjjjjjjjjjjjjjjjjjjjjj The crude title compound was obtained as a brown oil. LCMS (ESI) m/z: 451, 453 (M, M+2).
实施例105IExample 105I
4-(8-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯4-(8-Cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000265
Figure PCTCN2015075363-appb-000265
氮气保护下,实施例105H(29.7克，65.8毫摩尔，氰化锌(15.4克，131.71毫摩尔)，PD2(DBA)3(6.02克，6.58毫摩尔)，DPPF(7.30克，13.17mmol)和锌(8.65克，131.71毫摩尔)的DMF(300mL))混合物在120℃搅拌下5小时。冷却至室温后，将混合物过滤，将滤液蒸发，得到残余物通过柱色谱法纯化得到标题化合物粗品(35克，粗品)，为黄色泡沫状物。LCMS(ESI)m/z:398(M+1).Example 105H (29.7 g, 65.8 mmol, zinc cyanide (15.4 g, 131.71 mmol), PD2 (DBA) 3 (6.02 g, 6.58 mmol), DPPF (7.30 g, 13.17 mmol) and A mixture of zinc (8.65 g, 131.71 mmol) in DMF (300 mL) was stirred at 120 ° C for 5 hours. After cooling to room temperature, the mixture was filtered and evaporated. LCMS (ESI) m/z: 398 (M+1).
实施例105JExample 105J
4-(8-氨基甲酰基-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯 4-(8-carbamoyl-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine-1-carboxylic acid Butyl ester
Figure PCTCN2015075363-appb-000266
Figure PCTCN2015075363-appb-000266
在0℃下，向实施例105I(35克，粗，88.17毫摩尔)的1N氢氧化钠(140毫升，140毫摩尔)和DMSO(100毫升)溶液中滴加入30％过氧化氢(40毫升)。滴加完毕升温至40-50℃下搅拌2小时后，反应液用水(200毫升)稀释，乙酸乙酯/四氢呋喃＝3/1(200毫升×2)萃取，将合并的有机层用水(150毫升×2)，盐水(150毫升×2)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱纯化得到标题化合物(12.2g，收率：45％)，为黄色的固体。LCMS(ESI)m/z:416(M+1).To a solution of Example 105I (35 g, EtOAc, EtOAc (EtOAc) ). After the dropwise addition was completed, the mixture was heated to 40-50 ° C for 2 hours, and the reaction mixture was diluted with water (200 ml), ethyl acetate / tetrahydrofuran = 3 / 1 (200 ml × 2), and the combined organic layer was water (150 ml) The title compound (12.2 g, yield: 45%) was obtained as a yellow solid. EtOAc. LCMS (ESI) m/z: 416 (M+1).
实施例105KExample 105K
6-氟-3-(4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000267
Figure PCTCN2015075363-appb-000267
实施例105J(5克，12毫摩尔)的二氯甲烷/三氟乙酸(50毫升/10毫升)混合溶液在20℃搅拌2小时。将所得混合物蒸发，提供标题化合物可直接用于下一步骤而无需进一步纯化，为黄色油状物。A mixed solution of Example 105J (5 g, 12 mmol) of dichloromethane / trifluoroacetic acid (50 ml / 10 ml) was stirred at 20 ° C for 2 hours. The mixture was evaporated to give the title compound mjjjjjjjjj
实施例105LExample 105L
6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000268
Figure PCTCN2015075363-appb-000268
实施例105K的(3.8克，粗，12毫摩尔)，氰基硼氰化钠(2.8，60mmol)的丙酮(2.0克，34毫摩尔)和甲醇(50毫升)混合液在25℃下搅拌3小时。真空除去溶液后，残余物溶于乙酸乙酯/四氢呋喃＝5/1(200mL)中，有机层用水(50毫升×2)，盐水(50mL)洗涤后，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱纯化以提供标题化合物(4克，收率：90％)。1H-NMR(400MHz,DMSO-d6)δppm 1.11-1.61(m,9H),1.89-2.29(m,2H),2.47(br.s.,1H),2.55(br.s.,1H),2.77(d,J＝12.05Hz,1H),3.09-3.66(m,4H),7.53(dd,J＝8.28,2.51Hz,1H),7.63(dt,J＝10.92,2.26Hz,1H),7.79-7.99(m,1H),8.17(br.s.,1H),10.23-10.75(m,2H),12.49-12.93(m,1H).LCMS(ESI)m/z:358(M+1).A mixture of (3.8 g, crude, 12 mmol) of sodium cyanoborohydride (2.8, 60 mmol) in acetone (2.0 g, 34 mmol) and methanol (50 ml) was stirred at 25 ° C. hour. After the solution was removed in vacuo <~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Purification by column chromatography gave the title compound (4 g, yield: 90%). 1 H-NMR (400MHz, DMSO-d 6 ) δ ppm 1.11-1.61 (m, 9H), 1.89-2.29 (m, 2H), 2.47 (br.s., 1H), 2.55 (br.s., 1H) , 2.77 (d, J = 12.05 Hz, 1H), 3.09-3.66 (m, 4H), 7.53 (dd, J = 8.28, 2.51 Hz, 1H), 7.63 (dt, J = 10.92, 2.26 Hz, 1H), 7.79-7.99 (m, 1H), 8.17 (br.s., 1H), 10.23-10.75 (m, 2H), 12.49-12.93 (m, 1H). LCMS (ESI) m/z: 358 (M+1) ).
实施例106Example 106
6-氟-3-(4-甲基-1,1-二氧-2H-噻喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-3-(4-methyl-1,1-dioxo-2H-thiopyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000269
Figure PCTCN2015075363-appb-000269
实施例106AExample 106A
8-溴-6-氟-3-(4-甲基四氢-2H-噻喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑8-bromo-6-fluoro-3-(4-methyltetrahydro-2H-thiopyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole
Figure PCTCN2015075363-appb-000270
Figure PCTCN2015075363-appb-000270
本实施例中如实施例105A-105H中所述制备，二氢-2H-噻喃-4(3H)-酮替代4-氧代哌啶-1-羧酸叔丁酯。LCMS(ESI)m/z:368,370(M,M+2).In the present example, as described in Examples 105A-105H, dihydro-2H-thiopyran-4(3H)-one was substituted for tert-butyl 4-oxopiperidine-1-carboxylate. LCMS (ESI) m/z: 368, 370 (M, M+2).
实施例106BExample 106B
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基四氢-2H-噻喃1,1-二氧化物4-(8-bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methyltetrahydro-2H-thiopyran 1, 1-dioxide
Figure PCTCN2015075363-appb-000271
Figure PCTCN2015075363-appb-000271
实施例106A(0.1克，0.271毫摩尔)和mCPBA(0.94克，0.542毫摩尔)的二氯甲烷(15mL)和四氢呋喃(3mL)混合物在25℃搅拌3小时。该混合物用饱和亚硫酸钠水溶液(20mL)淬灭，水层用二氯甲烷(15毫升×3)萃取，合并的有机层用饱和碳酸氢钠水溶液(20毫升)，盐水(15毫升)洗涤，硫酸钠干燥，过滤并蒸发，以提供标题化合物可直接用于下一步骤而无需进一步纯化。A mixture of methylene chloride (15 mL) and THF (3 mL) m. The mixture was quenched with EtOAc EtOAc (EtOAc m. Dry, filter and evaporate to give the title compound.
实施例106CExample 106C
6-氟-3-(4-甲基-1,1-二氧-2H-噻喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-methyl-1,1-dioxo-2H-thiopyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000272
Figure PCTCN2015075363-appb-000272
这个实施例是为在实施例105I和105J中所述制备。1H NMR(400MHz,MeOD)δ:7.8798(s,1H),7.56-7.59(d,1H),7.46-7.48(d,1H),3.11(m,2H),2.95-3.01(m,2H),2.52(m,2H),2.13-2.19(m,2H),1.35(s,3H).LCMS(ESI)m/z:365(M+1).This example was prepared as described in Examples 105I and 105J. 1 H NMR (400MHz, MeOD) δ: 7.8798 (s, 1H), 7.56-7.59 (d, 1H), 7.46-7.48 (d, 1H), 3.11 (m, 2H), 2.95-3.01 (m, 2H) , 2.52 (m, 2H), 2.13-2.19 (m, 2H), 1.35 (s, 3H). LCMS (ESI) m/z: 365 (M+1).
实施例107Example 107
3-(1,4-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-(1,4-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000273
Figure PCTCN2015075363-appb-000273
实施例107AExample 107A
4-(1-氰基-2-乙氧基-2-氧代乙基)-4-乙基哌啶-1-甲酸叔丁酯4-(1-Cyano-2-ethoxy-2-oxoethyl)-4-ethylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000274
Figure PCTCN2015075363-appb-000274
-78℃氮气保护下1,4-乙基哌啶-4-基向实施例105A(1.0克，3.4毫摩尔)的四氢呋喃(20mL)混合物中滴加乙基溴化镁(2.83毫升，8.49毫摩尔)。在-78℃下搅拌1小时后，升温至32℃下搅拌15小时，用饱和的氯化铵水溶液(100mL)淬灭，水层用乙酸乙酯(100毫升×2)萃取，将合并的有机层用盐水(200mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(0.8g，收率：73％)，为无色油状物。LCMS(ESI)m/z:325(M+1).To a mixture of Example 105A (1.0 g, 3.4 mmol) in tetrahydrofuran (20 mL), EtOAc (2. Moore). After stirring at -78 °C for 1 hour, the mixture was stirred at EtOAc (EtOAc) (EtOAc (EtOAc) The layers were washed with EtOAc EtOAc EtOAc. LCMS (ESI) m/z: 356 (M+1).
实施例107BExample 107B
3-(1,4-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1,4-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000275
Figure PCTCN2015075363-appb-000275
本实施例中如实施例105中所述制备。1H-NMR(400MHz,MethanoL-d4)δppm 0.80(t,J＝7.47Hz,3H),1.28(t,J＝7.34Hz,3H),1.72(d,J＝7.40Hz,1H),1.89-2.14(m,1H),2.41-2.61(m,1H),3.06(d,J＝7.28Hz,3H),3.37-3.58(m,1H),7.35(dd,J＝8.16,2.51Hz,1H),7.69(dd,J＝10.92,2.64Hz,1H),7.76(s,1H),8.52(s,1H).LCMS(ESI)m/z:358(M+1).Prepared as described in Example 105 in this example. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 0.80 (t, J = 7.47 Hz, 3H), 1.28 (t, J = 7.34 Hz, 3H), 1.72 (d, J = 7.40 Hz, 1H), 1.89 -2.14 (m, 1H), 2.41-2.61 (m, 1H), 3.06 (d, J = 7.28 Hz, 3H), 3.37-3.58 (m, 1H), 7.35 (dd, J = 8.16, 2.51 Hz, 1H) ), 7.69 (dd, J = 10.92, 2.64 Hz, 1H), 7.76 (s, 1H), 8.52 (s, 1H). LCMS (ESI) m/z: 358 (M+1).
实施例108Example 108
3-(4-氰基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-cyano-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000276
Figure PCTCN2015075363-appb-000276
实施例108AExample 108A
4-氰基-4-(氰基甲基)哌啶-1-甲酸叔丁酯4-cyano-4-(cyanomethyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000277
Figure PCTCN2015075363-appb-000277
向实施例105A(2.0克，6.8毫摩尔)和氰化钾(1.71克，26.3毫摩尔)的乙醇(20毫升)/水(4mL)混合溶液在70-80℃下搅拌15小时。真空除去溶液后，残余物加入水(100ml)溶解，水相用乙酸乙酯(100毫升×2)萃取，将合并的有机层用盐水(200mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(1.3g，收率：79％)，为白色固体。LCMS(ESI)m/z:250(M+1).A mixed solution of Example 105A (2.0 g, 6.8 mmol) and potassium cyanide (1.71 g, 26.3 mmol) in ethanol (20 ml) / water (4 mL) was stirred at 70-80 ° C for 15 hours. After the solution was removed in vacuo, EtOAc EtOAc m. The title compound (1.3 g, yield: 79%) LCMS (ESI) m/z: 250 (M+1).
实施例108BExample 108B
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-1H-吡唑-4-基)-4-氰基哌啶-1-甲酸叔丁酯4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazol-4-yl)-4-cyanopiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000278
Figure PCTCN2015075363-appb-000278
这个实施例是为在实施例105E-105G描述制备。This example was prepared as described in Examples 105E-105G.
实施例108CExample 108C
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-氰基哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-cyanopiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000279
Figure PCTCN2015075363-appb-000279
在氮气保护下，实施例108B(660毫克，1.22毫摩尔)，碘化亚铜(70毫克，0.37毫摩尔)，N1，N2-二甲基乙烷-1,2-二胺(65毫克，0.74毫摩尔)和磷酸钾(780毫克，3.68毫摩尔)的DMF(15mL)混合液在70℃下搅拌10小时。冷却至室温，将所得混合物硅藻土过滤，滤液蒸发，残余物通过柱色谱法纯化得到标题化合物(470mg，收率：78％)，为白色固体。LCMS(ESI)m/z:462,464(M,M+2).Example 108B (660 mg, 1.22 mmol), cuprous iodide (70 mg, 0.37 mmol), N1, N2-dimethylethane-1,2-diamine (65 mg, A mixture of 0.74 mmol) and potassium phosphate (780 mg, 3.68 mmol) in DMF (15 mL) was stirred at 70 ° C for 10 hr. After cooling to room temperature, the obtained mixture was filtered. EtOAcjjjjjjjjjj LCMS (ESI) m/z: 462, 464 (M, M+2).
实施例108DExample 108D
3-(4-氰基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-cyanopiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000280
Figure PCTCN2015075363-appb-000280
本实施例中如实施例1G-1J中所述制备。LCMS(ESI)m/z:327(M+1).This example was prepared as described in Examples 1G-1J. LCMS (ESI) m/z: 327 (M+1).
实施例108EExample 108E
3-(4-氰基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-cyano-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000281
Figure PCTCN2015075363-appb-000281
本实施例中如实施例5中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)δppm 0.34(d,J＝5.90Hz,2H),0.67-0.75(m,2H),0.99-1.13(m,1H),2.37(br.s.,2H),2.58(br.s.,2H),2.75(d,J＝6.90Hz,2H),2.89-3.07(m,2H),3.39-3.61(m,2H),7.44(dd,J＝8.09,2.57Hz,1H),7.75(dd,J＝10.85,2.57Hz,1H),7.90(s,1H),8.34-8.47(m,1H).LCMS(ESI)m/z:381(M+1).This example was prepared as described in Example 5. 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 0.34 (d, J = 5.90 Hz, 2H), 0.67-0.75 (m, 2H), 0.99-1.13 (m, 1H), 2.37 (br.s., 2H), 2.58 (br.s., 2H), 2.75 (d, J = 6.90 Hz, 2H), 2.89-3.07 (m, 2H), 3.39-3.61 (m, 2H), 7.44 (dd, J = 8.09) , 2.57 Hz, 1H), 7.75 (dd, J = 10.85, 2.57 Hz, 1H), 7.90 (s, 1H), 8.34-8.47 (m, 1H). LCMS (ESI) m/z: 381 (M+1) ).
实施例109Example 109
3-(4-羟甲基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-Hydroxymethyl-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000282
Figure PCTCN2015075363-appb-000282
实施例109AExample 109A
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-1-(叔丁氧基羰基)哌啶-4-羧酸4-(8-Bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-1-(tert-butoxycarbonyl)piperidine-4 -carboxylic acid
Figure PCTCN2015075363-appb-000283
Figure PCTCN2015075363-appb-000283
实施例108C(800毫克，1.73毫摩尔)和40％的氢氧化钠水溶液(5毫升)的乙醇(25毫升)混合物在80-90℃下搅拌15小时。冷却至室温后，用1N的HCl将混合物酸化至pH值为3～4，用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水(50毫升×2)，盐水(50毫升×2)洗涤，硫酸钠干燥，过滤并蒸发，以提供标题化合物直接用于下一步骤而无需进一步纯化.(850毫克，纯度：79％产率：98％)，为黄色固体LCMS(ESI)m/z:481,483(M,M+2).A mixture of Example 108C (800 mg, 1.73 mmol) and 40% aqueous sodium hydroxide (5 ml) in ethanol (25 ml) was stirred at 80-90 ° C for 15 hours. After cooling to room temperature, the mixture was acidified to pH 3-4 with 1N EtOAc. EtOAc (EtOAc &lt;RTI ID=0.0&gt; 2) Washing, EtOAc (EtOAc) /z:481,483(M,M+2).
实施例109BExample 109B
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-4-(羟甲基)哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-4-(hydroxymethyl)piperidine-1-carboxylic acid Tert-butyl ester
Figure PCTCN2015075363-appb-000284
Figure PCTCN2015075363-appb-000284
在0℃氮气保护下，向实施例109A(800毫克，1.56毫摩尔)的四氢呋喃(15mL)混合物中滴加入101M硼烷二甲硫醚(1毫升，10毫摩尔)。滴加完毕后在0℃下搅拌2小时后，用甲醇(20mL)淬灭，真空蒸除溶剂，残余物通过柱色谱法纯化得到标题化合物，为白色固体。(508毫克，收率：70％)。LCMS(ESI)m/z:467,469(M,M+2).To a mixture of Example 109A (800 mg, 1.56 mmol) in THF (15 mL), EtOAc. After the completion of the dropwise addition, the title compound was obtained as a white solid. (508 mg, yield: 70%). LCMS (ESI) m/z: 467, 469 (M, M+2).
实施例109CExample 109C
4-(8-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-4-(羟甲基)哌啶-1-甲酸叔丁酯4-(8-Cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-4-(hydroxymethyl)piperidin-1- Tert-butyl formate
Figure PCTCN2015075363-appb-000285
Figure PCTCN2015075363-appb-000285
氮气保护下，实施例109B(450毫克，0.96毫摩尔)，氰化锌(225毫克，1.92毫摩尔)，PD2(DBA)3(176毫克，0.19毫摩尔)，DPPF(215毫克，0.38毫摩尔)和Zn(125毫克，1.92毫摩尔)的DMF(5mL)混合物在120℃搅拌下15小时。冷却至室温后，将所得混合物过滤，滤液真空浓缩,残余物通过柱色谱法纯化得到标题化合物，为褐色固体(387mg，收率：87％)。LCMS(ESI)m/z:414(M+1).Example 109B (450 mg, 0.96 mmol), zinc cyanide (225 mg, 1.92 mmol), PD2 (DBA) 3 (176 mg, 0.19 mmol), DPPF (215 mg, 0.38 mmol). A mixture of Zn (125 mg, 1.92 mmol) in DMF (5 mL) was stirred at 120 ° C for 15 h. After the mixture was cooled to room temperature, the obtained mixture was evaporated. LCMS (ESI) m/z: 414 (M+1).
实施例109DExample 109D
4-(8-甲酰氨-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-4-(羟甲基)哌啶-1-甲酸叔丁酯4-(8-formylamino-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-4-(hydroxymethyl)piperidine-1 - tert-butyl formate
Figure PCTCN2015075363-appb-000286
Figure PCTCN2015075363-appb-000286
在0℃下，向实施例109C(350毫克，0.85毫摩尔)和碳酸钾(600毫克，4.34毫摩尔)的DMSO(10mL)混合物溶液中滴加入30％H 2O2(10mL)。滴加完毕在25℃下搅拌10小时后，用水(50mL)稀释，水层用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水(50毫升×2)，盐水(50毫升×2)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物，为黄色固体(270mg，收率：68％)。LCMS(ESI)m/z:432(M+1).To a solution of a mixture of Example 109C (350 mg, 0.85 mmol) and potassium carbonate (600 mg, 4.43 mmol) in DMSO (10 mL) was added 30% H 2 O 2 (10 mL). After the completion of the dropwise addition, the mixture was stirred at 25 ° C for 10 hours, diluted with water (50 mL), and the aqueous layer was extracted with ethyl acetate (100 ml × 2). 2) Washing, drying with sodium sulfate, EtOAc (EtOAc) LCMS (ESI) m/z: 422 (M+1).
实施例109EExample 109E
6-氟-3-(4-(羟甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(4-(hydroxymethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000287
Figure PCTCN2015075363-appb-000287
实施例109D(100毫克，0.23毫摩尔)的二氯甲烷(10mL)和三氟乙酸(3mL)混合物在25℃搅拌3小时。将得到的混合物蒸发，得到标题化合物可直接用于下一步骤而无需进一步纯化，为黄色油状物。LCMS(ESI)m/z:332(M+1).A mixture of methylene chloride (10 mL) and trifluoroacetic acid (3 mL) The resulting mixture was evaporated to give crystall crystall LCMS (ESI) m/z: 332 (M+1).
实施例109FExample 109F
3-(4-羟甲基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(4-Hydroxymethyl-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000288
Figure PCTCN2015075363-appb-000288
这个实施例是为在实施例108E所述的方法制备。1H-NMR(400MHz,DMSO-d6+D2O)δppm 0.06-0.35(m,2H),0.44-0.70(m,2H),0.81-1.14(m,1H),1.57-2.01(m,1H),2.05-2.47(m,1H),2.57-2.98(m,1H),3.08-3.28(m,1H),3.32-3.52(m,1H),7.38-7.69(m,2H),7.80(s,1H),8.34(s,1H).LCMS(ESI)m/z:386(M+1).This example was prepared for the method described in Example 108E. 1 H-NMR (400 MHz, DMSO-d 6 + D 2 O) δ ppm 0.06-0.35 (m, 2H), 0.44-0.70 (m, 2H), 0.81-1.14 (m, 1H), 1.57-2.01 (m, 1H), 2.05-2.47 (m, 1H), 2.57-2.98 (m, 1H), 3.08-3.28 (m, 1H), 3.32-3.52 (m, 1H), 7.38-7.69 (m, 2H), 7.80 ( s, 1H), 8.34 (s, 1H). LCMS (ESI) m/z: 386 (M+1).
实施例110 Example 110
4-(8-甲酰氨-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-1-(环丙基甲基)哌啶-4-羧酸乙酯4-(8-formylamino-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-1-(cyclopropylmethyl)piperidine Ethyl 4-carboxylate
Figure PCTCN2015075363-appb-000289
Figure PCTCN2015075363-appb-000289
实施例110AExample 110A
1-(叔丁基)-4-甲基4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)哌啶-1,4-二羧酸二甲酯1-(tert-butyl)-4-methyl 4-(8-bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)piperidine -1,4-dicarboxylic acid dimethyl ester
Figure PCTCN2015075363-appb-000290
Figure PCTCN2015075363-appb-000290
在0℃氮气保护下，向实施例109A(250毫克，0.52毫摩尔)的甲醇/二氯甲烷＝10/1(1毫升)混合溶液中滴加入TMSCH2N2(0.52毫升，1.04毫摩尔)。0℃下搅拌5分钟后，用醋酸/水＝1/10(20毫升)淬灭，水层用二氯甲烷(50毫升×2)萃取，将合并的有机层用盐水洗涤，硫酸钠干燥，过滤并蒸发，残余物通过在柱色谱纯化得到标题化合物(200mg，收率：78％)LCMS(ESI)m/z:495,497(M,M+2).TMSCH2N2 (0.52 ml, 1.04 mmol) was added dropwise to a mixed solution of EtOAc (MeOH) (MeOH) After stirring for 5 minutes at 0 ° C, EtOAc EtOAc (EtOAc) Filtration and evaporation, EtOAc EtOAc m.
实施例110BExample 110B
4-(8-甲酰氨-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-1-(环丙基甲基)哌啶-4-羧酸乙酯4-(8-formylamino-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-1-(cyclopropylmethyl)piperidine Ethyl 4-carboxylate
Figure PCTCN2015075363-appb-000291
Figure PCTCN2015075363-appb-000291
这个实施例是为在实施例109C-109F描述的方法制备。(11mg,yield:37％).LCMS(ESI)m/z:414(M+1).1H-NMR(400MHz,MethanoL-d4)δppm 0.34(d,J＝5.90Hz,2H),0.67-0.75(m,2H),0.99-1.13(m,1H),This example was prepared for the method described in Examples 109C-109F. (11 mg, yield: 37%). LCMS (ESI) m/z: 414 (M+1). 1 H-NMR (400 MHz, Methano L-d4) δ ppm 0.34 (d, J = 5.90 Hz, 2H), 0.67- 0.75 (m, 2H), 0.99-1.13 (m, 1H),
2.37(br.s.,2H),2.58(br.s.,2H),2.75(d,J＝6.90Hz,2H),2.89-3.07(m,2H),3.39-3.61(m,2H),7.44(dd,J＝8.09,2.57Hz,1H),7.75(dd,J＝10.85,2.57Hz,1H),7.90(s,1H),8.34-8.47(m,1H).LCMS(ESI)m/z:414(M+1).2.37 (br.s., 2H), 2.58 (br.s., 2H), 2.75 (d, J = 6.90 Hz, 2H), 2.89-3.07 (m, 2H), 3.39-3.61 (m, 2H), 7.44 (dd, J=8.09, 2.57 Hz, 1H), 7.75 (dd, J = 10.85, 2.57 Hz, 1H), 7.90 (s, 1H), 8.34-8.47 (m, 1H). LCMS (ESI) m/ z: 414 (M + 1).
流程E Process E
Figure PCTCN2015075363-appb-000292
Figure PCTCN2015075363-appb-000292
实施例111Example 111
3-(1-(环丙基甲基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000293
Figure PCTCN2015075363-appb-000293
在-78℃下氮气保护下，向实施例53C(5.0克，21.0毫摩尔)的无水四氢呋喃(60mL)溶液中滴加入LDA(26毫升，52.0毫摩尔)。在-78℃下搅拌1小时后，滴加入醋酐(5.4克，52.0毫摩尔)，将所得混合物缓慢升温至室温并搅拌30分钟，混合物用饱和氯化铵水溶液(30mL)淬灭，水层用乙酸乙酯(30毫升×2)萃取，将合并的有机层蒸发，残余物通过柱色谱法纯化得到标题化合物(4.5克，收率：76.5％)，为黄色油状物。LCMS(ESI)m/z:281(M+1).LDA (26 mL, 52.0 mmol) was added dropwise to a solution of EXAMPLE 53C (5.0 g, 21.0 <RTIgt; After stirring at -78 ° C for 1 hour, acetic anhydride (5.4 g, 52.0 mmol) was added dropwise, the mixture was slowly warmed to room temperature and stirred for 30 min. The mixture was extracted with EtOAc (EtOAc m. LCMS (ESI) m/z: 281 (M+1).
实施例111BExample 111B
4-(1-氰基-2-(2-(2,6-二溴-4-氟苯基)亚肼基)丙基)-4-甲基哌啶-1-甲酸叔丁酯4-(1-Cyano-2-(2-(2,6-dibromo-4-fluorophenyl)phosphonium)propyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000294
Figure PCTCN2015075363-appb-000294
.实施例111A(2.0克，7.14毫摩尔)，乙酸(0.2毫升)和实施例1D(2.4克，8.57毫摩尔)的乙醇(30mL)混合物在70℃下搅拌16小时。真空去除溶液后，残余物通过柱色谱法纯化以提供标题化合物 (2.1g，收率：53.8％)，为浅黄色固体：A mixture of Example 111A (2.0 g, 7.14 mmol), acetic acid (0.2 mL) and EtOAc (EtOAc) After removing the solution in vacuo, the residue was purified by column chromatography to afford title compound (2.1 g, yield: 53.8%), as a pale yellow solid:
实施例111CExample 111C
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-3-甲基-1H-吡唑-4-基)-4-甲基哌啶-1-甲酸叔丁酯4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl)-4-methylpiperidine-1-carboxylic acid Butyl ester
Figure PCTCN2015075363-appb-000295
Figure PCTCN2015075363-appb-000295
实施例111B(2.1克，3.84毫摩尔)和碳酸钾(2.1克，15.4毫摩尔)的乙醇(30mL)混合物加热至80℃搅拌4小时。真空去除溶液后，残余物通过柱色谱法纯化以提供标题化合物(0.8克，收率：54.4％)，为淡红色固体。A mixture of Example 111B (2.1 g, 3.84 mmol) and potassium carbonate (2.1 g, 15.4 mmol) in ethanol (30 mL) was warmed to 80 ° C and stirred for 4 hours. After the solution was removed in vacuo, EtOAc m.
实施例111DExample 111D
4-(8-溴-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine-1 - tert-butyl formate
Figure PCTCN2015075363-appb-000296
Figure PCTCN2015075363-appb-000296
氮气保护下，实施例111C(700毫克，1.28毫摩尔)，碘化亚铜(73毫克，0.38毫摩尔)，磷酸钾(814毫克，3.84毫摩尔)和N，N-二甲基-1,2-乙烷-1,2-二胺(68毫克，0.76毫摩尔)的DMF(15mL)混合物在70℃下搅拌在5小时。冷却至室温后，将混合物过滤，将滤液真空浓缩1,2残余物通过柱色谱纯化得到标题化合物(400mg，收率：67.0％)，为黄色固体。LCMS(ESI)m/z:465,467(M,M+2).Example 111C (700 mg, 1.28 mmol), cuprous iodide (73 mg, 0.38 mmol), potassium phosphate (814 mg, 3.84 mmol) and N,N-dimethyl-1, A mixture of 2-ethane-1,2-diamine (68 mg, 0.76 mmol) in DMF (15 mL) was stirred at 70 ° C for 5 hr. After cooling to room temperature, the mixture was filtered. EtOAcjjjjjjjjjjj LCMS (ESI) m/z: 465, 467 (M, M+2).
实施例111EExample 111E
4-(8-氰基-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯4-(8-Cyano-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine- 1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000297
Figure PCTCN2015075363-appb-000297
N 2保护下，实施例111D(650毫克，1.39毫摩尔)，氰化锌(326毫克，2.78毫摩尔)，PD2(DBA)3(254毫克，0.28毫摩尔)，DPPF(309毫克，0.56毫摩尔)和Zn(181毫克，2.78毫摩尔)的DMF(8毫升)混合物在120℃下搅拌在3小时。冷却至室温后，将所得混合物过滤，并真空浓缩，残余物通过柱色谱法纯化得到标题化合物(450mg，收率：78.5％)，为黄色的固体。LCMS(ESI)m/z:412(M+1).Under the protection of N 2 , Example 111D (650 mg, 1.39 mmol), zinc cyanide (326 mg, 2.78 mmol), PD2 (DBA) 3 (254 mg, 0.28 mmol), DPPF (309 mg, 0.56 m) A mixture of MeOH and Zn (181 mg, 2.78 mmol) in DMF (8 mL) was stirred at 120 ° C for 3 hours. After cooling to rt, EtOAcqqqqqqm LCMS (ESI) m/z: 422 (M+1).
实施例111FExample 111F
4-(8-甲酰氨-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯 4-(8-formylamino-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine Tert-butyl 1-carboxylic acid
Figure PCTCN2015075363-appb-000298
Figure PCTCN2015075363-appb-000298
在0℃下，向实施例111E(450毫克，1.09毫摩尔)和碳酸钾(906毫克，6.56毫摩尔)的DMSO(10mL)混合物滴加入30％H 2O 2(6mL)。滴加完毕在25℃下搅拌16小时后，用水(50mL)稀释，水相用乙酸乙酯(50毫升×2)萃取，将合并的有机层，用饱和亚硫酸钠溶液(50mL×2)，盐水(100mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法得到标题化合物(450mg，收率：95.7％)，为白色固体。LCMS(ESI)m/z:430(M+1).To a mixture of Example 111E (450 mg, 1.09 mmol) and potassium carbonate (906 mg, 6.56 mmol) in DMSO (10 mL) was added 30% H 2 O 2 (6 mL). After the completion of the dropwise addition, the mixture was stirred at 25 ° C for 16 hours, then diluted with water (50 mL), and the aqueous phase was extracted with ethyl acetate (50 ml × 2). The mixture was washed with EtOAc EtOAc EtOAc. LCMS (ESI) m/z: 430 (M+1).
实施例111GExample 111G
3-(1-(环丙基甲基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000299
Figure PCTCN2015075363-appb-000299
这个实施例是为在实施例109E和109F中所述制备。(50mg,yield:56.2％).1H-NMR(400MHz,MethanoL-d4)ppm 0.41(d,J＝4.52Hz,2H),0.64-0.83(m,2H),1.12(br.s.,1H),1.47(br.s.,3H),2.09(br.s.,2H),2.50(s,3H),2.54-2.71(m,2H),2.84-3.29(m,4H),3.52(br.s.,2H),7.28(d,J＝8.03Hz,1H),7.48-7.69(m,1H),8.63(br.s.,1H).LCMS(ESI)m/z:384(M+1).This example was prepared as described in Examples 109E and 109F. (50mg, yield: 56.2%). 1 H-NMR (400MHz, Methano L-d 4 ) ppm 0.41 (d, J = 4.52 Hz, 2H), 0.64-0.83 (m, 2H), 1.12 (br.s., 1H), 1.47 (br.s., 3H), 2.09 (br.s., 2H), 2.50 (s, 3H), 2.54-2.71 (m, 2H), 2.84-3.29 (m, 4H), 3.52 ( Br.s., 2H), 7.28 (d, J = 8.03 Hz, 1H), 7.48-7.69 (m, 1H), 8.63 (br.s., 1H). LCMS (ESI) m/z: 384 (M +1).
实施例112Example 112
3-(1-乙基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000300
Figure PCTCN2015075363-appb-000300
本实施例中如实施例111中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)ppm 1.20-1.61(m,6H),2.09(br.s.,2H),2.49(s,3H),2.52-2.77(m,2H),3.17(br.s.,4H),3.49(br.s.,2H),7.16-7.34(m,1H),7.467.63(m,1H),8.46(s,1H).LCMS(ESI)m/z:358(M+1).This example was prepared as described in Example 111. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.20-1.61 (m, 6H), 2.09 (br.s., 2H), 2.49 (s, 3H), 2.52-2.77 (m, 2H), 3.17 ( Br.s., 4H), 3.49 (br.s., 2H), 7.16-7.34 (m, 1H), 7.467.63 (m, 1H), 8.46 (s, 1H). LCMS (ESI) m/z :358(M+1).
实施例113Example 113
3-(1-异丁基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-isobutyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000301
Figure PCTCN2015075363-appb-000301
本实施例中如实施例111中描述的方法制备。1H NMR(400MHz,DMSO-d6)0.84(d,J＝6.5Hz,7H),1.26(s,3H),1.76(d,J＝6.8Hz,3H),2.00(d,J＝7.3Hz,2H),2.13-2.29(m,3H),2.34(s,1H),2.41(s,3H),2.68(s,1H),7.36(dd,J＝2.5,8.3Hz,1H),7.55(dd,J＝2.5,11.0Hz,1H),8.04(s,1H),8.29(br,s,1H),10.63(s,1H).LCMS(ESI)m/z:386(M+1).This example was prepared as described in Example 111. 1 H NMR (400 MHz, DMSO-d 6 ) 0.84 (d, J = 6.5 Hz, 7H), 1.26 (s, 3H), 1.76 (d, J = 6.8 Hz, 3H), 2.00 (d, J = 7.3 Hz) , 2H), 2.13-2.29 (m, 3H), 2.34 (s, 1H), 2.41 (s, 3H), 2.68 (s, 1H), 7.36 (dd, J = 2.5, 8.3 Hz, 1H), 7.55 ( Dd, J = 2.5, 11.0 Hz, 1H), 8.04 (s, 1H), 8.29 (br, s, 1H), 10.63 (s, 1H). LCMS (ESI) m/z: 386 (M+1).
实施例114Example 114
3-(1-异丙基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-isopropyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000302
Figure PCTCN2015075363-appb-000302
本实施例中如实施例111中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)d ppm 1.34(d,J＝5.52Hz,6H),1.47(br.s.,3H),2.11(br.s.,2H),2.51(s,3H),2.53-2.72(m,2H),3.11(br.s.,2H),3.44(br.s.,3H),7.20-7.38(m,1H),7.59(dd,J＝10.92,2.64Hz,1H),8.66(br.s.,1H).LCMS(ESI)m/z:372(M+1).This example was prepared as described in Example 111. 1 H-NMR (400 MHz, Methano L-d 4 ) d ppm 1.34 (d, J = 5.52 Hz, 6H), 1.47 (br.s., 3H), 2.11 (br.s., 2H), 2.51 (s, 3H), 2.53-2.72 (m, 2H), 3.11 (br.s., 2H), 3.44 (br.s., 3H), 7.20-7.38 (m, 1H), 7.59 (dd, J = 10.92, 2.64 Hz, 1H), 8.66 (br.s., 1H). LCMS (ESI) m/z: 372 (M+1).
实施例115Example 115
3-(1,4-二甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1,4-Dimethylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
Figure PCTCN2015075363-appb-000303
Figure PCTCN2015075363-appb-000303
本实施例中如实施例111中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)ppm 1.46(s,3H),2.05(br.s.,2H),2.50(s,3H),2.56(d,J＝11.67Hz,2H),2.79(s,3H),3.09(br.s.,2H),3.34-3.41(m,2H),7.31(dd,J＝8.09,2.32Hz,1H),7.63(dd,J＝10.98,2.20Hz,1H),8.55(s,1H).LCMS(ESI)m/z:344(M+1).This example was prepared as described in Example 111. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.46 (s, 3H), 2.05 (br.s., 2H), 2.50 (s, 3H), 2.56 (d, J = 11.67 Hz, 2H), 2.79 (s, 3H), 3.09 (br.s., 2H), 3.34 - 3.41 (m, 2H), 7.31 (dd, J = 8.09, 2.32 Hz, 1H), 7.63 (dd, J = 10.98, 2.20 Hz, 1H), 8.55 (s, 1H). LCMS (ESI) m/z: 344 (M+1).
实施例116Example 116
3-(1-(2-羟基-2-甲基丙基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑3-(1-(2-hydroxy-2-methylpropyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazolium [1,2-b]pyrazole
-8-甲酰胺-8-carboxamide
Figure PCTCN2015075363-appb-000304
Figure PCTCN2015075363-appb-000304
本实施例中如实施例111中描述的方法制备。1H NMR(400MHz,DMSO-d6)1.02-1.14(m,6H),1.26(s,3H),1.69-1.81(m,2H),2.11-2.24(m,4H),2.32-2.44(m,6H),2.68(br,s,2H),7.37(dd,J＝2.5,8.3Hz,1H),7.56(dd,J＝2.5,11.0Hz,1H),8.06(s,1H),8.28(s,1H),10.65(s,1H).LCMS(ESI)m/z:402(M+1).This example was prepared as described in Example 111. 1 H NMR (400MHz, DMSO- d 6) 1.02-1.14 (m, 6H), 1.26 (s, 3H), 1.69-1.81 (m, 2H), 2.11-2.24 (m, 4H), 2.32-2.44 (m , 6H), 2.68 (br, s, 2H), 7.37 (dd, J = 2.5, 8.3 Hz, 1H), 7.56 (dd, J = 2.5, 11.0 Hz, 1H), 8.06 (s, 1H), 8.28 ( s, 1H), 10.65 (s, 1H). LCMS (ESI) m/z: 402 (M+1).
实施例117Example 117
3-(1-乙基-2,4-二甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 3-(1-Ethyl-2,4-dimethylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000305
Figure PCTCN2015075363-appb-000305
本实施例中如实施例111中描述的方法制备。1H NMR(400MHz,DMSO-d6)1.07(t,J＝7.0Hz,3H),1.13(d,J＝6.0Hz,3H),1.41(s,3H),1.84-1.72(m,1H),1.97(d,J＝10.8Hz,2H),2.05-2.16(m,1H),2.44(s,3H),2.54-2.70(m,2H),2.77(br,s,1H),2.90–3.03(m,2H),7.41(dd,J＝2.4,8.4Hz,1H),7.55(dd,J＝2.5,11.0Hz,1H),8.05(s,1H),8.33(s,1H),10.63(s,1H).LCMS(ESI)m/z:372(M+1).This example was prepared as described in Example 111. 1 H NMR (400 MHz, DMSO-d 6 ) 1.07 (t, J = 7.0 Hz, 3H), 1.13 (d, J = 6.0 Hz, 3H), 1.41 (s, 3H), 1.84-1.72 (m, 1H) , 1.97 (d, J = 10.8 Hz, 2H), 2.05-2.16 (m, 1H), 2.44 (s, 3H), 2.54-2.70 (m, 2H), 2.77 (br, s, 1H), 2.90 - 3.03 (m, 2H), 7.41 (dd, J = 2.4, 8.4 Hz, 1H), 7.55 (dd, J = 2.5, 11.0 Hz, 1H), 8.05 (s, 1H), 8.33 (s, 1H), 10.63 ( s, 1H). LCMS (ESI) m / z: 372 (M + 1).
实施例118Example 118
3-(1-乙基-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethyl-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000306
Figure PCTCN2015075363-appb-000306
本实施例中如实施例111中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.37-1.41(t,3H),1.58(s,3H),2.47-2.49(m,1H),2.51(s,3H),2.67-2.74(m,1H),3.29-3.30(m,2H),3.34-3.67(m,4H),7.33-7.35(d,1H),7.66-7.69(d,1H),8.52(bs,1H).LCMS(ESI)m/z:344(M+1).This example was prepared as described in Example 111. 1 H-NMR (MeOD, 400 MHz) δ: 1.37-1.41 (t, 3H), 1.58 (s, 3H), 2.47-2.49 (m, 1H), 2.51 (s, 3H), 2.67-2.74 (m, 1H) ), 3.29-3.30 (m, 2H), 3.34 - 3.67 (m, 4H), 7.33 - 7.35 (d, 1H), 7.66-7.69 (d, 1H), 8.52 (bs, 1H). LCMS (ESI) m /z:344(M+1).
实施例119Example 119
3-(1-异丙基-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-isopropyl-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000307
Figure PCTCN2015075363-appb-000307
本实施例中如实施例111中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.36-1.45(m,6H),1.52-1.59(m,3H),2.48(s,4H),2.61-2.73(m,1H),3.45-3.53(m,1H),3.55-3.82(m,4H),7.24-7.33(m,1H),7.56-7.68(m,1H),8.40-8.55(bs,1H).LCMS(ESI)m/z:358(M+1).This example was prepared as described in Example 111. 1 H-NMR (MeOD, 400 MHz) δ: 1.36-1.45 (m, 6H), 1.52-1.59 (m, 3H), 2.48 (s, 4H), 2.61-2.73 (m, 1H), 3.45-3.53 (m , 1H), 3.55-3.82 (m, 4H), 7.24-7.33 (m, 1H), 7.56-7.68 (m, 1H), 8.40-8.55 (bs, 1H). LCMS (ESI) m/z: 358 ( M+1).
实施例120Example 120
3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000308
Figure PCTCN2015075363-appb-000308
本实施例中如实施例111中描述的方法制备。1H-NMR(MeOD,400MHz)δ:0.59(d,2H),0.96-1.06(m,1H),1.53(s,3H),2.12-2.22(m,1H),2.48(s,5H),2.83-2.94(m,1H),2.98-3.08(m,2H),3.11-3.20(m,1H),7.33-7.36(m,1H),7.61-7.74(m,1H).LCMS(ESI)m/z:370(M+1).This example was prepared as described in Example 111. 1 H-NMR (MeOD, 400MHz ) δ: 0.59 (d, 2H), 0.96-1.06 (m, 1H), 1.53 (s, 3H), 2.12-2.22 (m, 1H), 2.48 (s, 5H), 2.83-2.94 (m, 1H), 2.98-3.08 (m, 2H), 3.11-3.20 (m, 1H), 7.33-7.36 (m, 1H), 7.61-7.74 (m, 1H). LCMS (ESI) m /z:370(M+1).
实施例121 Example 121
3-(1,3-二甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1,3-Dimethylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
Figure PCTCN2015075363-appb-000309
Figure PCTCN2015075363-appb-000309
本实施例中如实施例111中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)ppm 1.74(s,3H),2.37(s,3H),2.94(s,3H),4.27(d,J＝9.79Hz,2H),4.43(d,J＝9.29Hz,2H),7.29(d,J＝8.28Hz,1H),7.62(d,J＝10.92Hz,1H),8.51(br.s.,1H).LCMS(ESI)m/z:316(M+1).This example was prepared as described in Example 111. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.74 (s, 3H), 2.37 (s, 3H), 2.94 (s, 3H), 4.27 (d, J = 9.79 Hz, 2H), 4.43 (d, J=9.29 Hz, 2H), 7.29 (d, J = 8.28 Hz, 1H), 7.62 (d, J = 10.92 Hz, 1H), 8.51 (br.s., 1H). LCMS (ESI) m/z: 316 (M+1).
实施例122Example 122
3-(1-乙基-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-ethyl-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide
Figure PCTCN2015075363-appb-000310
Figure PCTCN2015075363-appb-000310
本实施例中如实施例111中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.01-1.08(m,3H),1.65-1.70(m,3H),2.34(s,3H),2.55-2.65(m,2H),3.47-3.53(m,2H),3.59-3.66(m,2H),7.28-7.36(dd,1H),7.63-7.73(dd,1H).LCMS(ESI)m/z:330(M+1).This example was prepared as described in Example 111. 1 H-NMR (MeOD, 400MHz) δ: 1.01-1.08 (m, 3H), 1.65-1.70 (m, 3H), 2.34 (s, 3H), 2.55-2.65 (m, 2H), 3.47-3.53 (m , 2H), 3.59-3.66 (m, 2H), 7.28-7.36 (dd, 1H), 7.63-7.73 (dd, 1H). LCMS (ESI) m/z: 330 (M+1).
实施例123Example 123
3-(1-异丙基-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-isopropyl-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-carboxamide
Figure PCTCN2015075363-appb-000311
Figure PCTCN2015075363-appb-000311
本实施例中如实施例111中描述的方法制备。1H-NMR(MeOD,400MHz)δ:1.26(d,J＝6.53Hz,6H),1.75(s,3H),2.40(s,3H),3.38(d,J＝5.90Hz,1H),4.20-4.28(m,2H),4.33-4.44(m,2H),7.27-7.43(dd,1H),7.62-7.76(dd,1H),8.43-8.58(bs,1H).LCMS(ESI)m/z:344(M+1).This example was prepared as described in Example 111. 1 H-NMR (MeOD, 400 MHz) δ: 1.26 (d, J = 6.53 Hz, 6H), 1.75 (s, 3H), 2.40 (s, 3H), 3.38 (d, J = 5.90 Hz, 1H), 4.20 -4.28 (m, 2H), 4.33-4.44 (m, 2H), 7.27-7.43 (dd, 1H), 7.62-7.76 (dd, 1H), 8.43-8.58 (bs, 1H). LCMS (ESI) m/ z:344 (M+1).
实施例124Example 124
3-(1-(环丙基甲基)-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(cyclopropylmethyl)-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2- b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000312
Figure PCTCN2015075363-appb-000312
本实施例中如实施例111中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)ppm 0.46(d,J＝4.02Hz,2H),0.66-0.82(m,2H),1.09(d,J＝6.02Hz,1H),1.76(s,3H),2.37(s,3H),3.19(br.s.,2H),4.19-4.40(m,2H),4.54(d,J＝9.16Hz,2H),7.24(br.s.,1H),7.57(br.s.,1H),8.53(br.s.,1H).LCMS(ESI)m/z:356(M+1). This example was prepared as described in Example 111. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 0.46 (d, J = 4.02 Hz, 2H), 0.66-0.82 (m, 2H), 1.09 (d, J = 6.02 Hz, 1H), 1.76 (s, 3H), 2.37 (s, 3H), 3.19 (br.s., 2H), 4.19-4.40 (m, 2H), 4.54 (d, J = 9.16 Hz, 2H), 7.24 (br.s., 1H) , 7.57 (br.s., 1H), 8.53 (br.s., 1H). LCMS (ESI) m/z: 356 (M+1).
实施例125Example 125
3-(1-(2-羟基-2-甲基丙基)-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺3-(1-(2-hydroxy-2-methylpropyl)-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo [1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000313
Figure PCTCN2015075363-appb-000313
本实施例中如实施例111中描述的方法制备。1H-NMR(400MHz,MethanoL-d4)ppm 1.32(s,6H),1.75(s,3H),2.30-2.43(m,3H),3.24(s,2H),4.35(d,J＝9.91Hz,2H),4.52(d,J＝9.29Hz,2H),7.26(d,J＝8.03Hz,1H),7.61(d,J＝11.04Hz,1H),8.50(br.s.,1H).LCMS(ESI)m/z:374(M+1).This example was prepared as described in Example 111. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.32 (s, 6H), 1.75 (s, 3H), 2.30-2.43 (m, 3H), 3.24 (s, 2H), 4.35 (d, J = 9.91) Hz, 2H), 4.52 (d, J = 9.29 Hz, 2H), 7.26 (d, J = 8.03 Hz, 1H), 7.61 (d, J = 11.04 Hz, 1H), 8.50 (br.s., 1H) .LCMS (ESI) m / z: 374 (M + 1).
实施例126Example 126
6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-2-methoxy-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000314
Figure PCTCN2015075363-appb-000314
实施例126AExample 126A
4-(1-氰基-2-(2-(2,6-二溴-4-氟苯基)肼基)-2-氧代乙基)-4-甲基哌啶-1-甲酸叔丁酯4-(1-Cyano-2-(2-(2,6-dibromo-4-fluorophenyl)indolyl)-2-oxoethyl)-4-methylpiperidine-1-carboxylic acid Butyl ester
Figure PCTCN2015075363-appb-000315
Figure PCTCN2015075363-appb-000315
氮气保护下，实施例105C(2.73克，粗，9.67毫摩尔)，HATU(5.51克，0.26毫摩尔)，实施例1D(3.29克，11.60毫摩尔)和三乙胺(2.84克，29.01毫摩尔)的DMF(20mL)混合物在25℃搅拌10小时。反应完毕后用水(100毫升)淬灭，用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水(50毫升×2)和盐水(50mL×2)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(4.50g，收率：85％)，为黄色的固体。Example 105C (2.73 g, crude, 9.67 mmol), HATU (5.51 g, 0.26 mmol), Example 1D (3.29 g, 11.60 mmol) and triethylamine (2.84 g, 29.01 mmol). The mixture of DMF (20 mL) was stirred at 25 ° C for 10 hours. After completion of the reaction, the mixture was evaporated with m~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ The residue was purified by EtOAc EtOAcqqqqq
实施例126BExample 126B
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-3-羟基-1H-吡唑-4-基)-4-甲基哌啶-1-甲酸叔丁酯4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-3-hydroxy-1H-pyrazol-4-yl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000316
Figure PCTCN2015075363-appb-000316
实施例126A(4.50克，8.21毫摩尔)和碳酸钾(2.27克，16.42毫摩尔)的乙醇(100mL)混合物在80℃下搅拌15小时。真空除去溶液后，残余物用水(100毫升)稀释，水层用乙酸乙酯(100毫升×2) 萃取，将合并的有机层用水(50毫升×2)和盐水(50mL×2)洗涤，硫酸钠干燥，过滤并蒸发，残余物用柱色谱法纯化得到标题化合物(3.81g，收率：84％)，为黄色固体。A mixture of Example 126A (4.50 g, 8.21 mmol) and potassium carbonate (2.27 g, 16.42 mmol) in ethanol (100 mL) was stirred at <RTIgt; After the solution was removed in vacuo, the residue was crystallisjjjjjjj The combined organic layer was washed with EtOAcqqqHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH ), as a yellow solid.
实施例126CExample 126C
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-3-甲氧基-1H-吡唑-4-基)-4-甲基哌啶-1-甲酸叔丁酯4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-3-methoxy-1H-pyrazol-4-yl)-4-methylpiperidine-1-carboxylic acid Tert-butyl ester
Figure PCTCN2015075363-appb-000317
Figure PCTCN2015075363-appb-000317
实施例126B(2.3克，3.65毫摩尔)，碘甲烷(517.80毫克，3.65毫摩尔)和碳酸钾(1.51克，10.94毫摩尔)的DMF(50ml)混合物在25℃下搅拌15小时。真空除去溶液后，将残余物用水(100毫升)稀释，水层用乙酸乙酯(100毫升×2)萃取，将合并的有机层用水(50毫升×2)，盐水(50毫升×2)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(590mg，收率：28.76％)，为黄色固体。A mixture of Example 126B (2.3 g, 3.65 mmol), EtOAc (EtOAc (EtOAc) After the solution was removed in vacuo, EtOAc (EtOAc m. The residue was dried with EtOAcjjjjjjjjjjj
实施例126DExample 126D
4-(8-溴-6-氟-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-2-methoxy-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine- 1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000318
Figure PCTCN2015075363-appb-000318
N 2保护下，实施例126C(680毫克，1.21毫摩尔)，碘化亚铜(69毫克，0.36毫摩尔)，N1，N2-二甲基乙烷-1,2-二胺(64毫克，0.73毫摩尔)和磷酸钾(770毫克，3.63毫摩尔)的DMF(15mL)混合物在70℃下搅拌在10小时。冷却至室温后，将所得混合物过滤，将滤液蒸发，残余物通过柱色谱法纯化得到标题化合物(455毫克收率：78％)，为白色固体。LCMS(ESI)m/z:481,483(M,M+2).Example 126C (680 mg, 1.21 mmol), cuprous iodide (69 mg, 0.36 mmol), N1, N2-dimethylethane-1,2-diamine (64 mg, A mixture of 0.73 mmol) and potassium phosphate (770 mg, 3.63 mmol) in DMF (15 mL) was stirred at 70 ° C for 10 hours. After cooling to room temperature, the obtained mixture was evaporated.jjjjjjjjjjj LCMS (ESI) m/z: 481, 48 (M, M+2).
实施例126EExample 126E
4-(8-氰基-6-氟-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯4-(8-Cyano-6-fluoro-2-methoxy-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine Tert-butyl 1-carboxylic acid
Figure PCTCN2015075363-appb-000319
Figure PCTCN2015075363-appb-000319
氮气保护下，实施例126D(400毫克，0.83毫摩尔)，氰化锌(108毫克，1.69毫摩尔)，PD2(DBA)3(152毫克，0.16毫摩尔)，DPPF(185毫克，0.33毫摩尔)和Zn(108毫克，1.66毫摩尔)的DMF(8毫升)混合物中在120℃搅拌15小时。冷却至室温后，将所得混合物过滤，滤液蒸发，残余物通过柱色谱法纯化得到标题化合物(330毫克收率：81％)，为黄色的固体。LCMS(ESI)m/z:428(M+1).Example 126D (400 mg, 0.83 mmol), zinc cyanide (108 mg, 1.69 mmol), PD2 (DBA) 3 (152 mg, 0.16 mmol), DPPF (185 mg, 0.33 mmol) It was stirred at 120 ° C for 15 hours with a mixture of Zn (108 mg, 1.66 mmol) in DMF (8 mL). After cooling to room temperature, the obtained mixture was evaporated,jjjjjjjjjj LCMS (ESI) m/z: 422 (M+1).
实施例126FExample 126F
4-(8-甲酰氨基-6-氟-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-甲酸叔丁酯 4-(8-formylamino-6-fluoro-2-methoxy-4H-benzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylper Butyl-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000320
Figure PCTCN2015075363-appb-000320
在0℃下，向实施例126E(200毫克，0.47毫摩尔)和碳酸钾(300毫克，2.17毫摩尔)的DMSO(5mL)混合溶液中滴加入30％H 2O 2(5mL)。在25℃下搅拌15小时后，用水(50mL)稀释，水层用乙酸乙酯(50毫升×3)萃取，将合并的有机层用水(50mL)和盐水(50mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化以提供标题化合物(195mg，收率：93％)，为白色固体。LCMS(ESI)m/z:446(M+1).To a mixed solution of Example 126E (200 mg, 0.47 mmol) and potassium carbonate (300 mg, 2.17 mmol) in DMSO (5 mL) was added dropwise 30% H 2 O 2 (5 mL). After stirring for 15 hours at 25 ° C, EtOAc (EtOAc) (EtOAc)EtOAc. The residue was purified by EtOAc EtOAcqqqqq LCMS (ESI) m/z: 446 (M+1).
实施例126GExample 126G
6-氟-2-甲氧基-3-(4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-2-methoxy-3-(4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000321
Figure PCTCN2015075363-appb-000321
实施例126F(100毫克，0.22毫摩尔)在二氯甲烷/三氟乙酸(10毫升/3毫升)的混合溶液在25℃搅拌3小时。真空除去溶液后，提供标题化合物直接用于下一个步骤而无需不进一步纯化。A mixed solution of Example 126F (100 mg, 0.22 mmol) in dichloromethane / trifluoroacetic acid (10 ml / 3 ml) was stirred at 25 ° C for 3 hours. After removal of the solution in vacuo, the title compound was taken directly to the next step without further purification.
实施例126HExample 126H
6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-2-methoxy-4H-benzo[4,5]imidazo[1,2-b]pyridyl Oxazole-8-carboxamide
Figure PCTCN2015075363-appb-000322
Figure PCTCN2015075363-appb-000322
实施例126G(78毫克，原油，0.22毫摩尔)，氰基硼氰化钠(140毫克，2.22毫摩尔)和丙酮(70毫克，1.2毫摩尔)的四氢呋喃/甲醇(15毫升/10毫升)混合液在24℃下搅拌15小时。将混合物用水(20mL)稀释，水层用乙酸乙酯(30毫升×2)萃取，将合并的有机层用水(20mL)和盐水(20mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物通过制备型HPLC纯化得到标题化合物(35毫克，产率：41％)，为白色固体。1H-NMR(400MHz,MethanoL-d4)δppm 1.27-1.52(m,9H),1.77-2.19(m,2H),2.69(br.s.,2H),2.84-3.28(m,2H),3.39-3.55(m,3H),4.06(s,3H),7.31(dd,J＝8.03,2.51Hz,1H),7.66(dd,J＝10.98,2.45Hz,1H),8.55(br.s.,1H).LCMS(ESI)m/z:388(M+1).Example 126G (78 mg, crude oil, 0.22 mmol), sodium cyanoborohydride (140 mg, 2.22 mmol) and acetone (70 mg, 1.2 mmol) in tetrahydrofuran / methanol (15 ml / 10 ml) The solution was stirred at 24 ° C for 15 hours. The mixture was diluted with H.sub.2 (EtOAc (EtOAc) (EtOAc (EtOAc) The title compound (35 mg, yield: 41%) 1 H-NMR (400 MHz, Methano L-d 4 ) δ ppm 1.27-1.52 (m, 9H), 1.77-2.19 (m, 2H), 2.69 (br.s., 2H), 2.84-3.28 (m, 2H), 3.39-3.55 (m, 3H), 4.06 (s, 3H), 7.31 (dd, J = 8.03, 2.51 Hz, 1H), 7.66 (dd, J = 10.98, 2.45 Hz, 1H), 8.55 (br.s. , 1H). LCMS (ESI) m / z: 388 (M + 1).
实施例127Example 127
2-苄甲氧基-6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 2-benzylmethoxy-6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000323
Figure PCTCN2015075363-appb-000323
实施例127AExample 127A
Figure PCTCN2015075363-appb-000324
Figure PCTCN2015075363-appb-000324
实施例126B(3.0克，5.48毫摩尔)，Boc 2O(10.0克，45.8毫摩尔)和DMAP(670毫克，5.48毫摩尔)混合物在80℃下搅拌3小时。冷却至室温后，混合物用碳酸氢钠水溶液(30mL)稀释，水层用二氯甲烷(100毫升×3)萃取，将合并的有机层用硫酸钠干燥，过滤并蒸发，以提供标题化合物可直接用于下一步骤而无需进一步纯化(4.5克粗品)。Example 126B (3.0 g, 5.48 mmol), a mixture of Boc 2 O (10.0 g, 45.8 mmol) and DMAP (670 mg, 5.48 mmol) was stirred at 80 ° C for 3 hours. After cooling to room temperature, the mixture was diluted w~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Used in the next step without further purification (4.5 g crude).
实施例127BExample 127B
Figure PCTCN2015075363-appb-000325
Figure PCTCN2015075363-appb-000325
实施例127A(4.5克，5.31毫摩尔)和碳酸钾(1.46克，10.62毫摩尔)的甲醇(40mL)混合物在20℃搅拌4小时。将混合物过滤，将滤液蒸发，残余物用色谱法在硅胶上纯化以提供标题化合物(3.1g，收率：80％)，为黄色固体。A mixture of Example 127A (4.5 g, 5.31 mmol) and EtOAc (EtOAc:EtOAc. The mixture was filtered, EtOAc EtOAcjjjjjjjj
实施例127CExample 127C
Figure PCTCN2015075363-appb-000326
Figure PCTCN2015075363-appb-000326
实施例127B(2.5克，3.35毫摩尔)，碳酸钾(925毫克，6.7毫摩尔)和苄溴(626毫克，3.68毫摩尔)的甲醇(30mL)混合物在60℃下搅拌8小时。将混合物过滤，将滤液蒸发，残余物用色谱法纯化得到标题化合物(1.4g粗品)，为白色固体。A mixture of Example 127B (2.5 g, 3.35 mmol), EtOAc (EtOAc, EtOAc) The mixture was filtered, and the~~~~~~~
实施例127DExample 127D
3-(苄氧基)-1-(2,6-二溴-4-氟苯基)-4-(4-甲基哌啶-4-基)-1H-吡唑-5-胺3-(Benzyloxy)-1-(2,6-dibromo-4-fluorophenyl)-4-(4-methylpiperidin-4-yl)-1H-pyrazole-5-amine
Figure PCTCN2015075363-appb-000327
Figure PCTCN2015075363-appb-000327
实施例127C(1.4克，1.63毫摩尔)的4M盐酸/乙酸乙酯(20mL)溶液在10℃下搅拌3小时。真空除去溶液后，以提供标题化合物(1.0g，收率：100％)直接用于下一步骤而无需进一步纯化，为黄色固体。A solution of Example 127C (1.4 g, 1. <RTI ID=0.0></RTI> After the solution was evaporated in vacuo tolulululululululululululu
实施例127EExample 127E
4-(5-氨基-3-(苄氧基)-1-(2,6-二溴-4-氟苯基)-1H-吡唑-4-基)-4-甲基哌啶-1-甲酸叔丁酯4-(5-Amino-3-(benzyloxy)-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazol-4-yl)-4-methylpiperidine-1 - tert-butyl formate
Figure PCTCN2015075363-appb-000328
Figure PCTCN2015075363-appb-000328
实施例127D(1.0克，1.78毫摩尔)，三乙胺(362毫克，3.56毫摩尔)和Boc 2O(776毫克，3.56毫摩尔)的二氯甲烷(15mL)混合物在10℃下搅拌4小时。该混合物用H 2O(20mL)稀释，水层用二氯甲烷(15毫升×2)萃取，将合并的有机层用水，盐水洗涤，硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化得到标题化合物(1.0g粗品)，为白色固体。A mixture of 127D (1.0 g, 1.78 mmol), triethylamine (362 mg, <RTIgt; </RTI> <RTIgt; </RTI> <RTIgt; </RTI> <RTIgt; The mixture was diluted with H2O (20 mL). EtOAc (EtOAc m. The title compound (1.0 g crude) was obtained as white solid.
实施例127FExample 127F
2-苄甲氧基-6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺2-benzylmethoxy-6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000329
Figure PCTCN2015075363-appb-000329
这个实施例是为在实施例126D-126H中所述制备。1H NMR(400MHz,DMSO-d6)0.95(d,J＝6.5Hz,6H),1.24(s,3H),1.60-1.72(m,2H),2.34(br,s,4H),2.66-2.77(m,3H),5.32(s,2H),7.29-7.55(m,7H),8.04(s,1H),8.34(br,s,1H),10.20(s,1H).LCMS(ESI)m/z:464(M+1).This example was prepared as described in Examples 126D-126H. 1 H NMR (400 MHz, DMSO-d 6 ) 0.95 (d, J = 6.5 Hz, 6H), 1.24 (s, 3H), 1.60-1.72 (m, 2H), 2.34 (br, s, 4H), 2.66- 2.77 (m, 3H), 5.32 (s, 2H), 7.29-7.55 (m, 7H), 8.04 (s, 1H), 8.34 (br, s, 1H), 10.20 (s, 1H). LCMS (ESI) m/z: 464 (M+1).
流程FProcess F
Figure PCTCN2015075363-appb-000330
Figure PCTCN2015075363-appb-000330
实施例128Example 128
6-氟-2-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺 6-fluoro-2-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000331
Figure PCTCN2015075363-appb-000331
实施例128AExample 128A
4-(2-氰基乙酰基)哌啶-1-甲酸叔丁酯4-(2-cyanoacetyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000332
Figure PCTCN2015075363-appb-000332
在-78℃氮气氛下，向乙腈(5.06克，123.4毫摩尔)的无水四氢呋喃(200毫升)溶液中滴加入n-BuLi(39.5毫升，98.6毫摩尔)。在-78℃搅拌2小时后，将1-(叔丁基)-4-甲基哌啶-1,4-二羧酸酯(20克，82.2毫摩尔)的四氢呋喃(100毫升)滴加到上述混合物中，滴加完毕升温至15℃搅拌下16小时后，用饱和氯化铵水溶液(100mL)淬灭，水相用乙酸乙酯(100毫升×2)萃取，合并的有机层用硫酸钠干燥，过滤并蒸发，残余物通过柱色谱法纯化提供标题化合物(7.9克，收率：38.1％)，为黄色固体。LCMS(ESI)m/z:253(M+1).N-BuLi (39.5 ml, 98.6 mmol) was added dropwise to a solution of acetonitrile (5.06 g, 123.4 mmol) in anhydrous tetrahydrofurane (200 ml). After stirring at -78 ° C for 2 hours, 1-(tert-butyl)-4-methylpiperidine-1,4-dicarboxylate (20 g, 82.2 mmol) in tetrahydrofuran (100 ml) was added dropwise. After the dropwise addition, the mixture was heated to 15 ° C and stirred for 16 hours, then quenched with saturated aqueous ammonium chloride (100 mL). It was dried, filtered and evaporated. LCMS (ESI) m/z: 253 (M+1).
实施例128BExample 128B
4-(2-氰基-1-(2-(2,6-二溴-4-氟苯基)亚肼基)乙基)哌啶-1-甲酸叔丁酯4-(2-Cyano-1-(2-(2,6-dibromo-4-fluorophenyl)phosphonium)ethyl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000333
Figure PCTCN2015075363-appb-000333
实施例128A(6.35克，25.16毫摩尔)和实施例1D(10克，35.2毫摩尔)的乙醇(80毫升)和HOAc(80毫升)混合溶液在85℃下搅拌16小时。冷却至室温后，将混合物蒸发，所得标题化合物将可直接用于下一步而无需进一步纯化(15克，粗品)。A mixed solution of Example 128A (6.35 g, 25.16 mmol) and Example 1D (10 g, 35.2 mmol) of ethanol (80 ml) and HOAc (80 ml) was stirred at 85 ° C for 16 hours. After cooling to rt, EtOAcqqqqqqqqqqqq
实施例128CExample 128C
4-(5-氨基-1-(2,6-二溴-4-氟苯基)-1H-吡唑-3-基)哌啶-1-甲酸叔丁酯4-(5-Amino-1-(2,6-dibromo-4-fluorophenyl)-1H-pyrazol-3-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000334
Figure PCTCN2015075363-appb-000334
实施例128B(13克，25.1毫摩尔)和三乙胺(12.7克，125.5毫摩尔)的乙醇(100mL)混合物加热到80℃约16小时。冷却至室温后，将混合物蒸发，残余物通过柱色谱纯化得到标题化合物(11克，收率：84.6％)，为黄色固体。A mixture of Example 128B (13 g, 25.1 mmol) and triethylamine (12.7 g, 125.5 mmol) in ethanol (100 mL) was warmed to <RTI ID=0.0> After cooling to room temperature, the~~~~~~~~~~~~~~~~~
实施例如128DImplementation such as 128D
4-(8-溴-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-2-基)哌啶-1-甲酸叔丁酯4-(8-Bromo-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000335
Figure PCTCN2015075363-appb-000335
氮气保护下，实施例128C(1.5克，2.9毫摩尔)，碘化亚铜(166毫克，0.87毫摩尔)，磷酸钾(1.8克，8.7毫摩尔)和N1，N2-二甲基乙烷-1,2-二胺(153毫克，1.74毫摩尔)的DMF(8mL)混合物在55℃下搅拌在18小时。冷却至室温后，用水(20mL)稀释，水层用乙酸乙酯(20毫升×2)萃取，将合并的有机层用水(20毫升)，盐水(20mL)洗涤，硫酸钠干燥，过滤并蒸发，残余物用柱色谱纯化以提供标题化合物(350mg，收率：27.6％)，为黄色固体。LCMS(ESI)m/z:437,439(M,M+2).Example 128C (1.5 g, 2.9 mmol), cuprous iodide (166 mg, 0.87 mmol), potassium phosphate (1.8 g, 8.7 mmol) and N1, N2-dimethylethane under nitrogen. A mixture of 1,2-diamine (153 mg, 1.74 mmol) in DMF (8 mL) was stirred at <RTIgt; After cooling to rt, EtOAc (EtOAc m.). The residue was purified with EtOAcqqqqqqq LCMS (ESI) m/z: 437, 437 (M, M+2).
实施例128EExample 128E
4-(8-氨基甲酰基-6-氟-4H-苯并[4,5]咪唑并[1,2-B]吡唑-2-基)哌啶-1-甲酸叔丁酯4-(8-carbamoyl-6-fluoro-4H-benzo[4,5]imidazo[1,2-B]pyrazol-2-yl)piperidine-1-carboxylic acid tert-butyl ester
Figure PCTCN2015075363-appb-000336
Figure PCTCN2015075363-appb-000336
氮气保护下，实施例128D(350毫克，0.8毫摩尔)，氰化锌(188毫克，1.6毫摩尔)，PD2(DBA)3(110毫克，0.12毫摩尔)，DPPF(133毫克，0.24毫摩尔)和锌粉(104毫克，1.6毫摩尔)的DMF(4mL)混合物在120℃搅拌下2小时。冷却至室温后，将所得混合物过滤，将滤液蒸发，残余物通过制备型TLC纯化得到标题化合物(50mg，收率：16.2％)为黄色固体。LCMS(ESI)m/z:402(M+1).Example 128D (350 mg, 0.8 mmol), zinc cyanide (188 mg, 1.6 mmol), PD2 (DBA) 3 (110 mg, 0.12 mmol), DPPF (133 mg, 0.24 mmol). A mixture of zinc powder (104 mg, 1.6 mmol) in DMF (4 mL) was stirred at 120 ° C for 2 h. After cooling to room temperature, the obtained mixture was evaporated,jjjjjjjjjjjjjj LCMS (ESI) m/z: 402 (M+1).
实施例128FExample 128F
6-氟-2-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺6-fluoro-2-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000337
Figure PCTCN2015075363-appb-000337
实施例128E(50毫克，0.125毫摩尔)的三氟乙酸(1毫升)和二氯甲烷(6mL)混合溶液中在20℃搅拌2小时。将得到的混合物蒸发，残留物通过制备型HPLC纯化得到标题化合物(23毫克，收率：59.0％)，为白色固体。1H-NMR(400MHz,MethanoL-d4)ppm 1.07-1.27(m,9H),2.51(d,J＝1.51Hz,2H),2.76-2.97(m,2H),3.34(d,J＝3.26Hz,2H),5.74(br.s.,1H),7.36～7.39(m,1H),7.68～7.72(m,1H).LCMS(ESI)m/z:302(M+1).Example 128E (50 mg, 0.125 mmol) of a mixture of trifluoroacetic acid (1 ml) and dichloromethane (6 mL) was stirred at 20 ° C for 2 hours. The resulting mixture was evaporated, EtOAcjjjjjjjjj 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.07-1.27 (m, 9H), 2.51 (d, J = 1.51 Hz, 2H), 2.76-2.97 (m, 2H), 3.34 (d, J = 3.26) Hz, 2H), 5.74 (br.s., 1H), 7.36 to 7.39 (m, 1H), 7.68 to 7.72 (m, 1H). LCMS (ESI) m/z: 302 (M+1).
实施例129Example 129
2-(1-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺2-(1-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide
Figure PCTCN2015075363-appb-000338
Figure PCTCN2015075363-appb-000338
实施例128F(20毫克，0.066毫摩尔)，40％的乙醛(0.2毫升)和氰基硼氰化钠(17毫克，0.264毫摩尔)的甲醇(5mL)混合溶液在10℃下搅拌16小时。反应完毕后用水(5ml)稀释，水层用二氯甲烷(20毫升×2)萃取，将合并的有机层蒸发，残留物通过制备型HPLC纯化得到标题化合物(17.36毫克，收率：78.9％)，为浅黄色固体。1H-NMR(400MHz,MethanoL-d4)ppm 1.38(t,J＝7.28Hz,3H),1.98-2.23(m,2H),2.28-2.49(m,2H),2.92-3.25(m,5H),3.57(d,J＝11.54Hz,2H),5.83(s,1H),7.29(dd, J＝8.28,2.51Hz,1H),7.61(dd,J＝10.92,2.51Hz,1H),8.60(br.s.,1H).LCMS(ESI)m/z:330(M+1).Example 128F (20 mg, 0.066 mmol), 40% acetaldehyde (0.2 mL) and sodium cyanoborohydride (17 mg, 0.264 mmol) in methanol (5 mL). . After completion of the reaction, the title compound (17.36 mg, yield: 78.9%) was obtained. , a pale yellow solid. 1 H-NMR (400 MHz, Methano L-d 4 ) ppm 1.38 (t, J = 7.28 Hz, 3H), 1.98-2.23 (m, 2H), 2.28-2.49 (m, 2H), 2.92-3.25 (m, 5H) ), 3.57 (d, J = 1.54 Hz, 2H), 5.83 (s, 1H), 7.29 (dd, J = 8.28, 2.51 Hz, 1H), 7.61 (dd, J = 10.92, 2.51 Hz, 1H), 8.60 (br.s., 1H). LCMS (ESI) m/z: 330 (M+1).
体外研究In vitro study
细胞PARylation分析Cell PARylation analysis
HCC1937细胞接种到96孔板，4×104个细胞/孔，37℃培养箱中培养过夜。细胞用被测试化合物处理30分钟后，用1mM过氧化氢处理10分钟。细胞用200UL预冷的PBS洗两次，并用100ul预先冷却的甲醇/丙酮(7:3)在冰浴下固定30分钟。风干后，用溶有5％脱脂奶粉的PBS-Tween-20封闭液(0.05％)在室温下封闭30分钟。细胞和anti-PAR 10H抗体按1：100比例在封闭液中室温下温育1小时，然后用PBS-Tween-20冲洗三次，然后加入含有羊抗小鼠的荧光素-5(6)-异硫氰酸酯(FITC)-联用的二抗和1μg/mL DAPI的封闭液中室温下避光温育1小时。PBS-Tween-20冲洗三次后，用荧光微型版计数器(Flexstation III，Molecular Device)分析数据。HCC1937 cells were seeded in 96-well plates at 4 × 10 4 cells/well and cultured overnight in a 37 ° C incubator. The cells were treated with the test compound for 30 minutes and then treated with 1 mM hydrogen peroxide for 10 minutes. Cells were washed twice with 200 UL pre-cooled PBS and fixed with 100 ul of pre-cooled methanol/acetone (7:3) for 30 minutes in an ice bath. After air drying, the cells were blocked with PBS-Tween-20 blocking solution (0.05%) in 5% skim milk powder for 30 minutes at room temperature. The cells and the anti-PAR 10H antibody were incubated at a ratio of 1:100 in blocking solution for 1 hour at room temperature, then washed three times with PBS-Tween-20, and then fluorescein-5(6)-different containing goat anti-mouse was added. The thiocyanate (FITC)-conjugated secondary antibody and 1 μg/mL DAPI blocking solution were incubated for 1 hour at room temperature in the dark. After rinsing three times with PBS-Tween-20, the data was analyzed using a fluorescent microplate counter (Flexstation III, Molecular Device).
PARP酶试验(依照HT通用PARP1比色法分析试剂盒说明书)。PARP enzyme assay (according to the HT Universal PARP1 Colorimetric Assay Kit).
组蛋白被包在96孔板中并4℃孵育过夜。用200UL PBST溶液洗涤该板3次后，将其用封闭液封闭，室温孵育30分钟后，用PBST溶液洗涤3次。将被测试化合物处理加入孔板中，之后将20μl稀释的PARP1(1nM)或20μl PARP2(3nM)溶液中加入到反应体系中孵育1或2小时。50μl链霉亲和素-HRP(1:50)的混合液加入到孔板中并室温孵育30分钟后，PBST缓冲液洗涤三次。100μl(HRP)(化学发光底物A和底物B(1:1))加入孔板。立即到酶标仪(Envision，PerkinElmer)上读数。Histones were packaged in 96-well plates and incubated overnight at 4 °C. After washing the plate 3 times with 200UL PBST solution, it was blocked with a blocking solution, incubated at room temperature for 30 minutes, and then washed 3 times with a PBST solution. The test compound was treated to be added to the well plate, and then 20 μl of diluted PARP1 (1 nM) or 20 μl of PARP2 (3 nM) solution was added to the reaction system for 1 or 2 hours. A mixture of 50 μl streptavidin-HRP (1:50) was added to the well plate and incubated for 30 minutes at room temperature, and washed three times with PBST buffer. 100 μl (HRP) (chemiluminescent substrate A and substrate B (1:1)) were added to the well plates. Immediately read on a microplate reader (Envision, PerkinElmer).
抗增殖试验Antiproliferative test
MDA-MB-436和MDA-MB-231细胞分别以每孔500和2000细胞的密度接种于96孔板中,过夜培养。培养基为RPMI 1640，内含有10％(V/V)FBS和1％(V/V)青霉素-链霉素.加入待测化合物后，处理8天。细胞生存力通过CCK8试剂盒测量。具体方法为10UL CCK8试剂加入到每个孔中，37℃在5％CO2培养箱并孵育3小时。振摇10分钟后，用Flexstation III(Molecular Device)450nm测定光吸收值(OD值)。MDA-MB-436 and MDA-MB-231 cells were seeded in 96-well plates at a density of 500 and 2000 cells per well, respectively, and cultured overnight. The medium was RPMI 1640 containing 10% (V/V) FBS and 1% (V/V) penicillin-streptomycin. After the test compound was added, it was treated for 8 days. Cell viability was measured by the CCK8 kit. Specifically, 10 UL CCK8 reagent was added to each well, and incubated at 37 ° C in a 5% CO 2 incubator for 3 hours. After shaking for 10 minutes, the light absorption value (OD value) was measured with a Flexstation III (Molecular Device) 450 nm.
针对化合物组合试验(与DNA损伤药物联用)，PF50值被用来计算药物的协同作用。PF50＝[被测化合物的IC 50]/[该化合物在固定DNA损伤药物浓度时的IC50]。在本研究中替莫唑胺(TMZ)被用作DNA损伤的药物。For the compound combination test (in combination with DNA damage drugs), the PF50 value was used to calculate the synergistic effect of the drug. PF50 = [IC 50 of test compound] / [IC50 of the compound at a fixed DNA damage drug concentration]. In this study, temozolomide (TMZ) was used as a drug for DNA damage.
本发明的化合物的PARP-1抑制酶的IC 50和细胞PARylation IC50数据在下面表I中提供。化合物的IC 50在1至100nM之间被标示为+++；化合物的IC50在101到1000nm之间被标示为++，化合物的IC50大于1000nm被标示为+。The IC50 and cellular PARylation IC50 data for the PARP-1 inhibitory enzymes of the compounds of the invention are provided in Table I below. The IC50 of the compound is indicated as +++ between 1 and 100 nM; the IC50 of the compound is indicated as ++ between 101 and 1000 nm, and the IC50 of the compound greater than 1000 nm is indicated as +.
表1Table 1
Figure PCTCN2015075363-appb-000339
Figure PCTCN2015075363-appb-000339
Figure PCTCN2015075363-appb-000340
Figure PCTCN2015075363-appb-000340

Claims (14)

  1. 式(I)所示化合物或其药学上可接受的盐，a compound of formula (I) or a pharmaceutically acceptable salt thereof,
    Figure PCTCN2015075363-appb-100001
    Figure PCTCN2015075363-appb-100001
    其中，among them,
    D选自-C(Rd1)(Rd2)-、-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、-C(＝O)O-、-C(＝O)-、-C(＝S)-、-S(＝O)-或-S(＝O)2-；D is selected from -C(R d1 )(R d2 )-, -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(=O 2 N(R d6 )-, -S(=O)N(R d7 )-, -O-, -S-, -C(=O)O-, -C(=O)-, -C( =S)-, -S(=O)- or -S(=O) 2 -;
    R1-3、Rd1、Rd2分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2，或选自任选被R01取代的C1-10烷基或杂烷基、C3-10环烃基或杂环烃基、被C3-10环烃基或杂环烃基取代的C1-10烷基或杂烷基；R 1-3 , R d1 , R d2 are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 or a C 1-10 alkyl group optionally substituted by R 01 Or a heteroalkyl group, a C 3-10 cycloalkyl or heterocycloalkyl group, a C 1-10 alkyl or heteroalkyl group substituted by a C 3-10 cycloalkyl or heterocycloalkyl;
    R01选自F、Cl、Br、I、CN、OH、SH、NH2、R02；R 01 is selected from the group consisting of F, Cl, Br, I, CN, OH, SH, NH 2 , R 02 ;
    R02选自C1-10烷基、C1-10烷氨基、N,N-二(C1-10烷基)氨基、C1-10烷氧基、C1-10烷酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷氨基、C3-10杂环烷氨基、C3-10环烷氧基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 02 is selected from C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1 -10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 cycloalkoxy, C 3-10 cycloalkyl acyl, C 3-10 cycloalkoxycarbonyl, C 3-10 cycloalkylsulfonyl, C 3-10 cycloalkylsulfinyl;
    杂原子或杂原子团分别独立地选自-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、-C(＝O)O-、-C(＝O)-、-C(＝S)-、-S(＝O)-和/或-S(＝O)2-；The heteroatoms or heteroatoms are independently selected from -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(=O) 2 N(R D6 )-, -S(=O)N(R d7 )-, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)- and/or -S(=O) 2 -;
    Rd3-d7分别独立地选自H、R03；R d3 - d7 are each independently selected from H, R 03 ;
    R03选自C1-10烷基、C1-10烷基酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 03 is selected from C 1-10 alkyl, C 1-10 alkyl acyl, C 1-10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 a cycloalkyl group, a C 3-10 cycloalkyl acyl group, a C 3-10 cycloalkoxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
    R02、R03任选地被R001取代；R 02 and R 03 are optionally substituted by R 001 ;
    R001选自F、Cl、Br、I、CN、OH、N(CH3)2、NH(CH3)、NH2、三氟甲基、氨甲基、羟甲基、甲基、甲氧基、甲酰基、甲氧羰基、甲磺酰基、甲基亚磺酰基；R 001 is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH 3 ) 2 , NH(CH 3 ), NH 2 , trifluoromethyl, aminomethyl, hydroxymethyl, methyl, methoxy Base, formyl group, methoxycarbonyl group, methylsulfonyl group, methylsulfinyl group;
    R01、R001、杂原子或杂原子团的数目分别独立地选自0、1、2或3。The number of R 01 , R 001 , heteroatoms or heteroatoms is independently selected from 0, 1, 2 or 3.
  2. 根据权利要求1所述化合物或其药学上可接受的盐，其中所述D选自-NH-、-N(CH3)-、-C(F)2-、-C(H)(F)-、-C(H)(OH)-。The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein said D is selected from the group consisting of -NH-, -N(CH 3 )-, -C(F) 2 -, -C(H)(F) -, -C(H)(OH)-.
  3. 根据权利要求1或2所述化合物或其药学上可接受的盐，其中所述R1-3分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2、C1-6烷基、C1-6烷氧基、苄氧基、-CH2N(R21)(R22)、
    Figure PCTCN2015075363-appb-100002
    Figure PCTCN2015075363-appb-100003
    The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein said R 1-3 are each independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-6 alkyl, C 1-6 alkoxy, benzyloxy, -CH 2 N(R 21 )(R 22 ),
    Figure PCTCN2015075363-appb-100002
    Figure PCTCN2015075363-appb-100003
    其中，among them,
    L、D21分别独立地选自-C(Rd1)(Rd2)-、-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、-C(＝O)-、-C(＝O)O-、-C(＝S)-、-S(＝O)-或-S(＝O)2-；L and D 21 are each independently selected from -C(R d1 )(R d2 )-, -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )- , -S(=O) 2 N(R d6 )-, -S(=O)N(R d7 )-, -O-, -S-, -C(=O)-, -C(=O) O-, -C(=S)-, -S(=O)- or -S(=O) 2 -;
    L还可以是仅起连接作用的单键；L can also be a single bond that only serves as a connection;
    T21-22分别独立地选自C(Rt)、N；T 21-22 are independently selected from C(R t ), N;
    X选自任选被R01取代的(CH2)n,n选自0、1、2或3，优选0、1、或2；X is selected from (CH2) n optionally substituted by R 01 , and n is selected from 0, 1, 2 or 3, preferably 0, 1, or 2;
    Y选自任选被R01取代的(CH2)m，m选自0、1、2或3，优选1、2、或3；Y is selected from (CH2) m optionally substituted by R 01 , and m is selected from 0, 1, 2 or 3, preferably 1, 2, or 3;
    R21-23、Rd3-d7分别独立地选自H、R03；R 21-23 , R d3 - d7 are each independently selected from H, R 03 ;
    R24-27、Rd1、Rd2、Rt分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2，或选自任选被R01取代的C1-10烷基或杂烷基、C3-10环烃基或杂环烃基、被C3-10环烃基或杂环烃基取代的C1-10烷基或杂烷基；R 24-27 , R d1 , R d2 , R t are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 or C 1- optionally substituted by R 01 a 10 alkyl or heteroalkyl group, a C 3-10 cycloalkyl or heterocycloalkyl group, a C 1-10 alkyl or heteroalkyl group substituted by a C 3-10 cycloalkyl or heterocycloalkyl;
    R01选自F、Cl、Br、I、CN、OH、SH、NH2、R02；R 01 is selected from the group consisting of F, Cl, Br, I, CN, OH, SH, NH 2 , R 02 ;
    R02选自C1-10烷基、C1-10烷氨基、N,N-二(C1-10烷基)氨基、C1-10烷氧基、C1-10烷酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷氨基、C3-10杂环烷氨基、C3-10环烷氧基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 02 is selected from C 1-10 alkyl, C 1-10 alkylamino, N,N-di(C 1-10 alkyl)amino, C 1-10 alkoxy, C 1-10 alkanoyl, C 1 -10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 cycloalkyl, C 3-10 cycloalkylamino, C 3-10 heterocycloalkylamino, C 3-10 cycloalkoxy, C 3-10 cycloalkyl acyl, C 3-10 cycloalkoxycarbonyl, C 3-10 cycloalkylsulfonyl, C 3-10 cycloalkylsulfinyl;
    杂原子或杂原子团分别独立地选自-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、C(＝O)O、-C(＝O)-、-C(＝S)-、-S(＝O)-和/或-S(＝O)2-；The heteroatoms or heteroatoms are independently selected from -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(=O) 2 N(R D6 )-, -S(=O)N(R d7 )-, -O-, -S-, C(=O)O, -C(=O)-, -C(=S)-, -S (=O)- and / or -S(=O) 2 -;
    Rd3-d7分别独立地选自H、R03；R d3 - d7 are each independently selected from H, R 03 ;
    R03选自C1-10烷基、C1-10烷基酰基、C1-10烷氧羰基、C1-10烷基磺酰基、C1-10烷基亚磺酰基、C3-10环烷基、C3-10环烷基酰基、C3-10环烷氧羰基、C3-10环烷基磺酰基、C3-10环烷基亚磺酰基；R 03 is selected from C 1-10 alkyl, C 1-10 alkyl acyl, C 1-10 alkoxycarbonyl, C 1-10 alkylsulfonyl, C 1-10 alkylsulfinyl, C 3-10 a cycloalkyl group, a C 3-10 cycloalkyl acyl group, a C 3-10 cycloalkoxycarbonyl group, a C 3-10 cycloalkylsulfonyl group, a C 3-10 cycloalkylsulfinyl group;
    R02、R03任选地被R001取代；R 02 and R 03 are optionally substituted by R 001 ;
    R001选自F、Cl、Br、I、CN、OH、N(CH3)2、NH(CH3)、NH2、三氟甲基、氨甲基、羟甲基、甲基、甲氧基、甲酰基、甲氧羰基、甲磺酰基、甲基亚磺酰基；R 001 is selected from the group consisting of F, Cl, Br, I, CN, OH, N(CH 3 ) 2 , NH(CH 3 ), NH 2 , trifluoromethyl, aminomethyl, hydroxymethyl, methyl, methoxy Base, formyl group, methoxycarbonyl group, methylsulfonyl group, methylsulfinyl group;
    R01、R001、杂原子或杂原子团的数目分别独立地选自0、1、2或3。The number of R 01 , R 001 , heteroatoms or heteroatoms is independently selected from 0, 1, 2 or 3.
  4. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R1、R3分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2、C1-3烷基、C1-3烷氧基、苄氧基或
    Figure PCTCN2015075363-appb-100004
    R101选自H、甲基、乙基、正丙基或异丙基；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 1 and R 3 are each independently selected from the group consisting of H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1 -3 alkyl, C 1-3 alkoxy, benzyloxy or
    Figure PCTCN2015075363-appb-100004
    R 101 is selected from H, methyl, ethyl, n-propyl or isopropyl;
    优选地，Preferably,
    R1选自H、甲基、甲氧基、苄氧基、
    Figure PCTCN2015075363-appb-100005
    R 1 is selected from the group consisting of H, methyl, methoxy, benzyloxy,
    Figure PCTCN2015075363-appb-100005
    R3选自H、F、Cl、Br、CN、甲基。R 3 is selected from the group consisting of H, F, Cl, Br, CN, and methyl.
  5. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自-CH2N(R201)(R202)，R201、R202分别独立地选自H、C1-3烷基、C1-3烷基酰基、C3-6环烷基酰基或C3-6环烷基；The compound according to claim 3, wherein R 2 is selected from -CH 2 N(R 201 )(R 202 ), and R 201 and R 202 are each independently selected from H, C 1 or a pharmaceutically acceptable salt thereof. a -3 alkyl group, a C 1-3 alkyl acyl group, a C 3-6 cycloalkyl acyl group or a C 3-6 cycloalkyl group;
    优选地， Preferably,
    R201、R202分别独立地选自H或环丙酰基；R 201 and R 202 are each independently selected from H or cyclopropionyl;
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100006
    R 2 is selected from
    Figure PCTCN2015075363-appb-100006
  6. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100007
    Figure PCTCN2015075363-appb-100008
    R203、R204、R217、R218分别独立地选自H、任选被取代的C1-3烷基、环丙基或环丙基亚甲基，取代基选自F、Cl、Br、I、CN、OH、NH2、甲基或甲氧基，取代基的数目为0、1、2或3；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100007
    Figure PCTCN2015075363-appb-100008
    R 203 , R 204 , R 217 , R 218 are each independently selected from H, optionally substituted C 1-3 alkyl, cyclopropyl or cyclopropyl methylene, and the substituent is selected from the group consisting of F, Cl, Br. , I, CN, OH, NH 2 , methyl or methoxy, the number of substituents is 0, 1, 2 or 3;
    优选地，Preferably,
    R203选自甲基、乙基、正丙基、异丙基、-CH2C(CH3)(CH3)(OH)、环丙基亚甲基，R 203 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, -CH 2 C(CH 3 )(CH 3 )(OH), cyclopropylmethylene,
    R204选自甲基、乙基、正丙基、异丙基；R 204 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl;
    R217-219分别独立选自乙基、甲基；R 217-219 are independently selected from the group consisting of ethyl and methyl;
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100009
    Figure PCTCN2015075363-appb-100010
    R 2 is selected from
    Figure PCTCN2015075363-appb-100009
    Figure PCTCN2015075363-appb-100010
  7. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100011
    R205、R206分别独立地选自H、任选被取代的C1-3烷基、环丙基或环丙基亚甲基，取代基选自F、Cl、Br、I、CN、OH、NH2、甲基或甲氧基，取代基的数目为0、1、2或3；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100011
    R 205 and R 206 are each independently selected from H, optionally substituted C 1-3 alkyl, cyclopropyl or cyclopropyl methylene, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl or methoxy, the number of substituents is 0, 1, 2 or 3;
    优选地，Preferably,
    R205、R206分别独立地优选H、甲基、乙基、正丙基、异丙基，R206还可优选F、Cl、Br、I、CN、OH、NH2；R 205 , R 206 are each independently preferably H, methyl, ethyl, n-propyl, isopropyl, and R 206 may also preferably be F, Cl, Br, I, CN, OH, NH 2 ;
    更优选地， More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100012
    R 2 is selected from
    Figure PCTCN2015075363-appb-100012
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100013
    R 2 is selected from
    Figure PCTCN2015075363-appb-100013
  8. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100014
    R207选自H、任选被取代的C1-3烷基、环丙基、环丙基亚甲基、环丁基、环丁基亚甲基、氧杂环丁基或氧杂环丁基亚甲基，取代基选自F、Cl、Br、I、CN、OH、NH2、甲基、三氟甲基、甲氧基、甲磺酰基，取代基的数目为0、1、2或3；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100014
    R 207 is selected from H, optionally substituted C 1-3 alkyl, cyclopropyl, cyclopropylmethylene, cyclobutyl, cyclobutyl methylene, oxetanyl or oxetane a methylidene group, the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, trifluoromethyl, methoxy, methylsulfonyl, and the number of substituents is 0, 1, 2 Or 3;
    优选地，Preferably,
    R207选自H、甲基、乙基、正丙基、异丙基、-CH2CF3、-CH2CH2CF3、-CH2CH2F、-CH2CH2S(＝O)2CH3、-CH2CH2CN、
    Figure PCTCN2015075363-appb-100015
    R 207 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, -CH 2 CF 3 , -CH 2 CH 2 CF 3 , -CH 2 CH 2 F, -CH 2 CH 2 S (=O ) 2 CH 3 , -CH 2 CH 2 CN,
    Figure PCTCN2015075363-appb-100015
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100016
    Figure PCTCN2015075363-appb-100017
    Figure PCTCN2015075363-appb-100018
    R 2 is selected from
    Figure PCTCN2015075363-appb-100016
    Figure PCTCN2015075363-appb-100017
    Figure PCTCN2015075363-appb-100018
  9. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100020
    R208选自H、任选被取代的C1-4烷基,取代基选自F、Cl、Br、I、CN、OH、NH2、甲基、三氟甲基、甲氧基、甲磺酰基，取代基的数目为0、1、2或3；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100020
    R 208 is selected from H, optionally substituted C 1-4 alkyl, and the substituent is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, trifluoromethyl, methoxy, A a sulfonyl group, the number of substituents being 0, 1, 2 or 3;
    优选地，Preferably,
    R208选自H、甲基、乙基、正丙基、异丙基、环丙基亚甲基、环丁基； R 208 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, cyclopropylmethylene, cyclobutyl;
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100021
    Figure PCTCN2015075363-appb-100022
    R 2 is selected from
    Figure PCTCN2015075363-appb-100021
    Figure PCTCN2015075363-appb-100022
  10. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100023
    R209选自-C(Rd1)(Rd2)-、-C(＝O)N(Rd3)-、-N(Rd4)-、-C(＝NRd5)-、-S(＝O)2N(Rd6)-、-S(＝O)N(Rd7)-、-O-、-S-、C(＝O)O、-C(＝O)-、-C(＝S)-、-S(＝O)-或-S(＝O)2-,Rd1-d7如权利要求1所定义；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100023
    R 209 is selected from -C(R d1 )(R d2 )-, -C(=O)N(R d3 )-, -N(R d4 )-, -C(=NR d5 )-, -S(= O) 2 N(R d6 )-, -S(=O)N(R d7 )-, -O-, -S-, C(=O)O, -C(=O)-, -C(= S)-, -S(=O)- or -S(=O) 2 -, R d1-d7 are as defined in claim 1;
    优选地，Preferably,
    R209选自O、S(＝O)2。R 209 is selected from the group consisting of O, S(=O) 2 .
  11. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100024
    R210选自H、F、Cl、Br、I、CN、OH、NH2、N,N-二(C1-3烷基)氨基、C1-3烷基氨基；    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100024
    R 210 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , N,N-di(C 1-3 alkyl)amino, C 1-3 alkylamino;
    优选地，Preferably,
    R210选自二甲基氨基、甲氨基、H、F、Cl、Br、I、CN、OH、NH2。R 210 is selected from the group consisting of dimethylamino, methylamino, H, F, Cl, Br, I, CN, OH, NH 2 .
  12. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100025
    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100025
    R211-214选自H或任选被R215取代的C1-4烷氧羰基、C1-4烷基、3-6元环烷基、3-6元环烷基亚甲基或5-6元不饱和杂环烃基，R211-213还选自F、Cl、Br、I、CN、OH、NH2，R 211-214 is selected from H or C 1-4 alkoxycarbonyl, C 1-4 alkyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkylmethylene or 5 optionally substituted by R 215 a -6 member unsaturated heterocyclic hydrocarbon group, R 211-213 is also selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 ,
    所述环烷基或不饱和杂环烃基上含有0、1或2个O、S或NR216，The cycloalkyl or unsaturated heterocyclic hydrocarbon group contains 0, 1 or 2 O, S or NR 216 ,
    R216选自任选H、R215取代的C1-4烷基，R 216 is selected from C 1-4 alkyl optionally substituted by H, R 215 ,
    R215选自F、Cl、Br、I、CN、OH、NH2、甲基、乙基、甲氧基、乙氧基、甲酰基、乙酰基、甲磺酰基、乙磺酰基、甲氧羰基、乙氧羰基、二甲基氨基、二乙基氨基、二甲基氨基羰基、二乙基氨基羰基、氧代，R215的数目为1、1、2或3，R 215 is selected from the group consisting of F, Cl, Br, I, CN, OH, NH 2 , methyl, ethyl, methoxy, ethoxy, formyl, acetyl, methylsulfonyl, ethylsulfonyl, methoxycarbonyl , ethoxycarbonyl, dimethylamino, diethylamino, dimethylaminocarbonyl, diethylaminocarbonyl, oxo, the number of R 215 is 1, 1, 2 or 3,
    任选地，R212与R213共同形成连接键-CH2-、-CH2CH2-或-CH2CH2CH2-；Optionally, R 212 and R 213 together form a linkage -CH 2 -, -CH 2 CH 2 - or -CH 2 CH 2 CH 2 -;
    优选地，Preferably,
    R211选自H、F、Cl、Br、I、CN、OH、NH2、甲基、乙基、羟甲基、甲氧羰基，R 211 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , methyl, ethyl, hydroxymethyl, methoxycarbonyl,
    R212选自H、F、Cl、Br、I、CN、OH、NH2、甲基，R 212 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 , methyl,
    R213选自H、F、Cl、Br、I、CN、OH、NH2，R 213 is selected from the group consisting of H, F, Cl, Br, I, CN, OH, NH 2 ,
    R214选自H、甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、-CH2C(OH)(CH3)2、-CH2C(F)(CH3)2、 -CH2CH2F、-CH2CF3、-CH2CH2CF3、-CH2CH2NH2、-CH2CH2OH、-CH2CH2CN、-CH2CH2OCH3、-CH2CH2CH2OCH3、-CH2CH2N(CH3)2、-S(＝O)2CH3、-CH2CH2S(＝O)2CH3、
    Figure PCTCN2015075363-appb-100026
    环丙基、环丙基亚甲基、
    Figure PCTCN2015075363-appb-100027
    Figure PCTCN2015075363-appb-100028
    R 214 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, -CH 2 C(OH)(CH 3 ) 2 , -CH 2 C ( F) (CH 3 ) 2 , -CH 2 CH 2 F, -CH 2 CF 3 , -CH 2 CH 2 CF 3 , -CH 2 CH 2 NH 2 , -CH 2 CH 2 OH, -CH 2 CH 2 CN , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 CH 2 OCH 3 , -CH 2 CH 2 N(CH 3 ) 2 , -S(=O) 2 CH 3 , -CH 2 CH 2 S(=O ) 2 CH 3 ,
    Figure PCTCN2015075363-appb-100026
    Cyclopropyl, cyclopropylmethylene,
    Figure PCTCN2015075363-appb-100027
    Figure PCTCN2015075363-appb-100028
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100029
    Figure PCTCN2015075363-appb-100030
    R 2 is selected from
    Figure PCTCN2015075363-appb-100029
    Figure PCTCN2015075363-appb-100030
    Figure PCTCN2015075363-appb-100031
    Figure PCTCN2015075363-appb-100031
  13. 根据权利要求3所述化合物或其药学上可接受的盐，其中所述R2选自
    Figure PCTCN2015075363-appb-100032
    T22选自N 或C(R224)；R220-224分别独立地选自H、F、Cl、Br、I、CN、OH、SH、NH2、C1-3烷氨基C1-3烷基、
    Figure PCTCN2015075363-appb-100033
    优选地，    The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein said R 2 is selected from
    Figure PCTCN2015075363-appb-100032
    T 22 is selected from N or C (R 224 ); R 220-224 are each independently selected from H, F, Cl, Br, I, CN, OH, SH, NH 2 , C 1-3 alkylamino C 1-3 alkyl,
    Figure PCTCN2015075363-appb-100033
    Preferably,
    所述C1-3烷氨基C1-3烷基选自甲氨基亚甲基；The C 1-3 alkylamino C 1-3 alkyl group is selected from the group consisting of methylaminomethylene;
    更优选地，More preferably,
    R2选自
    Figure PCTCN2015075363-appb-100034
    Figure PCTCN2015075363-appb-100035
    R 2 is selected from
    Figure PCTCN2015075363-appb-100034
    Figure PCTCN2015075363-appb-100035
  14. 根据权利要求1所述化合物或其药学上可接受的盐，其选自：A compound according to claim 1 or a pharmaceutically acceptable salt thereof selected from the group consisting of:
    1)6-氟代-3-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；1) 6-fluoro-3-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    2)3-(1-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；2) 3-(1-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    3)6-氟-3-(1-(2-氟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；3) 6-Fluoro-3-(1-(2-fluoroethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    4)3-(1-环丙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；4) 3-(1-Cyclopropylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    5)3-(1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；5) 3-(1-(Cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    6)6-氟-3-(1-(2-羟基-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；6) 6-Fluoro-3-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridinium Azole-8-carboxamide;
    7)6-氟-3-(1-(2-氟-2-甲基丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；7) 6-Fluoro-3-(1-(2-fluoro-2-methylpropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridinium Azole-8-carboxamide;
    8)3-(1-(环丙基甲酰基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；8) 3-(1-(Cyclopropylformyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Amide
    9)6-氟-3-(1-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；9) 6-fluoro-3-(1-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    10)6-氟-3-(1-异丙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；10) 6-fluoro-3-(1-isopropylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    11)6-氟-3-(1-(氧杂环丁烷-3-基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；11) 6-Fluoro-3-(1-(oxetan-3-yl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-formamide;
    12)6-氟-3-(1-丙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；12) 6-fluoro-3-(1-propylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    13)6-氟-3-(1-(2-氨乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；13) 6-Fluoro-3-(1-(2-aminoethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    14)3-(1-(2-(二甲胺基)乙基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；14) 3-(1-(2-(Dimethylamino)ethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    15)6-氟-3-(1-(2-甲氧基乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；15) 6-Fluoro-3-(1-(2-methoxyethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide;
    16)6-氟-3-(1-(2-羟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；16) 6-Fluoro-3-(1-(2-hydroxyethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    17)3-(1-乙基哌啶-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；17) 3-(1-ethylpiperidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    18)3-(1-乙基氮杂环庚烷-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；18) 3-(1-Ethylazepane-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    19)6-氟-3-(1-甲基氮杂环庚烷-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；19) 6-fluoro-3-(1-methylazepane-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    20)6-氟-3-(1-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；20) 6-fluoro-3-(1-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    21)3-(1-乙基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺； 21) 3-(1-ethylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    22)6-氟-3-(1-异丙基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；22) 6-fluoro-3-(1-isopropylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    23)6-氟-3-(吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；23) 6-fluoro-3-(pyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    24)6-氟-3-(1-甲基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；24) 6-fluoro-3-(1-methylpyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    25)3-(1-乙基吡咯烷-2-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；25) 3-(1-ethylpyrrolidin-2-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    26)3-(1-乙基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；26) 3-(1-ethylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    27)6-氟-3-(1-丙基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；27) 6-fluoro-3-(1-propylpyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    28)6-氟-3-(3-甲基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；28) 6-Fluoro-3-(3-methyl-3-azabicyclo[3.1.0]hexane-1-yl)-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    29)3-(3-乙基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；29) 3-(3-Ethyl-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    30)3-(3-环丁基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；30) 3-(3-Cyclobutyl-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    31)3-(3-环丙亚甲基-3-氮杂双环[3.1.0]己烷-1-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；31) 3-(3-Cyclopropione-3-azabicyclo[3.1.0]hexane-1-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide;
    32)6-氟-3-(3-异丙基-3-氮杂双环[3.1.0]己烷-1-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；32) 6-Fluoro-3-(3-isopropyl-3-azabicyclo[3.1.0]hexane-1-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    33)3-(3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；33) 3-(3-Azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
    34)3-(3-乙基-3-氮杂双环[3.1.0]己烷-6-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；34) 3-(3-Ethyl-3-azabicyclo[3.1.0]hexane-6-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    35)3-(8-乙基-8-氮杂双环[3.2.1]辛-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；35) 3-(8-Ethyl-8-azabicyclo[3.2.1]oct-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    36)6-氟-3-(4-羟基吡咯烷-2-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；36) 6-fluoro-3-(4-hydroxypyrrolidin-2-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    37)3-氰基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；37) 3-cyano-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    38)3-氰基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；38) 3-cyano-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    39)3-氨甲基-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；39) 3-aminomethyl-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    40)3-(环丙甲酰胺亚甲基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；40) 3-(cyclopropanecartamethylene)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    41)6-氟-3-(4-氟苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；41) 6-fluoro-3-(4-fluorophenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    42)6-氟-3-(2-氟-4-((甲胺亚甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；42) 6-Fluoro-3-(2-fluoro-4-((methylaminomethylene)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
    43)6-氟-3-(4-((甲基氨基)甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；43) 6-fluoro-3-(4-((methylamino)methyl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    44)6-氟-3-(2-氟-5-((甲基氨基)甲基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；44) 6-Fluoro-3-(2-fluoro-5-((methylamino)methyl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8 -formamide;
    45)6-氟-3-(吡啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；45) 6-fluoro-3-(pyridin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    46)6-氟-3-(4-(哌啶-3-基)苯基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；46) 6-fluoro-3-(4-(piperidin-3-yl)phenyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    47)6-氟-3-(四氢-2H-吡喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；47) 6-fluoro-3-(tetrahydro-2H-pyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    48)3-(4-(二甲基氨基)环己基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；48) 3-(4-(Dimethylamino)cyclohexyl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    49)6-氟-3-(4-甲基哌嗪-1-羰基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；49) 6-fluoro-3-(4-methylpiperazine-1-carbonyl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    50)3-(1-(环丙基甲基)哌啶-4-基)-4,4,6-三氟-4H-吡唑并[1,5-a]吲哚-8-甲酰胺；50) 3-(1-(Cyclopropylmethyl)piperidin-4-yl)-4,4,6-trifluoro-4H-pyrazolo[1,5-a]indole-8-carboxamide ;
    51)3-(1-乙基哌啶-4-基)-6-氟-4-羟基-4H-吡唑并[1,5-a]吲哚-8-甲酰胺；51) 3-(1-ethylpiperidin-4-yl)-6-fluoro-4-hydroxy-4H-pyrazolo[1,5-a]indole-8-carboxamide;
    52)3-(1-乙基哌啶-4-基)-6-氟-4-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；52) 3-(1-Ethylpiperidin-4-yl)-6-fluoro-4-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    53)6-氟-3-(4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；53) 6-fluoro-3-(4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    54)3-(1-乙基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；54) 3-(1-Ethyl-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    55)3-(1-环丙基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；55) 3-(1-Cyclopropyl-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
    56)6-氟-3-(1-(2-羟基-2-甲基丙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺； 56) 6-Fluoro-3-(1-(2-hydroxy-2-methylpropyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    57)3-(1-环丙基亚甲基-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；57) 3-(1-Cyclopropylmethylene-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole -8-formamide;
    58)3-(1-(4,4-二氟环己基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；58) 3-(1-(4,4-Difluorocyclohexyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2- b] pyrazole-8-carboxamide;
    59)6-氟-3-(4-甲基-1-(四氢-2H-吡喃-4-基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；59) 6-Fluoro-3-(4-methyl-1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
    60)6-氟-3-(1-(2-氟乙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；60) 6-Fluoro-3-(1-(2-fluoroethyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    61)6-氟-3-(4-甲基-1-(2,2,2-三氟乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；61) 6-Fluoro-3-(4-methyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    62)6-氟-3-(4-甲基-1-(2,2,2-三氟丙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；62) 6-Fluoro-3-(4-methyl-1-(2,2,2-trifluoropropyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    63)3-(1-((1-氰基环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；63) 3-(1-((1-Cyanocyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
    64)3-(1-((1-氰基环丁基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；64) 3-(1-((1-Cyanocyclobutyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
    65)6-氟-3-(4-甲基-1-(2-(甲基磺酰基)乙基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；65) 6-Fluoro-3-(4-methyl-1-(2-(methylsulfonyl)ethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    66)6-氟-3-(4-甲基-1-((四氢-2H-吡喃-4-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；66) 6-Fluoro-3-(4-methyl-1-((tetrahydro-2H-pyran-4-yl)methyl)piperidin-4-yl)-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
    67)3-(1-((1-氨基环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；67) 3-(1-((1-Aminocyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    68)6-氟-3-(4-甲基-1-(氧杂环丁烷-3-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；68) 6-Fluoro-3-(4-methyl-1-(oxetan-3-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
    69)6-氟-3-(1-(2-甲氧基乙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；69) 6-Fluoro-3-(1-(2-methoxyethyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    70)6-氟-3-(1-((1-羟基环丙基)甲基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；70) 6-Fluoro-3-(1-((1-hydroxycyclopropyl)methyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    71)6-氟-3-(4-甲基-1-((3-甲基氧杂环丁烷-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；71) 6-Fluoro-3-(4-methyl-1-((3-methyloxetan-3-yl)methyl)piperidin-4-yl)-4H-benzo[4, 5] imidazo[1,2-b]pyrazole-8-carboxamide;
    72)6-氟-3-(1-(3-甲氧基丙基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；72) 6-Fluoro-3-(1-(3-methoxypropyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    73)6-氟-3-(4-甲基-1-((1-(甲基磺酰基)环丙基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；73) 6-Fluoro-3-(4-methyl-1-((1-(methylsulfonyl)cyclopropyl)methyl)piperidin-4-yl)-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
    74)6-氟-3-(4-甲基-1-(噻唑-2-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；74) 6-Fluoro-3-(4-methyl-1-(thiazol-2-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    75)6-氟-3-(4-甲基-1-(甲磺酰基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；75) 6-Fluoro-3-(4-methyl-1-(methylsulfonyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide;
    76)6-氟-3-(1-(3-氟环丁基)-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；76) 6-Fluoro-3-(1-(3-fluorocyclobutyl)-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    77)6-氟-3-(4-甲基-1-(噻吩-2-基甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；77) 6-Fluoro-3-(4-methyl-1-(thiophen-2-ylmethyl)piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    78)3-(1-((1-乙基哌啶-4-基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；78) 3-(1-((1-ethylpiperidin-4-yl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazole And [1,2-b]pyrazole-8-carboxamide;
    79)6-氟-3-(4-甲基-1-((1-甲基氮杂环丁烷-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；79) 6-Fluoro-3-(4-methyl-1-((1-methylazetidin-3-yl)methyl)piperidin-4-yl)-4H-benzo[4, 5] imidazo[1,2-b]pyrazole-8-carboxamide;
    80)2-((4-(8-氨基甲酰基-6-氟-4H苯并[4,5]咪唑并[1,2-B]吡唑-3-基)-4-甲基哌啶-1-基)甲基)环丙烷羧酸乙酯；80) 2-((4-(8-carbamoyl-6-fluoro-4Hbenzo[4,5]imidazo[1,2-B]pyrazol-3-yl)-4-methylpiperidine Ethyl-1-methyl)methyl)cyclopropanecarboxylate;
    81)3-(1-((2-(二甲基氨基甲基)环丙基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；81) 3-(1-((2-(Dimethylaminomethyl)cyclopropyl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4, 5] imidazo[1,2-b]pyrazole-8-carboxamide;
    82)6-氟-3-(1-异丁基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺82) 6-Fluoro-3-(1-isobutyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
    83)6-氟-3-(4-甲基-1-((4-甲基噻唑-5-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；83) 6-Fluoro-3-(4-methyl-1-((4-methylthiazol-5-yl)methyl)piperidin-4-yl)-4H-benzo[4,5]imidazolium [1,2-b]pyrazole-8-carboxamide;
    84)6-氟-3-(4-甲基-1-((1-甲基-1H-咪唑-2-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺； 84) 6-Fluoro-3-(4-methyl-1-((1-methyl-1H-imidazol-2-yl)methyl)piperidin-4-yl)-4H-benzo[4,5 Imidazo[1,2-b]pyrazole-8-carboxamide;
    85)3-(1-((1,2-二甲基-1H-咪唑-5-基)甲基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；85) 3-(1-((1,2-Dimethyl-1H-imidazol-5-yl)methyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[ 4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    86)3-(1'-乙基-4-甲基-[1,4'-联哌啶]-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；86) 3-(1'-Ethyl-4-methyl-[1,4'-bipiperidino]-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    87)6-氟-3-(4-甲基-1-((6-氧代-1,6-二氢哒嗪-3-基)甲基)哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；87) 6-Fluoro-3-(4-methyl-1-((6-oxo-1,6-dihydropyridazin-3-yl)methyl)piperidin-4-yl)-4H-benzene And [4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    88)3-(1-(2-氰基乙基)-4-甲基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；88) 3-(1-(2-Cyanoethyl)-4-methylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    89)6-氯-3-(1-乙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；89) 6-Chloro-3-(1-ethyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    90)3-(1-乙基-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；90) 3-(1-Ethyl-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-A Amide
    91)3-(1,3-二甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；91) 3-(1,3-Dimethylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    92)6-氟-3-(1-异丙基-3-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；92) 6-Fluoro-3-(1-isopropyl-3-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
    93)3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；93) 3-(1-(Cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    94)6-氟-3-(3-甲基-1-(氧杂环丁烷-3-基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；94) 6-Fluoro-3-(3-methyl-1-(oxetan-3-yl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2 -b]pyrazole-8-carboxamide;
    95)6-氟-3-(1-(2-氟乙基)-3-甲基吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；95) 6-Fluoro-3-(1-(2-fluoroethyl)-3-methylpyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    96)3-(1-((2,2-二氟环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；96) 3-(1-((2,2-Difluorocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo [1,2-b]pyrazole-8-carboxamide;
    97)6-氟-3-(3-甲基-1-(2,2,2-三氟乙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；97) 6-Fluoro-3-(3-methyl-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    98)6-氟-3-(3-甲基-1-(2-(甲基磺酰基)乙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；98) 6-Fluoro-3-(3-methyl-1-(2-(methylsulfonyl)ethyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    99)6-氟-3-(3-甲基-1-(3,3,3-三氟丙基)吡咯烷-3-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；99) 6-fluoro-3-(3-methyl-1-(3,3,3-trifluoropropyl)pyrrolidin-3-yl)-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    100)3-(1-((1-氨基环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；100) 3-(1-((1-Aminocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    101)3-(1-((1-氰基环丁基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；101) 3-(1-((1-Cyanocyclobutyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
    102)3-(1-((1-氰基环丙基)甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；102) 3-(1-((1-Cyanocyclopropyl)methyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1 , 2-b]pyrazole-8-carboxamide;
    103)3-(1-(2-氰基异基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；103) 3-(1-(2-Cyanoisoyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    104)3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；104) 3-(1-(Cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    105)6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；105) 6-Fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8- Formamide
    106)6-氟-3-(4-甲基-1,1-二氧-2H-噻喃-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；106) 6-Fluoro-3-(4-methyl-1,1-dioxo-2H-thiopyran-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrr Azole-8-carboxamide;
    107)3-(1,4-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；107) 3-(1,4-ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    108)3-(4-氰基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；108) 3-(4-Cyano-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    109)3-(4-羟甲基-1-(环丙基甲基)哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；109) 3-(4-Hydroxymethyl-1-(cyclopropylmethyl)piperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    110)4-(8-甲酰氨-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-3-基)-1-(环丙基甲基)哌啶-4-羧酸乙酯；110) 4-(8-Formylamino-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazol-3-yl)-1-(cyclopropylmethyl) Ethyl piperidine-4-carboxylate;
    111)3-(1-(环丙基甲基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；111) 3-(1-(Cyclopropylmethyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    112)3-(1-乙基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；112) 3-(1-Ethyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    113)3-(1-异丁基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；113) 3-(1-Isobutyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    114)3-(1-异丙基-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；114) 3-(1-Isopropyl-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    115)3-(1,4-二甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺； 115) 3-(1,4-Dimethylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide;
    116)3-(1-(2-羟基-2-甲基丙基)-4-甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；116) 3-(1-(2-Hydroxy-2-methylpropyl)-4-methylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
    117)3-(1-乙基-2,4-二甲基哌啶-4-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；117) 3-(1-Ethyl-2,4-dimethylpiperidin-4-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2- b] pyrazole-8-carboxamide;
    118)3-(1-乙基-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；118) 3-(1-Ethyl-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    119)3-(1-异丙基-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；119) 3-(1-Isopropyl-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    120)3-(1-(环丙基甲基)-3-甲基吡咯烷-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；120) 3-(1-(Cyclopropylmethyl)-3-methylpyrrolidin-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    121)3-(1,3-二甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；121) 3-(1,3-Dimethylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyrazole- 8-carboxamide;
    122)3-(1-乙基-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；122) 3-(1-Ethyl-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b]pyridin Azole-8-carboxamide;
    123)3-(1-异丙基-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；123) 3-(1-Isopropyl-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1,2-b] Pyrazole-8-carboxamide;
    124)3-(1-(环丙基甲基)-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；124) 3-(1-(Cyclopropylmethyl)-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5]imidazo[1, 2-b]pyrazole-8-carboxamide;
    125)3-(1-(2-羟基-2-甲基丙基)-3-甲基氮杂-3-基)-6-氟-2-甲基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；125) 3-(1-(2-Hydroxy-2-methylpropyl)-3-methylaza-3-yl)-6-fluoro-2-methyl-4H-benzo[4,5] Imidazo[1,2-b]pyrazole-8-carboxamide;
    126)6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-2-甲氧基-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；126) 6-Fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-2-methoxy-4H-benzo[4,5]imidazo[1,2-b Pyrazole-8-carboxamide;
    127)2-苄甲氧基-6-氟-3-(1-异丙基-4-甲基哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；127) 2-Benzyloxy-6-fluoro-3-(1-isopropyl-4-methylpiperidin-4-yl)-4H-benzo[4,5]imidazo[1,2- b] pyrazole-8-carboxamide;
    128)6-氟-2-(哌啶-4-基)-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺；和128) 6-fluoro-2-(piperidin-4-yl)-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide;
    129)2-(1-乙基哌啶-4-基)-6-氟-4H-苯并[4,5]咪唑并[1,2-b]吡唑-8-甲酰胺。 129) 2-(1-Ethylpiperidin-4-yl)-6-fluoro-4H-benzo[4,5]imidazo[1,2-b]pyrazole-8-carboxamide.
PCT/CN2015/075363 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors WO2015154630A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
ES15777444T ES2754590T3 (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo [1,5-¿A] benzimidazole compounds as PARP inhibitors
KR1020167031520A KR101921486B1 (en) 2014-04-10 2015-03-30 ANALOGS OF 4H-Pyrazolo[1,5-a]benzimidazole compounds AS PARP INHIBITORS
RU2016144202A RU2672722C2 (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
EP15777444.9A EP3130592B1 (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
MX2016013265A MX368496B (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5-a]benzimidazole compound as parp inhibitors.
BR112016023397-2A BR112016023397B1 (en) 2014-04-10 2015-03-30 COMPOUND OF THE FORMULA OR A PHARMACEUTICALLY ACCEPTABLE SALT
AU2015245786A AU2015245786B2 (en) 2014-04-10 2015-03-30 Analogues of 4H-pyrazolo[1,5-a]benzimidazole compound as PARP inhibitors
CN201580017657.1A CN106459057B (en) 2014-04-10 2015-03-30 The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor
PL15777444T PL3130592T3 (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5- ]benzimidazole compound as parp inhibitors
JP2017504223A JP6359175B2 (en) 2014-04-10 2015-03-30 Analogs of 4H-pyrazolo [1,5-α] benzimidazole compounds as PARP inhibitors
US15/302,588 US9856262B2 (en) 2014-04-10 2015-03-30 Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors
DK15777444T DK3130592T3 (en) 2014-04-10 2015-03-30 ANALOGS OF 4H-PYRAZOLO [1,5-á] BENZIMIDAZOLE COMPOUNDS AS PARPIN HIBITORS
CA2944801A CA2944801C (en) 2014-04-10 2015-03-30 Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
SG11201608438YA SG11201608438YA (en) 2014-04-10 2015-03-30 Analogs of 4h-pyrazolo[1,5-α]benzimidazole compounds as parp inhibitors
NZ725165A NZ725165A (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
IL248258A IL248258B (en) 2014-04-10 2016-10-09 Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
ZA2016/07736A ZA201607736B (en) 2014-04-10 2016-11-09 Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410144173.0 2014-04-10
CN201410144173.0A CN104974161B (en) 2014-04-10 2014-04-10 The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor
CN201510113090 2015-03-13
CN201510113090.X 2015-03-13

Publications (1)

Publication Number Publication Date
WO2015154630A1 true WO2015154630A1 (en) 2015-10-15

Family

ID=54287319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/075363 WO2015154630A1 (en) 2014-04-10 2015-03-30 Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors

Country Status (22)

Country Link
US (1) US9856262B2 (en)
EP (1) EP3130592B1 (en)
JP (1) JP6359175B2 (en)
KR (1) KR101921486B1 (en)
CN (1) CN106459057B (en)
AU (1) AU2015245786B2 (en)
BR (1) BR112016023397B1 (en)
CA (1) CA2944801C (en)
DK (1) DK3130592T3 (en)
ES (1) ES2754590T3 (en)
HU (1) HUE047410T2 (en)
IL (1) IL248258B (en)
MX (1) MX368496B (en)
NZ (1) NZ725165A (en)
PL (1) PL3130592T3 (en)
PT (1) PT3130592T (en)
RU (1) RU2672722C2 (en)
SA (1) SA516380051B1 (en)
SG (1) SG11201608438YA (en)
TW (1) TWI671301B (en)
WO (1) WO2015154630A1 (en)
ZA (1) ZA201607736B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018197401A1 (en) 2017-04-27 2018-11-01 Bayer Animal Health Gmbh New bicyclic pyrazole derivatives
EP3357925A4 (en) * 2015-09-30 2019-05-01 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Salt type and crystal type of 4h-pyrazolo [1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN117534677A (en) * 2024-01-09 2024-02-09 广东省农业科学院农业质量标准与监测技术研究所 Imine-containing tricyclic fused heterocyclic compound and application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974161B (en) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor
CN115028641B (en) * 2022-07-19 2024-05-28 湖南大学 Method for synthesizing 5, 8-difunctional substituted imidazo [1,2-a ] pyrazine compound by cobalt catalysis
CN116969954B (en) * 2023-09-21 2023-11-28 广东省农业科学院农业质量标准与监测技术研究所 Tricyclic fused heterocyclic compounds containing lactam and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164061A1 (en) * 2012-05-04 2013-11-07 dedeMERCK PATENT GMBH Pyrrolotriazinone derivatives
WO2014009872A1 (en) * 2012-07-09 2014-01-16 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
WO2014023390A2 (en) * 2012-08-08 2014-02-13 Merck Patent Gmbh (aza-)isoquinolinone derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916051A (en) * 1987-04-07 1990-04-10 Konica Corporation Silver halide color photographic light-sensitive material
CA2550948A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
EP1973909A2 (en) * 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
WO2007144669A1 (en) * 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
MX2008016339A (en) * 2006-06-20 2009-01-16 Abbott Lab Pyrazoloquinazolinones as parp inhibitors.
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
ES2535511T3 (en) 2012-04-26 2015-05-12 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
EP2666775A1 (en) * 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
AR091271A1 (en) 2012-06-07 2015-01-21 Hoffmann La Roche PIRROLOPIRIMIDONA AND PIRROLOPIRIDONA, TANQUIRASA INHIBITORS
CN103570725B (en) 2012-08-01 2017-03-22 中国科学院上海药物研究所 Piperazidinoltriazole compound as well as preparation method and application thereof
CN104974161B (en) 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164061A1 (en) * 2012-05-04 2013-11-07 dedeMERCK PATENT GMBH Pyrrolotriazinone derivatives
WO2014009872A1 (en) * 2012-07-09 2014-01-16 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
WO2014023390A2 (en) * 2012-08-08 2014-02-13 Merck Patent Gmbh (aza-)isoquinolinone derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3130592A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3357925A4 (en) * 2015-09-30 2019-05-01 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Salt type and crystal type of 4h-pyrazolo [1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof
US10428073B2 (en) * 2015-09-30 2019-10-01 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
AU2016333293B2 (en) * 2015-09-30 2020-07-30 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Salt type and crystal type of 4H-pyrazolo (1, 5-alpha) benzimidazole compound and preparation method and intermediate thereof
US10941150B2 (en) 2015-09-30 2021-03-09 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018197401A1 (en) 2017-04-27 2018-11-01 Bayer Animal Health Gmbh New bicyclic pyrazole derivatives
CN117534677A (en) * 2024-01-09 2024-02-09 广东省农业科学院农业质量标准与监测技术研究所 Imine-containing tricyclic fused heterocyclic compound and application thereof
CN117534677B (en) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 Imine-containing tricyclic fused heterocyclic compound and application thereof

Also Published As

Publication number Publication date
AU2015245786B2 (en) 2018-03-15
TW201620913A (en) 2016-06-16
JP2017510653A (en) 2017-04-13
IL248258B (en) 2018-11-29
ES2754590T3 (en) 2020-04-20
MX2016013265A (en) 2017-05-03
HUE047410T2 (en) 2020-04-28
CN106459057B (en) 2019-06-07
JP6359175B2 (en) 2018-07-18
EP3130592A4 (en) 2017-09-06
RU2016144202A3 (en) 2018-05-15
US20170029430A1 (en) 2017-02-02
PT3130592T (en) 2019-11-21
RU2016144202A (en) 2018-05-15
US9856262B2 (en) 2018-01-02
SA516380051B1 (en) 2020-05-17
AU2015245786A1 (en) 2016-11-03
CA2944801A1 (en) 2015-10-15
EP3130592A1 (en) 2017-02-15
BR112016023397B1 (en) 2022-08-16
RU2672722C2 (en) 2018-11-19
CN106459057A (en) 2017-02-22
CA2944801C (en) 2019-02-12
NZ725165A (en) 2018-04-27
KR20170005807A (en) 2017-01-16
MX368496B (en) 2019-10-04
KR101921486B1 (en) 2018-11-26
EP3130592B1 (en) 2019-08-14
DK3130592T3 (en) 2019-11-04
ZA201607736B (en) 2017-09-27
PL3130592T3 (en) 2020-05-18
BR112016023397A2 (en) 2017-08-15
TWI671301B (en) 2019-09-11
SG11201608438YA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
TWI671301B (en) Analogue of 4H-pyrazolo[1,5-α]benzimidazole compound as a PARP inhibitor
EP3377482B1 (en) Modulators of ror-gamma
JP6976953B2 (en) Spiroheptane salicylamide as a ROCK inhibitor and related compounds
AU2021209257B2 (en) Bicyclic BET bromodomain inhibitors and uses thereof
EP2124951B1 (en) 5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
KR20210014108A (en) Pyridazinone as a PARP7 inhibitor
CN104974161B (en) The analog of 4H- pyrazolo [1,5- α] benzimidazole compound as PARP inhibitor
TWI676622B (en) Isoquinoline sulfonium derivatives as RHO kinase inhibitors
CN110869363A (en) 5-membered and bicyclic heterocyclic amides as ROCK inhibitors
CN110869361A (en) Five-membered amino heterocycle and 5, 6-or 6, 6-membered bicyclic amino heterocycle inhibitors of ROCK for the treatment of heart failure
CA2998705A1 (en) 1-phenylpyrrolidin-2-one derivatives as perk inhibitors
CA3074059A1 (en) Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN116589466A (en) Degradation of Bruton&#39;s Tyrosine Kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligands and methods of use thereof
CN105085525A (en) Isoquinoline sulfonyl derivatives as RHO kinases inhibitor
WO2019189555A1 (en) Heterocyclic compound
JP6977038B2 (en) GSK-3 inhibitor
TW202214634A (en) Heterocyclic compound and derivative thereof
TW202330519A (en) Pyrazolopyridine compounds as tam inhibitors
CN117659023A (en) Pyridine acetamide derivative, pharmaceutical composition containing same and medical application of pyridine acetamide derivative

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2944801

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15302588

Country of ref document: US

Ref document number: MX/A/2016/013265

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 248258

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017504223

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201606970

Country of ref document: ID

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016023397

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2015245786

Country of ref document: AU

Date of ref document: 20150330

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015777444

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015777444

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15777444

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20167031520

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2016144202

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2016/0003993

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112016023397

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161007